0001437749-24-03500610-Q Cyclo Therapeutics, Inc. 2024111320241113204253204253204253 0 0001437749-24-035006 10-Q 63 20240930 20241114
20241113 Cyclo Therapeutics, Inc. 0000922247 2836 593029743 NV 1231 10-Q 34 001-39780 241456511 6714 NW 16TH STREET, SUITE B
GAINESVILLE FL 32653 386-418-8060 PO BOX 1180 ALACHUA FL 32616-1180 CTD HOLDINGS INC 20000913 CYCLODEXTRIN TECHNOLOGIES
DEVELOPMENT INC 19941012 10-Q 1 ctdh20240930_10q.htm FORM 10-Q ctdh20240930_10q.htm Q3 2024 --12-31 false 0000922247 false false false
false 0 0 10 10 0 0 0 0 3 3 3 2 4 4 3 1 10 7 5 3 0 0 0 0.0001 0.0001 0.0001 0.0001 00009222472024-01-012024-09-30 thunderdome:item
00009222472024-07-012024-09-30 iso4217:USD 0000922247ctdh:NovemberNoteMemberctdh:RafaelHoldingsIncMemberus-
gaap:SubsequentEventMember2024-11-01 0000922247ctdh:OctoberNoteMemberctdh:RafaelHoldingsIncMemberus-gaap:SubsequentEventMember2024-
10-08 0000922247ctdh:AshlandIncMemberus-gaap:PurchaseCommitmentMember2024-09-30 0000922247ctdh:AshlandIncMemberus-
gaap:PurchaseCommitmentMember2023-01-012023-03-31 xbrli:shares 0000922247us-gaap:WarrantMember2023-01-012023-09-30 0000922247us-
gaap:WarrantMember2024-01-012024-09-30 0000922247us-gaap:WarrantMember2023-07-012023-09-30 0000922247us-gaap:WarrantMember2024-07-
012024-09-30 0000922247us-gaap:EmployeeStockOptionMember2023-01-012023-09-30 0000922247us-gaap:EmployeeStockOptionMember2024-01-
012024-09-30 0000922247us-gaap:EmployeeStockOptionMember2023-07-012023-09-30 0000922247us-gaap:EmployeeStockOptionMember2024-07-
012024-09-30 iso4217:USDxbrli:shares 0000922247ctdh:ApproximationMember2023-01-012023-09-30 0000922247ctdh:ApproximationMember2024-01-
012024-09-30 0000922247ctdh:ApproximationMember2023-07-012023-09-30 0000922247ctdh:ApproximationMember2024-07-012024-09-30
00009222472023-01-012023-09-30 00009222472023-07-012023-09-30 0000922247srt:MaximumMember2024-01-012024-09-30
0000922247srt:MinimumMember2024-01-012024-09-30 xbrli:pure utr:Y 0000922247ctdh:The2021EquityIncentivePlanMember2024-01-012024-09-30
0000922247ctdh:The2021EquityIncentivePlanMember2024-07-012024-09-30 0000922247ctdh:The2021EquityIncentivePlanMember2024-09-30
0000922247us-gaap:EmployeeStockOptionMemberctdh:The2021EquityIncentivePlanMember2024-01-012024-09-30 0000922247us-
gaap:EmployeeStockOptionMemberctdh:The2021EquityIncentivePlanMember2021-06-242021-06-24
0000922247ctdh:The2021EquityIncentivePlanMember2021-06-24 0000922247ctdh:The2019OmnibusIncentivePlanMember2024-01-012024-09-30
0000922247us-gaap:EmployeeStockOptionMemberctdh:The2019OmnibusIncentivePlanMember2024-01-012024-03-31
0000922247ctdh:The2019OmnibusIncentivePlanMember2019-08-29 0000922247ctdh:EmployeeAndBoardMember2023-07-012023-09-30
0000922247ctdh:EmployeeAndBoardMember2023-01-012023-09-30 0000922247ctdh:EmployeeAndBoardMember2024-07-012024-07-01
0000922247ctdh:EmployeeAndBoardMember2024-01-012024-09-30 0000922247ctdh:BoardMembersMember2023-01-012023-09-30
0000922247ctdh:BoardMembersMember2023-07-012023-09-30 0000922247ctdh:BoardMembersMember2022-01-012022-12-31
0000922247ctdh:BoardMembersMember2024-01-012024-09-30 0000922247ctdh:BoardMembersMember2024-07-012024-09-30
0000922247ctdh:BoardMembersMember2023-01-012023-12-31 00009222472023-12-31 00009222472024-09-30
0000922247ctdh:OfficeLeaseMember2023-01-012023-01-31 0000922247ctdh:RafaelHoldingsIncMember2024-09-30
0000922247ctdh:RafaelHoldingsIncMember2024-01-012024-09-30 0000922247ctdh:RafaelHoldingsIncMember2023-12-31
0000922247ctdh:RafaelHoldingsIncMember2024-07-012024-09-30 0000922247ctdh:SeptemberNoteMemberctdh:RafaelHoldingsIncMember2024-09-09
0000922247ctdh:AugustNoteMemberctdh:RafaelHoldingsIncMember2024-08-21 0000922247ctdh:JulyNoteMemberctdh:RafaelHoldingsIncMember2024-
07-16 0000922247ctdh:JuneNoteMemberctdh:RafaelHoldingsIncMember2024-06-11 0000922247ctdh:RafaelHoldingsIncMember2024-06-11
0000922247us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberctdh:CyclodexterinComplexesMember2023-01-012023-09-30
0000922247us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberctdh:CyclodexterinComplexesMember2024-01-012024-09-30
0000922247us-gaap:SalesRevenueNetMemberus-
gaap:ProductConcentrationRiskMemberctdh:BasicNaturalAndChemicallyModifiedCyclodexterinsMember2023-01-012023-09-30 0000922247us-
gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberctdh:BasicNaturalAndChemicallyModifiedCyclodexterinsMember2024-01-
012024-09-30 0000922247us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberctdh:ThreeMajorCustomersMember2023-01-
012023-09-30 0000922247us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-30 0000922247us-
gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberctdh:TwoMajorCustomersMember2023-07-012023-09-30 0000922247us-
gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberctdh:ThreeMajorCustomersMember2023-01-012023-09-30 0000922247us-
gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-30 0000922247us-gaap:SalesRevenueNetMemberus-
gaap:CustomerConcentrationRiskMemberctdh:TwoMajorCustomersMember2023-07-012023-09-30 0000922247us-gaap:SalesRevenueNetMemberus-
gaap:CustomerConcentrationRiskMember2023-07-012023-09-30 0000922247us-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMemberctdh:FourMajorCustomersMember2024-01-012024-09-30 0000922247us-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMember2024-01-012024-09-30 0000922247us-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMemberctdh:ThreeMajorCustomersMember2024-07-012024-09-30 0000922247us-gaap:SalesRevenueNetMemberus-
gaap:CustomerConcentrationRiskMemberctdh:FourMajorCustomersMember2024-01-012024-09-30 0000922247us-gaap:SalesRevenueNetMemberus-
gaap:CustomerConcentrationRiskMember2024-01-012024-09-30 0000922247us-gaap:SalesRevenueNetMemberus-
gaap:CustomerConcentrationRiskMemberctdh:ThreeMajorCustomersMember2024-07-012024-09-30 0000922247us-gaap:SalesRevenueNetMemberus-
gaap:CustomerConcentrationRiskMember2024-07-012024-09-30 0000922247us-gaap:ProductAndServiceOtherMember2023-01-012023-09-30
0000922247us-gaap:ProductAndServiceOtherMember2024-01-012024-09-30 0000922247us-gaap:ProductAndServiceOtherMember2023-07-012023-09-30
0000922247us-gaap:ProductAndServiceOtherMember2024-07-012024-09-30 0000922247ctdh:AquaplexMember2023-01-012023-09-30
0000922247ctdh:AquaplexMember2024-01-012024-09-30 0000922247ctdh:AquaplexMember2023-07-012023-09-30
0000922247ctdh:AquaplexMember2024-07-012024-09-30 0000922247ctdh:TrappsolHPBMember2023-01-012023-09-30
0000922247ctdh:TrappsolHPBMember2024-01-012024-09-30 0000922247ctdh:TrappsolHPBMember2023-07-012023-09-30
0000922247ctdh:TrappsolHPBMember2024-07-012024-09-30 0000922247ctdh:TrappsolCycloMember2023-01-012023-09-30
0000922247ctdh:TrappsolCycloMember2024-01-012024-09-30 0000922247ctdh:TrappsolCycloMember2023-07-012023-09-30
0000922247ctdh:TrappsolCycloMember2024-07-012024-09-30 0000922247us-gaap:ConvertibleNotesPayableMember2024-09-30 0000922247us-
gaap:ConvertibleNotesPayableMember2024-01-012024-09-30 0000922247us-gaap:ConvertibleNotesPayableMember2023-12-31 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputExpectedDividendRateMember2024-01-012024-09-30 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputExpectedDividendRateMember2024-07-012024-09-30 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2024-01-012024-09-30 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2024-01-012024-09-30 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2024-07-012024-09-30 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2024-07-012024-09-30 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2024-01-012024-09-30 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2024-01-012024-09-30 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2024-07-012024-09-30 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2024-07-012024-09-30 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2024-01-012024-09-30 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2024-01-012024-09-30 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2024-07-012024-09-30 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2024-07-012024-09-30 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputSharePriceMembersrt:MaximumMember2024-01-012024-09-30 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputSharePriceMembersrt:MinimumMember2024-01-012024-09-30 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputSharePriceMembersrt:MaximumMember2024-07-012024-09-30 0000922247us-
gaap:ConvertibleDebtMemberus-gaap:MeasurementInputSharePriceMembersrt:MinimumMember2024-07-012024-09-30 0000922247us-
gaap:FairValueMeasurementsRecurringMember2023-12-31 0000922247us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMember2023-12-31 0000922247us-gaap:FairValueMeasurementsRecurringMember2024-09-30 0000922247us-
gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0000922247us-
gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-01-012024-09-30 0000922247us-
gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30
0000922247ctdh:WarrantsToPurchaseCommonStockMember2023-07-012023-09-30 0000922247ctdh:WarrantsToPurchaseCommonStockMember2023-
01-012023-09-30 0000922247ctdh:WarrantsToPurchaseCommonStockMember2024-07-012024-09-30
0000922247ctdh:WarrantsToPurchaseCommonStockMember2024-01-012024-09-30
0000922247ctdh:MachineryAndFurnitureMembersrt:MaximumMember2024-09-30
0000922247ctdh:MachineryAndFurnitureMembersrt:MinimumMember2024-09-30
0000922247ctdh:ComputersAndVehiclesMembersrt:MaximumMember2024-09-30
0000922247ctdh:ComputersAndVehiclesMembersrt:MinimumMember2024-09-30 0000922247ctdh:RafaelHoldingsIncMemberus-
gaap:SubsequentEventMember2024-11-12 0000922247ctdh:MergerAgreementMember2024-08-21 00009222472023-09-30 00009222472022-12-31
0000922247us-gaap:RetainedEarningsMember2023-09-30 0000922247us-gaap:AdditionalPaidInCapitalMember2023-09-30 0000922247us-
gaap:CommonStockMember2023-09-30 0000922247us-gaap:RetainedEarningsMember2023-01-012023-09-30 0000922247us-
gaap:AdditionalPaidInCapitalMember2023-01-012023-09-30 0000922247us-gaap:CommonStockMember2023-01-012023-09-30 0000922247us-
gaap:ShareBasedPaymentArrangementNonemployeeMember2023-01-012023-09-30 0000922247us-

gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:RetainedEarningsMember2023-01-012023-09-30 0000922247us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-30 0000922247us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:CommonStockMember2023-01-012023-09-30 0000922247us-gaap:RetainedEarningsMember2022-12-31 0000922247us-gaap:AdditionalPaidInCapitalMember2022-12-31 0000922247us-gaap:CommonStockMember2022-12-31 0000922247us-gaap:RetainedEarningsMember2024-09-30 0000922247us-gaap:AdditionalPaidInCapitalMember2024-09-30 0000922247us-gaap:CommonStockMember2024-09-30 0000922247us-gaap:RetainedEarningsMember2024-01-012024-09-30 0000922247us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-30 0000922247us-gaap:CommonStockMember2024-01-012024-09-30 0000922247us-gaap:ShareBasedPaymentArrangementNonemployeeMember2024-01-012024-09-30 0000922247us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:RetainedEarningsMember2024-01-012024-09-30 0000922247us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-30 0000922247us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:CommonStockMember2024-01-012024-09-30 0000922247us-gaap:RetainedEarningsMember2023-12-31 0000922247us-gaap:AdditionalPaidInCapitalMember2023-12-31 0000922247us-gaap:CommonStockMember2023-12-31 0000922247us-gaap:RetainedEarningsMember2023-07-012023-09-30 0000922247us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-30 0000922247us-gaap:CommonStockMember2023-07-012023-09-30 0000922247us-gaap:ShareBasedPaymentArrangementNonemployeeMember2023-07-012023-09-30 0000922247us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:RetainedEarningsMember2023-07-012023-09-30 0000922247us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-30 0000922247us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:CommonStockMember2023-07-012023-09-30 00009222472023-06-30 0000922247us-gaap:RetainedEarningsMember2023-06-30 0000922247us-gaap:AdditionalPaidInCapitalMember2023-06-30 0000922247us-gaap:CommonStockMember2023-06-30 0000922247us-gaap:RetainedEarningsMember2024-07-012024-09-30 0000922247us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-30 0000922247us-gaap:CommonStockMember2024-07-012024-09-30 0000922247us-gaap:ShareBasedPaymentArrangementNonemployeeMember2024-07-012024-09-30 0000922247us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-30 0000922247us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:CommonStockMember2024-07-012024-09-30 00009222472024-06-30 0000922247us-gaap:RetainedEarningsMember2024-06-30 0000922247us-gaap:AdditionalPaidInCapitalMember2024-06-30 0000922247us-gaap:CommonStockMember2024-06-30 00009222472024-11-12 0000922247ctdh:WarrantsToPurchaseCommonStockMember2024-01-012024-09-30 0000922247us-gaap:CommonStockMember2024-01-012024-09-30

Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 10-Q Â â˜’ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2024 or â˜Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ____ to ____ Â Commission file number: 0-25466 Â CYCLO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Â Nevada Â 59-3029743 (State or other jurisdiction of incorporation or organization) Â (IRS Employer Identification No.) Â 6714 NW 16th Street, Suite B, Gainesville, Florida Â 32653 (Address of principal executive offices) Â (Zip Code) Â Registrant's telephone number, including area code: 386-418-8060 Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.0001 per share CYTH The Nasdaq Stock Market LLC Warrants to purchase Common Stock CYTHW The Nasdaq Stock Market LLC Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Â Â Â Â Â Â Â Â Â Â Â â˜’ YesÂ Â â˜ No Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Â Â Â Â Â Â Â Â Â Â Â â˜’ Yes â˜ No Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.Â Â Â Large accelerated filer â˜ Accelerated filer â˜ Â Non-accelerated filer â˜’ Smaller reporting company â˜’ Â Â Â Emerging growth company â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.Â â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) â˜Yes â˜’ No As of November 12,Â 2024,Â the Company had outstanding 28,768,055 shares of its common stock.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â CYCLO THERAPEUTICS, INC. FORM 10-QÂ TABLE OF CONTENTS Â Â Description Â Page Â Â Â Â PART I FINANCIAL INFORMATION Â 1 Item 1. Financial Statements. Â 1 Â Condensed Consolidated Balance Sheets as of September 30, 2024 (Unaudited) and December 31, 2023. Â 1 Â Condensed Consolidated Statements of Operations (Unaudited) for the Three and Nine Months Ended SeptemberÂ 30, 2024 and 2023. Â 2 Â Condensed Consolidated Statement of Stockholdersâ€™Â Equity (Deficit) (Unaudited) for the Three Months Ended SeptemberÂ 30, 2024 and 2023. Â 3 Â Condensed Consolidated Statement of Stockholdersâ€™Â Equity (Deficit) (Unaudited) for the Nine Months Ended SeptemberÂ 30, 2024 and 2023. Â 4 Â Condensed Consolidated Statements of Cash Flows (Unaudited) for the Nine Months Ended SeptemberÂ 30, 2024 and 2023. Â 5 Â Notes to Condensed (Unaudited) Consolidated Financial Statements. Â 6 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. Â 21 Item 3. Quantitative and Qualitative Disclosures about Market Risk. Â 26 Item 4. Controls and Procedures. Â 27 PART II OTHER INFORMATION Â 28 Item 1. Legal Proceedings. Â 28 Item 1A. Risk Factors. Â 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. Â 28 Item 3. Defaults Upon Senior Securities. Â 28 Item 4. Mine Safety Disclosures. Â 28 Item 5. Other Information. Â 28 Item 6. Exhibits. Â 29 Â Â Â Â SIGNATURES Â 31 Â Â Â Â PART I. FINANCIAL INFORMATION Â Item 1. Financial Statements. Â Â CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS Â Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â (unaudited) Â Â Â Â Â ASSETS Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â CURRENT ASSETS Â Â Â Â Â Â Â Â Cash and cash equivalents Â $ 928,010 Â Â $ 9,246,592 Â Accounts receivable, net of allowances of $0 and $10,272, respectively Â Â 187,682 Â Â Â 122,379 Â Inventory Â Â 236,110 Â Â Â 254,352 Â Prepaid insurance and services Â Â 177,836 Â Â Â 384,889 Â Prepaid clinical expenses Â Â 1,726,970 Â Â Â 2,310,045 Â Total current assets Â Â 3,256,608 Â Â Â 12,318,257 Â Â Â Â Â Â Â Â Â Â FURNITURE AND EQUIPMENT, NET Â Â 19,988 Â Â Â 38,332 Â Â Â Â Â Â Â Â Â RIGHT-OF-USE LEASE ASSETS, NET Â Â 26,636 Â Â Â 890,949 Â Â Â Â Â Â Â Â Â NON-CURRENT PREPAID CLINICAL EXPENSES Â Â 1,950,670 Â Â Â - Â Â Â Â Â Â Â Â Â TOTAL ASSETS Â $ 5,253,902 Â Â $ 13,247,538 Â Â Â Â Â Â Â Â Â LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â CURRENT LIABILITIES Â Â Â Â Â Â Â Â Current portion of lease liabilities Â $ 20,116 Â Â $ 1,010,631 Â Convertible note payable Â Â 12,178,000 Â Â Â - Â Accounts payable and accrued expenses Â Â 6,521,983 Â Â Â 7,457,416 Â Total current liabilities Â Â 18,720,099 Â Â Â 8,468,047 Â Â Â Â Â Â Â Â Â LONG-TERM LIABILITIES Â Â Â Â Â Â Â Â Lease liabilities, net of current portion Â Â 7,143 Â Â Â 22,484 Â Total long-term liabilities Â Â 7,143 Â Â Â 22,484 Â Commitments and contingencies (Note 13) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â STOCKHOLDERS' EQUITY (DEFICIT) Â Â Â Â Â Â Â Â Preferred stock, par value $.0001 per share, 5,000,000 shares authorized, 0 outstanding Â Â - Â Â Â - Â Common stock, par value $.0001 per share, 250,000,000 shares authorized, 28,768,055 and 28,556,072 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Â Â 2,877 Â Â Â 2,856 Â Additional paid-in capital Â Â 89,537,725 Â Â Â 88,610,832 Â Accumulated deficit Â Â (103,013,942) Â Â (83,856,681) Total stockholders' equity (deficit) Â Â (13,473,340) Â Â 4,757,007 Â Â Â Â Â Â Â Â Â TOTAL LIABILITIES AND STOCKHOLDERS' EQUITYÂ (deficit) Â $ 5,253,902 Â Â $ 13,247,538 Â Â See accompanying Notes to Condensed Consolidated Financial Statements. Â Â - 1 - Â CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Â Â Â Â Three Months Ended Â Â Nine Months Ended Â Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â REVENUES Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Product sales Â $ 233,772 Â Â $ 495,477 Â Â $ 559,326 Â Â $ 765,006 Â Cost of goods sold (exclusive of direct and indirect overhead and handling costs) Â Â 16,798 Â Â Â 38,767 Â Â Â 42,002 Â Â Â 68,872 Â GROSS PROFIT Â Â 216,974 Â Â Â 456,710 Â Â Â 517,324 Â Â Â 696,134 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â EXPENSES Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Personnel Â Â 843,157 Â Â Â 834,878 Â Â Â 2,581,207 Â Â Â 2,526,700 Â Research and development Â Â 5,492,844 Â Â Â 3,469,067 Â Â Â 11,830,127 Â Â Â 10,037,433 Â Repairs and maintenance Â Â 3,495 Â Â Â 847 Â Â Â 13,822 Â Â Â 9,162 Â Professional fees Â Â 1,412,432 Â Â Â 597,095 Â Â Â 2,430,263 Â Â Â 1,494,332 Â Office and other Â Â 640,590 Â Â Â 220,607 Â Â Â 2,361,381 Â Â Â 775,922 Â Board of Director fees and costs Â Â 111,281 Â Â Â 95,560 Â Â Â 327,061 Â Â Â 243,143 Â Depreciation Â Â 2,177 Â Â Â 4,819 Â Â Â 6,531 Â Â Â 14,457 Â Freight and shipping Â Â 441 Â Â Â 1,297 Â Â Â 1,315 Â Â Â 2,519 Â Loss on disposal of equipment Â Â - Â Â Â - Â Â Â 11,813 Â Â Â - Â Total expenses Â Â 8,506,417 Â Â Â 5,224,170 Â Â Â 19,563,520 Â Â Â 15,103,668 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â LOSS FROM OPERATIONS Â Â (8,289,443) Â Â (4,767,460) Â Â (19,046,196) Â Â (14,407,534) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â OTHER INCOME (EXPENSE) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Investment and other income (expense), net Â Â 549,621 Â Â Â (3,893) Â Â 591,312 Â Â Â (7,359) Lease income Â Â 373,878 Â Â Â - Â Â Â 1,475,623 Â Â Â - Â Loss on change in fair value of convertible promissory note Â Â (1,467,000) Â Â - Â Â Â (2,178,000) Â Â - Â Total other income (expense), net Â Â (543,501) Â Â (3,893) Â Â (111,065) Â Â (7,359) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â LOSS BEFORE PROVISION FOR INCOME TAXES Â Â (8,832,944) Â Â (4,771,353) Â Â (19,157,261) Â Â (14,414,893) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â PROVISION FOR INCOME TAXES Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â NET LOSS Â $ (8,832,944) Â $ (4,771,353) Â $ (19,157,261) Â $ (14,414,893) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â BASIC AND DILUTED NET LOSS PER COMMON SHARE Â $ (0.31) Â $ (0.29) Â $ (0.67) Â $ (1.00) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â WEIGHTED AVERAGE NUMBER OF COMMON SHARES BASIC AND DILUTED OUTSTANDING Â Â 28,729,641 Â Â Â 16,191,723 Â Â Â 28,674,910 Â Â Â 14,394,920 Â Â See accompanying Notes to Condensed Consolidated Financial Statements. Â - 2 - Â Â CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (DEFICIT) FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024 and 2023 (Unaudited) Â Â Â Â Common Stock Â Â Â Â Â Â Â Â Â Â

Total Â Â Â Shares Â Â Par Value Â Â Additional Paid-In Capital Â Â Accumulated Deficit Â Â Stockholdersâ€™ Equity (Deficit) Â Balance, June 30, 2024 Â Â 28,696,028 Â Â $ 2,870 Â Â $ 89,055,380 Â Â $ (94,180,998) Â $ (5,122,748) Â Merger recapitalization transaction costs Â Â - Â Â Â - Â Â Â (1,396) Â Â - Â Â Â (1,396) Â Adjustment to merger recapitalization liability Â Â - Â Â Â - Â Â Â 214,169 Â Â Â - Â Â Â 214,169 Â Stock issued to nonemployees Â Â 72,027 Â Â Â 7 Â Â Â 90,747 Â Â Â Â Â Â 90,754 Â Stock-based compensation Â Â - Â Â Â - Â Â Â 178,825 Â Â Â - Â Â Â 178,825 Â Net loss Â Â - Â Â Â - Â Â Â - Â Â Â (8,832,944) Â Â (8,832,944) Â Balance, September 30, 2024 Â Â 28,768,055 Â Â $ 2,877 Â Â $ 89,537,725 Â Â $ (103,013,942) Â $ (13,473,340) Â Balance, June 30, 2023 Â Â 15,308,449 Â Â $ 1,531 Â Â $ 71,956,553 Â Â $ (73,442,919) Â $ (1,484,835) Â Sale of common stock Â Â 4,000,000 Â Â Â 400 Â Â Â 4,999,600 Â Â Â - Â Â Â 5,000,000 Â Exercise of stock options Â Â 1,155 Â Â Â - Â Â Â 1,478 Â Â Â - Â Â Â 1,478 Â Stock issued to nonemployees Â Â 55,485 Â Â Â 6 Â Â Â 75,454 Â Â Â - Â Â Â 75,460 Â Stock-based compensation Â Â - Â Â Â - Â Â Â 126,580 Â Â Â Â Â Â Â 126,580 Â Net loss Â Â - Â Â Â - Â Â Â - Â Â Â (4,771,353) Â Â (4,771,353) Â Balance, September 30, 2023 Â Â 19,365,089 Â Â $ 1,937 Â Â $ 77,159,665 Â Â $ (78,214,272) Â $ (1,052,670) Â See accompanying Notes to Condensed Consolidated Financial Statements. Â - 3 - Â Â CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (DEFICIT) FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 and 2023 (Unaudited) Â Â Â Common Stock Â Â Â Â Â Â Â Â Â Â Total Â Â Â Shares Â Â Par Value Â Â Additional Paid-In Capital Â Â Accumulated Deficit Â Â Stockholdersâ€™ Equity Deficit) Â Balance, December 31, 2023 Â Â 28,556,072 Â Â $ 2,856 Â Â $ 88,610,832 Â Â $ (83,856,681) Â $ 4,757,007 Â Merger recapitalization transaction costs Â Â - Â Â Â - Â Â Â (95,911) Â Â - Â Â Â (95,911) Â Adjustment to merger recapitalization liability Â Â - Â Â Â - Â Â Â 214,169 Â Â Â - Â Â Â 214,169 Â Stock issued to nonemployees Â Â 211,983 Â Â Â 21 Â Â Â 287,370 Â Â Â - Â Â Â 287,391 Â Stock-based compensation Â Â - Â Â Â - Â Â Â 521,265 Â Â Â - Â Â Â 521,265 Â Net loss Â Â - Â Â Â - Â Â Â - Â Â Â (19,157,261) Â Â (19,157,261) Â Balance, September 30, 2024 Â Â 28,768,055 Â Â $ 2,877 Â Â $ 89,537,725 Â Â $ (103,013,942) Â $ (13,473,340) Â Balance, December 31, 2022 Â Â 8,481,848 Â Â $ 849 Â Â $ 64,533,074 Â Â $ (63,799,379) Â $ 734,544 Â Sale of common stock and accompanying warrants, net Â Â 9,007,853 Â Â Â 900 Â Â Â 12,145,989 Â Â Â - Â Â Â 12,146,889 Â Exercise of warrants Â Â 1,678,696 Â Â Â 168 Â Â Â - Â Â Â - Â Â Â 168 Â Exercise of stock options Â Â 1,155 Â Â Â - Â Â Â 1,478 Â Â Â - Â Â Â 1,478 Â Stock issued to nonemployees Â Â 195,537 Â Â Â 20 Â Â Â 219,694 Â Â Â - Â Â Â 219,714 Â Stock-based compensation Â Â - Â Â Â - Â Â Â 259,430 Â Â Â - Â Â Â 259,430 Â Net loss Â Â - Â Â Â - Â Â Â - Â Â Â (14,414,893) Â Â (14,414,893) Â Balance, September 30, 2023 Â Â 19,365,089 Â Â $ 1,937 Â Â $ 77,159,665 Â Â $ (78,214,272) Â $ (1,052,670) Â See accompanying Notes to Condensed Consolidated Financial Statements. Â - 4 - Â Â Â CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Â Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â CASH FLOWS FROM OPERATING ACTIVITIES Â Â Â Â Â Â Â Â Net loss Â $ (19,157,261) Â $ (14,414,893) Â Â Â Â Â Â Â Â Â Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Â Â Depreciation and amortization Â Â 6,531 Â Â Â 14,457 Â Loss on disposal of equipment Â Â 11,813 Â Â Â - Â Stock-based compensation Â Â 521,265 Â Â Â 259,430 Â Stock compensation to nonemployees Â Â 287,391 Â Â Â 219,714 Â Loss on change in fair value of convertible promissory note Â Â 2,178,000 Â Â Â - Â Increase or decrease in: Â Â Â Â Â Â Â Â Accounts receivable, net Â Â (65,303) Â Â (248,769) Inventory, net Â Â 18,242 Â Â Â 44,736 Â Prepaid clinical expenses Â Â (1,367,595) Â Â (841,350) Prepaid insurance and services Â Â 65,510 Â Â Â (49,187) Other Â Â - Â Â Â 1,883 Â Accounts payable and accrued expenses Â Â (721,264) Â Â 3,123,835 Â Total adjustments Â Â 934,590 Â Â Â 2,524,749 Â Â Â Â Â Â Â Â Â Â NET CASH USED IN OPERATING ACTIVITIES Â Â (18,222,671) Â Â (11,890,144) Â Â Â Â Â Â Â Â Â CASH FLOWS FROM FINANCING ACTIVITIES Â Â Â Â Â Â Â Â Net proceeds from sale of warrants Â Â - Â Â Â 2,917,581 Â Net proceeds from sale of stock Â Â - Â Â Â 9,229,308 Â Merger transaction costs Â Â (95,911) Â Â - Â Exercise of stock options Â Â - Â Â Â 1,478 Â Exercise of warrants Â Â - Â Â Â 168 Â Net proceeds from issuance of convertible note Â Â 10,000,000 Â Â Â - Â NET CASH PROVIDED BY FINANCING ACTIVITIES Â Â 9,904,089 Â Â Â 12,148,535 Â Â Â Â Â Â Â Â Â Â NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Â Â (8,318,582) Â Â 258,391 Â Â Â Â Â Â Â Â Â Â CASH AND CASH EQUIVALENTS, beginning of period Â Â 9,246,592 Â Â Â 1,543,418 Â Â Â Â Â Â Â Â Â Â CASH AND CASH EQUIVALENTS, end of period Â $ 928,010 Â Â $ 1,801,809 Â Â Â Â Â Â Â Â Â Â SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Â Â Â Â Â Â Â Â Cash paid for interest Â $ 2,318 Â Â $ 9,807 Â Â See accompanying Notes to Condensed Consolidated Financial Statements. Â - 5 - Â CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Â The information presented herein as of SeptemberÂ 30, 2024 and for the three and nine months ended SeptemberÂ 30, 2024 and 2023 is unaudited. Â Â (1) ORGANIZATION AND DESCRIPTION OF BUSINESS: Â Cyclo Therapeutics, Inc. (the â€œCompany,â€ â€œwe,â€ â€œourâ€ or â€œusâ€) was incorporated in August 1990 as a Florida corporation under the name Cyclodextrin Technologies Development, Inc. with operations beginning in July 1992. In conjunction with a restructuring in 2000, we changed our name to CTD Holdings, Inc. We changed our name to Cyclo Therapeutics, Inc. in September 2019 to better reflect our current business and, on November 6, 2020, we reincorporated from the State of Florida to the State of Nevada. Â On December 27, 2023, the Company completed a strategic combination pursuant to that certain Agreement and Plan of Merger, dated as of September 21, 2023, by and among the Company, Cameo Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company ("Merger Subâ€), and Applied Molecular Transport Inc., a Delaware corporation ("AMTIâ€), providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of the Company (the "AMTI Mergerâ€). Â We are a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of neurodegenerative diseases. We filed a Type II Drug Master File with the U.S. Food and Drug Administration (â€œFDAâ€) in 2014 for our lead drug candidate, TrappsolÂ® Cycloâ„¢ (hydroxypropyl beta cyclodextrin) as a treatment for Niemann-Pick Type C disease (â€œNPCâ€). NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. In 2015, we launched an International Clinical Program for TrappsolÂ® Cycloâ„¢ as a treatment for NPC. In 2016, we filed an Investigational New Drug application (â€œINDâ€) with the FDA, which described our Phase I clinical plans for a randomized, double blind, parallel group study at a single clinical site in the U.S. The Phase I study evaluated the safety and pharmacokinetics of TrappsolÂ® Cycloâ„¢ along with markers of cholesterol metabolism and markers of NPC during a 12-week treatment period of intravenous administration of TrappsolÂ® Cycloâ„¢ every two weeks to participants 18 years of age and older. The IND was approved by the FDA in September 2016, and in January 2017 the FDA granted Fast Track designation to TrappsolÂ® Cycloâ„¢ for the treatment of NPC. Initial patient enrollment in the U.S. Phase I study commenced in September 2017, and in May 2020 we announced top line data showing TrappsolÂ® Cycloâ„¢ was well tolerated in this study. Â We have also completed a Phase I/II clinical study approved by European regulatory bodies with clinical trial centers in the United Kingdom, Sweden, and Israel. The Phase I/II study evaluated the safety, tolerability and efficacy of TrappsolÂ® Cycloâ„¢ through a range of clinical outcomes, including neurologic, respiratory, and measurements of cholesterol metabolism and markers of NPC. Consistent with the 12-week Phase I study (single US site), the European/Israel study administered TrappsolÂ® Cycloâ„¢ intravenously to NPC patients every two weeks in a double-blind, randomized trial, but differs in that the study period was for 48 weeks (24 doses). In March of 2021 we announced that 100% of patients who completed the trial (9 out of 12) improved or remained stable, and 89% met the outcome measure in at least two domains of the 17-domain NPC severity scale. We did not conduct a Phase II trial in the U.S. and instead relied on the data obtained from our Phase I/II trial abroad to support the commencement of our Phase III trial in the U.S. Â In February 2020 we had a face-to-face â€œType Câ€ meeting with the FDA with respect to the initiation of our pivotal Phase III clinical trial of TrappsolÂ® Cycloâ„¢ based on the clinical data obtained to date. At that meeting, we also discussed with the FDA submitting a New Drug Application (NDA) under Section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for the treatment of NPC in pediatric and adult patients with TrappsolÂ® Cycloâ„¢. A similar request was submitted to the European Medicines Agency (â€œEMAâ€) in February 2020, seeking scientific advice and protocol assistance from the EMA for proceeding with a Phase III clinical trial in Europe. In October 2020 we received a â€œStudy May Proceedâ€ notification from the FDA with respect to the proposed Phase III clinical trial, and in June of 2021 we commenced enrollment in TransportNPC, a pivotal Phase III study of TrappsolÂ® Cycloâ„¢ for the treatment of NPC. In May 2024, we enrolled the last of the 104 patients enrolled in the Phase III study. Â - 6 - Â CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Â (1) ORGANIZATION AND DESCRIPTION OF BUSINESS: (CONTINUED) Â We are also exploring the use of cyclodextrins in the treatment of Alzheimerâ€™s disease. In January 2018, the FDA authorized a single patient IND expanded access program using TrappsolÂ® Cycloâ„¢ for the treatment of Alzheimerâ€™s disease. Based on the data collected from this patient combined with the data from our NPC studies, we prepared a synopsis for an early-stage protocol using TrappsolÂ® Cycloâ„¢ intravenously to treat Alzheimerâ€™s disease that was presented to the FDA in January of 2021. We received feedback from the FDA on this synopsis in April 2021 and incorporated the feedback into an IND for a Phase II study for the treatment of Alzheimerâ€™s disease with TrappsolÂ® Cycloâ„¢ that we submitted to the FDA in November 2021. In December of 2021, we received IND clearance from the FDA, allowing us to proceed with our Phase II study of TrappsolÂ® Cycloâ„¢ for the treatment of Alzheimerâ€™s disease. U.S. sites for the study were activated during the second half of 2022, with patient dosing beginning in the first quarter of 2023. Â We also continue to operate our legacy fine chemical business, consisting of the sale of cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. However, our core business has transitioned to a biotechnology company primarily focused on the development of cyclodextrin- based biopharmaceuticals for the treatment of disease from a business that had been primarily reselling basic cyclodextrin products. Â Proposed Acquisition by Rafael Holdings Â On August 21, 2024, the Company entered into an Agreement and Plan of Merger (the â€œMerger Agreementâ€) with Rafael Holdings, Inc. (â€œRafaelâ€), a Delaware corporation; and Tandem Therapeutics, Inc., a Nevada corporation and a wholly-owned subsidiary of Rafael (â€œFirst Merger Subâ€); and Tandem Therapeutics, LLC, a Nevada limited liability company and a wholly-owned subsidiary of the Rafael (â€œSecond Merger Subâ€). Pursuant to the terms of the Merger Agreement, the Rafael, First Merger Sub and the Company will be merged with and into Rafael (the â€œFirst Mergerâ€), with the Company surviving the Merger as a wholly-owned subsidiary of Rafael. Immediately following the First Merger, the Company will merge with and into the Second Merger Sub (the â€œSecond Mergerâ€, and together with the First Merger, the â€œMergerâ€) with Rafael being the surviving entity of the Second Merger. The name of the Surviving Entity will be changed to Cyclo Therapeutics, LLC. Â At the closing of the Merger, each outstanding share of Company common stock will be converted into the right to receive a number of shares of Rafael Class B common stock calculated in accordance with the Merger Agreement (the â€œExchange Ratioâ€). The Exchange Ratio was initially estimated to be 0.3112 shares of Rafael Class B common stock for each share of Company common stock. The actual exchange ratio will be determined at the time of closing based on valuing Company common stock at $0.95 per share and Rafael at the combined value of its cash, cash equivalents, marketable securities, real estate and certain other financial holdings plus amounts loaned by Rafael to the Company between the signing of the Merger Agreement and the closing of the Merger, less certain of Rafaelâ€™s current liabilities. In addition, the cash value with take into account the funding of the Companyâ€™s operations by Rafael with convertible notes through closing, as discussed at Note (7). Any fractional shares of Rafael Class B common stock will be rounded up to the nearest whole share. Â All compensatory options to purchase Company common stock will be converted into an option to acquire Rafael Class B common stock, as described in the Merger Agreement. Â Unless otherwise provided for in outstanding warrant agreements, all outstanding warrants to purchase Cyclo common stock (other than those held by Rafael which will be cancelled) will automatically be converted into warrants to purchase a number of shares of Rafael Class B common stock, at an adjusted exercise price per share based upon the Exchange Ratio. Certain holders of Cyclo warrants, representing 5,498,914 Cyclo warrant shares, have the right to elect to receive cash payment in an amount equal to the Black Sholes Value of the unexercised portion of their warrants on the date of consummation of the Merger in lieu of receiving warrants to purchase Rafael Class B common stock. Â Holders of Cyclo Public Warrants will receive Rafael Public Warrants in exchange for their Cyclo Public Warrants. Â

(1) ORGANIZATION AND DESCRIPTION OF BUSINESS: (CONTINUED) Â The Merger Agreement contains specified termination rights of each of the Company and Rafael. In connection with a termination of the Merger Agreement in specified circumstances, the terminating party will be reimbursed for transaction costs of up to $250,000. If the Merger Agreement is terminated by Company due to the Companyâ€™s board of directors making an adverse change recommendation, the Company will be required to pay a $400,000 termination fee to Rafael. Â The boards of directors of each of the Company and Rafael have approved the Merger Agreement and the transactions contemplated thereby, subject to the satisfaction or waiver of customary conditions, including the requisite approval by the Company's and Rafael's stockholders and the effectiveness of a registration statement to register the shares of Rafael Class B common stock to be issued in connection with the transaction. The transaction is expected to close in late December. Â Although the Company has entered into the Merger Agreement and intends to consummate the proposed Merger, there is no assurance that the Company will be able to successfully consummate the proposed Merger on a timely basis, or at all. Â Going Concern and Liquidity Â For the three and nine months ended September 30, 2024, the Company incurred a net loss of $8,832,944 and $19,157,261, respectively. The Company has an accumulated deficit of $103,013,942 at SeptemberÂ 30, 2024. Our recent losses have predominantly resulted from research and development expenses for our TrappsolÂ®Â Cycloâ„¢ product and other general operating expenses, including personnel expenses and board advisory fees. We believe our expenses will continue to increase as we continue to conduct clinical trials and seek regulatory approval for the use of TrappsolÂ®Â Cycloâ„¢ in the treatment of NPC and Alzheimerâ€™s disease. Â For the nine months ended SeptemberÂ 30, 2024, the Companyâ€™s operations used $18,222,671 in cash, and at SeptemberÂ 30, 2024, the Company had a cash and cash equivalents balance of $928,010 and negative working capital of $15,463,491. We will need to raise additional capital in the foreseeable future to fund the development of our drug product candidates through clinical development, manufacturing and commercialization. Â Rafael has agreed to fund the Company through the earlier of the consummation of the Merger or termination of the Merger Agreement in such amounts as may be necessary for the Company to operate its business and pay its debts and obligations as they become due, provided that the Company is not in active discussions regarding an acquisition proposal and is being operated in a manner consistent with the terms of the Merger Agreement and the financial forecast previously shared with Rafael.Â As discussed in Note 7, the Company has borrowed $15,000,000 from Rafael through November 12, 2024. Â We intend to continue to borrow from Rafael through the consummation of the Merger or termination of the Merger Agreement.Â If the Merger Agreement is terminated, we intend to continue to raise such capital through the sale of equity securities from time to time, the issuance of debt securities, the sale or licensing of existing assets or assets in development, or from other non-dilutive funding mechanisms. Our ability to obtain such additional capital will likely be subject to various factors, including our overall business performance and market conditions. If we cannot raise the additional funds required for our anticipated operations, we may be required to reduce the scope of or eliminate our research and development programs, delay our clinical trials and the ability to seek regulatory approvals, downsize our general and administrative infrastructure, and/or seek alternative measures to avoid insolvency. If we raise additional funds through future offerings of shares of our common stock or other securities, such offerings would cause dilution of current stockholdersâ€™ percentage ownership in the Company, which could be substantial. Future offerings also could have a material and adverse effect on the price of our common stock. Â Our condensed consolidated financial statements for the three and nine months ended SeptemberÂ 30, 2024, were prepared on the basis of a going concern, which contemplates that we will be able to realize assets and discharge liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon the availability of equity or debt financing as noted above, including from Rafael. Various factors including our overall business performance and market conditions raise substantial doubt about our ability to continue as a going concern. The condensed and consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. Â

(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Â Â The following is a summary of the more significant accounting policies of the Company that affect the accompanying condensed consolidated financial statements: Â (a) BASIS OF PRESENTATIONâ€“â€“The condensed consolidated financial statements include the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The interim condensed consolidated financial statements of the Company included in this Quarterly Report on Form 10-Q, including these notes, are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Such adjustments are of a normal, recurring nature. The condensed consolidated financial statements, and these notes, have been prepared in accordance with generally accepted accounting principles and do not contain certain information included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023. The condensed consolidated financial statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Â (b) CASH AND CASH EQUIVALENTSâ€“â€“Cash and cash equivalents consist of cash and any highly liquid investments with an original purchased maturity of three months or less. The Company maintains deposits in financial institutions in excess of federally insured limits of $250,000, in the amount of $928,010 at September 30, 2024. Â (c) ACCOUNTS RECEIVABLEâ€“â€“Accounts receivable are unsecured and non-interest bearing and stated at the amount we expect to collect from outstanding balances. Customer account balances with invoices dated over 90 days old are considered past due. The Company does not accrue interest on past due accounts. Customer payments are allocated to the specific invoices identified on the customerâ€™s remittance advice or, if unspecified, applied to the oldest unpaid invoices. Â The carrying amount of accounts receivable is reduced by an allowance for credit losses that reflects managementâ€™s best estimate of expected credit losses. The Company reviews each customer balance where all or a portion of the balance exceeds 90 days from the invoice date. Based on the Companyâ€™s assessment of the customer's current and forecasted creditworthiness, the Company estimates the portion, if any, of the balance that will not be collected, and writes off receivables as a charge to the allowance for credit losses when, in managementâ€™s estimation, it is probable that the receivable is worthless. The Company determined an allowance for credit losses was not necessary as of September 30, 2024. The allowance for credit losses at December 31, 2023 approximated $10,000. Â The Company develops and documents its allowance for credit losses on its trade receivables based on portfolio segments, which include domestic and international customers. The determination of portfolio segments is based primarily on the customersâ€™ geographical location. Our quantitative allowance for credit loss estimates was determined using the method that uses an aging schedule. The Company also considers qualitative adjustments that may relate to unique risks, changes in current economic conditions that may not be reflected in quantitatively derived results, or other relevant factors to further inform our estimate of the allowance for credit losses. Â (d) INVENTORY AND COST OF PRODUCTS SOLDâ€“â€“Inventory consists of cyclodextrin products and chemical complexes purchased for resale recorded at the lower of cost (first-in, first-out) or net realizable value. Cost of products sold includes the acquisition cost of the products sold and does not include any allocation of inbound or outbound freight charges, indirect overhead expenses, warehouse and distribution expenses, or depreciation and amortization expense. The Company records a specific reserve for inventory items that are determined to be obsolete. The Company determined no reserve for obsolete inventory was necessary as of September 30, 2024 and December 31, 2023. Â The Companyâ€™s reserve for obsolete inventory is based on the Companyâ€™s best estimates of product sales and customer demands. It is reasonably possible that the estimates used by the Company to determine its provisions for inventory write-downs will be materially different from actual write-downs. These differences could result in materially higher than expected inventory provisions and related costs, which could have a material adverse effect on the Companyâ€™s results of operations and financial condition in the near term. Â

(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (CONTINUED) Â (e) PREPAID CLINICAL EXPENSESâ€“â€“Prepaid clinical expenses consist of our active pharmaceutical ingredients and other raw materials for our pharmaceutical drug TrappsolÂ® Cycloâ„¢ expected to be used in our clinical trial program recorded at cost. In addition, advance payments for goods or services for future research and development activities are included as prepaid clinical expenses. Prepaid clinical expenses are expensed as research and development costs as the goods are delivered or the related services are performed. Prepaid clinical expenses expected to be utilized beyond one year from the balance sheet date are classified as non-current assets. Â (f) FURNITURE AND

EQUIPMENTâ€“â€“Furniture and equipment are recorded at cost, less accumulated depreciation. Depreciation is computed using primarily the straight-line method over the estimated useful lives of the assets (generally three to five years for computers and vehicles and seven to ten years for machinery, equipment and office furniture). We periodically review our long-lived assets to determine if the carrying value of assets may not be recoverable. If an impairment is identified, we recognize a loss for the difference between the carrying amount and the estimated fair value of the asset.Â Â (g) LEASESâ€“â€“The Company leases office and warehouse space. The Company determines if an arrangement is a lease at inception. Contracts containing a lease are further evaluated for classification as an operating or finance lease where the Company is a lessee, or as an operating, sales-type or direct financing lease where the Company is a lessor, based on their terms. Operating leases are included in right-of-use ("ROU") lease assets and lease liabilities on the Companyâ€™s condensed consolidated balance sheets. The Company subleases office space under one existing lease to a third party. Sublease income is reported as other income in the condensed consolidated statements of operations. Â ROU assets represent the Companyâ€™s right to use an underlying asset for the lease term and lease liabilities represent the Companyâ€™s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Companyâ€™s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The lease ROU asset also includes any lease payments made and excludes lease incentives. The Companyâ€™s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable lease payments are expensed as incurred. The Companyâ€™s lease agreements do not contain any material residual value guarantees or material restrictive covenants. Â In evaluating contracts to determine if they qualify as a lease, the Company considers factors such as if the Company has obtained substantially all of the rights to the underlying asset through exclusivity, if it can direct the use of the asset by making decisions about how and for what purpose the asset will be used and if the lessor has substantive substitution rights. This evaluation may require significant judgment. Â (h) REVENUE RECOGNITIONâ€“â€“Revenues are recognized when our customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under Accounting Standard Update (â€œASUâ€) No. 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. Â Product revenues Â The majority of our revenue is garnered in North America from companies in the pharmaceutical industry that are manufacturing or conducting research with our fine chemical products. In other countries, we sell our products primarily to wholesale distributors and other third-party distribution partners. Â - 10 - Â CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Â (2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (CONTINUED) Â Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. Â We treat shipping and handling costs performed after a customer obtains control of the product as a fulfillment cost. We have identified one performance obligation in our contracts with customers which is the delivery of product to our customers.Â The transaction price is recognized in full when we deliver the product to our customer, which is the point at which we have satisfied our performance obligation. Â For additional information on our revenues, please read Note 3, Revenues, to these condensed consolidated financial statements. Â (i) SHIPPING AND HANDLING FEESâ€“â€“Shipping and handling fees, if billed to customers, are included in product sales. Shipping and handling costs associated with inbound and outbound freight are expensed as incurred and included in freight and shipping expense. Â (j) ADVERTISINGâ€“â€“Advertising costs are charged to operations when incurred. We incur minimal advertising expenses. Â (k) RESEARCH AND DEVELOPMENT COSTSâ€“â€“Research and development costs are expensed as incurred. The Company records amounts paid in advance of the service being rendered as a prepaid asset, and the expense recognized when the service is performed. Research and development costs are primarily comprised of materials used in our clinical trials, personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on our contracts with our vendors and are realized in the ordinary course of business.Â Â (l) INCOME TAXESâ€“â€“Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In addition, tax benefits related to positions considered uncertain are recognized only when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions shall initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts. As of September 30, 2024 and December 31, 2023, the Company has recorded a full valuation allowance against its deferred tax assets. Â (m) NET LOSS PER COMMON SHAREâ€“â€“ Basic and fully diluted net loss per common share is computed using a simple weighted average of common shares outstanding during the periods presented, as outstanding warrants to purchase 15,686,916 shares of common stock were antidilutive for the three and nine months ended SeptemberÂ 30, 2024, and warrants to purchase 13,733,117 shares of common stock were antidilutive for the three and nine months ended September 30, 2023. Additionally, outstanding options to purchase 1,779,161 shares of common stock were antidilutive for the three and nine months ended September 30, 2024 and outstanding options to purchase 790,945 shares of common stock were antidilutive for the three and nine months ended September 30, 2023, and therefore also excluded. Â (n) STOCK-BASED COMPENSATIONâ€“â€“The Company periodically awards stock to employees, directors, and consultants. In the case of employees and consultants, an expense is recognized equal to the fair value of the stock determined using the closing trading price of the stock on the award date. With respect to directors, the Company accrues stock compensation expense on a quarterly basis based on the Companyâ€™s historical director compensation policies, and each quarter recognizes such expense based on the trading price of the common stock during such quarter. Â - 11 - Â CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Â (2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (CONTINUED) Â This expense is then trued up at the time the shares are issued to directors based on the trading price at the time of issuance. Â The Company periodically issues stock options under its 2021 Equity Incentive Plan. The Company uses the Black-Scholes valuation method to estimate the fair value of stock options at grant date. Compensation expense is recognized on the straight-line basis over the requisite service period, which is generally the vesting period. Â (o) FAIR VALUE MEASUREMENTS AND DISCLOSURESâ€“â€“Accounting Standards Codification ("ASCâ€) 820 "Fair Value Measurements and Disclosuresâ€ requires companies to determine fair value based on the price that would be received to sell the asset or paid to transfer the liability to a market participant. ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Â The guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following categories: Â â— Level 1: Quoted market prices in active markets for identical assets or liabilities. Â Â â— Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Â Â â— Level 3: Unobservable inputs that are not corroborated by market data. Â Long-lived assets are measured at fair value on a non-recurring basis and are subject to fair value adjustments when there is evidence of impairment. Â For short-term classes of our financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable, and which are not reported at fair value, the carrying amounts approximate fair value due to their short-term nature.Â Â Â As of September 30, 2024, money market funds and a convertible notes payable were the only financial instruments measured and recorded at fair value on a recurring basis on the Companyâ€™s condensed consolidated balance sheets. Money market funds were recorded within cash and cash equivalents. We classified the convertible notes payable as a Level 3 fair value measurement and used the Black-Scholes model to calculate the fair value as of the date of issuance, and for each reporting period. Key inputs for the simulation are summarized below. The Black-Scholes simulation uses inputs such as the stock price, volatility, the contractual term of the convertible notes payable, risk free interest rates and dividend yields. The following table presents money market funds and the convertible notes payable at their level within the fair value hierarchy for the periods indicated. As of December 31, 2023, money market funds were the only financial instrument measured and recorded at fair value on a recurring basis on the Companyâ€™s condensed consolidated balance sheets. Â - 12 - Â CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Â (2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (CONTINUED) Â Â Fair Value Hierarchy Level Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair Value Â September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â â€‹ Â Â Â Â Â Â Â Â Â Money market funds invested in U.S. government obligations Level 1 Â $ - Â Â Â Â Â Â Â Â Â $ - Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Convertible notes payable (Note 7) Level 3 Â Â 10,000,000 Â Â $ - Â Â $ 2,178,000 Â Â $ 12,178,000 Â Total Â $ 10,000,000 Â Â $ - Â Â $ 2,178,000 Â Â $ 12,178,000 Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â â€‹ Â Â Â Â Â Â Â Â Money market funds invested in U.S. government obligations Level 1 Â $ 4,792,338 Â Â $ - Â Â $ - Â Â $ 4,792,338 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities: Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Convertible notes payable (Note 7) Level 3 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total Â $ 4,792,338 Â Â $ - Â Â $ - Â Â $ 4,792,338 Â Â The range of key inputs for the Black-Scholes simulation for the three and nine months ended September 30, 2024, were as follows: Â Â Â Three months ended Â Â Nine months ended Â Key Inputs Â September 30, 2024 Â Â September 30, 2024 Â Stock Price Â Â $0.68 â€“ $1.26 Â Â Â $0.68 â€“ $1.27 Â Term (years) Â Â 0.09 â€“ 0.33 Â Â Â 0.09 â€“ 0.37 Â Risk-Free interest rate Â Â 4.7 â€“ 5.40 Â Â Â 4.7 â€“ 5.40 Â Volatility Â Â 53% - 110% Â Â Â 53% - 110% Â Dividend yield Â Â Â - Â Â Â Â Â - Â Â Â Convertible Notes Payable Â The following table sets forth a summary of the changes in the fair value of our convertible notes payable categorized within Level 3 of the fair value hierarchy: Â Balance as of December 31, 2023 Â $ - Â Issuance of Convertible Notes Â Â 10,000,000 Â Change in fair value of Notes Â Â 2,178,000 Â Balance as of September 30, 2024 Â $ 12,178,000

Â Â Â (p) USE OF ESTIMATESâ€"â€"The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions, including regarding contingencies, that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Companyâ€™s most significant estimates relate to inventory obsolescence, stock-based compensation, fair value of convertible notes issued, warrant liability valuation, fair value of warrants issued, assumed liabilities, and allowance for credit losses. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates. Â - 13 - Â CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Â (2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (CONTINUED) Â (q) RECENT ACCOUNTING PRONOUNCEMENTSâ€"â€" Â In December 2023, the Financial Accounting Standards Board (FASB) issued ASU 2023-09, "Income Taxes (Topic 740) - Improvements to Income Tax Disclosures." The new guidance is intended to enhance the transparency and decision usefulness of income tax disclosures by requiring disaggregated information about a reporting entity's effective tax rate reconciliation and information on income taxes paid. The amendment is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis, with retrospective application permitted. The Company is in the process of evaluating the impact that the adoption of ASU 2023-09 will have on its condensed consolidated financial statements and related disclosures. Â In November 2023, theÂ FASBÂ issuedÂ ASU 2023-07, â€œSegment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures,â€ which is intended to improve reportable segment disclosure requirements, primarily through additional and more detailed information about a reportable segment's expenses. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with retrospective application required and early adoption permitted. The Company is currently evaluating the effect this new guidance will have on its condensed consolidated financial statements and related disclosures. Â In June 2022, the FASB issued ASU No. 2022-03, â€œFair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictionsâ€ ("ASU 2022-03â€) which clarifies guidance for fair value measurement of an equity security subject to a contractual sale restriction and establishes new disclosure requirements for such equity securities. ASU 2022-03 is effective for fiscal years beginning after DecemberÂ 15, 2023 and for interim periods within those fiscal years, with early adoption permitted. The Company adopted the new guidance as of JanuaryÂ 1, 2024, and it did not have a material impact on its condensed consolidated financial statements. Â (r) WARRANTSâ€"â€"The Company accounts for its warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants considering the authoritative guidance in ASC 480, â€œDistinguishing Liabilities from Equityâ€ (â€œASC 480â€) and ASC 815, â€œDerivatives and Hedgingâ€ (â€œASC 815â€). The assessment considers whether the warrants meet the definition of a liability pursuant to ASC 480 and meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Companyâ€™s own common stock and satisfy additional conditions for equity classification. Warrants that are liability-classified are measured at fair value at each reporting date in accordance with the guidance in ASC 820, â€œFair Value Measurement,â€ with any subsequent changes in fair value recognized in the statement of operations in the period of change. The fair value of liability classified warrants was not material at SeptemberÂ 30, 2024 and December 31, 2023. Â Â (3) REVENUES: Â The Company operates in one business segment, which primarily focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life-threatening rare diseases and medical conditions. However, substantially all of the Companyâ€™s revenues are derived from the sale of cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. Â Revenues by product are summarized as follows: Â Â Â Â Three Months Ended September 30 Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â TrappsolÂ® HPB Â $ 36,727 Â Â $ 342,184 Â Â $ 256,331 Â Â $ 485,412 Â TrappsolÂ® Fine Chemical Â Â 196,146 Â Â Â 152,135 Â Â Â 300,085 Â Â Â 267,338 Â AquaplexÂ® Â Â 94 Â Â Â 60 Â Â Â 658 Â Â Â 9,922 Â Other Â Â 805 Â Â Â 1,098 Â Â Â 2,252 Â Â Â 2,334 Â Total revenues Â $ 233,772 Â Â $ 495,477 Â Â $ 559,326 Â Â $ 765,006 Â Â Â - 14 - Â CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Â Â (4) MAJOR CUSTOMERS AND SUPPLIERS: Â For the three months ended SeptemberÂ 30, 2024, three major customers accounted for 91% of total revenues. For the nine months ended September 30, 2024, four major customers accounted for 90% of total revenues. Accounts receivable for these major customers represent 71% of total accounts receivable at SeptemberÂ 30, 2024. Accounts receivable balances for four customers accounted for 92% of total accounts receivable at SeptemberÂ 30, 2024. Â For the three months ended SeptemberÂ 30, 2023, two major customers accounted for 90% of total revenues. For the nine months ended September 30, 2023, three major customers accounting for 86% of total revenues. Accounts receivable for these major customers represent 76% of total accounts receivable at SeptemberÂ 30, 2023. Accounts receivable balances for three customers accounted for 97% of total accounts receivable at SeptemberÂ 30, 2023. Â The Company purchases inventory primarily from four vendors; however, the Company believes it can maintain purchases at similar levels through other readily available vendors in the marketplace. The Company maintains vendors both domestically and internationally. Â For the nine months ended September 30, 2024 and 2023, the product mix of our revenues consisted of 99% basic natural and chemically modified cyclodextrins and 1% cyclodextrin complexes. For the three months ended September 30, 2024 and 2023, the product mix of our revenues consisted entirely of basic natural and chemically modified cyclodextrins. Â Â (5) CONCENTRATIONS OF CREDIT RISK: Â Significant concentrations of credit risk for all financial instruments owned by the Company are as follows: Â The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash equivalents represent highly liquid investments with maturities of 90 days or less at the date of purchase. Credit risk related to cash and cash equivalents is based on the creditworthiness of the financial institutions at which these funds are held. The Company has cash balances at financial institutions which throughout the year may exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows. To reduce its risk associated with the failure of such financial institutions, the Company evaluates the rating of the financial institutions in which it holds deposits. Any material loss that the Company may experience in the future could have an adverse effect on its ability to pay its operational expenses or make other payments and may require the Company to move its cash to other high quality financial institutions. Currently, the Company is reviewing its bank relationships in order to mitigate its risk to ensure that its exposure is limited or reduced to the Federal Deposit Insurance Corporation protection limits. Â The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable. Â The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements. Â - 15 - Â CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Â Â (6) ACCOUNTS PAYABLE AND ACCRUED EXPENSES: Â Accounts payable and accrued expenses consistÂ of the following:Â Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Accounts payable Â $ 5,023,095 Â Â $ 4,856,530 Â Accrued bonus compensation Â Â 615,893 Â Â Â 1,590,776 Â Accrued board expense Â Â 115,856 Â Â Â 92,110 Â Accrued clinical research Â Â 520,382 Â Â Â 137,642 Â Sub-lease deposit liability Â Â 51,897 Â Â Â 243,742 Â Merger liabilities Â Â 96,838 Â Â Â 487,402 Â Other Â Â 98,022 Â Â Â 49,214 Â Total accounts payable and accrued expenses Â $ 6,521,983 Â Â $ 7,457,416 Â Â Â (7) CONVERTIBLE NOTES PAYABLE: On June 11, 2024, the Company entered into a Note Purchase Agreement (the "Initial NPAâ€) with Rafael Holdings, Inc., a Delaware corporation ("Rafaelâ€), the holder of approximately 31.5% of our common stock, pursuant to which the Company issued and sold a convertible promissory note in the principal amount of $2,000,000 (the "June Noteâ€) to Rafael. Â On July 16, 2024, the Company entered into an Amended and Restated Note Purchase Agreement (the "Amended NPAâ€) with Rafael, which amended and restated the Initial NPA in its entirety, pursuant to which the Company issued and sold a second convertible promissory note in the principal amount of $2,000,000 (the "July Noteâ€) to Rafael. Â On August 21, 2024, the Company entered into a Second Amended and Restated Note Purchase Agreement (the "Second Amended NPAâ€) with Rafael, which amended and restated the Amended NPA dated July 16, 2024 in its entirety, pursuant to which the Company issued and sold a third convertible promissory note in the principal amount of $3,000,000 (the "August Noteâ€) to Rafael. Â On September 9, 2024, the Company entered into a Third Amended and Restated Note Purchase Agreement (the "Third Amended NPAâ€) with Rafael, which amended and restated the Second Amended NPA dated August 21, 2024 in its entirety, pursuant to which the Company issued and sold a fourth convertible promissory note in the principal amount of $3,000,000 (the "September Noteâ€) to Rafael. Â On October 8, 2024, the Company and Rafael entered into an Amendment to Convertible Promissory Notes, which amended the maturity date for each of the June Note, July Note, August Note and September Note to December 21, 2024. Â On October 8, 2024, the Company entered into a Fourth Amended and Restated Note Purchase Agreement (the "Fourth Amended NPAâ€) with Rafael, which amended and restated the Third Amended NPA dated September 9, 2024 in its entirety, pursuant to which the Company issued and sold a fifth convertible promissory note in the principal amount of $3,000,000 (the "October Noteâ€) to Rafael. Â On November 7, 2024, the Company entered into a Fifth Amended and Restated Note Purchase Agreement (the "Fifth Amended NPAâ€) with Rafael, which amended and restated the Fourth Amended NPA dated October 8, 2024 in its entirety, pursuant to which the Company issued and sold a sixth convertible promissory note in the principal amount of $2,000,000 (the "November Note,â€ and together with the June Note, July Note, August Note, September Note and October Note, the "Notes,â€ and each a "Noteâ€) to Rafael. Each Note matures on December 21, 2024 and bears interest at a rate of 5% per annum, payable upon maturity. Â - 16 - Â CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Â (7) CONVERTIBLE NOTES PAYABLE: (CONTINUED) Â Each Note may be prepaid by the Company in full at any time. The principal amount of each Note is convertible into shares of our common stock, prior to the repayment of such Note, at the option of Rafael; automatically if the Company enters into a Qualified Financing (as defined) and at the option of Rafael if a Sale Transaction (as defined) occurs prior to repayment of such Note, all at the price and on the terms and conditions set forth in such Note; provided, however, that Rafael may not elect to convert a Note if, following such conversion, Rafael will beneficially own more than 49.9% of the outstanding common stock of the Company. Upon the occurrence of an Event of Default (as defined) under any Note, including the failure of the Company to pay the principal or interest under any Note, when due, the obligations of the Company under each Note may be accelerated. The Company has used and intends to use the proceeds of the Notes for working capital and general corporate purposes. Â Due to these embedded features within the Notes, the Company elected to account for the Notes and the embedded features at fair value at inception. Subsequent changes in fair value are recorded as a component of other income (loss) in the condensed consolidated statements of operations. Â Interest expense on the Notes totaled

$129,452 and $163,973 for the three and nine months ended September 30, 2024 and is included in the fair value of the Notes. Â The following table presents the Notes as of September 30, 2024: Â Balance as of December 31, 2023 Â $ - Â Issuance of convertible Notes Â Â 10,000,000 Â Change in fair value of Notes Â Â 2,178,000 Â Balance as of September 30, 2024 Â $ 12,178,000 Â Â Â (8) LEASES: Â The Company entered into an operating lease in January 2023 for office and warehouse space, which has a lease term expiring in January 2026, with an option to extend for an additional three years. As it is not reasonably certain the Company will exercise the option to extend, the additional three years have not been included in the lease term. This lease replaced an existing operating lease which expired in January 2023. The Company also assumed an operating lease for office space which is being subleased to a third party. The lease and sublease agreement expired in August 2024. Â Right-of-use lease assets are recorded net of accumulated amortization of $880,084 and $17,242 as of SeptemberÂ 30, 2024 and December 31, 2023, respectively. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Lease expense for the three and nine months ended September 30, 2024 was $363,185 and $1,437,196, respectively. Lease expense for the three and nine months ended September 30, 2023 was $7,612 and $22,759, respectively. Â - 17 - Â CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Â Â (9) EQUITY TRANSACTIONS: Â The Company accrues stock compensation expense over the period earned for employees and board members. Stock compensation expense for board members is included in â€œBoard of Directors fees and costsâ€ on our condensed consolidated statement of operations, and stock compensation expense for officers and employees that are not board members is included in â€œPersonnelâ€ and â€œResearch and developmentâ€ on our condensed consolidated statement of operations. Â In the three and nine months ended September 30, 2024, the Company recognized compensation expense of approximately $104,500 and $311,137 to board members, in addition to $92,000 of accrued stock compensation as of December 31, 2023 and issued 72,027 and 211,983 shares of common stock to board members in the three and nine months ended September 30, 2024. In the three and nine months ended September 30, 2023, the Company recognized compensation expense to board members of $75,460Â and $185,635, in addition to $30,750 of accrued stock compensation as of December 31, 2022, and issued 55,485 and 195,537 shares of common stock to board members in the three and nine months ended September 30, 2023. The Company did not issue any shares to employees during the three and nine months ended SeptemberÂ 30, 2024 and 2023. Â Â (10) INCOME TAXES: Â The Company reported a net loss for the three and nine months ended SeptemberÂ 30, 2024 and 2023. The Company increased its deferred tax asset valuation allowance rather than recognize an income tax benefit. Â Â (11) EQUITY INCENTIVE PLAN: Â On August 29, 2019, the Companyâ€™s stockholders approved the Companyâ€™s 2019 Omnibus Equity Incentive Plan at a special meeting of stockholders (the â€œIncentive Planâ€). The Incentive Plan provides for the issuance of up to 68,437 shares of common stock pursuant to the grant of shares of common stock, stock options or other awards, to employees, officers or directors of, and consultants to, the Company and its subsidiaries. Options granted under the Incentive Plan may either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986, or may be non-qualified options, and are exercisable over periods not exceeding ten years from date of grant. As of SeptemberÂ 30, 2024, we had awarded 68,437 shares of common stock as awards under the Incentive Plan, with no shares of common stock remaining available for future awards under the Incentive Plan. Â On June 24, 2021, the Companyâ€™s stockholders approved the Companyâ€™s 2021 Equity Incentive Plan at its annual meeting of stockholders (the â€œ2021 Planâ€). The 2021 Plan provides for the issuance of up to 3,000,000 shares of common stock pursuant to the grant of shares of common stock, stock options or other awards, to employees, officers or directors of, and consultants to, the Company and its subsidiaries. Options granted under the 2021 Plan may either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended, or may be non-qualified options, and are exercisable over periods not exceeding ten years from date of grant. As of SeptemberÂ 30, 2024, we had awarded 608,820 shares of common stock and granted options to purchase 1,671,441 shares of common stock under the 2021 Plan, with 719,739 shares of common stock remaining available for future awards. During the three months ended September 30, 2024, no options to purchase common stock were granted and during the nine months ended September 30, 2024, the Company granted options to purchase 879,341 shares of common stock under the 2021 Plan. The options granted during the nine months ended September 30, 2024 were valued using the Black Scholes option pricing model using the following assumptions: (i) expected term of 3.00 to 6.25 years; (ii) risk free interest rate of 4.41%; (iii) expected volatility of 102.97% to 111.25%; and (iv) dividend yield of 0.0%. The weighted-average grant date fair value of the options issued by the Company during the nine months ended September 30, 2024 ranged from $0.83 to $1.06 per share. Â - 18 - Â CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Â Â (12) NET LOSS PER SHARE: Â The following table sets forth the computation of basic and diluted earnings per common share. Â Â Â Three Months Ended Â Â Nine Months Ended Â Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Numerator Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (8,832,944) Â $ (4,771,353) Â $ (19,157,261) Â $ (14,414,893) Denominator Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average common shares outstanding, basic and diluted Â Â 28,729,641 Â Â Â 16,191,723 Â Â Â 28,674,910 Â Â Â 14,394,920 Â Net loss per share, basic and diluted Â $ (0.31) Â $ (0.29) Â $ (0.67) Â $ (1.00) Â Â Â The Company reported a net loss for the three and nine months ended September 30, 2024 and 2023, therefore, the basic and diluted net loss per share are the same in the respective periods because the inclusion of potential common shares would have an anti-dilutive effect. Potential shares of common stock that are excluded from the computation of diluted weighted-average shares outstanding are as follows: Â Â Â Three Months Ended Â Â Nine Months Ended Â Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock options Â Â 1,779,161 Â Â Â 790,945 Â Â Â 1,779,161 Â Â Â 790,945 Â Warrants Â Â 15,686,916 Â Â Â 13,733,117 Â Â Â 15,686,916 Â Â Â 13,733,117 Â Â Â Â (13) PURCHASE COMMITMENTS: Â In connection with an agreement executed in January 2022 with Ashland, Inc., the Company committed to purchase the minimum amounts of goods used in its normal operations based on completion of certain milestones. The first milestone was met during the first quarter of 2023, and $980,000 of goods were purchased and received. In the second quarter of 2023, the Company was invoiced for the second milestone, and began to receive product during the first quarter of 2024. Milestone three was achieved in the third quarter of 2024 and final payment was made. No future minimum purchases remain as of September 30, 2024. Â - 19 - Â CYCLO THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Â Â (14) SUBSEQUENT EVENTS: Â Nasdaq Delisting Notice Â On October 4, 2024, the Company received two letters from The Nasdaq Stock Market ("Nasdaqâ€) stating that the Company was not in compliance with the following four Nasdaq Listing Rules: (1) failing to maintain a closing bid price of no less than $1.00 per share for 30 consecutive trading days, (2) stockholdersâ€™ equity of the Company was below the minimum requirement of $2.5 million, (3) failing to maintain a minimum Market Value of Listed Securities of $35 million, and (4) failing to maintain net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years. Â Pursuant to the Nasdaq Listing Rules, the Company has 180 calendar days from October 4, 2024 (until April 2, 2025) to regain compliance with the Nasdaq Listing Rules. In the event the Company does not regain compliance with item (1) above prior to the expiration of the compliance period, the Company may be granted an additional 180 calendar days to regain compliance, subject to certain conditions. In the event the Company does not regain compliance with item (2) above prior to the expiration of the compliance period, the Company will receive written notification from Nasdaq that its securities are subject to delisting. Â Convertible Promissory Notes Â On October 8, 2024, the Company entered into the Fourth Amended NPA with Rafael, pursuant to which the Company issued and sold a convertible promissory note in the principal amount of $3,000,000 to Rafael. On November 7, 2024, the Company entered into the Fifth Amended NPA with Rafael, pursuant to which the Company issued and sold a convertible promissory note in the principal amount of $2,000,000 to Rafael. For additional information on these convertible promissory notes, please read Note 7, Convertible Notes Payable, to these condensed consolidated financial statements. Â - 20 - Â Â Â Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. Â The following discussion and analysis provides information to explain our results of operations and financial condition.Â Â You should also read our unaudited condensed consolidated financial statements and their notes included in this Form 10-Q, and our audited consolidated financial statements and their notes and other information included in our Annual Report on Form 10-K for the year ended December 31, 2023.Â Â This report may contain forward-looking statements. Forward-looking statements within this Form 10-Q are identified by words such as â€œbelieves,â€ â€œanticipates,â€ â€œexpects,â€ â€œintends,â€ â€œmay,â€ â€œwill,â€ â€œplansâ€ and other similar expressions; however, these words are not the exclusive means of identifying such statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.Â Â These forward-looking statements are subject to significant risks, uncertainties and other factors, which may cause actual results to differ materially from those expressed in, or implied by, these forward-looking statements.Â Â Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements to reflect events, circumstances or developments occurring subsequent to the filing of this Form 10-Q with the U.S. Securities and Exchange Commission (the â€œSECâ€) or for any other reason and you should not place undue reliance on these forward-looking statements.Â Â You should carefully review and consider the various disclosures the Company makes in this report and our other reports filed with the SEC that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business. Â Overview Â We are a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of neurodegenerative diseases. We filed a Type II Drug Master File with the U.S. Food and Drug Administration (â€œFDAâ€) in 2014 for our lead drug candidate, TrappsolÂ® Cycloâ„¢ (hydroxypropyl beta cyclodextrin) as a treatment for Niemann-Pick Type C disease (â€œNPCâ€). NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. In 2015, we launched an International Clinical Program for TrappsolÂ® Cycloâ„¢ as a treatment for NPC. In 2016, we filed an Investigational New Drug application (â€œINDâ€) with the FDA, which described our Phase I clinical plans for a randomized, double blind, parallel group study at a single clinical site in the U.S. The Phase I study evaluated the safety and pharmacokinetics of TrappsolÂ® Cycloâ„¢ along with markers of cholesterol metabolism and markers of NPC during a 12-week treatment period of intravenous administration of TrappsolÂ® Cycloâ„¢ every two weeks to participants 18 years of age and older. The IND was approved by the FDA in September 2016, and in January 2017 the FDA granted Fast Track designation to TrappsolÂ® Cycloâ„¢ for the treatment of NPC. Initial patient enrollment in the U.S. Phase I study commenced in September 2017, and in May 2020 we announced top line data showing TrappsolÂ® Cycloâ„¢ was well tolerated in this study. Â We have also completed a Phase I/II clinical study approved by European regulatory bodies with clinical trial centers in the United Kingdom, Sweden, and Israel. The Phase I/II study evaluated the safety, tolerability and efficacy of TrappsolÂ® Cycloâ„¢ through a range of clinical outcomes, including neurologic, respiratory, and measurements of cholesterol metabolism and markers of NPC. Consistent with the 12-week Phase Â study (single US site), the European/Israel study administered TrappsolÂ® Cycloâ„¢ intravenously to NPC patients every two weeks in a double-blind, randomized trial, but differs in that the study period was for 48 weeks (24 doses). In March of 2021 we announced that 100% of patients who completed the trial (9 out of 12) improved or remained stable, and 89% met the outcome measure in at least two domains of the 17-domain NPC severity scale. We did not conduct a Phase II trial in the U.S. and instead relied on the data obtained from our Phase I/II trial abroad to support the commencement of our Phase III trial in the U.S. Â In February 2020 we had a face-to-face â€œType Câ€ meeting with the FDA with respect to the initiation of our pivotal Phase III clinical trial of TrappsolÂ® Cycloâ„¢ based on the clinical data obtained to date. At that meeting, we also discussed with the FDA submitting a New Drug Application (NDA) under Section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for the treatment of NPC in pediatric and adult patients with TrappsolÂ® Cycloâ„¢. A similar request was submitted to the European Medicines Agency (â€œEMAâ€) in February 2020, seeking scientific advice and protocol assistance from the EMA for proceeding with a Phase III clinical trial in Europe. In October 2020 we received a â€œStudy May Proceedâ€ notification from the FDA with respect to the proposed Phase III clinical trial, and in June of 2021 we commenced enrollment in TransportNPC, a pivotal Phase III study of TrappsolÂ® Cycloâ„¢ for the treatment of NPC. In May 2024, we enrolled the last of the 104 patients enrolled in the Phase III study. Â - 21 - Â Â On May 17, 2010, the FDA designated TrappsolÂ® Cycloâ„¢ as an orphan drug for the treatment of NPC, which would provide us with the exclusive right to sell TrappsolÂ® Cycloâ„¢ for the treatment of NPC for seven years following FDA drug approval. In April 2015, we also obtained Orphan Drug Designation for TrappsolÂ® Cycloâ„¢ in Europe, which will provide us with ten years of market exclusivity following regulatory approval, which period will be extended to 12 years upon acceptance by the EMAâ€™s Pediatric Committee of our pediatric investigation plan (PIP) demonstrating that TrappsolÂ® Cycloâ„¢ addresses the pediatric population. On January 12, 2017, we received Fast Track Designation from the FDA, and on December 1, 2017, the FDA designated NPC a Rare Pediatric Disease. Â We are also exploring the use of cyclodextrins in the treatment of Alzheimerâ€™s disease. In January 2018, the FDA authorized a single patient IND expanded access program using TrappsolÂ® Cycloâ„¢ for the treatment of Alzheimerâ€™s disease. Based on the data collected from this patient combined with the data from our NPC studies, we prepared a synopsis for an early stage protocol using TrappsolÂ® Cycloâ„¢ intravenously to treat Alzheimerâ€™s disease that was presented to the FDA in January of 2021. We received feedback from the FDA on this synopsis in April 2021 and incorporated the feedback into an IND for a Phase II study for the treatment of Alzheimerâ€™s disease with TrappsolÂ® Cycloâ„¢ that we submitted to the FDA in November 2021. In December of 2021, we received IND clearance from the FDA, allowing us to proceed with our Phase II study of TrappsolÂ® Cycloâ„¢ for the treatment of Alzheimerâ€™s disease. U.S. sites for the study were activated during the second half of 2022, with patient dosing beginning in the first quarter of 2023. Â We filed an international patent application in October 2019 under the Patent Cooperation Treaty directed to the treatment of Alzheimerâ€™s disease with cyclodextrins, and we are pursuing national and regional stage applications based on this international application. The terms of any patents resulting from these national or regional stage applications would be expected to expire in 2039 if all the requisite maintenance fees are paid. Â On January 2024, we received a notice of allowance of our patent application for the treatment of Alzheimerâ€™s disease from the U.S. Patent and Trademark Office ("USPTOâ€) regarding our Patent Application No. 17/289,137 "Methods of Treating Alzheimerâ€™s Disease.â€ In July 2024 we received a notice of decision from the European Patent Office to grant a patent application regarding the methods to treat Alzheimerâ€™s Disease, with an effective date of August 21, 2024. Â We also continue to operate our legacy fine chemical business, consisting of the sale of cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. However, our core business has transitioned to a biotechnology company primarily focused on the development of cyclodextrin- based biopharmaceuticals for the treatment of disease from a business that had been primarily reselling basic cyclodextrin products. Â Proposed Acquisition by Rafael Holdings Â On August 21, 2024, the Company entered into an Agreement and Plan of Merger (the â€œMerger Agreementâ€) with Rafael Holdings, Inc. (â€œRafaelâ€), a Delaware corporation; and Tandem Therapeutics, Inc., a Nevada corporation and a wholly-owned subsidiary of the Rafael (â€œFirst Merger Subâ€); and Tandem Therapeutics, LLC, a Nevada limited liability company and a wholly-owned subsidiary of the Rafael (â€œSecond Merger Subâ€). Pursuant to the terms of the Merger Agreement, the Rafael, First Merger Sub and the Company will be merged with and into Rafael (the â€œFirst Mergerâ€), with Company surviving the Merger as a wholly-owned subsidiary of Rafael. Immediately following the First Merger, the Company will merge with and into the Second Merger Sub (the â€œSecond Mergerâ€, and together with the First Merger, the â€œMergerâ€) with Rafael being the surviving entity of the Second Merger. The name of the Surviving Entity will be changed to Cyclo Therapeutics, LLC. More information regarding the proposed acquisition and the terms of the Merger Agreement are discussed in Note 1 â€“ Organization and Description of Business of the notes to the Condensed Consolidated Financial Statements contained elsewhere in this Quarterly Report on Form 10-Q. Â Subsequent events Â Nasdaq Delisting Notice Â On October 4, 2024, the Company received two letters from The Nasdaq Stock Market ("Nasdaqâ€) stating that the Company was not in compliance with the following four Nasdaq Listing Rules: (1) failing to maintain a closing bid price of no less than $1.00 per share for 30 consecutive trading days, (2) stockholdersâ€™ equity of the Company was below the minimum requirement of $2.5 million, (3) failing to maintain a minimum Market Value of Listed Securities of $35 million, and (4) failing to maintain net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years. Â - 22 - Â Â Pursuant to the Nasdaq Listing Rules, the Company has 180 calendar days from October 4, 2024 (until April 2, 2025) to regain compliance with the Nasdaq Listing Rules. In the event the Company does not regain compliance with item (1) above prior to the expiration of the compliance period, the Company may be granted an additional 180 calendar days to regain compliance, subject to certain conditions. In the event the Company does not regain compliance with item (2) above prior to the expiration of the compliance period, the Company will receive written notification from Nasdaq that its securities are subject to delisting. Â Convertible Promissory Notes Â On October 8, 2024, the Company entered into the Fourth Amended NPA with Rafael, pursuant to which the Company issued and sold a convertible promissory note in the principal amount of $3,000,000 to Rafael. On November 7, 2024, the Company entered into the Fifth Amended NPA with Rafael, pursuant to which the Company issued and sold a convertible promissory note in the principal amount of $2,000,000 to Rafael. For additional information on these convertible promissory notes, please read Note 7, Convertible Notes Payable, to these condensed consolidated financial statements. Â Results of Operations â€“ Three and Nine Months Ended SeptemberÂ 30, 2024 Compared to Three and Nine Months Ended September 30, 2023 Â We reported net losses of approximately $8,832,000 and $19,157,000 for the three and nine months ended SeptemberÂ 30, 2024, compared to net losses of approximately $4,771,000 and $14,415,000 for the three and nine months ended SeptemberÂ 30, 2023. Â Total revenues for the three month period ended SeptemberÂ 30, 2024, decreased 53% to approximately $234,000 compared to approximately $495,000 for the same period in 2023. Total revenues for the nine month period ended SeptemberÂ 30, 2024, decreased 27% to approximately $559,000 compared to approximately $765,000 for the same period in 2023. Our change in the mix of our product sales for the three and nine months ended SeptemberÂ 30, 2024 and 2023 is as follows: Â TrappsolÂ® HPB Our sales of TrappsolÂ® HPB decreased by 89% for the three month period ended SeptemberÂ 30, 2024, to approximately $37,000 compared to approximately $342,000 for the three months ended SeptemberÂ 30, 2023. Our sales of TrappsolÂ® HPB decreased by 47% for the nine month period ended SeptemberÂ 30, 2024, to approximately $256,000 compared to approximately $485,000 for the nine months ended SeptemberÂ 30, 2023. Sales of cyclodextrin are very volatile and hard to predict. The decrease was caused by a reclassification of revenue derived from compassionate sales of TrappsolÂ® Cycloâ„¢ Â Other TrappsolÂ® products Our sales of other TrappsolÂ® products increased by 29% for the three month period ended SeptemberÂ 30, 2024, to approximately $196,000 compared to approximately $152,000 for the three months ended SeptemberÂ 30, 2023. Our sales of other TrappsolÂ® products increased by 12% for the nine month period ended SeptemberÂ 30, 2024, to approximately $300,000, compared to approximately $267,000 for the nine months ended SeptemberÂ 30, 2023. Â AquaplexÂ® Our sales of AquaplexÂ® for the three month period ended SeptemberÂ 30, 2024, were approximately $100, as compared to sales of AquaplexÂ® for the three months ended SeptemberÂ 30, 2023 of approximately $60. Our sales of AquaplexÂ® for the nine month period ended SeptemberÂ 30, 2024, were approximately $660, as compared to sales of AquaplexÂ® for the nine months ended SeptemberÂ 30, 2023 of approximately $10,000. Â - 23 - Â Â The largest customers for our legacy fine chemical business continue to follow historical product ordering trends by placing periodic large orders that represent a significant share of our annual sales volume. During the nine months ended SeptemberÂ 30, 2024, our four largest customers accounted for 90% of our sales; the largest accounted for 35% of sales. During the nine months ended SeptemberÂ 30, 2023, our three largest customers accounted for 86% of our sales; the largest accounted for 42% of sales. Historically, our usual smaller sales of HPB occur more frequently throughout the year compared to our large sales that we receive periodically. The timing of when we receive and are able to complete these two kinds of sales has a significant effect on our quarterly revenues and operating results and makes period to period comparisons difficult. Â Our cost of products sold (excluding any allocation of direct and indirect overhead and handling costs) for the three month period ended SeptemberÂ 30, 2024, decreased 56% to approximately $17,000 compared to approximately $39,000 for the same period in 2023. Our cost of products sold (excluding any allocation of direct and indirect overhead and handling costs) for the nine month period ended SeptemberÂ 30, 2024, decreased 39% to approximately $42,000 compared to approximately $69,000 for the same period in 2023. Our cost of products sold (excluding any allocation of direct and indirect overhead and handling costs) as a percentage of sales was 8% for the nine months ended SeptemberÂ 30, 2024, and 9% for the nine months ended September 30, 2023.Â Historically, the timing and product mix of sales to our large customers has had a significant effect on our sales, cost of products sold (excluding any allocation of direct and indirect overhead and handling costs) and the related margin. We did not experience any significant increases in material costs during 2023 or the first nine months of 2024. Â Our gross margins may not be comparable to those of other entities, since some entities include all the costs related to their distribution network in cost of goods sold. Our cost of goods sold includes only the cost of products sold and does not include any allocation of inbound or outbound freight charges, indirect overhead expenses, warehouse and distribution expenses, or depreciation expense. Our employees provide receiving, inspection, warehousing and shipping operations for us. The cost of our employees is included in personnel expense. Our other costs of warehousing and shipping functions are included in office and other expense. Â As we buy inventory from foreign suppliers, the change in the value of the U.S. dollar in relation to the Euro, Yen and Yuan has an effect on our cost of inventory. Our main supplier of specialty cyclodextrins and complexes, Cyclodextrin Research & Development Laboratory, is located in Hungary and its prices are set in Euros. The cost of our bulk inventory often changes due to fluctuations in the U.S. dollar. The cost of shipping from outside the U.S. also has a significant effect on our inventory acquisition costs. When we experience short-term increases in currency fluctuation or supplier price increases, we are often not able to raise our prices sufficiently to maintain our historical margins.Â Â Therefore, our margins on these sales may decline.Â Â Personnel expenses increased by 1%, to approximately $843,000 for the three months ended SeptemberÂ 30, 2024, compared to approximately $835,000 for the three months ended September 30, 2023. Personnel expenses increased by 2%, to approximately $2,581,000 for the nine months ended SeptemberÂ 30, 2024 compared to approximately $2,527,000 for the nine months ended September 30, 2023. The increase in personnel expenses is primarily due to an increase in stock compensation expense. We expect to maintain our level of employees and related costs in the near term. Â Research and development expenses increased 58% to approximately $5,493,000 for the three months ended SeptemberÂ 30, 2024, compared to approximately $3,469,000 for the three months ended September 30, 2023. Research and development expenses increased 18% to approximately $11,830,000 for the nine months ended SeptemberÂ 30, 2024, compared to approximately $10,037,000 for the nine months ended September 30, 2023. Research and development expenses as a percentage of our total operating expenses decreased to 60% for the nine months ended SeptemberÂ 30, 2024 from 66% for the nine months ended September 30, 2023. The overall increase in research and development expense resulted in the spending related to the NPC program, while the decrease was related to an increase in operating expenses. Â Professional fees increased 137% to approximately $1,412,000 for the three months ended SeptemberÂ 30, 2024, compared to approximately $597,000 for the three months ended September 30, 2023. Professional fees increased 63% to approximately $2,430,000 for the nine months ended SeptemberÂ 30, 2024, compared to approximately $1,494,000 for the nine months ended September 30, 2023. Professional fees may continue to increase in the future due to Merger expenses and the continuation of product development. Â Office and other expenses increased 190% to approximately $641,000 for the three months ended SeptemberÂ 30, 2024, compared to approximately $221,000 for the three months ended September 30, 2023. Office and other expenses increased 204% to approximately $2,361,000 for the nine months ended SeptemberÂ 30, 2024, compared to approximately $776,000 for the nine months ended September 30, 2023. The increase is attributable to lease expense for a lease assumed in December 2023. The lease expense is offset by sublease income. Â Â Â We increased our valuation allowance to offset the increase in our deferred tax asset from our net operating loss and did not recognize an income benefit or provision for the three or nine months ended SeptemberÂ 30, 2024, and 2023, respectively. Â Liquidity and Capital Resources Â Our cash and cash equivalents decreased to approximately $928,000 as of SeptemberÂ 30, 2024, compared to approximately $9,247,000 as of DecemberÂ 31, 2023. We had negative working capital of approximately $15,463,491 as of SeptemberÂ 30, 2024, compared to positive working capital of approximately $3,850,000 at December 31, 2023. Cash used in operations was approximately $18,223,000 for the nine months ended SeptemberÂ 30, 2024, compared to approximately $11,890,000 for the same period in 2023. Â The Company has continued to realize losses from operations. As a result of our recent note financings with Rafael, we have had sufficient cash to meet our ongoing operating costs and capital expenditure requirements. Rafael has agreed to fund the Company through the earlier of the consummation of the Merger or termination of the Merger Agreement in such amounts as may be necessary for the Company to operate its business and pay its debts and obligations as they become due, provided that the Company is not in active discussions regarding an acquisition proposal and is being operated in a manner consistent with the terms of the Merger Agreement and the financial forecast previously shared with Rafael.Â As discussed in Note 7, the Company has borrowed $15,000,000 from Rafael through November 12, 2024. Â We intend to continue to borrow from Rafael through the consummation of the Merger or termination of the Merger Agreement.Â If the Merger Agreement is terminated, we will need to raise additional capital through the sale of our securities or the entering into of alternative transactions in order to support our ongoing operations and continue our clinical trials. These activities are necessary to fund the development of our drug product candidates through clinical development, manufacturing and commercialization. Our ability to obtain such additional capital will likely be subject to various factors, including our overall business performance, market conditions and our ability to identify strategic partners. There can be no guarantee that the Company will be successful in its ability to raise capital to fund future operational and development initiatives. Â Our condensed consolidated financial statements as of and for the nine months ended SeptemberÂ 30, 2024 and the consolidated financial statements as of and for the year ended December 31, 2023 were prepared on the basis of a going concern, which contemplates that we will be able to realize assets and discharge liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon the availability of equity or debt financing or an alternative strategy as noted above. As stated above, various factors including our overall business performance, market conditions and the ability to identify strategic partners raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties. Â At December 31, 2023, we had approximately $49,807,000 in net state and federal operating loss carryforwards expiring from 2024 through 2037, including $41,409,000 that will not expire, that can be used to offset our current and future taxable net income and reduce our income tax liabilities. We experienced an "ownership change" within the meaning of Section 382(g) of the Internal Revenue Code during the year ended December 31, 2023. As a result of the â€œownership changeâ€ we are limited in our ability to utilize our net operating loss carryforwards and certain other built in deductions in computing our taxable income beginning with the ownership change date. We have not performed an analysis to determine such limitations. We have provided a 100% valuation allowance on our deferred tax asset based on our expected future expenses related to our clinical trials and other development initiatives.Â Â We had no off-balance sheet arrangements as of SeptemberÂ 30, 2024. Â Cash Flows Â Operating Activities Â Net cash used in operating activities was approximately $18,223,000 for the nine month period ended SeptemberÂ 30, 2024, compared to net cash used in operating activities of approximately $11,890,000 for the nine month period ended SeptemberÂ 30, 2023. The increase in net cash used in operating activities was primarily due to the increase in activities for our clinical trials and on-going operational expenses. Â Â Â Investment Activities Â The Company had no net cash provided by or used in investing activities for the nine month periods ended SeptemberÂ 30, 2024 and SeptemberÂ 30, 2023. Â Financing Activities Â Net cash provided by financing activities was approximately $9,904,000 for the nine month period ended SeptemberÂ 30, 2024, compared to net cash provided by financing activities of approximately $12,149,000 for the nine month period ended SeptemberÂ 30, 2023. The decrease in net cash provided by financing activities is attributable to proceeds from the sale of warrants and stock during the nine months ended September 30, 2023, that did not occur during the nine months ended September 30, 2024. During the nine month period ended September 30, 2024, the Company received proceeds of $10,000,000 from convertible notes payable to Rafael. Â Critical Estimates Â Our discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these condensed consolidated financial statements requires us to make judgments, estimates, and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported revenue and expenses during the reporting periods. We continually evaluate our judgments, estimates and assumptions. We base our estimates on the terms of underlying agreements, our expected course of development, historical experience and other factors we believe are reasonable based on the circumstances, the results of which form our managementâ€™s basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Â There were no significant changes to our critical accounting policies during the quarter ended SeptemberÂ 30, 2024. For informationÂ about critical accounting policies, see the discussion of critical accounting policies in our Annual Report on FormÂ 10-K for the fiscalÂ year ended December 31, 2023. Â Item 3.Â Â Quantitative and Qualitative Disclosures About Market Risk. Â Not applicable. Â Â Â Item 4. Controls and Procedures. Â a.Â Â Evaluation of Disclosure Controls and Procedures. Â Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this report (the "Evaluation Date"). Based on such evaluation, our principal executive officer and principal financial officer, have concluded that, at the end of the period covered by this report, the Companyâ€™s disclosure controls and procedures were not effective as of September 30, 2024. Â b. Material Weakness over Complex Equity Instruments Â During the preparation of our interim condensed consolidated financial statements for the period ended MarchÂ 31, 2023, we identified a material weakness in our internal controls relating to the accounting of complex equity instruments. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Specifically, the controls related to the evaluation of the appropriate accounting classification of warrants as equity classified. Â Remediation Plan Â Management, with the oversight from our Audit Committee and the Board of Directors, updated our internal controls to remediate the material weakness by supplementing our internal procedures through the contracted review of equity transactions by technical accounting experts. Â We will not be able to conclude whether the actions we are taking will fully remediate the material weakness in our internal control over financial reporting until the updated controls have operated for a sufficient period of time and management has concluded, through testing, that such controls are operating effectively. We may also conclude that additional measures may be required to remediate the material weakness in our internal control over financial reporting, which may necessitate further action.Â Â c.Â Changes in Internal Control. Â Other than the remediation plan discussed above, we made no changes in our internal control over financial reporting (as defined in Rules 13a-15(f)) and 15d-15(f) under the Exchange Act) identified in connection with the evaluation of our internal controls that occurred during our last fiscal quarter that has materially affected, or which is reasonably likely to materially affect, our internal controls over financial reporting. We are now taking actions to remediate the material weakness, which may result in changes in our internal control over financial reporting in subsequent periods. Â Â Â PART II. OTHER INFORMATION Â Item 1.Â Legal Proceedings Â From time to time, we are a party to claims and legal proceedings arising in the ordinary course of business. Our management evaluates our exposure to these claims and proceedings individually and in the aggregate and allocates additional monies for potential losses on such litigation if it is possible to estimate the amount of loss and if the amount of the loss is probable. We are not currently involved in any litigation nor to our knowledge, is any litigation threatened against us, the outcome of which would, in our judgment based on information currently available to us, have a material adverse effect on our financial position or results of operations. Â Item 1A. Risk Factors Â In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors discussed in Part I, ItemÂ 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which is available atÂ www.sec.govÂ and on our website atÂ www.cyclotherapeutics.com. Any of the risk factors contained in our Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023 could materially affect our business, financial condition or future results, and such risk factors may not be the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. We do not undertake to update any of the "forward-looking" statements or to announce the results of any revisions to these "forward-looking" statements except as required by law. Â Item 2.Â Unregistered Sales of Equity Securities and Use of Proceeds Â On June 3, 2024, the Company issued an aggregate of 81,644 fully vested shares of its common stock to its non-employee directors in lieu of cash compensation.Â These grants reflect director compensation for the first quarter of 2024.Â The number of shares received in lieu of cash was calculated based on the closing price of the Companyâ€™s common stock on June 3, 2024 which was $1.28 per share.Â Â The shares of common stock issued to the non-employee directors contain a Rule 144 restrictive legend and are exempt from registration in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, as a transaction by an issuer not involving a public offering.Â Â Item 3.Â Defaults Upon Senior Securities Â None. Â Item 4.Â Mine Safety Disclosures Â None. Â Â Â Item 5.Â Other Information Â During the fiscal quarter ended SeptemberÂ 30, 2024,Â noneÂ of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any â€œnon-Rule 10b5-1 trading arrangement,â€ as defined in Item 408(a) of Regulation S-K.Â Â Â - 28 - Â Â Â Item 6. Exhibits Â EXHIBIT NO.Â Â DESCRIPTION Â Â Â 2.1+ Â Agreement and Plan of Merger, dated as of August 21, 2024, by and among the Company, Rafael, First Merger Sub and Second Merger SubÂ (incorporated by reference to Exhibit 2.1 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on August 22, 2024) Â Â Â 3.1 Â Articles of Incorporation of Cyclo Therapeutics, Inc., a Nevada corporation (incorporated by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission (â€œSECâ€) on November 10, 2020) Â Â Â 3.2 Â Certificate of Amendment to Articles of Incorporation of Cyclo Therapeutics, Inc., filed June 24, 2021 (incorporated by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on June 25, 2021) Â Â Â 3.3 Â Certificate of Amendment to Articles of Incorporation of Cyclo Therapeutics, Inc. filed March 7, 2023 (incorporated by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on March 8, 2023) Â Â Â 3.4 Â Bylaws of Cyclo Therapeutics, Inc., a Nevada corporation (incorporated by reference to Exhibit 3.2 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on November 10, 2020) Â Â Â 10.1 Â Convertible Promissory Note dated July 16, 2024 payable to Rafael(incorporated by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on July 17, 2024) Â Â Â 10.2 Â Form of Lock-Up AgreementÂ (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on August 22, 2024) Â Â Â 10.3 Â Form of Voting AgreementÂ (incorporated by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on August 22, 2024) Â Â Â 10.4 Â Form of Support AgreementÂ (incorporated by reference to Exhibit 10.3 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on August 22, 2024) Â Â Â 10.5 Â Convertible Promissory Note dated August 21, 2024 payable to RafaelÂ (incorporated by reference to Exhibit 10.5 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on August 22, 2024) Â Â Â 10.6 Â Convertible Promissory Note dated September 9, 2024 payable to Rafael (incorporated by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on September 9, 2024) Â Â Â 10.7 Â Convertible Promissory Note dated October 8, 2024 payable to RafaelÂ (incorporated by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on October 8, 2024) Â Â Â 10.8 Â Amendment to Convertible Promissory Notes dated as of October 8, 2024 by and among the Company and RafaelÂ (incorporated by reference to Exhibit 10.3 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on October 8, 2024) Â Â Â 10.9 Â Fifth Amended and Restated Note Purchase Agreement dated as of November 7, 2024 by and among the Company and Rafael (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on November 7, 2024) Â Â Â 10.10 Â Convertible Promissory Note dated November 7, 2024 payable to Rafael (incorporated by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on November 7, 2024) Â - 29 - Â Â 31.1* Â Rule 13a-14(a)/15d-14a(a) Certification of Chief Executive Officer Â Â Â 31.2* Rule 13a-14(a)/15d-14a(a) Certification of Chief Financial Officer Â Â Â 32.1** Â Section 1350 Certification of Chief Executive Officer Â Â Â 32.2** Â Section 1350 Certification of Chief Financial Officer Â Â Â 101.INS* Â Inline XBRL Instance Document Â Â Â 101.SCH* Â Inline XBRL Taxonomy Extension Schema Document Â Â Â 101.CAL* Â Inline XBRL Taxonomy Extension Calculation Linkbase Document Â Â Â 101.DEF* Â Inline XBRL Taxonomy Extension Definition Linkbase Document Â Â Â 101.LAB* Â Inline XBRL Taxonomy Extension Label Linkbase Document Â Â Â 101.PRE* Â Inline XBRL Taxonomy Extension Presentation Linkbase Document Â Â Â 104* Â Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101) Â Â + The schedules and exhibits to this document have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. The Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules or exhibits so furnished. Â *Filed herewith Â **Furnished herewith Â - 30 - Â Â SIGNATURES Â Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â CYCLO THERAPEUTICS, INC. Â Â Â Date:Â Â November 13, 2024 By: /s/Â N. Scott FineÂ Â Â N. Scott Fine Â Â Chief Executive Officer Â Â (principal executive officer) Â Â Â Â Â Â Â Â Â Â Â Date:Â Â November 13, 2024 By: /s/Â Joshua M. FineÂ Â Â Joshua M. Fine Â Â Chief Financial Officer Â Â (principal financial and accounting officer) Â - 31 - EX-31.1 2 ex_743569.htm EXHIBIT 31.1 ex_743569.htm EXHIBIT 31.1 Â CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Â I, N. Scott Fine, certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of Cyclo Therapeutics, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and Â 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): Â a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and Â b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Â Date:Â Â November 13, 2024 By: /s/Â N. Scott Fine Â Â N. Scott Fine Â Â Chief Executive Officer Â Â (principal executive officer) Â Â EX-31.2 3 ex_743570.htm EXHIBIT 31.2 ex_743570.htm EXHIBIT 31.2 Â CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Â I, N. Scott Fine, certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of Cyclo Therapeutics, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and Â 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): Â a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and Â b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Â Date:Â Â November 13, 2024 By: /s/Â N. Scott Fine Â Â N. Scott Fine Â Â Chief Executive Officer Â Â (principal executive officer) Â Â EX-32.1 4 ex_743571.htm EXHIBIT 32.1 ex_743571.htm EXHIBIT 32.1 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with this Quarterly Report on Form 10-Q of Cyclo Therapeutics, Inc. (the â€œCompanyâ€) for the fiscal quarter ended SeptemberÂ 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, N. Scott Fine, certify, pursuant to 18 U.S.C. Â§1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: Â Â (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â Â (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date:Â Â November 13, 2024 /s/ N. Scott Fine Â N. Scott Fine Â Chief Executive Officer Â (principal executive, financial and accounting officer) Â Â EX-32.2 5 ex_743572.htm EXHIBIT 32.2 ex_743572.htm EXHIBIT 32.2 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with this Quarterly Report on Form 10-Q of Cyclo Therapeutics, Inc. (the â€œCompanyâ€) for the fiscal quarter ended

SeptemberÂ 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Joshua M. Fine, certify, pursuant to 18 U.S.C. Â§1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: Â Â (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â Â (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date:Â Â November 13, 2024 /s/ Joshua M. Fine Â Joshua M. Fine Â Chief Financial Officer Â (principal financial and accounting officer) Â Â EX-101.SCH 6 ctdh-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parenthetical) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Organization and Description of Business link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Revenues link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Major Customers and Suppliers link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Concentrations of Credit Risk link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Accounts Payable and Accrued Expenses link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Convertible Notes Payable link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Leases link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Equity Transactions link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Equity Incentive Plan link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Net Loss Per Share link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 13 - Purchase Commitments link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 995465 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995466 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 995467 - Disclosure - Note 3 - Revenues (Tables) link:calculationLink link:definitionLink link:presentationLink 995468 - Disclosure - Note 6 - Accounts Payable and Accrued Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Note 7 - Convertible Notes Payable (Tables) link:calculationLink link:definitionLink link:presentationLink 995470 - Disclosure - Note 12 - Net Loss Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Note 1 - Organization and Description of Business (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Values (Details) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Key Inputs (Details) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Changes in Fair Value of Notes (Details) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 3 - Revenues (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 3 - Revenues - Revenues by Product (Details) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 4 - Major Customers and Suppliers (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 6 - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 7 - Convertible Notes Payable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 7 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 8 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 9 - Equity Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 11 - Equity Incentive Plan (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note 12 - Net Loss Per Share - Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note 11 - Net Loss Per Share - Antidilutive Securities Weighted Average Shares Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note 13 - Purchase Commitments (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995488 - Disclosure - Note 14 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 7 ctdh-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 ctdh-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Fair Value Measurement, Policy [Policy Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Note To Financial Statement Details Textual Personnel Significant Accounting Policies Note 2 - Summary of Significant Accounting Policies us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Note 3 - Revenues Note 6 - Accounts Payable and Accrued Expenses Note 7 - Convertible Notes Payable Note 12 - Net Loss Per Share LONG-TERM LIABILITIES us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Note 2 - Summary of Significant Accounting Policies - Fair Values (Details) Note 2 - Summary of Significant Accounting Policies - Key Inputs (Details) Note 2 - Summary of Significant Accounting Policies - Changes in Fair Value of Notes (Details) Income Tax Disclosure [Text Block] Note 3 - Revenues - Revenues by Product (Details) Note 6 - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details) Note 7 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) Warrants To Purchase Common Stock [Member] Represents warrants outstanding to purchase common stock. us-gaap_ShareBasedCompensation Stock-based compensation Merger liabilities Note 12 - Net Loss Per Share - Earnings Per Share (Details) us-gaap_LiabilitiesCurrent Total current liabilities Share-Based Payment Arrangement, Nonemployee [Member] Lessee, Leases [Policy Text Block] Note 11 - Net Loss Per Share - Antidilutive Securities Weighted Average Shares Outstanding (Details) NON-CURRENT PREPAID CLINICAL EXPENSES Notes To Financial Statements Notes To Financial Statements [Abstract] Convertible Debt [Table Text Block] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Earnings Per Share, Policy [Policy Text Block] us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted Purchase Commitment, Remaining Minimum Amount Committed Computers and Vehicles [Member] Represents long-lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and the equipment used primarily for road transportation. Purchase Commitment, Excluding Long-Term Commitment [Axis] Adjustment to merger recapitalization liability Amount of increase (decrease) in APIC sue to merger recapitalization liability. Purchase Commitment, Excluding Long-Term Commitment [Domain] Purchase Commitment [Member] Income Tax, Policy [Policy Text Block] Machinery and Furniture [Member] Represents the tangible person property used to produce good and services and equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Employee and Board [Member] Person or persons classified as employees and members of the board of directors. Research and Development Expense, Policy [Policy Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Depreciation and amortization us-gaap_AssetsCurrent Total current assets Cash and cash equivalents, fair value ctdh_NumberOfMajorCustomers Number of Major Customers Represents the number of major customers. Share-Based Payment Arrangement [Policy Text Block] Equity [Text Block] Convertible note payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Advertising Cost [Policy Text Block] Preferred stock, par value $.0001 per share, 5,000,000 shares authorized, 0 outstanding Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] ctdh_WorkingCapitalDeficit Working Capital Deficit The difference between the current assets and current liabilities that is used as a financial metric for operating liquidity. Cost of goods sold (exclusive of direct and indirect overhead and handling costs) The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period, excluding direct and indirect overhead and handling costs. Key inputs Value of input used to measure convertible debt. Adjustments to reconcile net loss to net cash used in operating activities: Measurement Frequency [Axis] Measurement Frequency [Domain] October Note [Member] Represents the October note. Fair Value, Recurring [Member] September Note [Member] Represents the September note. Common Stock, Shares Authorized (in shares) ctdh_BusinessAcquisitionMaximumReimbursementOfCosts Business Acquisition, Maximum Reimbursement of Costs Amount of maximum reimbursement of costs in the business acquisition. Accounts payable and accrued expenses Total accounts payable and accrued expenses ctdh_BusinessAcquisitionNumberOfWarrantsAbleToReceiveCash Business Acquisition, Number of Warrants Able to Receive Cash The number of warrants able to receive cash in the business acquisition. Common Stock, Shares, Issued (in shares) Accrued clinical research Amount of accrued clinical research, classified as current. ctdh_BusinessAcquisitionTerminationFee Business Acquisition, Termination Fee Amount of fee if termination of the business acquisition occurs. Common Stock, Par or Stated Value Per Share (in dollars per share) November Note [Member] Represents the November note. Statistical Measurement [Domain] Maximum [Member] Minimum [Member] Lessee, Operating Leases [Text Block] Accounts payable Product and Service [Axis] Product and Service [Domain] Statistical Measurement [Axis] ctdh_OperatingLeaseRightOfUsseAssetAmortization Operating Lease, Right-of-Use Asset, Amortization Amount of amortization expense attributable to right-of-use asset from operating lease. Accrued bonus compensation Common stock, par value $.0001 per share, 250,000,000 shares authorized, 28,768,055 and 28,556,072 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Other Cash paid for interest us-gaap_PolicyTextBlockAbstract Accounting Policies Preferred Stock, Shares Authorized (in shares) Inventory, net us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Prepaid insurance and services Preferred Stock, Par or Stated Value Per Share (in dollars per share) Product sales Total revenues Convertible notes payable, gross unrealized losses Represents the loss from a change in the fair value of convertible promissory notes. us-gaap_InventoryValuationReserves Inventory Valuation Reserves Fair Value, Inputs, Level 3 [Member] Fair Value Hierarchy and NAV [Domain] Customer [Axis] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Fair Value, Inputs, Level 1 [Member] Customer [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Grantee Status [Domain] Grantee Status [Axis] Product and Service, Other [Member] Fair Value Hierarchy and NAV [Axis] Warrants [Policy Text Block] The disclosure for the accounting policy for warrants. Convertible notes payable, gross unrealized gains Represents the gain from the change in fair value of convertible promissory notes. CURRENT LIABILITIES us-gaap_Assets TOTAL ASSETS SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life Plan Name [Axis] ctdh_OwnershipPercentage Ownership Percentage Percentage of ownership. Plan Name [Domain] CASH FLOWS FROM OPERATING ACTIVITIES us-gaap_OperatingLeaseExpense Operating Lease, Expense ctdh_ChangeInFairValueOfConvertibleNotesPayable Change in fair value of Note Amount of change in fair value of convertible notes payable. June Note [Member] Represents the June note. Revenue [Policy Text Block] Statement [Line Items] Accounts receivable, net of allowances of $0 and $10,272, respectively us-gaap_NumberOfOperatingSegments Number of Operating Segments July Note [Member] Represents the July note. August Note [Member] Represents the August note. Ashland, Inc. [Member] Represents Ashland, Inc. Additional paid-in capital REVENUES Share-Based Payment Arrangement [Text Block] Total, gross unrealized losses Amount of gross unrealized losses on financial instruments. Property, Plant and Equipment, Policy [Policy Text Block] Investment and other income (expense), net Total, amortized cost Amount of amortized cost of financial instruments. us-gaap_NonoperatingIncomeExpense Total other income (expense), net Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Total, fair value Fair value portion of financial instrument. Award Type [Domain] CURRENT ASSETS Net loss NET LOSS Net loss Net Income (Loss) Attributable to Parent Award Type [Axis] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations CASH AND CASH EQUIVALENTS, beginning of period CASH AND CASH EQUIVALENTS, end of period Inventory, Policy [Policy Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS us-gaap_NetCashProvidedByUsedInFinancingActivities NET CASH PROVIDED BY FINANCING ACTIVITIES Commitments and Contingencies ctdh_LesseeOperatingLeaseExtensionOptionRenewalTerm Lessee, Operating Lease, Extension Option, Renewal Term Term of lessee's operating lease renewal under extension option, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Two Major Customers [Member] Represents information pertaining to two major customers. us-gaap_OperatingIncomeLoss LOSS FROM OPERATIONS us-gaap_NetCashProvidedByUsedInOperatingActivities NET CASH USED IN OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities Share-Based Payment Arrangement, Option [Member] Warrant [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] us-gaap_GrossProfit GROSS PROFIT Antidilutive Securities, Name [Domain] Counterparty Name [Axis] Counterparty Name [Domain] STOCKHOLDERS' EQUITY Commitments and Contingencies Disclosure [Text Block] FURNITURE AND EQUIPMENT, NET OTHER INCOME (EXPENSE) ctdh_APICMergerRecapitalizationOptionIncreaseForCostRecognition Merger recapitalization transaction costs Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under merger recapitalization. us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities Merger transaction costs Long-Term Debt, Type [Axis] Accrued board expense Amount of accrued board expense, classified as current. Long-Term Debt, Type [Domain] Exercise of warrants Value of stock issued as a result of the exercise of warrants. Exercise of warrants (in shares) Number of shares issued as a result of the exercise of warrants during the current period. us-gaap_CostsAndExpenses Total expenses Merger Agreement [Member] Represents the merger agreement. us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities Total adjustments EXPENSES Net proceeds from sale of warrants Scenario [Domain] ctdh_GainLossOnChangeInFairValueOfConvertibleDebt Loss on change in fair value of convertible promissory note Loss on change in fair value of convertible promissory note The amount of gain (loss) on change in fair value of convertible debt. us-gaap_ProceedsFromWarrantExercises Exercise of warrants Retained Earnings [Member] Earnings Per Share [Text Block] us-gaap_ProceedsFromStockOptionsExercised Exercise of stock options Convertible Debt [Member] Board of Director fees and costs Net proceeds from sale of stock Convertible Notes Payable [Member] Title and Position [Domain] Approximation [Member] Related to approximation. Title and Position [Axis] Scenario [Axis] us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Accounts payable and accrued expenses Additional Paid-in Capital [Member] Common Stock [Member] PROVISION FOR INCOME TAXES Equity Components [Axis] Equity Component [Domain] us-gaap_LongTermDebt Long-Term Debt us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest LOSS BEFORE PROVISION FOR INCOME TAXES us-gaap_ConvertibleNotesPayable Balance Balance Cyclodexterin Complexes [Member] Represents information pertaining to Cyclodexterin complexes. Basic Natural and Chemically Modified Cyclodexterins [Member] Represents information pertaining to basic natural and chemically modified cyclodexterins. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Major Customers and Suppliers Disclosure [Text Block] The entire disclosure for major customers and suppliers during the reporting period. Disaggregation of Revenue [Table Text Block] us-gaap_AllocatedShareBasedCompensationExpense Share-Based Payment Arrangement, Expense Money market funds invested in U.S. government obligations, gross unrealized losses Amount of unrealized gain before deducting unrealized loss on cash and cash equivalents. Change in fair value of Note Money market funds invested in U.S. government obligations, fair value Amount of unrealized loss before deducting unrealized gain on cash and cash equivalents. Revenue from Contract with Customer [Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] dei_DocumentQuarterlyReport Document Quarterly Report Receivable [Policy Text Block] Entity Incorporation, State or Country Code Amendment Flag Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Four Major Customers [Member] Represents information pertaining to four major customers. dei_DocumentTransitionReport Document Transition Report dei_CityAreaCode City Area Code Basis of Accounting, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Aquaplex [Member] Represents information about Aquaplex. Concentration Risk Disclosure [Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Trappsol HPB [Member] Represents information bout Trappsol HPB. dei_EntityInteractiveDataCurrent Entity Interactive Data Current Trappsol Cyclo [Member] Represents information about Trappsol Cyclo. Repairs and maintenance Represents the costs related to repairs and maintenance. Board Members [Member] information regarding awards relating to board members. us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Security Exchange Name Common Stock, Shares, Outstanding (in shares) Preferred Stock, Shares Outstanding (in shares) Preferred Stock, Shares Outstanding (in shares) Title of 12(b) Security Freight and shipping Represents the costs related to freight and shipping. us-gaap_IncreaseDecreaseInOtherOperatingAssets Other Revenue from Contract with Customer, Shipping and Handling Fees, Policy [Policy Text Block] Disclosure of accounting policy for the classification of shipping and handling fees, including whether the fees are included in cost of sales or included in other income statement accounts. Current Fiscal Year End Date us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage Net proceeds from issuance of convertible note Issuance of convertible Note Convertible notes payable, fair value Document Fiscal Period Focus Document Fiscal Year Focus Three Major Customers [Member] Represents information pertaining to three major customers. dei_DocumentPeriodEndDate Document Period End Date Sub-lease deposit liability dei_EntityFileNumber Entity File Number Entity Emerging Growth Company Convertible notes payable, amortized cost Debt Instrument, Face Amount dei_DocumentType Document Type Sale of common stock value of common stock and prefunded warrants issued during period. Entity Small Business dei_EntityShellCompany Entity Shell Company Sale of common stock (in shares) Amount of common stock and prefunded warrants issued during the period. Document Information [Line Items] Document Information [Table] us-gaap_IncreaseDecreaseInPrepaidInsurance Prepaid insurance and services us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Balance Balance Entity Filer Category Debt Instrument [Axis] dei_EntityCurrentReportingStatus Entity Current Reporting Status Debt Instrument, Name [Domain] Issuance of Convertible Note ctdh_PurchaseCommitmentGoodsPurchasedDuringPeriod Purchase Commitment, Goods Purchased During Period Represents the amount of goods purchased on a purchase commitment during the period. Antidilutive Securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Rafael Holdings, Inc. [Member] Represents Rafael Holdings, Inc. Stock-based compensation us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable, net us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage Entity Tax Identification Number Entity Central Index Key Lease income dei_EntityRegistrantName Entity Registrant Name Organization and Description of Business [Text Block] Disclosure for organization and description of business. Liability Class [Axis] Fair Value by Liability Class [Domain] Product Concentration Risk [Member] Entity [Domain] Customer Concentration Risk [Member] Legal Entity [Axis] Office Lease [Member] Represents information regarding an office lease. Statement [Table] Entity Address, Address Line One Statement of Financial Position [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] WEIGHTED AVERAGE NUMBER OF COMMON SHARES BASIC AND DILUTED OUTSTANDING (in shares) Accounts Payable and Accrued Liabilities Disclosure [Text Block] Non-Rule 10b5-1 Arrangement Terminated [Flag] Entity Address, City or Town Prepaid Expenses [Policy Text Block] Disclosure of accounting policy for prepaid expenses. Rule 10b5-1 Arrangement Terminated [Flag] Rule 10b5-1 Arrangement Adopted [Flag] Entity Address, Postal Zip Code BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share) Business Acquisition [Axis] Entity Address, State or Province Business Acquisition, Acquiree [Domain] Concentration Risk Type [Axis] Non-Rule 10b5-1 Arrangement Adopted [Flag] us-gaap_AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss Concentration Risk Type [Domain] Material Terms of Trading Arrangement [Text Block] Statement of Cash Flows [Abstract] dei_EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding (in shares) Depreciation Statement of Stockholders' Equity [Abstract] Lease Contractual Term [Domain] Lease Contractual Term [Axis] Income Statement [Abstract] Revenue Benchmark [Member] Accounts Receivable [Member] Professional fees ctdh_SharebasedCompensationNonemployees Stock compensation to nonemployees The aggregate amount of noncash, equity-based nonemployee remuneration. Long-Term Debt [Text Block] us-gaap_IncreaseDecreaseInInventories Inventory, net Trading Symbol Schedule of Accounts Payable and

Accrued Liabilities [Table Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] dei_LocalPhoneNumber Local Phone Number us-gaap_GainLossOnDispositionOfAssets Loss on disposal of equipment Exercise of stock options Exercise of stock options (in shares) us-gaap_TableTextBlock Notes Tables Exercise of stock options Related and Nonrelated Parties [Axis] The 2021 Equity Incentive Plan [Member] Represents the 2021 Equity Incentive Plan. Related and Nonrelated Parties [Domain] us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture (in shares) Office and other us-gaap_LiabilitiesNoncurrent Total long-term liabilities Fair Value, Assets Measured on Recurring Basis [Table Text Block] CASH FLOWS FROM FINANCING ACTIVITIES us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Prepaid clinical expenses Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer, excluding prepaid insurance. Line of Credit Facility, Lender [Domain] Stock issued to nonemployees Stock issued to nonemployees (in shares) Lender Name [Axis] us-gaap_LiabilitiesAndStockholdersEquity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) The 2019 Omnibus Incentive Plan [Member] Represents the 2019 Omnibus Equity Incentive Plan. Accumulated deficit Retained Earnings (Accumulated Deficit) Research and development ctdh_IncreaseDecreasePrepaidClinicalExpenses Prepaid clinical expenses The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for clinical expenses that bring economic benefits for future periods. Money Market Funds [Member] Measurement Input, Share Price [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Measurement Input, Price Volatility [Member] us-gaap_InterestExpenseDebt Interest Expense, Debt Increase or decrease in: us-gaap_StockholdersEquity Total stockholders' equity (deficit) Balance Balance Measurement Input, Risk Free Interest Rate [Member] us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Lease liabilities, net of current portion Subsequent Event [Member] Measurement Input, Expected Dividend Rate [Member] Class of Stock [Axis] Measurement Input, Expected Term [Member] Class of Stock [Domain] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Current portion of lease liabilities Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Events [Text Block] RIGHT-OF-USE LEASE ASSETS, NET Measurement Input Type [Axis] Measurement Input Type [Domain] us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense Deferred Compensation Arrangement with Individual, Compensation Expense EX-101.PRE 9 ctdh-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.CAL 10 ctdh-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 12, 2024 Document Information [Line Items] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 0-25466 Â Entity Registrant Name CYCLO THERAPEUTICS, INC. Â Entity Incorporation, State or Country Code NV Â Entity Tax Identification Number 59-3029743 Â Entity Address, Address Line One 6714 NW 16th Street, Suite B Â Entity Address, City or Town Gainesville Â Entity Address, State or Province FL Â Entity Address, Postal Zip Code 32653 Â City Area Code 386 Â Local Phone Number 418-8060 Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding (in shares) Â 28,768,055 Entity Central Index Key 0000922247 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â Common Stock [Member] Â Â Document Information [Line Items] Â Â Title of 12(b) Security Common Stock, par value $.0001 per share Â Trading Symbol CYTH Â Security Exchange Name NASDAQ Â Warrants To Purchase Common Stock [Member] Â Â Document Information [Line Items] Â Â Title of 12(b) Security Warrants to purchase Common Stock Â Trading Symbol CYTHW Â Security Exchange Name NASDAQ Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name:

dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=ctdh_WarrantsToPurchaseCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) Sep. 30, 2024 Dec. 31, 2023 CURRENT ASSETS Â Â Cash and cash equivalents $ 928,010 $ 9,246,592 Accounts receivable, net of allowances of $0 and $10,272, respectively 187,682 122,379 Inventory, net 236,110 254,352 Prepaid insurance and services 177,836 384,889 Prepaid clinical expenses 1,726,970 2,310,045 Total current assets 3,256,608 12,318,257 FURNITURE AND EQUIPMENT, NET 19,988 38,332 RIGHT-OF-USE LEASE ASSETS, NET 26,636 890,949 NON-CURRENT PREPAID CLINICAL EXPENSES 1,950,670 0 TOTAL ASSETS 5,253,902 13,247,538 CURRENT LIABILITIES Â Â Current portion of lease liabilities 20,116 1,010,631 Convertible note payable 12,178,000 0 Accounts payable and accrued expenses 6,521,983 7,457,416 Total current liabilities 18,720,099 8,468,047 LONG-TERM LIABILITIES Â Â Lease liabilities, net of current portion 7,143 22,484 Total long-term liabilities 7,143 22,484 Commitments and Contingencies Â STOCKHOLDERS' EQUITY Â Â Preferred stock, par value $.0001 per share, 5,000,000 shares authorized, 0 outstanding 0 0 Common stock, par value $.0001 per share, 250,000,000 shares authorized, 28,768,055 and 28,556,072 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 2,877 2,856 Additional paid-in capital 89,537,725 88,610,832 Accumulated deficit (103,013,942) (83,856,681) Total stockholders' equity (deficit) (13,473,340) 4,757,007 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) $ 5,253,902 $ 13,247,538 X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer, excluding prepaid insurance. + ReferencesNo definition available. + Details Name: ctdh_PrepaidExpensesCurrentExcludingPrepaidInsurance Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -

Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleNotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type:

xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance

Sheets (Current Period Unaudited) (Parentheticals) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Preferred Stock, Par or Stated Value Per Share (in dollars per share) $ 0.0001 $ 0.0001 Preferred Stock, Shares Authorized (in shares) 5,000,000 5,000,000 Preferred Stock, Shares Outstanding (in shares) 0 0 Preferred Stock, Shares Outstanding (in shares) 0 0 Common Stock, Par or Stated Value Per Share (in dollars per share) $ 0.0001 $ 0.0001 Common Stock, Shares Authorized (in shares) 250,000,000 250,000,000 Common Stock, Shares, Outstanding (in shares) 28,768,055 28,556,072 Common Stock, Shares, Issued (in shares) 28,768,055 28,556,072 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations (Unaudited) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 REVENUES Â Â Â Â Product sales $ 233,772 $ 495,477 $ 559,326 $ 765,006 Cost of goods sold (exclusive of direct and indirect overhead and handling costs) 16,798 38,767 42,002 68,872 GROSS PROFIT 216,974 456,710 517,324 696,134 EXPENSES Â Â Â Â Personnel 843,157 834,878 2,581,207 2,526,700 Research and development 5,492,844 3,469,067 11,830,127 10,037,433 Repairs and maintenance 3,495 847 13,822 9,162 Professional fees 1,412,432 597,095 2,430,263 1,494,332 Office and other 640,590 220,607 2,361,381 775,922 Board of Director fees and costs 111,281 95,560 327,061 243,143 Depreciation 2,177 4,819 6,531 14,457 Freight and shipping 441 1,297 1,315 2,519 Loss on disposal of equipment 0 0 11,813 0 Total expenses 8,506,417 5,224,170 19,563,520 15,103,668 LOSS FROM OPERATIONS (8,289,443) (4,767,460) (19,046,196) (14,407,534) OTHER INCOME (EXPENSE) Â Â Â Â Investment and other income (expense), net 549,621 (3,893) 591,312 (7,359) Lease income 373,878 0 1,475,623 0 Loss on change in fair value of convertible promissory note (1,467,000) 0 (2,178,000) 0 Total other income (expense), net (543,501) (3,893) (111,065) (7,359) LOSS BEFORE PROVISION FOR INCOME TAXES (8,832,944) (4,771,353) (19,157,261) (14,414,893) PROVISION FOR INCOME TAXES 0 0 0 0 NET LOSS $ (8,832,944) $ (4,771,353) $ (19,157,261) $ (14,414,893) BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share) $ (0.31) $ (0.29) $ (0.67) $ (1) WEIGHTED AVERAGE NUMBER OF COMMON SHARES BASIC AND DILUTED OUTSTANDING (in shares) 28,729,641 16,191,723 28,674,910 14,394,920 X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period, excluding direct and indirect overhead and handling costs. + ReferencesNo definition available. + Details Name: ctdh_CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the costs related to freight and shipping. + ReferencesNo definition available. + Details Name: ctdh_FreightAndShipping Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of gain (loss) on change in fair value of convertible debt. + ReferencesNo definition available. + Details Name: ctdh_GainLossOnChangeInFairValueOfConvertibleDebt Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the costs related to repairs and maintenance. + ReferencesNo definition available. + Details Name: ctdh_RepairsAndMaintenance Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationNonproduction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-

323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3 + Details Name: us-gaap_GainLossOnDispositionOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -

SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5 + Details Name: us-gaap_LeaseIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33:

http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNoninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NoninterestExpenseDirectorsFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeDisclosureNonoperatingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of selling, general and administrative expense classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherSellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_ProfessionalFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SalariesAndWages Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -

Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) Common Stock [Member] Share-Based Payment Arrangement, Nonemployee [Member] Common Stock [Member] Additional Paid-in Capital [Member] Share-Based Payment Arrangement, Nonemployee [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Share-Based Payment Arrangement, Nonemployee [Member] Retained Earnings [Member] Share-Based Payment Arrangement, Nonemployee [Member] Total Balance (in shares) at Dec. 31, 2022 Â 8,481,848 Â Â Â Â Â Â Balance at Dec. 31, 2022 Â $ 849 Â $ 64,533,074 Â $ (63,799,379) Â $ 734,544 Stock issued to nonemployees (in shares) 195,537 Â Â Â Â Â Â Â Stock issued to nonemployees $ 20 Â $ 219,694 Â $ 0 Â $ 219,714 Â Stock-based compensation Â 0 Â 259,430 Â 0 Â 259,430 Net loss Â $ 0 Â 0 Â (14,414,893) Â (14,414,893) Sale of common stock (in shares) Â 9,007,853 Â Â Â Â Â Â Sale of common stock Â $ 900 Â 12,145,989 Â 0 Â 12,146,889 Exercise of stock options (in shares) Â 1,155 Â Â Â Â Â Â Exercise of stock options Â $ 0 Â 1,478 Â 0 Â 1,478 Exercise of warrants (in shares) Â 1,678,696 Â Â Â Â Â Â Exercise of warrants Â $ 168 Â 0 Â 0 Â 168 Balance (in shares) at Sep. 30, 2023 Â 19,365,089 Â Â Â Â Â Â Balance at Sep. 30, 2023 Â $ 1,937 Â 77,159,665 Â (78,214,272) Â (1,052,670) Balance (in shares) at Jun. 30, 2023 Â 15,308,449 Â Â Â Â Â Â Balance at Jun. 30, 2023 Â $ 1,531 Â 71,956,553 Â (73,442,919) Â (1,484,835) Stock issued to nonemployees (in shares) 55,485 Â Â Â Â Â Â Â Stock issued to nonemployees $ 6 Â 75,454 Â 0 Â 75,460 Â Stock-based compensation Â 0 Â 126,580 Â Â Â 126,580 Net loss Â $ 0 Â 0 Â (4,771,353) Â (4,771,353) Sale of common stock (in shares) Â 4,000,000 Â Â Â Â Â Â Sale of common stock Â $ 400 Â 4,999,600 Â 0 Â 5,000,000 Exercise of stock options (in shares) Â 1,155 Â Â Â Â Â Â Exercise of stock options Â $ 0 Â 1,478 Â 0 Â 1,478 Balance (in shares) at Sep. 30, 2023 Â 19,365,089 Â Â Â Â Â Â Balance at Sep. 30, 2023 Â $ 1,937 Â 77,159,665 Â (78,214,272) Â (1,052,670) Balance (in shares) at Dec. 31, 2023 Â 28,556,072 Â Â Â Â Â Â Balance at Dec. 31, 2023 Â $ 2,856 Â 88,610,832 Â (83,856,681) Â 4,757,007 Merger recapitalization transaction costs Â 0 Â (95,911) Â 0 Â (95,911) Adjustment to merger recapitalization liability Â 0 Â 214,169 Â 0 Â 214,169 Stock issued to nonemployees (in shares) 211,983 Â Â Â Â Â Â Â Stock issued to nonemployees $ 21 Â 287,370 Â $ 0 Â 287,391 Â Stock-based compensation Â 0 Â 521,265 Â 0 Â 521,265 Net loss Â $ 0 Â 0 Â (19,157,261) Â (19,157,261) Balance (in shares) at Sep. 30, 2024 Â 28,768,055 Â Â Â Â Â Â Balance at Sep. 30, 2024 Â $ 2,877 Â 89,537,725 Â (103,013,942) Â (13,473,340) Balance (in shares) at Jun. 30, 2024 Â 28,696,028 Â Â Â Â Â Â Balance at Jun. 30, 2024 Â $ 2,870 Â 89,055,380 Â (94,180,998) Â (5,122,748) Merger recapitalization transaction costs Â 0 Â (1,396) Â 0 Â (1,396) Adjustment to merger recapitalization liability Â 0 Â 214,169 Â 0 Â 214,169 Stock issued to nonemployees (in shares) 72,027 Â Â Â Â Â Â Â Stock issued to nonemployees $ 7 Â $ 90,747 Â Â Â $ 90,754 Â Stock-based compensation Â 0 Â 178,825 Â 0 Â 178,825 Net loss Â $ 0 Â 0 Â (8,832,944) Â (8,832,944) Balance (in shares) at Sep. 30, 2024 Â 28,768,055 Â Â Â Â Â Â Balance at Sep. 30, 2024 Â $ 2,877 Â $ 89,537,725 Â $ (103,013,942) Â $ (13,473,340) X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for option under merger recapitalization. + ReferencesNo definition available. + Details Name: ctdh_APICMergerRecapitalizationOptionIncreaseForCostRecognition Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in APIC sue to merger recapitalization liability. + ReferencesNo definition available. + Details Name: ctdh_AdjustmentsToAPICMergerRecapitalizationLiability Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of common stock and prefunded warrants issued during the period. + ReferencesNo definition available. + Details Name: ctdh_StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrants Namespace Prefix: ctdh_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued as a result of the exercise of warrants during the current period. + ReferencesNo definition available. + Details Name: ctdh_StockIssuedDuringPeriodSharesWarrantsExercised Namespace Prefix: ctdh_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definitionvalue of common stock and prefunded warrants issued during period. + ReferencesNo definition available. + Details Name: ctdh_StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrants Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of warrants. + ReferencesNo definition available. + Details Name: ctdh_StockIssuedDuringPeriodValueWarrantsExercised Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -

Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 CASH FLOWS FROM OPERATING ACTIVITIES Â Â Net loss $ (19,157,261) $ (14,414,893) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation and amortization 6,531 14,457 Loss on disposal of equipment 11,813 0 Stock-based compensation 521,265 259,430 Stock compensation to nonemployees 287,391 219,714 Loss on change in fair value of convertible promissory note 2,178,000 0 Increase or decrease in: Â Â Accounts receivable, net (65,303) (248,769) Inventory, net 18,242 44,736 Prepaid clinical expenses (1,367,595) (841,350) Prepaid insurance and services 65,510 (49,187) Other 0 1,883 Accounts payable and accrued expenses (721,264) 3,123,835 Total adjustments 934,590 2,524,749 NET CASH USED IN OPERATING ACTIVITIES (18,222,671) (11,890,144) CASH FLOWS FROM FINANCING ACTIVITIES Â Â Net proceeds from sale of warrants 0 2,917,581 Net proceeds from sale of stock 0 9,229,308 Merger transaction costs (95,911) 0 Exercise of stock options 0 1,478 Exercise of warrants 0 168 Net proceeds from issuance of convertible note 10,000,000 0 NET CASH PROVIDED BY FINANCING ACTIVITIES 9,904,089 12,148,535 NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (8,318,582) 258,391 CASH AND CASH EQUIVALENTS, beginning of period 9,246,592 1,543,418 CASH AND CASH EQUIVALENTS, end of period 928,010 1,801,809 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Â Â Cash paid for interest $ 2,318 $ 9,807 X - DefinitionThe amount of gain (loss) on change in fair value of convertible debt. + ReferencesNo definition available. + Details Name: ctdh_GainLossOnChangeInFairValueOfConvertibleDebt Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for clinical expenses that bring economic benefits for future periods. + ReferencesNo definition available. + Details Name: ctdh_IncreaseDecreasePrepaidClinicalExpenses Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of noncash, equity-based nonemployee remuneration. + ReferencesNo definition available. + Details Name: ctdh_SharebasedCompensationNonemployees Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3 + Details Name: us-gaap_GainLossOnDispositionOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) of consideration paid in advance for insurance that provides economic benefits in future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3:

http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for financing costs associated with business combinations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Note 1 - Organization and Description of Business 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Organization and Description of Business [Text Block] (1) ORGANIZATION AND DESCRIPTION OF BUSINESS: Â Cyclo Therapeutics, Inc. (the â€œCompany,â€ â€œwe,â€ â€œourâ€ or â€œusâ€) was incorporated in August 1990 as a Florida corporation under the name Cyclodextrin

Technologies Development, Inc. with operations beginning in July 1992. In conjunction with a restructuring in 2000, we changed our name to CTD Holdings, Inc. We changed our name to Cyclo Therapeutics, Inc. in September 2019 to better reflect our current business and, on November 6, 2020, we reincorporated from the State of Florida to the State of Nevada. Â On December 27, 2023, the Company completed a strategic combination pursuant to that certain Agreement and Plan of Merger, dated as of September 21, 2023, by and among the Company, Cameo Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company ("Merger Subâ€), and Applied Molecular Transport Inc., a Delaware corporation ("AMTIâ€), providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of the Company (the "AMTI Mergerâ€). Â We are a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of neurodegenerative diseases. We filed a Type II Drug Master File with the U.S. Food and Drug Administration (â€œFDAâ€) in 2014 for our lead drug candidate, TrappsolÂ® Cycloâ„¢ (hydroxypropyl beta cyclodextrin) as a treatment for Niemann-Pick Type C disease (â€œNPCâ€). NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. In 2015, we launched an International Clinical Program for TrappsolÂ® Cycloâ„¢ as a treatment for NPC. In 2016, we filed an Investigational New Drug application (â€œINDâ€) with the FDA, which described our Phase I clinical plans for a randomized, double blind, parallel group study at a single clinical site in the U.S. The Phase I study evaluated the safety and pharmacokinetics of TrappsolÂ® Cycloâ„¢ along with markers of cholesterol metabolism and markers of NPC during a 12-week treatment period of intravenous administration of TrappsolÂ® Cycloâ„¢ every two weeks to participants 18 years of age and older. The IND was approved by the FDA in September 2016, and in January 2017 the FDA granted Fast Track designation to TrappsolÂ® Cycloâ„¢ for the treatment of NPC. Initial patient enrollment in the U.S. Phase I study commenced in September 2017, and in May 2020 we announced top line data showing TrappsolÂ® Cycloâ„¢ was well tolerated in this study. Â We have also completed a Phase I/II clinical study approved by European regulatory bodies with clinical trial centers in the United Kingdom, Sweden, and Israel. The Phase I/II study evaluated the safety, tolerability and efficacy of TrappsolÂ® Cycloâ„¢ through a range of clinical outcomes, including neurologic, respiratory, and measurements of cholesterol metabolism and markers of NPC. Consistent with the 12-week Phase I study (single US site), the European/Israel study administered TrappsolÂ® Cycloâ„¢ intravenously to NPC patients every two weeks in a double-blind, randomized trial, but differs in that the study period was for 48 weeks (24 doses). In March of 2021 we announced that 100% of patients who completed the trial (9 out of 12) improved or remained stable, and 89% met the outcome measure in at least two domains of the 17-domain NPC severity scale. We did not conduct a Phase II trial in the U.S. and instead relied on the data obtained from our Phase I/II trial abroad to support the commencement of our Phase III trial in the U.S. Â In February 2020 we had a face-to-face â€œType Câ€ meeting with the FDA with respect to the initiation of our pivotal Phase III clinical trial of TrappsolÂ® Cycloâ„¢ based on the clinical data obtained to date. At that meeting, we also discussed with the FDA submitting a New Drug Application (NDA) under Section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for the treatment of NPC in pediatric and adult patients with TrappsolÂ® Cycloâ„¢. A similar request was submitted to the European Medicines Agency (â€œEMAâ€) in February 2020, seeking scientific advice and protocol assistance from the EMA for proceeding with a Phase III clinical trial in Europe. In October 2020 we received a â€œStudy May Proceedâ€ notification from the FDA with respect to the proposed Phase III clinical trial, and in June of 2021 we commenced enrollment in TransportNPC, a pivotal Phase III study of TrappsolÂ® Cycloâ„¢ for the treatment of NPC. In May 2024, we enrolled the last of the 104 patients enrolled in the Phase III study. Â We are also exploring the use of cyclodextrins in the treatment of Alzheimerâ€™s disease. In January 2018, the FDA authorized a single patient IND expanded access program using TrappsolÂ® Cycloâ„¢ for the treatment of Alzheimerâ€™s disease. Based on the data collected from this patient combined with the data from our NPC studies, we prepared a synopsis for an early-stage protocol using TrappsolÂ® Cycloâ„¢ intravenously to treat Alzheimerâ€™s disease that was presented to the FDA in January of 2021. We received feedback from the FDA on this synopsis in April 2021 and incorporated the feedback into an IND for a Phase II study for the treatment of Alzheimerâ€™s disease with TrappsolÂ® Cycloâ„¢ that we submitted to the FDA in November 2021. In December of 2021, we received IND clearance from the FDA, allowing us to proceed with our Phase II study of TrappsolÂ® Cycloâ„¢ for the treatment of Alzheimerâ€™s disease. U.S. sites for the study were activated during the second half of 2022, with patient dosing beginning in the first quarter of 2023. Â We also continue to operate our legacy fine chemical business, consisting of the sale of cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. However, our core business has transitioned to a biotechnology company primarily focused on the development of cyclodextrin- based biopharmaceuticals for the treatment of disease from a business that had been primarily reselling basic cyclodextrin products. Â Proposed Acquisition by Rafael Holdings Â On August 21, 2024, the Company entered into an Agreement and Plan of Merger (the â€œMerger Agreementâ€) with Rafael Holdings, Inc. (â€œRafaelâ€), a Delaware corporation; and Tandem Therapeutics, Inc., a Nevada corporation and a wholly-owned subsidiary of Rafael (â€œFirst Merger Subâ€); and Tandem Therapeutics, LLC, a Nevada limited liability company and a wholly-owned subsidiary of the Rafael (â€œSecond Merger Subâ€). Pursuant to the terms of the Merger Agreement, the Rafael, First Merger Sub and the Company will be merged with and into Rafael (the â€œFirst Mergerâ€), with the Company surviving the Merger as a wholly-owned subsidiary of Rafael. Immediately following the First Merger, the Company will merge with and into the Second Merger Sub (the â€œSecond Mergerâ€, and together with the First Merger, the â€œMergerâ€) with Rafael being the surviving entity of the Second Merger. The name of the Surviving Entity will be changed to Cyclo Therapeutics, LLC. Â At the closing of the Merger, each outstanding share of Company common stock will be converted into the right to receive a number of shares of Rafael Class B common stock calculated in accordance with the Merger Agreement (the â€œExchange Ratioâ€). The Exchange Ratio was initially estimated to be 0.3112 shares of Rafael Class B common stock for each share of Company common stock. The actual exchange ratio will be determined at the time of closing based on valuing Company common stock at $0.95 per share and Rafael at the combined value of its cash, cash equivalents, marketable securities, real estate and certain other financial holdings plus amounts loaned by Rafael to the Company between the signing of the Merger Agreement and the closing of the Merger, less certain of Rafaelâ€™s current liabilities. In addition, the cash value with take into account the funding of the Companyâ€™s operations by Rafael with convertible notes through closing, as discussed at Note (7). Any fractional shares of Rafael Class B common stock will be rounded up to the nearest whole share. Â All compensatory options to purchase Company common stock will be converted into an option to acquire Rafael Class B common stock, as described in the Merger Agreement. Â Unless otherwise provided for in outstanding warrant agreements, all outstanding warrants to purchase Cyclo common stock (other than those held by Rafael which will be cancelled) will automatically be converted into warrants to purchase a number of shares of Rafael Class B common stock, at an adjusted exercise price per share based upon the Exchange Ratio. Certain holders of Cyclo warrants, representing 5,498,914 Cyclo warrant shares, have the right to elect to receive cash payment in an amount equal to the Black Sholes Value of the unexercised portion of their warrants on the date of consummation of the Merger in lieu of receiving warrants to purchase Rafael Class B common stock. Â Holders of Cyclo Public Warrants will receive Rafael Public Warrants in exchange for their Cyclo Public Warrants. Â The Merger Agreement contains specified termination rights of each of the Company and Rafael. In connection with a termination of the Merger Agreement in specified circumstances, the terminating party will be reimbursed for transaction costs of up to $250,000. If the Merger Agreement is terminated by Company due to the Companyâ€™s board of directors making an adverse change recommendation, the Company will be required to pay a $400,000 termination fee to Rafael. Â The boards of directors of each of the Company and Rafael have approved the Merger Agreement and the transactions contemplated thereby, subject to the satisfaction or waiver of customary conditions, including the requisite approval by the Company's and Rafael's stockholders and the effectiveness of a registration statement to register the shares of Rafael Class B common stock to be issued in connection with the transaction. The transaction is expected to close in late December. Â Although the Company has entered into the Merger Agreement and intends to consummate the proposed Merger, there is no assurance that the Company will be able to successfully consummate the proposed Merger on a timely basis, or at all. Â Going Concern and Liquidity Â For the three and nine months ended September 30, 2024, the Company incurred a net loss of $8,832,944 and $19,157,261, respectively. The Company has an accumulated deficit of $103,013,942 at SeptemberÂ 30, 2024. Our recent losses have predominantly resulted from research and development expenses for our TrappsolÂ®Â Cycloâ„¢ product and other general operating expenses, including personnel expenses and board advisory fees. We believe our expenses will continue to increase as we continue to conduct clinical trials and seek regulatory approval for the use of TrappsolÂ®Â Cycloâ„¢ in the treatment of NPC and Alzheimerâ€™s disease. Â For the nine months ended SeptemberÂ 30, 2024, the Companyâ€™s operations used $18,222,671 in cash, and at SeptemberÂ 30, 2024, the Company had a cash and cash equivalents balance of $928,010 and negative working capital of $15,463,491. We will need to raise additional capital in the foreseeable future to fund the development of our drug product candidates through clinical development, manufacturing and commercialization. Â Rafael has agreed to fund the Company through the earlier of the consummation of the Merger or termination of the Merger Agreement in such amounts as may be necessary for the Company to operate its business and pay its debts and obligations as they become due, provided that the Company is not in active discussions regarding an acquisition proposal and is being operated in a manner consistent with the terms of the Merger Agreement and the financial forecast previously shared with Rafael.Â As discussed in Note 7, the Company has borrowed $15,000,000 from Rafael through November 12, 2024. Â We intend to continue to borrow from Rafael through the consummation of the Merger or termination of the Merger Agreement.Â If the Merger Agreement is terminated, we intend to continue to raise such capital through the sale of equity securities from time to time, the issuance of debt securities, the sale or licensing of existing assets or assets in development, or from other non-dilutive funding mechanisms. Our ability to obtain such additional capital will likely be subject to various factors, including our overall business performance and market conditions. If we cannot raise the additional funds required for our anticipated operations, we may be required to reduce the scope of or eliminate our research and development programs, delay our clinical trials and the ability to seek regulatory approvals, downsize our general and administrative infrastructure, and/or seek alternative measures to avoid insolvency. If we raise additional funds through future offerings of shares of our common stock or other securities, such offerings would cause dilution of current stockholdersâ€™ percentage ownership in the Company, which could be substantial. Future offerings also could have a material and adverse effect on the price of our common stock. Â Our condensed consolidated financial statements for the three and nine months ended SeptemberÂ 30, 2024, were prepared on the basis of a going concern, which contemplates that we will be able to realize assets and discharge liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon the availability of equity or debt financing as noted above, including from Rafael. Various factors including our overall business performance and market conditions raise substantial doubt about our ability to continue as a going concern. The condensed and consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. Â Â X - DefinitionDisclosure for organization and description of business. + ReferencesNo definition available. + Details Name: ctdh_OrganizationAndDescriptionOfBusinessTextBlock Namespace Prefix: ctdh_ Data Type: dtr-types:textBlockItemType

Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Significant Accounting Policies [Text Block] (2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Â Â The following is a summary of the more significant accounting policies of the Company that affect the accompanying condensed consolidated financial statements: Â (a) BASIS OF PRESENTATIONâ€“â€“The condensed consolidated financial statements include the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The interim condensed consolidated financial statements of the Company included in this Quarterly Report on Form 10-Q, including these notes, are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Such adjustments are of a normal, recurring nature. The condensed consolidated financial statements, and these notes, have been prepared in accordance with generally accepted accounting principles and do not contain certain information included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023. The condensed consolidated financial statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Â (b) CASH AND CASH EQUIVALENTSâ€“â€“Cash and cash equivalents consist of cash and any highly liquid investments with an original purchased maturity of three months or less. The Company maintains deposits in financial institutions in excess of federally insured limits of $250,000, in the amount of $928,010 at September 30, 2024. Â (c) ACCOUNTS RECEIVABLEâ€“â€“Accounts receivable are unsecured and non-interest bearing and stated at the amount we expect to collect from outstanding balances. Customer account balances with invoices dated over 90 days old are considered past due. The Company does not accrue interest on past due accounts. Customer payments are allocated to the specific invoices identified on the customerâ€™s remittance advice or, if unspecified, applied to the oldest unpaid invoices. Â The carrying amount of accounts receivable is reduced by an allowance for credit losses that reflects managementâ€™s best estimate of expected credit losses. The Company reviews each customer balance where all or a portion of the balance exceeds 90 days from the invoice date. Based on the Companyâ€™s assessment of the customer's current and forecasted creditworthiness, the Company estimates the portion, if any, of the balance that will not be collected, and writes off receivables as a charge to the allowance for credit losses when, in managementâ€™s estimation, it is probable that the receivable is worthless. The Company determined an allowance for credit losses was not necessary as of September 30, 2024. The allowance for credit losses at December 31, 2023 approximated $10,000. Â The Company develops and documents its allowance for credit losses on its trade receivables based on portfolio segments, which include domestic and international customers. The determination of portfolio segments is based primarily on the customersâ€™ geographical location. Our quantitative allowance for credit loss estimates was determined using the method that uses an aging schedule. The Company also considers qualitative adjustments that may relate to unique risks, changes in current economic conditions that may not be reflected in quantitatively derived results, or other relevant factors to further inform our estimate of the allowance for credit losses. Â (d) INVENTORY AND COST OF PRODUCTS SOLDâ€“â€“Inventory consists of cyclodextrin products and chemical complexes purchased for resale recorded at the lower of cost (first-in, first-out) or net realizable value. Cost of products sold includes the acquisition cost of the products sold and does not include any allocation of inbound or outbound freight charges, indirect overhead expenses, warehouse and distribution expenses, or depreciation and amortization expense. The Company records a specific reserve for inventory items that are determined to be obsolete. The Company determined no reserve for obsolete inventory was necessary as of September 30, 2024 and December 31, 2023. Â The Companyâ€™s reserve for obsolete inventory is based on the Companyâ€™s best estimates of product sales and customer demands. It is reasonably possible that the estimates used by the Company to determine its provisions for inventory write-downs will be materially different from actual write-downs. These differences could result in materially higher than expected inventory provisions and related costs, which could have a material adverse effect on the Companyâ€™s results of operations and financial condition in the near term. Â (e) PREPAID CLINICAL EXPENSESâ€“â€“Prepaid clinical expenses consist of our active pharmaceutical ingredients and other raw materials for our pharmaceutical drug TrappsolÂ® Cycloâ„¢ expected to be used in our clinical trial program recorded at cost. In addition, advance payments for goods or services for future research and development activities are included as prepaid clinical expenses. Prepaid clinical expenses are expensed as research and development costs as the goods are delivered or the related services are performed. Prepaid clinical expenses expected to be utilized beyond one year from the balance sheet date are classified as non-current assets. Â (f) FURNITURE AND EQUIPMENTâ€“â€“Furniture and equipment are recorded at cost, less accumulated depreciation. Depreciation is computed using primarily the straight-line method over the estimated useful lives of the assets (generally three to five years for computers and vehicles and seven to ten years for machinery, equipment and office furniture). We periodically review our long-lived assets to determine if the carrying value of assets may not be recoverable. If an impairment is identified, we recognize a loss for the difference between the carrying amount and the estimated fair value of the asset.Â Â (g) LEASESâ€“â€“The Company leases office and warehouse space. The Company determines if an arrangement is a lease at inception. Contracts containing a lease are further evaluated for classification as an operating or finance lease where the Company is a lessee, or as an operating, sales-type or direct financing lease where the Company is a lessor, based on their terms. Operating leases are included in right-of-use ("ROU") lease assets and lease liabilities on the Companyâ€™s condensed consolidated balance sheets. The Company subleases office space under one existing lease to a third party. Sublease income is reported as other income in the condensed consolidated statements of operations. Â ROU assets represent the Companyâ€™s right to use an underlying asset for the lease term and lease liabilities represent the Companyâ€™s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Companyâ€™s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The lease ROU asset also includes any lease payments made and excludes lease incentives. The Companyâ€™s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable lease payments are expensed as incurred. The Companyâ€™s lease agreements do not contain any material residual value guarantees or material restrictive covenants. Â In evaluating contracts to determine if they qualify as a lease, the Company considers factors such as if the Company has obtained substantially all of the rights to the underlying asset through exclusivity, if it can direct the use of the asset by making decisions about how and for what purpose the asset will be used and if the lessor has substantive substitution rights. This evaluation may require significant judgment. Â (h) REVENUE RECOGNITIONâ€“â€“Revenues are recognized when our customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under Accounting Standard Update (â€œASUâ€) No. 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. Â Product revenues Â The majority of our revenue is garnered in North America from companies in the pharmaceutical industry that are manufacturing or conducting research with our fine chemical products. In other countries, we sell our products primarily to wholesale distributors and other third-party distribution partners. Â Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. Â We treat shipping and handling costs performed after a customer obtains control of the product as a fulfillment cost. We have identified one performance obligation in our contracts with customers which is the delivery of product to our customers.Â The transaction price is recognized in full when we deliver the product to our customer, which is the point at which we have satisfied our performance obligation. Â For additional information on our revenues, please read Note 3, Revenues, to these condensed consolidated financial statements. Â (i) SHIPPING AND HANDLING FEESâ€“â€“Shipping and handling fees, if billed to customers, are included in product sales. Shipping and handling costs associated with inbound and outbound freight are expensed as incurred and included in freight and shipping expense. Â (j) ADVERTISINGâ€“â€“Advertising costs are charged to operations when incurred. We incur minimal advertising expenses. Â (k) RESEARCH AND DEVELOPMENT COSTSâ€“â€“Research and development costs are expensed as incurred. The Company records amounts paid in advance of the service being rendered as a prepaid asset, and the expense recognized when the service is performed. Research and development costs are primarily comprised of materials used in our clinical trials, personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on our contracts with our vendors and are realized in the ordinary course of business.Â Â (l) INCOME TAXESâ€“â€“Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In addition, tax benefits related to positions considered uncertain are recognized only when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions shall initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts. As of September 30, 2024 and December 31, 2023, the Company has recorded a full valuation allowance against its deferred tax assets. Â (m) NET LOSS PER COMMON SHAREâ€“â€“ Basic and fully diluted net loss per common share is computed using a simple weighted average of common shares outstanding during the periods presented, as outstanding warrants to purchase 15,686,916 shares of common stock were antidilutive for the three and nine months ended SeptemberÂ 30, 2024, and warrants to purchase 13,733,117 shares of common stock were antidilutive for the three and nine months ended September 30, 2023. Additionally, outstanding options to purchase 1,779,161 shares of common stock were antidilutive for the three and nine months ended September 30, 2024 and outstanding options to purchase 790,945 shares of common stock were antidilutive for the three and nine months ended September 30, 2023, and therefore also excluded. Â (n) STOCK-BASED

COMPENSATIONâ€“â€“The Company periodically awards stock to employees, directors, and consultants. In the case of employees and consultants, an expense is recognized equal to the fair value of the stock determined using the closing trading price of the stock on the award date. With respect to directors, the Company accrues stock compensation expense on a quarterly basis based on the Companyâ€™s historical director compensation policies, and each quarter recognizes such expense based on the trading price of the common stock during such quarter. Â This expense is then trued up at the time the shares are issued to directors based on the trading price at the time of issuance. Â The Company periodically issues stock options under its 2021 Equity Incentive Plan. The Company uses the Black-Scholes valuation method to estimate the fair value of stock options at grant date. Compensation expense is recognized on the straight-line basis over the requisite service period, which is generally the vesting period. Â (o) FAIR VALUE MEASUREMENTS AND DISCLOSURESâ€“â€“Accounting Standards Codification ("ASCâ€) 820 "Fair Value Measurements and Disclosuresâ€ requires companies to determine fair value based on the price that would be received to sell the asset or paid to transfer the liability to a market participant. ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Â The guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following categories: Â â— Level 1: Quoted market prices in active markets for identical assets or liabilities. Â Â â— Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Â Â â— Level 3: Unobservable inputs that are not corroborated by market data. Â Long-lived assets are measured at fair value on a non-recurring basis and are subject to fair value adjustments when there is evidence of impairment. Â For short-term classes of our financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable, and which are not reported at fair value, the carrying amounts approximate fair value due to their short-term nature.Â Â Â As of September 30, 2024, money market funds and a convertible notes payable were the only financial instruments measured and recorded at fair value on a recurring basis on the Companyâ€™s condensed consolidated balance sheets. Money market funds were recorded within cash and cash equivalents. We classified the convertible notes payable as a Level 3 fair value measurement and used the Black-Scholes model to calculate the fair value as of the date of issuance, and for each reporting period. Key inputs for the simulation are summarized below. The Black-Scholes simulation uses inputs such as the stock price, volatility, the contractual term of the convertible notes payable, risk free interest rates and dividend yields. The following table presents money market funds and the convertible notes payable at their level within the fair value hierarchy for the periods indicated. As of December 31, 2023, money market funds were the only financial instrument measured and recorded at fair value on a recurring basis on the Companyâ€™s condensed consolidated balance sheets. Â Â Fair Value Hierarchy Level Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair Value Â September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â â€‹ Â Â Â Â Â Â Â Â Â Money market funds invested in U.S. government obligations Level 1 Â $ - Â Â Â Â Â Â Â Â Â Â $ - Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Convertible notes payable (Note 7) Level 3 Â Â 10,000,000 Â Â $ - Â Â $ 2,178,000 Â Â $ 12,178,000 Â Total Â $ 10,000,000 Â Â $ - Â Â $ 2,178,000 Â Â $ 12,178,000 Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â â€‹ Â Â Â Â Â Â Â Â Â Money market funds invested in U.S. government obligations Level 1 Â $ 4,792,338 Â Â $ - Â Â $ - Â Â $ 4,792,338 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities: Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Convertible notes payable (Note 7) Level 3 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total Â $ 4,792,338 Â Â $ - Â Â $ - Â Â $ 4,792,338 Â Â The range of key inputs for the Black-Scholes simulation for the three and nine months ended September 30, 2024, were as follows: Â Â Â Three months ended Â Â Nine months ended Â Key Inputs Â September 30, 2024 Â Â September 30, 2024 Â Stock Price Â Â $0.68 â€“ $1.26 Â Â Â $0.68 â€“ $1.27 Â Term (years) Â Â 0.09 â€“ 0.33 Â Â Â 0.09 â€“ 0.37 Â Risk-Free interest rate Â Â 4.7 â€“ 5.40 Â Â Â 4.7 â€“ 5.40 Â Volatility Â Â 53% - 110% Â Â Â 53% - 110% Â Dividend yield Â Â Â - Â Â Â Â Â - Â Â Â Convertible Notes Payable Â The following table sets forth a summary of the changes in the fair value of our convertible notes payable categorized within Level 3 of the fair value hierarchy: Â Balance as of December 31, 2023 Â $ - Â Issuance of Convertible Notes Â Â 10,000,000 Â Change in fair value of Notes Â Â 2,178,000 Â Balance as of September 30, 2024 Â $ 12,178,000 Â Â Â (p) USE OF ESTIMATESâ€“â€“The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions, including regarding contingencies, that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Companyâ€™s most significant estimates relate to inventory obsolescence, stock-based compensation, fair value of convertible notes issued, warrant liability valuation, fair value of warrants issued, assumed liabilities, and allowance for credit losses. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates. Â (q) RECENT ACCOUNTING PRONOUNCEMENTSâ€“â€“ Â In December 2023, the Financial Accounting Standards Board (FASB) issued ASU 2023-09, "Income Taxes (Topic 740) - Improvements to Income Tax Disclosures." The new guidance is intended to enhance the transparency and decision usefulness of income tax disclosures by requiring disaggregated information about a reporting entity's effective tax rate reconciliation and information on income taxes paid. The amendment is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis, with retrospective application permitted. The Company is in the process of evaluating the impact that the adoption of ASU 2023-09 will have on its condensed consolidated financial statements and related disclosures. Â In November 2023, theÂ FASBÂ issuedÂ ASU 2023-07, â€œSegment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures,â€ which is intended to improve reportable segment disclosure requirements, primarily through additional and more detailed information about a reportable segment's expenses. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with retrospective application required and early adoption permitted. The Company is currently evaluating the effect this new guidance will have on its condensed consolidated financial statements and related disclosures. Â In June 2022, the FASB issued ASU No. 2022-03, â€œFair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictionsâ€ ("ASU 2022-03â€) which clarifies guidance for fair value measurement of an equity security subject to a contractual sale restriction and establishes new disclosure requirements for such equity securities. ASU 2022-03 is effective for fiscal years beginning after DecemberÂ 15, 2023 and for interim periods within those fiscal years, with early adoption permitted. The Company adopted the new guidance as of JanuaryÂ 1, 2024, and it did not have a material impact on its condensed consolidated financial statements. Â (r) WARRANTSâ€“â€“The Company accounts for its warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants considering the authoritative guidance in ASC 480, â€œDistinguishing Liabilities from Equityâ€ (â€œASC 480â€) and ASC 815, â€œDerivatives and Hedgingâ€ (â€œASC 815â€). The assessment considers whether the warrants meet the definition of a liability pursuant to ASC 480 and meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Companyâ€™s own common stock and satisfy additional conditions for equity classification. Warrants that are liability-classified are measured at fair value at each reporting date in accordance with the guidance in ASC 820, â€œFair Value Measurement,â€ with any subsequent changes in fair value recognized in the statement of operations in the period of change. The fair value of liability classified warrants was not material at SeptemberÂ 30, 2024 and December 31, 2023. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Revenues 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Revenue from Contract with Customer [Text Block] (3) REVENUES: Â The Company operates in one business segment, which primarily focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life-threatening rare diseases and medical conditions. However, substantially all of the Companyâ€™s revenues are derived from the sale of cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. Â Revenues by product are summarized as follows: Â Â Â Â Three Months Ended September 30 Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â TrappsolÂ® HPB Â $ 36,727 Â Â $ 342,184 Â Â $ 256,331 Â Â $ 485,412 Â TrappsolÂ® Fine Chemical Â Â 196,146 Â Â Â 152,135 Â Â Â 300,085 Â Â Â 267,338 Â AquaplexÂ® Â Â 94 Â Â Â 60 Â Â Â 658 Â Â Â 9,922 Â Other Â Â 805 Â Â Â 1,098 Â Â Â 2,252 Â Â Â 2,334 Â Total revenues Â $ 233,772 Â Â $ 495,477 Â Â $ 559,326 Â Â $ 765,006 Â Â Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Major Customers and Suppliers 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Major Customers and Suppliers Disclosure [Text Block] (4) MAJOR CUSTOMERS AND SUPPLIERS: Â For the three months ended SeptemberÂ 30, 2024, three major customers accounted for 91% of total revenues. For the nine months ended September 30, 2024, four major customers accounted for 90% of total revenues. Accounts receivable for these major customers represent 71% of total accounts receivable at SeptemberÂ 30, 2024. Accounts receivable balances for four customers accounted for 92% of total accounts receivable at SeptemberÂ 30, 2024. Â For the three months ended SeptemberÂ 30, 2023, two major customers accounted for 90% of total revenues. For the nine months ended September 30, 2023, three major customers accounting for 86% of total revenues. Accounts receivable for these major customers represent 76% of total accounts receivable at SeptemberÂ 30, 2023. Accounts receivable balances for three customers accounted for 97% of total accounts receivable at SeptemberÂ 30, 2023. Â The Company purchases inventory primarily from four vendors; however, the Company believes it can maintain purchases at similar levels through other readily available vendors in the marketplace. The Company maintains vendors both domestically and internationally. Â For the nine months ended September 30, 2024 and 2023, the product mix of our revenues consisted of 99% basic natural and chemically modified cyclodextrins and 1% cyclodextrin complexes. For the three months ended September 30, 2024 and 2023, the product mix of our revenues consisted entirely of basic natural and chemically modified cyclodextrins. Â X - DefinitionThe entire disclosure for major customers and suppliers during the reporting period. + ReferencesNo definition available. + Details Name: ctdh_MajorCustomersAndSuppliersDisclosureTextBlock Namespace Prefix: ctdh_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Concentrations of Credit Risk 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Concentration Risk Disclosure [Text Block] (5) CONCENTRATIONS OF CREDIT RISK: Â Significant concentrations of credit risk for all financial instruments owned by the Company are as follows: Â The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash equivalents represent highly liquid investments with maturities of 90 days or less at the date of purchase. Credit risk related to cash and cash equivalents is based on the creditworthiness of the financial institutions at which these funds are held. The Company has cash balances at financial institutions which throughout the year may exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows. To reduce its risk associated with the failure of such financial institutions, the Company evaluates the rating of the financial institutions in which it holds deposits. Any material loss that the Company may experience in the future could have an adverse effect on its ability to pay its operational expenses or make other payments and may require the Company to move its cash to other high quality financial institutions. Currently, the Company is reviewing its bank relationships in order to mitigate its risk to ensure that its exposure is limited or reduced to the Federal Deposit Insurance Corporation protection limits. Â The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable. Â The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements. Â Â X - DefinitionThe entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent + Details Name: us-gaap_ConcentrationRiskDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Accounts Payable and Accrued Expenses 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Accounts Payable and Accrued Liabilities Disclosure [Text Block] (6) ACCOUNTS PAYABLE AND ACCRUED EXPENSES: Â Accounts payable and accrued expenses consistÂ of the following:Â Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Accounts payable Â $ 5,023,095 Â Â $ 4,856,530 Â Accrued bonus compensation Â Â 615,893 Â Â Â 1,590,776 Â Accrued board expense Â Â 115,856 Â Â Â 92,110 Â Accrued clinical research Â Â 520,382 Â Â Â 137,642 Â Sub-lease deposit liability Â Â 51,897 Â Â Â 243,742 Â Merger liabilities Â Â 96,838 Â Â Â 487,402 Â Other Â Â 98,022 Â Â Â 49,214 Â Total accounts payable and accrued expenses Â $ 6,521,983 Â Â $ 7,457,416 Â Â X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Convertible Notes Payable 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Long-Term Debt [Text Block] (7) CONVERTIBLE NOTES PAYABLE: On June 11, 2024, the Company entered into a Note Purchase Agreement (the "Initial NPAâ€) with Rafael Holdings, Inc., a Delaware corporation ("Rafaelâ€), the holder of approximately 31.5% of our common stock, pursuant to which the Company issued and sold a convertible promissory note in the principal amount of $2,000,000 (the "June Noteâ€) to Rafael. Â On July 16, 2024, the Company entered into an Amended and Restated Note Purchase Agreement (the "Amended NPAâ€) with Rafael, which amended and restated the Initial NPA in its entirety, pursuant to which the Company issued and sold a second convertible promissory note in the principal amount of $2,000,000 (the "July Noteâ€) to Rafael. Â On August 21, 2024, the Company entered into a Second Amended and Restated Note Purchase Agreement (the "Second Amended NPAâ€) with Rafael, which amended and restated the Amended NPA dated July 16, 2024 in its entirety, pursuant to which the Company issued and sold a third convertible promissory note in the principal amount of $3,000,000 (the "August Noteâ€) to Rafael. Â On September 9, 2024, the Company entered into a Third Amended and Restated Note Purchase Agreement (the "Third Amended NPAâ€) with Rafael, which amended and restated the Second Amended NPA dated August 21, 2024 in its entirety, pursuant to which the Company issued and sold a fourth convertible promissory note in the principal amount of $3,000,000 (the "September Noteâ€) to Rafael. Â On October 8, 2024, the Company and Rafael entered into an Amendment to Convertible Promissory Notes, which amended the maturity date for each of the June Note, July Note, August Note and September Note to December 21, 2024. Â On October 8, 2024, the Company entered into a Fourth Amended and Restated Note Purchase Agreement (the "Fourth Amended NPAâ€) with Rafael, which amended and restated the Third Amended NPA dated September 9, 2024 in its entirety, pursuant to which the Company issued and sold a fifth convertible promissory note in the principal amount of $3,000,000 (the "October Noteâ€) to Rafael. Â On November 7, 2024, the Company entered into a Fifth Amended and Restated Note Purchase Agreement (the "Fifth Amended NPAâ€) with Rafael, which amended and restated the Fourth Amended NPA dated October 8, 2024 in its entirety, pursuant to which the Company issued and sold a sixth convertible promissory note in the principal amount of $2,000,000 (the "November Note,â€ and together with the June Note, July Note, August Note, September Note and October Note, the "Notes,â€ and each a "Noteâ€) to Rafael. Each Note matures on December 21, 2024 and bears interest at a rate of 5% per annum, payable upon maturity. Â Each Note may be prepaid by the Company in full at any time. The principal amount of each Note is convertible into shares of our common stock, prior to the repayment of such Note, at the option of Rafael; automatically if the Company enters into a Qualified Financing (as defined) and at the option of Rafael if a Sale Transaction (as defined) occurs prior to repayment of such Note, all at the price and on the terms and conditions set forth in such Note; provided, however, that Rafael may not elect to convert a Note if, following such conversion, Rafael will beneficially own more than 49.9% of the outstanding common stock of the Company. Upon the occurrence of an Event of Default (as defined) under any Note, including the failure of the Company to pay the principal or interest under any Note, when due, the obligations of the Company under each Note may be accelerated. The Company has used and intends to use the proceeds of the Notes for working capital and general corporate purposes. Â Due to these embedded features within the Notes, the Company elected to account for the Notes and the embedded features at fair value at inception. Subsequent changes in fair value are recorded as a component of other income (loss) in the condensed consolidated statements of operations. Â Interest expense on the Notes totaled $129,452 and $163,973 for the three and nine months ended September 30, 2024 and is included in the fair value of the Notes. Â The following table presents the Notes as of September 30, 2024: Â Balance as of December 31, 2023 Â $ - Â Issuance of convertible Notes Â Â 10,000,000 Â Change in fair value of Notes Â Â 2,178,000 Â Balance as of September 30, 2024 Â $ 12,178,000 Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent + Details Name: us-gaap_LongTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Leases 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Lessee, Operating Leases [Text Block] (8) LEASES: Â The Company entered into an operating lease in January 2023 for office and warehouse space, which has a lease term expiring in January 2026, with an option to extend for an additional three years. As it is not reasonably certain the Company will exercise the option to extend, the additional three years have not been included in the lease term. This lease replaced an existing operating lease which expired in January 2023. The Company also assumed an operating lease for office space which is being subleased to a third party. The lease and sublease agreement expired in August 2024. Â Right-of-use lease assets are recorded net of accumulated amortization of $880,084 and $17,242 as of SeptemberÂ 30, 2024 and December 31, 2023, respectively. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Lease expense for the three and nine months ended September 30, 2024 was $363,185 and $1,437,196, respectively. Lease expense for the three and nine months ended September 30, 2023 was $7,612 and $22,759, respectively. Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Equity Transactions 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Equity [Text Block] (9) EQUITY TRANSACTIONS: Â The Company accrues stock compensation expense over the period earned for employees and board members. Stock compensation expense for board members is included in â€œBoard of Directors fees and costsâ€ on our condensed consolidated statement of operations, and stock compensation expense for officers and employees that are not board members is included in â€œPersonnelâ€ and â€œResearch and developmentâ€ on our condensed consolidated statement of operations. Â In the three and nine months ended September 30, 2024, the Company recognized compensation expense of approximately $104,500 and $311,137 to board members, in addition to $92,000 of accrued stock compensation as of December 31, 2023 and issued 72,027 and 211,983 shares of common stock to board members in the three and nine months ended September 30, 2024. In the three and nine months ended September 30, 2023, the Company recognized compensation expense to board members of $75,460Â and $185,635, in addition to $30,750 of accrued stock compensation as of December 31, 2022, and issued 55,485 and 195,537 shares of common stock to board members in the three and nine months ended September 30, 2023. The Company did not issue any shares to employees during the three and nine months ended SeptemberÂ 30, 2024 and 2023. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Note 10 - Income Taxes 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Income Tax Disclosure [Text Block] (10) INCOME TAXES: Â The Company reported a net loss for the three and nine months ended SeptemberÂ 30, 2024 and 2023. The Company increased its deferred tax asset valuation allowance rather than recognize an income tax benefit. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Equity Incentive Plan 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Share-Based Payment Arrangement [Text Block] (11) EQUITY INCENTIVE PLAN: Â On August 29, 2019, the Companyâ€™s stockholders approved the Companyâ€™s 2019 Omnibus Equity Incentive Plan at a special meeting of stockholders (the â€œIncentive Planâ€). The Incentive Plan provides for the issuance of up to 68,437 shares of common stock pursuant to the grant of shares of common stock, stock options or other awards, to employees, officers or directors of, and consultants to, the Company and its subsidiaries. Options granted under the Incentive Plan may either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986, or may be non-qualified options, and are exercisable over periods not exceeding ten years from date of grant. As of SeptemberÂ 30, 2024, we had awarded 68,437 shares of common stock as awards under the Incentive Plan, with no shares of common stock remaining available for future awards under the Incentive Plan. Â On June 24, 2021, the Companyâ€™s stockholders approved the Companyâ€™s 2021 Equity Incentive Plan at its annual meeting of stockholders (the â€œ2021 Planâ€). The 2021 Plan provides for the issuance of up to 3,000,000 shares of common stock pursuant to the grant of shares of common stock, stock options or other awards, to employees, officers or directors of, and consultants to, the Company and its subsidiaries. Options granted under the 2021 Plan may either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended, or may be non-qualified options, and are exercisable over periods not exceeding ten years from date of grant. As of SeptemberÂ 30, 2024, we had awarded 608,820 shares of common stock and granted options to purchase 1,671,441 shares of common stock under the 2021 Plan, with 719,739 shares of common stock remaining available for future awards. During the three months ended September 30, 2024, no options to purchase common stock were granted and during the nine months ended September 30, 2024, the Company granted options to purchase 879,341 shares of common stock under the 2021 Plan. The options granted during the nine months ended September 30, 2024 were valued using the Black Scholes option pricing model using the following assumptions: (i) expected term of 3.00 to 6.25 years; (ii) risk free interest rate of 4.41%; (iii) expected volatility of 102.97% to 111.25%; and (iv) dividend yield of 0.0%. The weighted-average grant date fair value of the options issued by the Company during the nine months ended September 30, 2024 ranged from $0.83 to $1.06 per share. Â Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Net Loss Per Share 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Earnings Per Share [Text Block] (12) NET LOSS PER SHARE: Â The following table sets forth the computation of basic and diluted earnings per common share. Â Â Â Three Months Ended Â Â Nine Months Ended Â Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Numerator Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (8,832,944) Â $ (4,771,353) Â $ (19,157,261) Â $ (14,414,893) Denominator Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average common shares outstanding, basic and diluted Â Â 28,729,641 Â Â Â 16,191,723 Â Â Â 28,674,910 Â Â Â 14,394,920 Â Net loss per share, basic and diluted Â $ (0.31) Â $ (0.29) Â $ (0.67) Â $ (1.00) Â Â Â The Company reported a net loss for the three and nine months ended September 30, 2024 and 2023, therefore, the basic and diluted net loss per share are the same in the respective periods because the inclusion of potential common shares would have an anti-dilutive effect. Potential shares of common stock that are excluded from the computation of diluted weighted-average shares outstanding are as follows: Â Â Â Three Months Ended Â Â Nine Months Ended Â Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock options Â Â 1,779,161 Â Â Â 790,945 Â Â Â 1,779,161 Â Â Â 790,945 Â Warrants Â Â 15,686,916 Â Â Â 13,733,117 Â Â Â 15,686,916 Â Â Â 13,733,117 Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Note 13 - Purchase Commitments 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Commitments and Contingencies Disclosure [Text Block] (13) PURCHASE COMMITMENTS: Â In connection with an agreement executed in January 2022 with Ashland, Inc., the Company committed to purchase the minimum amounts of goods used in its normal operations based on completion of certain milestones. The first milestone was met during the first quarter of 2023, and $980,000 of goods were purchased and received. In the second quarter of 2023, the Company was invoiced for the second milestone, and began to receive product during the first quarter of 2024. Milestone three was achieved in the third quarter of 2024 and final payment was made. No future minimum purchases remain as of September 30, 2024. Â Â X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Note 14 - Subsequent Events 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Subsequent Events [Text Block] (14) SUBSEQUENT EVENTS: Â Nasdaq Delisting Notice Â On October 4, 2024, the Company received two letters from The Nasdaq Stock Market ("Nasdaqâ€) stating that the Company was not in compliance with the following four Nasdaq Listing Rules: (1) failing to maintain a closing bid price of no less than $1.00 per share for 30 consecutive trading days, (2) stockholdersâ€™ equity of the Company was below the minimum requirement of $2.5 million, (3) failing to maintain a minimum Market Value of Listed Securities of $35 million, and (4) failing to maintain net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years. Â Pursuant to the Nasdaq Listing Rules, the Company has 180 calendar days from October 4, 2024 (until April 2, 2025) to regain compliance with the Nasdaq Listing Rules. In the event the Company does not regain compliance with item (1) above prior to the expiration of the compliance period, the Company may be granted an additional 180 calendar days to regain compliance, subject to certain conditions. In the event the Company does not regain compliance with item (2) above prior to the expiration of the compliance period, the Company will receive written notification from Nasdaq that its securities are subject to delisting. Â Convertible Promissory Notes Â On October 8, 2024, the Company entered into the Fourth Amended NPA with Rafael, pursuant to which the Company issued and sold a convertible promissory note in the principal amount of $3,000,000 to Rafael. On November 7, 2024, the Company entered into the Fifth Amended NPA with Rafael, pursuant to which the Company issued and sold a convertible promissory note in the principal amount of $2,000,000 to Rafael. For additional information on these convertible promissory notes, please read Note 7, Convertible Notes Payable, to these condensed consolidated financial statements. Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Insider Trading Arr Line Items Â Â Material Terms of Trading Arrangement [Text Block] Â Item 5.Â Other Information Â During the fiscal quarter ended SeptemberÂ 30, 2024,Â noneÂ of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any â€œnon-Rule 10b5-1 trading arrangement,â€ as defined in Item 408(a) of Regulation S-K.Â Â Â Â Non-Rule 10b5-1 Arrangement Adopted [Flag] false Â Rule 10b5-1 Arrangement Adopted [Flag] false Â Rule 10b5-1 Arrangement Terminated [Flag] false Â Non-Rule 10b5-1 Arrangement Terminated [Flag] false Â X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a + Details Name: ecd_InsiderTradingArrLineItems Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X -

ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Accounting, Policy [Policy Text Block] (a) BASIS OF PRESENTATIONâ€“â€“The condensed consolidated financial statements include the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The interim condensed consolidated financial statements of the Company included in this Quarterly Report on Form 10-Q, including these notes, are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Such adjustments are of a normal, recurring nature. The condensed consolidated financial statements, and these notes, have been prepared in accordance with generally accepted accounting principles and do not contain certain information included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023. The condensed consolidated financial statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Â Cash and Cash Equivalents, Policy [Policy Text Block] (b) CASH AND CASH EQUIVALENTSâ€“â€“Cash and cash equivalents consist of cash and any highly liquid investments with an original purchased maturity of three months or less. The Company maintains deposits in financial institutions in excess of federally insured limits of $250,000, in the amount of $928,010 at September 30, 2024. Receivable [Policy Text Block] (c) ACCOUNTS RECEIVABLEâ€“â€“Accounts receivable are unsecured and non-interest bearing and stated at the amount we expect to collect from outstanding balances. Customer account balances with invoices dated over 90 days old are considered past due. The Company does not accrue interest on past due accounts. Customer payments are allocated to the specific invoices identified on the customerâ€™s remittance advice or, if unspecified, applied to the oldest unpaid invoices. Â The carrying amount of accounts receivable is reduced by an allowance for credit losses that reflects managementâ€™s best estimate of expected credit losses. The Company reviews each customer balance where all or a portion of the balance exceeds 90 days from the invoice date. Based on the Companyâ€™s assessment of the customer's current and forecasted creditworthiness, the Company estimates the portion, if any, of the balance that will not be collected, and writes off receivables as a charge to the allowance for credit losses when, in managementâ€™s estimation, it is probable that the receivable is worthless. The Company determined an allowance for credit losses was not necessary as of September 30, 2024. The allowance for credit losses at December 31, 2023 approximated $10,000. Â The Company develops and documents its allowance for credit losses on its trade receivables based on portfolio segments, which include domestic and international customers. The determination of portfolio segments is based primarily on the customersâ€™ geographical location. Our quantitative allowance for credit loss estimates was determined using the method that uses an aging schedule. The Company also considers qualitative adjustments that may relate to unique risks, changes in current economic conditions that may not be reflected in quantitatively derived results, or other relevant factors to further inform our estimate of the allowance for credit losses. Inventory, Policy [Policy Text Block] (d) INVENTORY AND COST OF PRODUCTS SOLDâ€“â€“Inventory consists of cyclodextrin products and chemical complexes purchased for resale recorded at the lower of cost (first-in, first-out) or net realizable value. Cost of products sold includes the acquisition cost of the products sold and does not include any allocation of inbound or outbound freight charges, indirect overhead expenses, warehouse and distribution expenses, or depreciation and amortization expense. The Company records a specific reserve for inventory items that are determined to be obsolete. The Company determined no reserve for obsolete inventory was necessary as of September 30, 2024 and December 31, 2023. Â The Companyâ€™s reserve for obsolete inventory is based on the Companyâ€™s best estimates of product sales and customer demands. It is reasonably possible that the estimates used by the Company to determine its provisions for inventory write-downs will be materially different from actual write-downs. These differences could result in materially higher than expected inventory provisions and related costs, which could have a material adverse effect on the Companyâ€™s results of operations and financial condition in the near term. Prepaid Expenses [Policy Text Block] (e) PREPAID CLINICAL EXPENSESâ€“â€“Prepaid clinical expenses consist of our active pharmaceutical ingredients and other raw materials for our pharmaceutical drug TrappsolÂ® Cycloâ„¢ expected to be used in our clinical trial program recorded at cost. In addition, advance payments for goods or services for future research and development activities are included as prepaid clinical expenses. Prepaid clinical expenses are expensed as research and development costs as the goods are delivered or the related services are performed. Prepaid clinical expenses expected to be utilized beyond one year from the balance sheet date are classified as non-current assets. Â Property, Plant and Equipment, Policy [Policy Text Block] (f) FURNITURE AND EQUIPMENTâ€“â€“Furniture and equipment are recorded at cost, less accumulated depreciation. Depreciation is computed using primarily the straight-line method over the estimated useful lives of the assets (generally three to five years for computers and vehicles and seven to ten years for machinery, equipment and office furniture). We periodically review our long-lived assets to determine if the carrying value of assets may not be recoverable. If an impairment is identified, we recognize a loss for the difference between the carrying amount and the estimated fair value of the asset.Â Â Lessee, Leases [Policy Text Block] (g) LEASESâ€“â€“The Company leases office and warehouse space. The Company determines if an arrangement is a lease at inception. Contracts containing a lease are further evaluated for classification as an operating or finance lease where the Company is a lessee, or as an operating, sales-type or direct financing lease where the Company is a lessor, based on their terms. Operating leases are included in right-of-use ("ROU") lease assets and lease liabilities on the Companyâ€™s condensed consolidated balance sheets. The Company subleases office space under one existing lease to a third party. Sublease income is reported as other income in the condensed consolidated statements of operations. Â ROU assets represent the Companyâ€™s right to use an underlying asset for the lease term and lease liabilities represent the Companyâ€™s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Companyâ€™s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The lease ROU asset also includes any lease payments made and excludes lease incentives. The Companyâ€™s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable lease payments are expensed as incurred. The Companyâ€™s lease agreements do not contain any material residual value guarantees or material restrictive covenants. Â In evaluating contracts to determine if they qualify as a lease, the Company considers factors such as if the Company has obtained substantially all of the rights to the underlying asset through exclusivity, if it can direct the use of the asset by making decisions about how and for what purpose the asset will be used and if the lessor has substantive substitution rights. This evaluation may require significant judgment. Â Revenue [Policy Text Block] (h) REVENUE RECOGNITIONâ€“â€“Revenues are recognized when our customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under Accounting Standard Update (â€œASUâ€) No. 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. Â Product revenues Â The majority of our revenue is garnered in North America from companies in the pharmaceutical industry that are manufacturing or conducting research with our fine chemical products. In other countries, we sell our products primarily to wholesale distributors and other third-party distribution partners. Â Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. Â We treat shipping and handling costs performed after a customer obtains control of the product as a fulfillment cost. We have identified one performance obligation in our contracts with customers which is the delivery of product to our customers.Â The transaction price is recognized in full when we deliver the product to our customer, which is the point at which we have satisfied our performance obligation. Â For additional information on our revenues, please read Note 3, Revenues, to these condensed consolidated financial statements. Â Revenue from Contract with Customer, Shipping and Handling Fees, Policy [Policy Text Block] (i) SHIPPING AND HANDLING FEESâ€“â€“Shipping and handling fees, if billed to customers, are included in product sales. Shipping and handling costs associated with inbound and outbound freight are expensed as incurred and included in freight and shipping expense. Â Advertising Cost [Policy Text Block] (j) ADVERTISINGâ€“â€“Advertising costs are charged to operations when incurred. We incur minimal advertising expenses. Â Research and Development Expense, Policy [Policy Text Block] (k) RESEARCH AND DEVELOPMENT COSTSâ€“â€“Research and development costs are expensed as incurred. The Company records amounts paid in advance of the service being rendered as a prepaid asset, and the expense recognized when the service is performed. Research and development costs are primarily comprised of materials used in our clinical trials, personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on our contracts with our vendors and are realized in the ordinary course of business.Â Â Income Tax, Policy [Policy Text Block] (l) INCOME TAXESâ€“â€“Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In addition, tax benefits related to positions considered uncertain are recognized only when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions shall initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts. As of September

30, 2024 and December 31, 2023, the Company has recorded a full valuation allowance against its deferred tax assets. Â Earnings Per Share, Policy [Policy Text Block] (m) NET LOSS PER COMMON SHAREâ€“â€“ Basic and fully diluted net loss per common share is computed using a simple weighted average of common shares outstanding during the periods presented, as outstanding warrants to purchase 15,686,916 shares of common stock were antidilutive for the three and nine months ended SeptemberÂ 30, 2024, and warrants to purchase 13,733,117 shares of common stock were antidilutive for the three and nine months ended September 30, 2023. Additionally, outstanding options to purchase 1,779,161 shares of common stock were antidilutive for the three and nine months ended September 30, 2024 and outstanding options to purchase 790,945 shares of common stock were antidilutive for the three and nine months ended September 30, 2023, and therefore also excluded. Â Share-Based Payment Arrangement [Policy Text Block] (n) STOCK-BASED COMPENSATIONâ€“â€“The Company periodically awards stock to employees, directors, and consultants. In the case of employees and consultants, an expense is recognized equal to the fair value of the stock determined using the closing trading price of the stock on the award date. With respect to directors, the Company accrues stock compensation expense on a quarterly basis based on the Companyâ€™s historical director compensation policies, and each quarter recognizes such expense based on the trading price of the common stock during such quarter. Â This expense is then trued up at the time the shares are issued to directors based on the trading price at the time of issuance. Â The Company periodically issues stock options under its 2021 Equity Incentive Plan. The Company uses the Black-Scholes valuation method to estimate the fair value of stock options at grant date. Compensation expense is recognized on the straight-line basis over the requisite service period, which is generally the vesting period. Â Fair Value Measurement, Policy [Policy Text Block] (o) FAIR VALUE MEASUREMENTS AND DISCLOSURESâ€“â€“Accounting Standards Codification ("ASCâ€) 820 "Fair Value Measurements and Disclosuresâ€ requires companies to determine fair value based on the price that would be received to sell the asset or paid to transfer the liability to a market participant. ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Â The guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following categories: Â â— Level 1: Quoted market prices in active markets for identical assets or liabilities. Â Â â— Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Â Â â— Level 3: Unobservable inputs that are not corroborated by market data. Â Long-lived assets are measured at fair value on a non-recurring basis and are subject to fair value adjustments when there is evidence of impairment. Â For short-term classes of our financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable, and which are not reported at fair value, the carrying amounts approximate fair value due to their short-term nature.Â Â Â As of September 30, 2024, money market funds and a convertible notes payable were the only financial instruments measured and recorded at fair value on a recurring basis on the Companyâ€™s condensed consolidated balance sheets. Money market funds were recorded within cash and cash equivalents. We classified the convertible notes payable as a Level 3 fair value measurement and used the Black-Scholes model to calculate the fair value as of the date of issuance, and for each reporting period. Key inputs for the simulation are summarized below. The Black-Scholes simulation uses inputs such as the stock price, volatility, the contractual term of the convertible notes payable, risk free interest rates and dividend yields. The following table presents money market funds and the convertible notes payable at their level within the fair value hierarchy for the periods indicated. As of December 31, 2023, money market funds were the only financial instrument measured and recorded at fair value on a recurring basis on the Companyâ€™s condensed consolidated balance sheets. Â Â Fair Value Hierarchy Level Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair Value Â September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â â€‹ Â Â Â Â Â Â Â Â Â Money market funds invested in U.S. government obligations Level 1 Â $ - Â Â Â Â Â Â Â Â Â Â $ - Â Liabilities: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Convertible notes payable (Note 7) Level 3 Â Â 10,000,000 Â Â $ - Â Â $ 2,178,000 Â Â $ 12,178,000 Â Total Â $ 10,000,000 Â Â $ - Â Â $ 2,178,000 Â Â $ 12,178,000 Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â â€‹ Â Â Â Â Â Â Â Â Â Money market funds invested in U.S. government obligations Level 1 Â $ 4,792,338 Â Â $ - Â Â $ - Â Â $ 4,792,338 Â Liabilities: Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Convertible notes payable (Note 7) Level 3 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total Â $ 4,792,338 Â Â $ - Â Â $ - Â Â $ 4,792,338 Â Â The range of key inputs for the Black-Scholes simulation for the three and nine months ended September 30, 2024, were as follows: Â Â Â Three months ended Â Â Nine months ended Â Key Inputs Â September 30, 2024 Â Â September 30, 2024 Â Stock Price Â Â $0.68 â€“ $1.26 Â Â Â $0.68 â€“ $1.27 Â Term (years) Â Â 0.09 â€“ 0.33 Â Â Â 0.09 â€“ 0.37 Â Risk-Free interest rate Â Â 4.7 â€“ 5.40 Â Â Â 4.7 â€“ 5.40 Â Volatility Â Â 53% - 110% Â Â Â 53% - 110% Â Dividend yield Â Â Â - Â Â Â Â Â - Â Â Â Convertible Notes Payable Â The following table sets forth a summary of the changes in the fair value of our convertible notes payable categorized within Level 3 of the fair value hierarchy: Â Balance as of December 31, 2023 Â $ - Â Issuance of Convertible Notes Â Â 10,000,000 Â Change in fair value of Notes Â Â 2,178,000 Â Balance as of September 30, 2024 Â $ 12,178,000 Â Â Â Use of Estimates, Policy [Policy Text Block] (p) USE OF ESTIMATESâ€“â€“The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions, including regarding contingencies, that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Companyâ€™s most significant estimates relate to inventory obsolescence, stock-based compensation, fair value of convertible notes issued, warrant liability valuation, fair value of warrants issued, assumed liabilities, and allowance for credit losses. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates. New Accounting Pronouncements, Policy [Policy Text Block] (q) RECENT ACCOUNTING PRONOUNCEMENTSâ€“â€“ Â In December 2023, the Financial Accounting Standards Board (FASB) issued ASU 2023-09, "Income Taxes (Topic 740) - Improvements to Income Tax Disclosures." The new guidance is intended to enhance the transparency and decision usefulness of income tax disclosures by requiring disaggregated information about a reporting entity's effective tax rate reconciliation and information on income taxes paid. The amendment is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis, with retrospective application permitted. The Company is in the process of evaluating the impact that the adoption of ASU 2023-09 will have on its condensed consolidated financial statements and related disclosures. Â In November 2023, theÂ FASBÂ issuedÂ ASU 2023-07, â€œSegment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures,â€ which is intended to improve reportable segment disclosure requirements, primarily through additional and more detailed information about a reportable segment's expenses. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with retrospective application required and early adoption permitted. The Company is currently evaluating the effect this new guidance will have on its condensed consolidated financial statements and related disclosures. Â In June 2022, the FASB issued ASU No. 2022-03, â€œFair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictionsâ€ ("ASU 2022-03â€) which clarifies guidance for fair value measurement of an equity security subject to a contractual sale restriction and establishes new disclosure requirements for such equity securities. ASU 2022-03 is effective for fiscal years beginning after DecemberÂ 15, 2023 and for interim periods within those fiscal years, with early adoption permitted. The Company adopted the new guidance as of JanuaryÂ 1, 2024, and it did not have a material impact on its condensed consolidated financial statements. Warrants [Policy Text Block] Â (r) WARRANTSâ€“â€“The Company accounts for its warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants considering the authoritative guidance in ASC 480, â€œDistinguishing Liabilities from Equityâ€ (â€œASC 480â€) and ASC 815, â€œDerivatives and Hedgingâ€ (â€œASC 815â€). The assessment considers whether the warrants meet the definition of a liability pursuant to ASC 480 and meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Companyâ€™s own common stock and satisfy additional conditions for equity classification. Warrants that are liability-classified are measured at fair value at each reporting date in accordance with the guidance in ASC 820, â€œFair Value Measurement,â€ with any subsequent changes in fair value recognized in the statement of operations in the period of change. The fair value of liability classified warrants was not material at SeptemberÂ 30, 2024 and December 31, 2023. X - DefinitionDisclosure of accounting policy for prepaid expenses. + ReferencesNo definition available. + Details Name: ctdh_PrepaidExpensesPolicyTextBlock Namespace Prefix: ctdh_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the classification of shipping and handling fees, including whether the fees are included in cost of sales or included in other income statement accounts. + ReferencesNo definition available. + Details Name: ctdh_RevenueFromContractWithCustomerShippingAndHandlingFeesPolicyPolicyTextBlock Namespace Prefix: ctdh_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionThe disclosure for the accounting policy for warrants. + ReferencesNo definition available. + Details Name: ctdh_WarrantsPolicyTextBlock Namespace Prefix: ctdh_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for advertising cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 35 -Topic 720 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1 + Details Name: us-gaap_AdvertisingCostsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContentReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6 + Details Name: us-gaap_InventoryPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1 + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2 + Details Name: us-gaap_ReceivablesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4 + Details Name: us-gaap_RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph

(SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Fair Value, Assets Measured on Recurring Basis [Table Text Block] Â Fair Value Hierarchy Level Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair Value Â September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â â€‹ Â Â Â Â Â Â Â Â Money market funds invested in U.S. government obligations Level 1 Â $ - Â Â Â Â Â Â Â Â Â Â $ - Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Convertible notes payable (Note 7) Level 3 Â Â 10,000,000 Â Â $ - Â Â $ 2,178,000 Â Â $ 12,178,000 Â Total Â $ 10,000,000 Â Â $ - Â Â $ 2,178,000 Â Â $ 12,178,000 Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â â€‹ Â Â Â Â Â Â Â Â Â Money market funds invested in U.S. government obligations Level 1 Â $ 4,792,338 Â Â $ - Â Â $ - Â Â $ 4,792,338 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities: Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Convertible notes payable (Note 7) Level 3 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total Â $ 4,792,338 Â Â $ - Â Â $ - Â Â $ 4,792,338 Â Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Â Â Three months ended Â Â Nine months ended Â Key Inputs Â September 30, 2024 Â Â September 30, 2024 Â Stock Price Â Â $0.68 â€“ $1.26 Â Â Â $0.68 â€“ $1.27 Â Term (years) Â Â 0.09 â€“ 0.33 Â Â Â 0.09 â€“ 0.37 Â Risk-Free interest rate Â Â 4.7 â€“ 5.40 Â Â Â 4.7 â€“ 5.40 Â Volatility Â Â 53% - 110% Â Â Â 53% - 110% Â Dividend yield Â Â Â - Â Â Â Â Â - Â Â Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Balance as of December 31, 2023 Â $ - Â Issuance of Convertible Notes Â Â 10,000,000 Â Change in fair value of Notes Â Â 2,178,000 Â Balance as of September 30, 2024 Â $ 12,178,000 Â X - DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Revenues (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Disaggregation of Revenue [Table Text Block] Â Â Three Months Ended September 30 Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â TrappsolÂ® HPB Â $ 36,727 Â Â $ 342,184 Â Â $ 256,331 Â Â $ 485,412 Â TrappsolÂ® Fine Chemical Â Â 196,146 Â Â Â 152,135 Â Â Â 300,085 Â Â Â 267,338 Â AquaplexÂ® Â Â 94 Â Â Â 60 Â Â Â 658 Â Â Â 9,922 Â Other Â Â 805 Â Â Â 1,098 Â Â Â 2,252 Â Â Â 2,334 Â Total revenues Â $ 233,772 Â Â $ 495,477 Â Â $ 559,326 Â Â $ 765,006 Â X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Accounts Payable and Accrued Expenses (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Accounts payable Â $ 5,023,095 Â Â $ 4,856,530 Â Accrued bonus compensation Â Â 615,893 Â Â Â 1,590,776 Â Accrued board expense Â Â 115,856 Â Â Â 92,110 Â Accrued clinical research Â Â 520,382 Â Â Â 137,642 Â Sub-lease deposit liability Â Â 51,897 Â Â Â 243,742 Â Merger liabilities Â Â 96,838 Â Â Â 487,402 Â Other Â Â 98,022 Â Â Â 49,214 Â Total accounts payable and accrued expenses Â $ 6,521,983 Â Â $ 7,457,416 Â X - DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Convertible Notes Payable (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Convertible Debt [Table Text Block] Balance as of December 31, 2023 Â $ - Â Issuance of convertible Notes Â Â 10,000,000 Â Change in fair value of Notes Â Â 2,178,000 Â Balance as of September 30, 2024 Â $ 12,178,000 Â X - DefinitionTabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount. + ReferencesNo definition available. + Details Name: us-gaap_ConvertibleDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Net Loss Per Share (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Â Â Three Months Ended Â Â Nine Months Ended Â Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Numerator Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (8,832,944) Â $ (4,771,353) Â $ (19,157,261) Â $ (14,414,893) Denominator Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average common shares outstanding, basic and diluted Â Â 28,729,641 Â Â Â 16,191,723 Â Â Â 28,674,910 Â Â Â 14,394,920 Â Net loss per share, basic and diluted Â $ (0.31) Â $ (0.29) Â $ (0.67) Â $ (1.00) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Â Â Three Months Ended Â Â Nine Months Ended Â Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock options Â Â 1,779,161 Â Â Â 790,945 Â Â Â 1,779,161 Â Â Â 790,945 Â Warrants Â Â 15,686,916 Â Â Â 13,733,117 Â Â Â 15,686,916 Â Â Â 13,733,117 Â X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Note 1 - Organization and Description of Business (Details Textual) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Nov. 12, 2024 Aug. 21, 2024 Dec. 31, 2023 Net Income (Loss) Attributable to Parent $ 8,832,944 $ 4,771,353 $ 19,157,261 $ 14,414,893 Â Â Â Retained Earnings (Accumulated Deficit) 103,013,942 Â 103,013,942 Â Â Â $ 83,856,681 Net Cash Provided by (Used in) Operating Activities Â Â (18,222,671) $ (11,890,144) Â Â Â Cash and Cash Equivalents, at Carrying Value 928,010 Â 928,010 Â Â Â $ 9,246,592 Working Capital Deficit $ (15,463,491) Â $ (15,463,491) Â Â Â Â Rafael Holdings, Inc. [Member] | Subsequent Event [Member] Â Â Â Â Â Â Â Long-Term Debt Â Â Â Â $ 15,000,000 Â Â Merger Agreement [Member] Â Â Â Â Â Â Â Business Acquisition, Number of Warrants Able to Receive Cash Â Â Â Â Â 5,498,914 Â Business Acquisition, Maximum Reimbursement of Costs Â Â Â Â Â $ 250,000 Â Business Acquisition, Termination Fee Â Â Â Â Â $ 400,000 Â X - DefinitionAmount of maximum reimbursement of costs in the business acquisition. + ReferencesNo definition available. + Details Name: ctdh_BusinessAcquisitionMaximumReimbursementOfCosts Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe number of warrants able to receive cash in the business acquisition. + ReferencesNo definition available. + Details Name: ctdh_BusinessAcquisitionNumberOfWarrantsAbleToReceiveCash Namespace Prefix: ctdh_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of fee if termination of the business acquisition occurs. + ReferencesNo definition available. + Details Name: ctdh_BusinessAcquisitionTerminationFee Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe difference between the current assets and current liabilities that is used as a financial metric for operating liquidity. + ReferencesNo definition available. + Details Name: ctdh_WorkingCapitalDeficit Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LineOfCreditFacilityAxis=ctdh_RafaelHoldingsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=ctdh_MergerAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Cash and Cash Equivalents, at Carrying Value $ 928,010 Â $ 928,010 Â $ 9,246,592 Accounts Receivable, Allowance for Credit Loss 0 Â 0 Â 10,000 Inventory Valuation Reserves $ 0 Â $ 0 Â $ 0 Warrants To Purchase Common Stock [Member] Â Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 15,686,916 13,733,117 15,686,916 13,733,117 Â Share-Based Payment Arrangement, Option [Member] Â Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1,779,161 790,945 1,779,161 790,945 Â Computers and Vehicles [Member] | Minimum [Member] Â Â Â Â Â Property, Plant and Equipment, Useful Life 3 years Â 3 years Â Â Computers and Vehicles [Member] | Maximum [Member] Â Â Â Â Â Property, Plant and Equipment, Useful Life 5 years Â 5 years Â Â Machinery and Furniture [Member] | Minimum [Member] Â Â Â Â Â Property, Plant and Equipment, Useful Life 7 years Â 7 years Â Â Machinery and Furniture [Member] | Maximum [Member] Â Â Â Â Â Property, Plant and Equipment, Useful Life 10 years Â 10 years Â Â X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of valuation reserve for inventory. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryValuationReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ctdh_WarrantsToPurchaseCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ctdh_ComputersAndVehiclesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ctdh_MachineryAndFurnitureMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies - Fair Values (Details) - USD ($) 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Cash and cash equivalents $ 928,010 $ 9,246,592 Fair Value, Recurring [Member] Â Â Total, amortized cost 10,000,000 4,792,338 Total, gross unrealized losses 2,178,000 0 Total, fair value 12,178,000 4,792,338 Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] Â Â Convertible notes payable, amortized cost 10,000,000 Â Convertible notes payable, gross unrealized gains 0 Â Convertible notes payable, gross unrealized losses 2,178,000 Â Convertible notes payable, fair value 12,178,000 Â Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] Â Â Cash and cash equivalents 0 4,792,338 Cash and cash equivalents, fair value $ 0 4,792,338 Money market funds invested in U.S. government obligations, gross unrealized losses Â 0 Money market funds invested in U.S. government obligations, fair value Â $ 0 X - DefinitionAmount of unrealized gain before deducting unrealized loss on cash and cash equivalents. + ReferencesNo definition available. + Details Name: ctdh_CashAndCashEquivalentsGrossUnrealizedGain Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of unrealized loss before deducting unrealized gain on cash and cash equivalents. + ReferencesNo definition available. + Details Name: ctdh_CashAndCashEquivalentsGrossUnrealizedLoss Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of financial instrument. + ReferencesNo definition available. + Details Name: ctdh_FinancialInstrumentFairValue Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionAmount of gross unrealized losses on financial instruments. + ReferencesNo definition available. + Details Name: ctdh_FinancialInstrumentGrossUnrealizedLosses Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortized cost of financial instruments. + ReferencesNo definition available. + Details Name: ctdh_FinancialInstrumentsAmortizedCost Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionRepresents the gain from the change in fair value of convertible promissory notes. + ReferencesNo definition available. + Details Name: ctdh_GainFromChangeInFairValueOfConvertiblePromissoryNotes Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the loss from a change in the fair value of convertible promissory notes. + ReferencesNo definition available. + Details Name: ctdh_LossFromChangeInFairValueOfConvertiblePromissoryNotes Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DebtInstrumentFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies - Key Inputs (Details) - Convertible Debt [Member] 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Measurement Input, Share Price [Member] | Minimum

[Member] Â Â Key inputs 0.68 0.68 Measurement Input, Share Price [Member] | Maximum [Member] Â Â Key inputs 1.26 1.27 Measurement Input, Expected Term [Member] | Minimum [Member] Â Â Key inputs 0.09 0.09 Measurement Input, Expected Term [Member] | Maximum [Member] Â Â Key inputs 0.33 0.37 Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] Â Â Key inputs 0.047 0.047 Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] Â Â Key inputs 0.054 0.054 Measurement Input, Price Volatility [Member] | Minimum [Member] Â Â Key inputs 0.53 0.53 Measurement Input, Price Volatility [Member] | Maximum [Member] Â Â Key inputs 1.10 1.10 Measurement Input, Expected Dividend Rate [Member] Â Â Key inputs 0 0 X - DefinitionValue of input used to measure convertible debt. + ReferencesNo definition available. + Details Name: ctdh_ConvertibleDebtMeasurementInput Namespace Prefix: ctdh_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies - Changes in Fair Value of Notes (Details) - Convertible Notes Payable [Member] 9 Months Ended Sep. 30, 2024 USD ($) Balance $ 0 Issuance of Convertible Note 10,000,000 Change in fair value of Note 2,178,000 Balance $ 12,178,000 X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Revenues (Details Textual) 3 Months Ended Sep. 30, 2024 Number of Operating Segments 1 X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Revenues - Revenues by Product (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Total revenues $ 233,772 $ 495,477 $ 559,326 $ 765,006 Trappsol Cyclo [Member] Â Â Â Â Total revenues 36,727 342,184 256,331 485,412 Trappsol HPB [Member] Â Â Â Â Total revenues 196,146 152,135 300,085 267,338 Aquaplex [Member] Â Â Â Â Total revenues 94 60 658 9,922 Product and Service, Other [Member] Â Â Â Â Total revenues $ 805 $ 1,098 $ 2,252 $ 2,334 X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=ctdh_TrappsolCycloMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ctdh_TrappsolHPBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ctdh_AquaplexMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Major Customers and Suppliers (Details Textual) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Customer Concentration Risk [Member] | Revenue Benchmark [Member] Â Â Â Â Number of Major Customers 3 2 4 3 Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Three Major Customers [Member] Â Â Â Â Concentration Risk, Percentage 91.00% Â Â 86.00% Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Four Major Customers [Member] Â Â Â Â Concentration Risk, Percentage Â Â 90.00% Â Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Two Major Customers [Member] Â Â Â Â Concentration Risk, Percentage Â 90.00% Â Â Customer Concentration Risk [Member] | Accounts Receivable [Member] Â Â Â Â Number of Major Customers Â Â 4 3 Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Major Customers [Member] Â Â Â Â Concentration Risk, Percentage 71.00% Â Â 97.00% Customer Concentration Risk [Member] | Accounts Receivable [Member] | Four Major Customers [Member] Â Â Â Â Concentration Risk, Percentage Â Â 92.00% Â Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Major Customers [Member] Â Â Â Â Concentration Risk, Percentage Â 76.00% Â Â Product Concentration Risk [Member] | Revenue Benchmark [Member] | Basic Natural and Chemically Modified Cyclodexterins [Member] Â Â Â Â Concentration Risk, Percentage Â Â 99.00% 99.00% Product Concentration Risk [Member] | Revenue Benchmark [Member] | Cyclodexterin Complexes [Member] Â Â Â Â

Concentration Risk, Percentage Â Â 1.00% 1.00% X - DefinitionRepresents the number of major customers. + ReferencesNo definition available. + Details Name: ctdh_NumberOfMajorCustomers Namespace Prefix: ctdh_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=ctdh_ThreeMajorCustomersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=ctdh_FourMajorCustomersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=ctdh_TwoMajorCustomersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ctdh_BasicNaturalAndChemicallyModifiedCyclodexterinsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ctdh_CyclodexterinComplexesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Accounts payable $ 5,023,095 $ 4,856,530 Accrued bonus compensation 615,893 1,590,776 Accrued board expense 115,856 92,110 Accrued clinical research 520,382 137,642 Sub-lease deposit liability 51,897 243,742 Merger liabilities 96,838 487,402 Other 98,022 49,214 Total accounts payable and accrued expenses $ 6,521,983 $ 7,457,416 X - DefinitionAmount of accrued board expense, classified as current. + ReferencesNo definition available. + Details Name: ctdh_AccruedBoardExpenseCurrent Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accrued clinical research, classified as current. + ReferencesNo definition available. + Details Name: ctdh_AccruedClinicalResearchCurrent Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedBonusesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe current portion, due within one year or one operating cycle, if longer, of deposits held other than customer deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DepositLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Convertible Notes Payable (Details Textual) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Nov. 01, 2024 Oct. 08, 2024 Sep. 09, 2024 Aug. 21, 2024 Jul. 16, 2024 Jun. 11, 2024 Rafael Holdings, Inc. [Member] Â Â Â Â Â Â Â Â Debt Instrument, Interest Rate, Stated Percentage 5.00% 5.00% Â Â Â Â Â Â Interest Expense, Debt $ 129,452 $ 163,973 Â Â Â Â Â Â Rafael Holdings, Inc. [Member] | June Note [Member] Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â Â Â Â Â Â Â $ 2,000,000 Rafael Holdings, Inc. [Member] | July Note [Member] Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â Â Â Â Â Â $ 2,000,000 Â Rafael Holdings, Inc. [Member] | August Note [Member] Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â Â Â Â Â $ 3,000,000 Â Â Rafael Holdings, Inc. [Member] | September Note [Member] Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â Â Â Â $ 3,000,000 Â Â Â Rafael Holdings, Inc. [Member] | October Note [Member] | Subsequent Event [Member] Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â Â Â $ 3,000,000 Â Â Â Â Rafael Holdings, Inc. [Member] | November Note [Member] | Subsequent Event [Member] Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â Â $ 2,000,000 Â Â Â Â Â Rafael Holdings, Inc. [Member] Â Â Â Â Â Â Â Â Ownership Percentage Â Â Â Â Â Â Â 31.50% X - DefinitionPercentage of ownership. + ReferencesNo definition available. + Details Name: ctdh_OwnershipPercentage Namespace Prefix: ctdh_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher

FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_LineOfCreditFacilityAxis=ctdh_RafaelHoldingsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ctdh_JuneNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ctdh_JulyNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ctdh_AugustNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ctdh_SeptemberNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ctdh_OctoberNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ctdh_NovemberNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ctdh_RafaelHoldingsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - USD ($) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Issuance of convertible Note $ 10,000,000 $ 0 Rafael Holdings, Inc. [Member] Â Â Balance 0 Â Issuance of convertible Note 10,000,000 Â Change in fair value of Note 2,178,000 Â Balance $ 12,178,000 Â X - DefinitionAmount of change in fair value of convertible notes payable. + ReferencesNo definition available. + Details Name: ctdh_ChangeInFairValueOfConvertibleNotesPayable Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncluding the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_ConvertibleNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_LineOfCreditFacilityAxis=ctdh_RafaelHoldingsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Leases (Details Textual) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended Jan. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Operating Lease, Right-of-Use Asset, Amortization Â $ 880,084 Â $ 880,084 Â $ 17,242 Operating Lease, Expense Â $ 363,185 $ 7,612 $ 1,437,196 $ 22,759 Â Office Lease [Member] Â Â Â Â Â Â Lessee, Operating Lease, Extension Option, Renewal Term 3 years Â Â Â Â Â X - DefinitionTerm of lessee's operating lease renewal under extension option, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: ctdh_LesseeOperatingLeaseExtensionOptionRenewalTerm Namespace Prefix: ctdh_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to right-of-use asset from operating lease. + ReferencesNo definition available. + Details Name: ctdh_OperatingLeaseRightOfUsseAssetAmortization Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_LeaseContractualTermAxis=ctdh_OfficeLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Equity Transactions (Details Textual) - USD ($) 3 Months Ended 9 Months Ended 12 Months Ended Jul. 01, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Dec. 31, 2022 Board Members [Member] Â Â Â Â Â Â Â Share-Based Payment Arrangement, Expense Â $ 104,500 $ 75,460 $ 311,137 $ 185,635 Â Â Deferred Compensation Arrangement with Individual, Compensation Expense Â Â Â Â Â $ 92,000 $ 30,750 Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture (in shares) Â 72,027 55,485 211,983 195,537 Â Â Employee and Board [Member] Â Â Â Â Â Â Â Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture (in shares) 0 Â 0 0 0 Â Â X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe compensation expense recognized during the period pertaining to the deferred compensation arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 710 -SubTopic 10 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483043/710-10-30-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_TitleOfIndividualAxis=ctdh_BoardMembersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=ctdh_EmployeeAndBoardMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Equity Incentive Plan (Details Textual) - $ / shares 3 Months Ended 9 Months Ended Jun. 24, 2021 Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2024 Aug. 29, 2019 Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Â Â Â 4.41% Â Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Â Â Â 0.00% Â Minimum [Member] Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Â Â Â 3 years Â Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Â Â Â 102.97% Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Â Â Â $ 0.83 Â Maximum [Member] Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Â Â Â 6 years 3 months Â Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Â Â Â 111.25% Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Â Â Â $ 1.06 Â The 2019 Omnibus Incentive Plan [Member] Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Â Â Â Â 68,437 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Â Â Â 68,437 Â The 2019 Omnibus Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Â Â 10 years Â Â The 2021 Equity Incentive Plan [Member] Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized 3,000,000 Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Â Â Â 1,671,441 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Â 719,739 Â 719,739 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Â 0 Â 879,341 Â The 2021 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period 10 years Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Â Â Â 608,820 Â X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data

Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRate of weighted-average expected volatility for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=ctdh_The2019OmnibusIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=ctdh_The2021EquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Net Loss Per Share - Earnings Per Share (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Net loss $ (8,832,944) $ (4,771,353) $ (19,157,261) $ (14,414,893) WEIGHTED AVERAGE NUMBER OF COMMON SHARES BASIC AND DILUTED OUTSTANDING (in shares) 28,729,641 16,191,723 28,674,910 14,394,920 BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share) $ (0.31) $ (0.29) $ (0.67) $ (1) Approximation [Member] Â Â Â Â BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share) $ (0.31) $ (0.29) $ (0.67) $ (1) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name

Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_StatementScenarioAxis=ctdh_ApproximationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Net Loss Per Share - Antidilutive Securities Weighted Average Shares Outstanding (Details) - shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Payment Arrangement, Option [Member] Â Â Â Â Antidilutive Securities (in shares) 1,779,161 790,945 1,779,161 790,945 Warrant [Member] Â Â Â Â Antidilutive Securities (in shares) 15,686,916 13,733,117 15,686,916 13,733,117 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Note 13 - Purchase Commitments (Details Textual) - Ashland, Inc. [Member] - Purchase Commitment [Member] - USD ($) 3 Months Ended Mar. 31, 2023 Sep. 30, 2024 Purchase Commitment, Goods Purchased During Period $ 980,000 Â Purchase Commitment, Remaining Minimum Amount Committed Â $ 0 X - DefinitionRepresents the amount of goods purchased on a purchase commitment during the period. + ReferencesNo definition available. + Details Name: ctdh_PurchaseCommitmentGoodsPurchasedDuringPeriod Namespace Prefix: ctdh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMinimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_CounterpartyNameAxis=ctdh_AshlandIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=us-gaap_PurchaseCommitmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Note 14 - Subsequent Events (Details Textual) - Subsequent Event [Member] - Rafael Holdings, Inc. [Member] - USD ($) Nov. 01, 2024 Oct. 08, 2024 October Note [Member] Â Â Debt Instrument, Face Amount Â $ 3,000,000 November Note [Member] Â Â Debt Instrument, Face Amount $ 2,000,000 Â X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic

470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=ctdh_RafaelHoldingsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ctdh_OctoberNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ctdh_NovemberNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx

M4$L#!!0 (%BE;5D'04UB@0 +$ 0 9&K]C4')O<',O87!P+GAM;$V/0\',O87!P+GAM;$V/0\',O87!P+GAM;$V/0\',O87!P+GAM;$V/0\',O87!P+GAM;$V/0\',O87!P+GAM;$V/0\',O87!P+GAM;$V/0\',O87!P+GAM;$V/0\',O87!P+GAM;$V/0\',O87!P+GAM;$V/0\'

[0_']HD'V?=-D_?5'V/UA!,LN.MHPF^]>7.J'<$*H60=5BJ%H" M54M1:GW3=MD_/3O['S8J-/NGFNQ?+75"F2'59/_Z4B>4&VNXITJ=4'"J QM+
MG;3+_JDY^S_CCG&]BZ W%PB"!:;#P^P[J*L'L(%ZP$^LLV!JDD\)"7RI.')C[L+8$C94+82J15"U M&*J60-52E%K?MD?OU#-0%ABYT(*I@3XELDV1.?>,J3DW]3WF2?-
MP_YWB_\^U'F8"!:;#P^P[J*L'L(%ZP$^LLV!JDD\)"7RI.')C[L+8$C94+82J15"U M&*J60-52E%K?MD?OU#-0%ABYT(*I@3XELDV1.?>,J3DW]3WF2?-
$"*5&FG'* M2RV@P.3$, -IXZ8H:M\O76V F6L#8]9:F*5&'Q'5"@S98!X>08&Q!C@E 7$\ MZLJ7:U!P>A:X;Y NC6<_G<9SK7F@:3S3O,6+
[[F^K90:H=P0JA9!U6*H6@)5 M2U%J?=-V:3Q[41JO-RHTC6=J&B^,*J?Q4&;(U'#:#QSF>50Y"D+3> UW2FQF M$Q9P.8Z'DE,MF7&/,7XBCV=='L]>E,Z/-X-
7)O*]^="N2%4 M+8*JQ5"U!*J6HM3ZINWR>'9V'C]L5&@>SW1YO'S=-X,R0Z;)XP-Q*L"4)=90 M;JSA3@-.?#L(?'F^@^;Q.K!#*/7XB=46O
OD^2\,Y,W:8ZW$AP-Y*##4 ,5A M1'Z'C@@*C8='F4"!Z> H^\[IXGC^R^-X,V&T?X;C>"@PU "U<3R4&@\/,X$"
MT^%A]AW4Q?'\U\7Q7(WC/7'$4]Y5&K&0]5"J%H$58NA:@E4+46I]5W;I?$< MF\9SS5NRRRZ%AO$:8&![7(*&4&@$58NA:HE^@\CW@:8H:-
]71V^QCTOMS5*C M#YS#J3T4&&J Q/-]):^ 4N/A82908#H\S+Y5NM2>OSRU-S<=;8WAU!X*#/EP M:@\%QAK@U/<9#3B7S0$-
[<_A]NW19?;\UV3V9MG1UCD[LX=R0ZA:!%6+H6H) M5"U%J?5-VV7V')?9FZ5&&_6LS![*##7,$YD]E!MKN"~~R@YU9+UF?W%T6]'6?N.).:7:?4+F[DE3;K8?~~
~~GWA7-DVYVCY\S+-%7K5_M('Y_7Y;-CR?M)S(>/J?T^O]02P,$% @ 6*5M64Z%BT2I?06J04.VJ[N8YJ8XML0LW&@[?WZ&R=L K'C[4KMAY*7\>29UV>B-~~
~~9T$XK/?$M3N+/BV2;,X31[ZHEM1L.X6+1) M>L2R^KU R-+.X+RX L\&YWR7)RRE\PR)W6839J^7-.'/%QW<^7%AP9[6N;S0~~
~~M&YQOPR>ZI/G]=I[!6:_2$K,-307C*0KB_/U1O0+R&$!:2YP6A;8AP5V86B)K##K*LS#P7G&GU$FI4&;/"A\ M4ZP&:U@JP[C,,[C+8%T^&/$TAJ#0&,&1X~~
~~F+PQQ.ECG\0+1R@?@*C4*Q1M<0 M<8$^W*?A+F8@\Q%UT?WR"GWX->-Y+P 9O7VY;8!C5VZU"WUVFUR_R_H M^F,V=8FN%[-;-)N/%\.[R?0O-~~
~~!S=31XF=Y/Q4N>U4JNCURI+^DQLPXA>=*!F M!<,NK M\CB2J;^3]<%2!,TS"W.6/I7=A^6,BC.=A>Y[AO&=E)WXJ5_YJ6\,XQ4%I1$+~~
~~MRY:;QBC<\"QG_Q47=):7ZMRCB/5=NQE650BBZGKZD'H55,\(]49#&3&RY M"!/9N.CW'=O**.N@>BH*[&.[@565LO0X_0JG;\2YS'GTK2NI)T81WP ?BU9O~~
~~M^LK#78))WVU@5,6(&SAV"]"@ AK\'.@)Q*(H>$HWVX2_4JHM[D#%XGMVT$P! MC1@./.SH(6.KIC/K35D0KPH9_ BUOLWXA@G! MLU>P*J=:%K,T.#W?~~
~~LJR&/1K!%O?C(VK&QB8U22.8S-3@SF R.1RS5-MQ#JK> MJ>6\E[93PTEM.#$&<1A%?"=;,_0>RO8A!.N3[,9:PXGB^"ZT'*M9QSHYXOA>~~
~~M/V@)4TWUV$BD$*8]=!C(HG:,MMIJ?.*0)D15S'$\N]\"L*9B;.;B>4:W(8-N-M-S=8!)V1OLB2UM?O0=>)G[#=]]R@V75TDKZ#;;3M.,T@:N" B:V;~~
~~[LMV&N*Q&:. MO.,YI&E8#VE:G"KM!;;C!HI_=?1(',]IJ_R:(+&9(:?C.U1,^O?+\16:3 \\ MYF.5_KK0$0CI>TVBU(IB/[!@9 +C)S59$NN7=BG7D^EP.OHY?~~
~~&+DX%\EF_?2 M=NJ$FF6)DXJ_IDYBILZJK\\7LX?)%?3VRW_>WAQ55@P"R['\H(E?114E1AUW!Z51Z,-[Z?/ QOQM,[O2TJ=79]~~
~~M&_NNWYQ=-9+$]8_W?:>FU!Q+S!S;BO<3>]1/+$WEZQC(JBW-&(^U1J@,&A"G M[P:*#:H@=AW;P2T%8==$.YMWI08C*$QE1OBVNK,,B&\ILZU&#H.8;~~
~~[6,.7;-MD+9Y'[J\G\]OQK>-=WB#KB;+T~~

;\8H]DUJB8(2*WKV>(6AI_95&O%N^Y/ MWTO;J4-J_K7-_%N\#R]V*"O8FK,TI_4[<[OH.CX#2:QC_+I8(XJ%?A66+\NIJ]8%E6'Q6:%R_Q&>C\C-
)K:;\:G,;9E!2-B5T M!2JMSQYD4U9^""E/3@=CY\?KI2I]MZ\ MXL]NW)M7MFU*4^D;E_EVM5+N_JTN[?KUWF0O?O"K62P;^N#PS:M:+?2M;GZK
M;QO^.TRK%&:E*V]LE3D]?[UW/OGI[3$]SP_\;O3:]W[.2).9M9_IE\OB]=Z8 M! *ESAM:0>&_.WVARY(6@AA_AC7WTI;T8O_GN/H'UAVZS)37%[;\PO3-
\O7> MV5Y6Z+EJR^97N_Y9!WU.:+W]?'3;8EEX^S,;6;V6+ MZ2-;O,BN;-4L??:^*G0Q?/0XB:9IU'FM].="]J]^B [&H^RZ7AZO&.]HV2# M(U[O:(<-?-
;8[(.I5)4;56:WC6HT8J_9JJ\L=[Q].4JCGWRMV_^]I?)_'+'<(>)V&/=ZW^YGO]E/WO)_VER=Z6-O_\?]N4V+G-=B6>3IYE M'W_]Q_GUY;_./UU^O,[.K]]E[]
[?7OQZ><._?_R0O?WM]O+Z_>WM3]G%?5[: M[_2.U7KMC&Y'V6759X=9!\K2)WKU4R[;'K*?CP:9*H"4),HA"S>WY-
K6RUZ$LTRB[42MNP3G;:SEB9@Q$$?*=+ MM59.0SY76]V*?YKVT97F?V76%/7T[\Z8P0#[:NZ-LT[UNU;_]Y6PZG;Q\-N(% MSNNZ-
'CWR@+%VE*Y[)-3E<[=G^Z=7WVZ[!:KG;W#YM).,Z;KV3+9!K: M'-C3+'EC4\&LM,1((/J,?H8&[,WD M@\IR1*+)D8*^05'(9@;)F2\K6]J%A 4MQ
XO]!UJ2NVSG *M0+0[4^T31!>D M,]'FC4_J JA8#4<%9*ITB^_U0E>:['6GL\)XC1<]"S(W)0?>I_M:9Y>7V3O7 M+K(KY1NH^P'?
B4EHU=\.;@^R#]86DHGTW'D!E#823%CA^&SZ,GNZO"^<_7(/ M+>O[,IOI1@V.\$R\TNE,.UT;E/.JVK\O^6=1[2*JG:2\OKGH7()?,D/K./8,
M%)RCPI29:AOK[0H_.22Q]V0_,B4R/"T(R$!9I%"!LOC0M37E78XXT61'U+D5 MI)[9TOB5N / M>0QLNO,(9-'6=E6"X!&B1V0NAZ(H"M)#
(NG8#S"0OCLD@UZ M@EC56:G:"LR%/(+/L97@!:2]B)%UX^S"]15;99>9MQGQYB)N]YRW"[%">]U! M,[.(NUV#D'! *,KA?!@-E]?O4C2D8$*(8,FER9<(;
<+T&5:F^+A9DDDON]2H M 6H2VN2,SR'WVKE5%GJ,ELXV];(I[8 N#6$J '.:5=Y3]^ILF7LI(>FNM&D+)>*I"CW'XV' $,K#N-
6A*RLM)@ M@9^UXS<>"0S:H/<41631.@HKE4VF^VNM/_<<5&MGD(IX$/#EU)VN; L7#A/R M&^(!4X!;S=IFM#BS M@1BAD #Z)SW\ \)#
(R%J$A5F$^@?!=NFQ M%?="])J&*$Z-=>AS7<'H)3_2#X&A^P&\>"+7Q0,M3I,65XHTF(XI+0 TMN7G M&UMG1"ZH\B+REG9-
[MLE.MEO#9J.5TO"9]FT60*+6!C&Z"7Z!_K14U%0L4U<;"]#-;&)! CLOT*K 4_^::8,0GZ\!^6.=_MH-82;Y3=KG418>G2.Z7+0?Z0+
(^GT"@H.3.E"0FEYW-LGM]_*U*;)=)ZL10(M0"12%D7!T7W!+!K8:;J\;+GP<]%#%37YB."Y-HXU%\%70.W6">/]H7P\0'%' MAX9'$3\)RF)N#H/H:
<"=WVX9<9X)Y8O>.!3C17^%K-4.]MIEAEZJ@VHA*P@D-M0FS[!^D,'ZH-D_L!)CL %7^# [8@%V8^3TX':++++6+*,A2EE&3'9V'II]-C MK-P.\8PKQ)5R
'(8"2DQV4@)6G R'O^5ODZB@D/U8EERE\+OZ0MR)STZF3ZC M*BEQC*WA+Y1)8EQP4*G%DVXP5"&$3OLO8-T0T@"MD$>F.!'VG:Y'1?
M/F$;>K(=!:5'1&E..G"3K+*@VK8B=M4EW&60M0\@@@KP(,B-TTQCK7S-2&!G M&UMG1... M&UMG1

```
F_9T0&M<-U"4Z";ZL5"D74@]PWJBRE*]!#1 M$SCO;\38*J%\A\T N[6P'L;W"G,+F=>!2 U !"92AHU72B(>__*O3BFF#$MC MA ;V$.C"594=
[/!I#_#!0.HDR[!5'?\'Z^S22OWN<;,%T+_)-,YF1"O"G'N@U:/R[EB YJVEHD"O4DH M"UFBO5.^8.(,J7P(*#,G<876HVE1+<4M>*X-
B.L/WPW/3M^(,9HX@.STY?&; MFO"L&B1 @"LN%: MB:K #W"!ZX9]0V90O4.F3*<>$I_,= C"$;*EP<04/J " M4%%MFY M,!+*$7PXK+;E#:9"\U&'[47?
5HD,.@ MJE1X"(&RCT*YJ8'A,N=0&83%G+I0I)8?A4@87"-F10>+0_'A[N9R>GMW,R'? MB"GZ]04XRZ:0?JB*7!-#D!R8H#LN%&J+YSW*I3%CJ=85TR
VZ'WQ/C;OVI+/ MK,H0[=0!%V5D$!.BASG"LJV/@BAEC*T;/JL6%81?P(10R6,TQ4%=0.*L?X%Z M9(&GH+?P]V!Y*,XGHRW-C!U !C:6
WC,2"BD#\Z,BL<[_(7EC $(56 <142C MZC MB"0#R85WIE"V.)/U\6$./9_ MF@TEB.!5@ .1N*'-8&T*XKY9'"&I#_9OKN[V#SU)F+_(#?XATW(.RD)688=E
MWU&0:ZA0*R.RU;S)?F(XQ,DIQFXYV@TPTS4=0&TE5HP+K%T4Y2-65WD%1 P\ M.#MM3#I8-
8T+$%J1K9PD;@Y2&F&!IIV((IF)8:^[X8V4X,G52XDC/%)!0X"PU) M@$X@"0$T5+.N0+D;UQ(A4<$]P?3/35%PYZC8 CBN7,M[J3,NZ74A"J+C#8]/
M&_\$71;T%I4Y=PQY1#!_-9'6,G6>X(N[*8@W5LON6V6B)L%8\RE9]+F&V;@L MTL"*8)+9B;H<747LP J(*V]$4:\O\H>@UQ.;
E7(QHI$6Q<3&V=KSVD]YW-) MY%LXTA9!L)#X+5\$7-([Y.4C2#:Q:4O@FT$&X(\>.7V*6A+B.Z?QK=X&%ZE=_M7
M\UBG&W,SI927!X91*4605WP4!&P>2"8 .!AR% ((TYU)<8]&YH69Z0$[U MD4L)BTM (,6M M+X]M&2OPZ*9:KE@2+8:$CU2E
R%)0!.=JZ)'K6H$!I@+@57"I5((1UPV 6EM M*5;FP5<+0>1 :B"9A]1*10_['(B"8JHX+9P8H+3CY/)N@AV JY\A=-MJXMY@9%-M&T=2 M'@K>?
2+)U.=PHS"92SO7&G':#LM)Y'Q-NEE/=AZ+^,ZX< [6Z!QP74^Y7@G5 ME9RO0=)N[=<7OT7@8ZF9L:K;[-R)0^J6:B/6!F)P,GA)H><8$I*#C@8&9MBJ
MD."6[S9D+P^08,>#-Z/9'7T:OCD4EZ8OC@?#TZ/!J]?B0!_Z!L!C4(L#>^B: M3(&0;^#.^%:RO!SJ4U11NT(;^7=:C1Z%9VL]PZM1VQOCX43A;?
>'H6'1?9-7 MDJ_>&N7V );MH#()RP'%@H?(1@MKV"=1PY2&2Q9A$;1J:_G)^*8;"I^[B/9U M*8MCNY0Y@M9710RD90A620T9 M3<,7 I(H-.*/&Z0$H%-
M3.XSVD)R]>V#BG<'![_MO^>-9LAX&X4^[EDW;38W6B 0J(L[$5'0'_OLV/5T?3KNS!;'1(F)002 M0..5WFQ\$Q1,4YJQ)T2,0M(NY*+$KN:3-
(_*J^PB(2U=@+,(Q0/:E2!O]!9W MJ56HN 2O3 (O1C'BPUUV!Q!/#'L+*#?Q:
M*_>:L+!X(;^\+R"LV9(0TBB>.VS)!S0]KG!$NEY'P2:/#0DHYX8C)9J:H/&^ MDUY0I9X37_M-LQA],OVS7Z;7USCGA9617^"?<_SR8=
(N%,PZA6>AJ!Z^$)"L M9%S-"2SH;:6Y#66'C/$)>01-,%@^02O__72NQ9.I:1?F=X6P"D MOWNHM1]\.A2C]Q\G-[?3&1"A-7. -=62$YKXO"ZI[#F
MUKOKU(Q!=)]7XHDXQ4&H(+U[++G?CEMXVKA5R!4>R-T MG 4%<31>YLO
N^NWJ$,@E2;/57;D"Y=U:902/>JG9KOKHN'V(&$O42&8Q\\0%//5=,E]XYU<7&JG4C8ZE-_\2Q8-;?O%D@Z<@W/H)_!H8
M,]_.;">H=:ZD_0Q)@YU+1L\Q")9V8+ H!E:$S,1QJ\5N M I&5F#JH7AE X8:&(AEO4H& M''^*<>,@3V;> ].D4
'TD=2*K@K.8>=8*:?)C8,,N]OCJXN)N!W]J^V8WJN% M(E4LY9>OK*"%B;Y 98<8+H'B"ODI=^]DR2$LSYB81F=OKLH'Y0Q:AW]M3SA9
MGC=R5=1=@++QU-1,QWB1+$O5U.*\A9J!Y..XZJ%Q2!%J0=,F2$YI)I$L8S0L5^6^&-;BJ\D!B:A\1N/HF?ZLJ"L">3U6ECAJ<_,"
MM89;5Z.AM$!]D6%TQG63B=(58%X0>=TT,?Y:PVA76_,!)?(5GIQK/B1.)?PP MCUCBNFL9S124T1A<1 LVIBMRLTN,X7V[^/G@;XR87AE.'[QG=GI%:(
7X1D2 M)CI)I?-.382PT&4K,DH4#W_.S0,P:1G\?R"8ZT37$RR6*L=XOF1KFI-NWIH9 M;MJOE;11E'XS$^E!<3F[%^=5L)JXG-Q Q75Q< M74)\.
[IIC8_BF)T;H<+]4'XSZLVA :59I0TEQNLU@ \+51'!T\*BQ5PR (H MI$3H0<8EDRQ^UC8&2-.J"&7K]KARC_HDTP=_"C-F+XO/?BY8O>J^&+
ML'Z]86F2SP 1]3!+37CI>Q4,'K<&:3B6.HT\&8 <0)[VSDY/> M<'CV%P-Q N(5'&V&0XD1?:*2>@U9[^SL56_X8OA74\>G(D]"<_9JT'MU^ORO M)E*
(N@N%PY_;=7XW\>O1O-)C@<=H%3&CO.QGC59/ETU1+) M<2"#C8$DR+YYI.R/R\^F<(<",L+.S>#^A@;2>5]V^0&]V'!Q=.4I M@L8!8&\,;W$_Y?
=PH(9[*4].2*T@.C %#ZZX;9M+^T-43&J*YMT&-DA(YBBZKC9_SPP(;DY:%G>VFK=B3!S(^!5"\ M$@;G\#1:_V;*VI!+VL!SP6L@)V7H*D
YAF+R>X4N;NH;=^(ZDWESSS-R6QR84@,P2+:>3JW&7B&PUX+;'05HM..J=@#.N MDVB?!8:Z5#P*H@2>&JF313 &YE!\&$UOQ,?
1^=U$7$Q&L[N;"1899EQUF,[& MX$3AMU:@W=%DL(!56D]E'.R/9N/097AY/!#['Y! 'XE %QSYK,.8UWMM447A M-^L>\ITA&]7%&_VYB-
ZMCK<.$^KU 2-JQ1#3J*Y=5UA-P84.M"I8(ESX_J:+ MGQ]YOF$MB\^84V$6GVB !]))RL>C,,H9W<.RN:PT'Q +1.$>0'>XC]F&YNF F$C-
"2F>2$6BNRI)'HQ MW7'"WLO28$O@]=X/W[UZ8;'!@K*%B+X\HHD68CV'':X7%!WK*JK. M$P;)KF-JO<[S.82!_WTC'_%'%S?
2LIZ8]2A03)F>BPY:B3)DHX7YPE8VH@>> M=N(X0#?0]&N)>X-W9S2&$3>;*5!% MB:P/+'?3M$(%I,+UKJ.-+\#KC]7JO\GG=J+XI1? M8D
M]'LC[M?"0W@89>_G BL$=WDHM?R,E8GMG\_I;$ZT\-ZV9=H;MS03/2Y$%R=O M]CJ4G$\ L^>^Z\_Z8HE18>*=('%!;\>S0 MNT@QY$.\\-) ?
TG=R$5IB81:LOG;;.UTR+]I[4;KBWX42) [38^#4[/ M[5VV5]I#@SHER+K$M>LG,HS7:!CWOA_T7[P4OLKV_;!__*+CM[.]6[21!U14 M/A2#_N!5N#
[HGYQL_7*V=P/6\NC#EK44I_VS<./S_NE@ZX>]C\%4B^ M#(>#OT4?]]XW;"UQ/^8]OT/FVO&^RPY;%^_2L%3K?2C1P<+M; &U2G:(F8_"
M_ZC]N==+'[%W&.K7>^^<89/=9ID,PM2Y5[QC&]E:C??&W.W"SGD#=+ZQUNCF MIAVULEC_Q<'F4-S-)G@\<3*[G5Z,;KM.)7"G,!S,^[8WMN!-V)-
#OO,<6^?+ M-#K>NN%8=9?CJTSX?4&$E)_:"LE8?3XYC'[7G4.*+K&DSK6_^,4IA5K*(O4S MJ/
_!/)4T=EZ$<[:1]LN='YZ:KZ3$CX\#R_4(2'K'L5=X]G)>"2S1J<^.%L? M3^,#@#91%*=1?.32M;ABU6M)SK; JB_M14))VC]+I%: A)A#
MQR=/S8ZR%^:P= /)<>Z.R$1WG1S M=0F?QUS?:;5!IGEM'^K.3/VRK,Z"SSN#I=*##Z/9NT-?WAO-[FB!H\&KGMB? MC/,[%FGJ3VCK5PN4459
MX:)C"30T+:,PDI&4]0!) M@!K-;RUBW+2E,3OW2H5OM8B^P1R) ;4J+E$V6]H B M(L3$2?SQRTZ)Y_O(%/A'(\GO^3IHJ.7&0J]Y+2>"+OC@-6I,O(-
RQ9WXH"$? M(HCF5I-6U"-/52EU]J3$Q]O]W49C:XU2Y7\GM*Z/U7Z?DPM__B/YWRVHCDZI MZZ0\I2:1$+O3I7!S2WB5=]S: BW77R:M_Z@@>
=4C[LEE8?\CX^/!B=!6KNK M\5YD(>,Z?"UVW ,ZZ/HH,TR\N>@\J^N6XZ@&,L,)\1M_# >0]&*-#8([#U5H M%+BC[!G(Z0)7#:0C
>HN.!DZ<:H8(LL0/<9U5-FHRK@74P2(_) 52+6V*\4L MVZ%$! :WU!K;\5O^:GS^6^$/M:X=\L]3__&:7V7C0\,2K[L*74- .6C_A\PK MS%R&<>]?
HV5)J8#;?L> ,];?+M,0JA2'XK?1SJA0:,GR$S_T: O=S2%[O_0@-OW:F M-H0Y=8I.7PY$S_WI>DGHL^@=KY!@+.E-MI8/9?#K7L.OX66Y(WY';'T[OVGW
M0A9+'-//U (>'?3/GN_S(2S_I30;>F/LW)2E6=-'?'>)*O &N+XP$(^[+[A! M>(7PVW\#4$L#!!0 ( %BE;5GA)?Z"#P, %<& 8 >&PO=V]R:W-H
M965T&UL?57?;]LX#'[/7T%XPW '^&I;_ITE 9IG84\E$5B!J>ZZI1]'CR4^T*; VUZB_MO>2=LZ(DI+1;/[*YY9K"&&%F38(G#Y/N,*J,D!$ MX^>
:8TNC>&I_(I^V\5.L6RYPI6H_BYS7*^8< & ];Q[AUU+/_DFB]F4AQ! M&FU",T(7:F=-Y,K&/,I:2[HMR4XO[H1&\.$/>, G; ZH9HXF6'/I9 /$LH=@
M;T"D\%DTNE!PT^28_VKO$)V1$WOEM&07 =?87H'OVL!<%ES \\<8_0[/OQ"C M BW@MFQXDY6\@K7F&JFV]-EX>[C@/)QIDZEJ>89SB_I
H7Q":_'AG1>Y'R^0 M#4:RP27TQ? .L).BAA4E5E+A4E'H E9=.:"$[QM\UK"L1/;XXQS_BQ[.\___M_QT>;K[=W'V]64]A4R#YKEO>O
#UO^0F@64#HL&Q4&#[ JT4^8'H<8E#6Y?__M8 YAQ\A$_W2W@/?F3'+#9"P&PO"4AB863[OD=2D(1VX+'_6]X:YRN:&E MD>T%$7@A ?@AN7=M-
PF!13'!))/KGP?>5O@\&*#I.S>M^6/RGWH_&PO=V]R:W-H965TWES6P4[&N#/S3NW-$__MA$C61$]A\#&=1/T@" TF/C
H^6QQCL8$(I'Q;\L9=2X#\/C_P/ZACEUB62N' M!+R+CZ#;O&]FH405(Y3T4+%@6%MLU7 M[=L\' '>]K\"&+2 0:V[<52KO%-
>3<=,.^!@+6SAIPZU1HLX;4-15IYE50O. M3S^11QC!+[!0_Q##O/:([$#9%%9561HMHW'LQ5= Q$G+.VMX!U_AO88%69\[
M>&]33%_B8]'8"1TP>EPN?_\HHQN0\P$^1WD8$8JF\!@*#U(VR>D:N:O=16N64<7-ZUO@ M0X'OJ#5MW@\"G5-1*OL,9<5)+H?4@;9;J22QS+&6?J/-
,V1,1>-2UE)B]PYR MVN$6^:(6<&!9HR1V&T@\),I":&Y>GB-ZY<'I0AO%8,34N""&JDT.)$P,H4$& MEVJKQ&AM\.!2A-6^1-(3^M)(MGLO0C@X
M%N9Z71JM5/7_BE SM.D42,F45HF7!K,'RB!DB"4J6TFD"4D'=EYH9.7Z^E5H M@CH!\5RQ')I %&Z*5EE!J3 IQ41K0@X&L9R0-K1T$!]VU/OT"
M4$L#!!0 ( %BE;5FSN(P;8@4 ',, 9 >&PO=V]R:W-H965TX]V[=Z?S^=KYQU 11?%4&QLN!E6,S=EH M%(J*:AF&KB&+G=+Y6D:\^N4H-
)ZD2D:U&4W&XW>C6FH[F)ZGM2]^>N[::+2E M+UZ$MJZEWUR1<>N+P=O!=N%>+ZO("Z/I>2.7-*?X1_/%XVW4HRA=DPW:6>&I MO!AF=/7D-
?;J7G)01<:U#85QH/8F_'^@IBBOC MBL=_#GG^*O9ASW\Z_5G,/M_-/MX]W%\^W'Z^FXO/-V)V__'Z]D'/95;0.(8T19<^TMB'Z-E$MW-J2$HN-
B!5!A74C[49( MA"4#+ VZ1C@3#\]]/X87@&(E8S*DI\8%8"*YKSN&W.!#%(W7Z$C:; (!&2HA MKATU)=\^C(62&SQZ82C@PIA(49 E;S>M+RITH.&V-
%,0G@SV<[0O MNJY#ZEU*0#X,F5E PXP5Y!#2[;R^SZR.;>8-CJPK751\)N!4:U5(5%=DU' W M.P(.YNL7T@"*DO$+L%M,[]IEA2]&
(V%=GNC3E3B%:3Y8@R464;V?5=>FW/*94E M94XY?KG01L<-)Z8!%B_UY.%6QK:!4E'4\A%T__ST;HO2O;!L]QQY:YO@*S= M*M.
<$H"%;,YE*;ZV,MU\F!A4&:O(1K/9YUAS?:\P'C"W#+V0MBM#MJMTDTAU M'II-+D =2R[A/MM8I*3C3">OIY[%*T!/VL[RS3I)QS M;J]KN+)\T_4]D6?
JQ$HJW_0Y\Y@2+7>V2MIEB@I,%A%5[)J4L-T5OQ4KJ25K M37K/5EV0A\:*T?C>1S_)#TNA1BIA.EX M^,OI ,&D$3>_1->DL7+A(KA+CQ5^%9#G
]@O'538O? %_>^,Z;]02P,$% M @ 6*5M62A>/$XZ P R 8 !D !X;"]W;W)K&ULC57;;N,V$'WW5PS41=$"VN@NRZYMP(Z]:(%-UHB37E#T@9;'-A%*5$EJ
MG?Q]AY*BN*C7Z(,D7F;.G!D.CR8GJ9[U$='-2R%*/76.QE1CS]/Y$0NF;V2% M)>WLI2J8H:DZ>+I2R'-4R&\T/=3KV"\=&:39FVM9A-
9&\%+7"O0=5$P];I M(4]3)W#>%A[XX6CL@C>;5.R &S1/U5K1S.M1=KS 4G-9@L+]U)D'XT5L[1N#_M7SF>]-D8;"9;*9_MY)?=U/$M(128&XO
Z/,5;U$("T0T_NXPG3ZD=3P?OZ%__M:G*G7+9,XZT4O_&=.4Z=S($=[EDMS(,\_8Q=/HG%RZ70S1M.K6V:.)#7VLBB
M9[+NC0:UNR5;04"*W=V4=6X@]4+-8%&/?$,Q;2> M7M[A+UK\\!OX([B3I3EJ6)4[W/W;WR.N/>'PC? BO JXP>H&(M^%T__C*WA1
M7X"HP8NN%$"#D?")EZS,.1.P,K_=(5LW).-KZ'/KA[29\ZV7'##*9\EU[F0NE8(?S[BBX&%D/GS7Y?R MN1KQW7Y[N'S>PGO\Q7WQ>P?
Q^";3X\+1:PNKW]>I^L]J,W]NJ M.F/,.L;8M17DDFZY-B#W8(X(>RE(+'AY&__HN.DLMJCLF0^6F'>3P!W8!K"O M:/"?(!\@<6G#]4<)C6,W2U(WB?
S!6ZFVLJQMU,+&9XT\I$'B9J,(C<9^>YP MF)X9,]5SA<#:)2F,0C<(WA%S*AS/J7ELD9C*CY"$OAME(031T$WC<+"IMQ\% MDH"0:%127/V;
(:FB:G6SG1A9-5JUE8:4KQD> MZ5>#RAK0_E[2=>TF-D#_\YK] U!+ P04 " !8I6U9Y1F/!3P' ?%@ M&0 'AL+W=O16;B]TTFV3WXN+B?
J"EL4U4(K4D%;!NC#DF8. M9\Z\2![-C/WJID1>/.:9=L>MJ??%8;?KDBGETG5,01I?QL;FTN/13KJNL"33 MH)1GW4&O][&;2Z5;)T?AW8T].3*ESY2F&RM?
2SL\H,[/C5K]5O[A5DZGG M%]V3HT).Z([\G\6-Q5.W04E53MHIHX6E\7'KM']XML/R0> O13.W\%NP)R-C MOO+#57K
M/[DVGL2>^"#.C7X@Z]4H(\$OG;B1 'S0/QNM)\Z M<:E32I?UN["O,7)0&WDVV AX1T5'#'MM,>@ =C;@#1NGAP%ON,%I)[P1GY66
M.E$R$W=>>D*R>;?.WPBWLQZ.Z^;0%3*AXQ8*PY%]H ;)+S_U/_8^;3!VIS%V M9Q/ZR6]&3S[2'U7( RLI0*I<&G M#*DC;DJ;3%$JXG1B*;
JMEFG=:659[:O;TY_^6E_,.A_>H]\]U-Q*\>2,O&K MR5*E)ZXMKG32:0/O@C(YDY9$8FQAK REO-V*\C5&M&@*9;+"C(4L"FL>%6J6 MLKD8]CN[/_-
K4UK Y#D04%?)U[8H2NM*"? @^VRJDNF2:\JY$IY)G0H';%B3 M+!0)EL@A8>Q<:'9:Z:!<6(6,*N"DS$T):"R\-6CW>CW^6_$0^&2J&A9@0/2I
M$_F&W?V/W^9;BU/0FU96WI+C-$Z_$85:Y84HM"LJY *RK9$98"&*[+7RCJU2 MEOS\GU/J"*2F;\@LF-O [&DY05,5@^_)Y;MHVBL87M%\+=$+^B(-
;Y<2X\?) M]U-E7\_]<(7[BML-[*.1H\N.4*4'W\'_?;#N%?0O*[Z6_>=!K(*PDD,_'H8Q M.A/L>JLX/+&\(11?$F]89']=(
+7L26O[3>!:SPO;AINGBP.\W657\9'1RZM M\O-)-RV@B1$X 1_;;IB6S1EW!8+617L6O:.K;B@)+ZH(_)M!U[7&&& ^]C.%9"7 M6I/(V4$]KB>>&E#E
MEH(7TM=-9?!I[5;3*K0["/':;,D\)"]D75EAMMD&_FR*L,W%MT@@<_%P/*E-Z] S-1Y6E*-??J\!T MQ)]%Y7 @S9).0OX"[_*A8NPBWB
LU4:K/Y]/0NX6D@SL_B%0:+B<'+-Y470+RB>D\'/51U[>BQ8L2[ M^@8$'$-_JS\X:._L#H+#6_V/P_;!WK#APD\Q:<,GC>Q$382[G3@@GP9%?3T3
M8^ZJE V#O4[:VO_%J,?$>:I/+^,H1#S9G858!-^>KW?X[DQFD@LK2C339!BG MR5!LB0_OKAP/YUA]R;.;KGZO'J?OSD/$5@(&I2@X:/?W]H/<\J)K:-
@2_49: MK+L&ZBYWS5OF]O/TWCI]R0>KTY_EW:B4+89C:':Z^SM MMH2-UY'QP9LB7 &.C,<<"3^G)%'4+(#O8P/WJ@=>H+D3/OD_4$L#!!0 ( M
%BE;5F^"O?W1P, %,' 9 >&PO=V]R:W-H965TVOCZWG/\(!N[K2NA%4!K3G$:1SDJLF3Z2#0J:*:2J MF:&AVD2Z4H]!<"E!8+(*ST>EJ;/-=PF>.G=[Z
M!JOD1LI;.WB=+X+8$L(*,V,1&/W=X3E6E04B&M][S&!H:0NWOQ_1+YUVTG+# M-)[+Z@O/3;D(9@'D6+"V,A]D]PI[/<<6+Y.5=K_0^=R4DK-
6&UGWQ<2@YL+__ML_M^';8*9O%?"I*^('&\?2/'\B4S;#E7L@-ELPG-?CBIKIK(<6$W96T4S7*J
M,\MWTB#,X!"ND+3I>60(U$Y%60^P\@#)7P!.X*T4IM1P(7+,?Z^/B,S *'ED MM$KV JZQ.8(T#B&)D_$>O'10F#J\=(]"#4;")1=,9)Q5L#;,
()TLLU.OAQOO MAK.7Y%0W+,-%0+= H[K#8/GTR6@2O]A#=CR0'>]#7UZAUH@AO&]0,B_L;M+/9L_AZN)L?;$^A8\EPKFL&R8>@-8%%>; !2T: M$R
'+I7E0G%XPT1+5]AN40KD#""+@F=(V3ET3&$I6TIT'4/H2IZ54#(-K$<@ M_!KPON'*HOZ. Z$";DK?V%U<8D':D:!M)XJS/.=VAG;2E
H1G)4AL@B"/DP490=;6;45'( =62V7X#^8:T=S!;!:'\6SLE!R, MIF$R3@C+3M&YI$-S@VHXG"[I)69]=.2B:4@ =8/.;;J'([^!5BTY&3H)GF'#
```

```
M'MP1!*X=Q8W@/XB1=2K01C&GR6ZD=1W*D7?4Q)2XM8:[P&V&7Q7+3MCZVE]0 MM!=TEXR.!!ZDDS0$XG8:CD\F_Q?QWO]3WFX:34>*
[)4DX/3[YL]6N MVQ1M&5V-:N/L7$,F6V&\YPW1X<4X\T;Y*]T_-V^9VG"A:34+*HV/IL&PO=V]R:W-H965T>^Z-
U'@MU9,N$0ULZDKHB5<:TUP$@*]"KNF9J.\ *KB=>Y.T$ M#WQ9&BL(IN.&+7&.YE SKV@7[%%R7J/07 I06$R\J^ABUK?Z3N%7CFM]L 8;
MR:.43W9SFT^\T!+""C-C$1C]/.,U5I4%(AJ?.TQO[](:'JYWZ.]=[!3+(] X M+:O?>&[*B3?T(,>"K2KS(-K%V0=VJQ%BU]!&\%'*4RIX4;DF+^T
M#XC9GEZ\HS>+3P+.L>E!$OH0AW'_!%ZR#S=Q>,F)<#48">^Y8"+CK(*Y80:I MS%NX_G$X.S$7NF$93CP:"8WJ&;WIVS?
1>7AY@FQ_3[9_"GW:E>2/!6X, MS"J9/?UYC.))D.,4?QC]"#>_?+I=__Z+AZN[^=7UXO;GN_D%+$J$:UDW3&QI
M8#*UHFQ1#V9/D)&49I&Y6<*-72/(9U1@R*9!Q64.R)3 '.BN *R;2FZ1[)G( MX5$RE4.-]2,JW:.PY!==5WT+15:<<&^T[G!.16YJR
M*'AF&5K=+_&:DAE@"D%(\Z]"N:S]_OK/9M0=E72X%_\OY/-8;!;"F M47+#Z>[$:@MG4=CWTS!T_LZ2*/*C9&!G\46.?)L8EN?<@='IV2CV0[*R>*XC
MC]:%:=<+F'64(TAJF31*/4 M3ZFH_V=>D]Z+6RKGN1NT8_=MGJZC76P M_^R:_@U02P,$% @ 6*5M68/-#?R: @ F@4 !D !X;"]W;W)K&UL?
53;;MLP#/T5P@.&#=ABQTF[+DL,-&F+]:%=T607 M8-B#8C.Q4%GR)#I)]_6C;-=-
@30OEBCQ'!Z*)L=;8Q]#JXE^N<_$&8C$NQQCG2]_+.LA5V+)DL4#MI-%A<38+S
M_F@Z]/ZUPP^)6[>W!Y_)TI@';UQGDR#R@E!A2IY!\++!&2KEB5C&WY8SZ$)Z MX/[^B?VJSIUS60J',Z-^RHSR27 60(8K42FZ-
]NOV.9SXOE2HUS]A6WC.S@) M(*TXF4*WR0I!(QM9LP7IO9O.;.M4: MS>*D]D69D^5;R3A*;@TA]"/X"-8O<2'K*D3%C\)F\9'">=8]F 0?8 XBH='^
9=HH.:;W D40=DX$IJ MH5,I%,Q)$/((/1@?S;>B&A^E\KXQ<*5*X$[@JDRZ<.?0XJ/$ Y;_KM MV;V96C?"KJ5VH'#%T*CWB?O<-I.@,&PO=V]R:W H
M965TO+''X\%6FV>[1G3P6N3*#H.U M<^5-&-IDC86P;5VBHI5,FT(X,LTJM*5!D7I0D8=QIW,9%D*J8#3P!O,H_A!.C@=%;,.Q-
M;#SPJ7HTB9.*#V7A#*U*PKG1O78(4007,'VII-O!3"6H>*=@G@LU"!T%8=

%D_@LX0++-G0[+8@[<>\,7W>? M<=?S=<]D;,%I^"R54(D4.2R<<$B5YNRI?&NZWFDZOC0WMA0)#@.Z%1;-!H/1-M^W?19>?VC-
C>7FSO'/MHL18&+R94=BG,Q8XUPM@8H59>+_S[A*\.)KE.GO\[ MI?TL^VGM'Z+H(TR_?9\]_0.S^[OI_=/LQQ3F?XWO;^!!P;A:455"?,T'$M'7
MK1'N=%$*M7O_KA]'5[<6J&R3Y[7.4S061%D:O:$$3GDR!SP42BXK>[H$03@0 M8$OT1U50H4NU IT=!_G
Y,P:=VZ/\7XRNOW8AB=R^86;EM>@>63L#R=Z**@?N+#0UD9!CCV9/S*L,'J3OJW&I@NN2?1-ML@%-, -B*TQJ6TR#19GK'2)9.LMDPNF17RH-
=3+-1M8"H5(B5I::#P7D>CXZ M";\N:=Y62RM3*8Q$VX:')JQ722=2T1VM\_YE7PJQ Y1>V9(VA9SY-K.ZETKD M,J, EJ;?,,=)';(Z-(J.[1$WJ"J6E_JMC:
[[ERW.B@-1!*751[YC1-"B'R^TR!E. M7&PO=V]R:W-H965T(?#!KCQS\1)+PG0=AEVP-8%3>_Z<+@'Q:9CH[;D27+3_?=' MR4Z6K&G>#HAC42(_?
A1)R=.MD$^J0-3P4E=S4KNS*=V;BGG4]'JJN2XE*#:NF;RQPU68CMS M F7KBC=Q.>!5QA,X#(=R'TP_@,7K0/-[)XT9EP%6@!GTK.>%JR
M"E::::0RT^I4O!U N MA(9"(.V:%)6)9'#Q4$C$HWJYN".^QS.4?TK.FHRI"'Z13$F8O^A@=-?6*)D6
M\L*4A.XA@^&#%VDR1PHV'4B<'$#8:)&XZ"7H[=F)[QA-8O M/B(7U'86\M&V.&:7[)F<;/ H( 5TY"E-P5.\[HFM",=N$D[<41Q ,'*#24!B M9&9'2>Q.
A_(9S2A8>C_)&^VS<*?0B2N_B#J6?N#<+(;C9(^DH'OT\@D\I8R MQ?@/.D<;RAX9,^ [)Y1/FTUM,V(\<).(NDL$FD3-T=;;;K2*9M-=8TQGJ3-L
M#HZQ8C5!R.Z9=;->TT:Q%)F"-::L59UJR=.J57VM-=3)7)L& M/L["5K15!@6EB!C03Y>7EH4!Q3PG^_$L][:[U.5[%$VM1=Z8M@SQA5R:^',I
MZE,EOXMP^VMMO"X*"\A4WU/JZO_I@)4-0#2&H (JLH3*FTH[F?C4 / M3$K:)U(>NJ/QB&IQ!$'D)E'D!D'RQNRIX\T[N(:H#3?VLE6T8RW7W8VTG]W?
MY]?=-?93O?L8^,KDIB3^%>9DZ@^2H0.RNV [08O&7FIKH>F*M,."ODE0&@5: MSP7EN!>,@_U7SOP_4$L#!!0 ( %BE;5GO&(!P2 , !X' 9 >&PO
M=V]R:W-H965T%\DDKI[[GGN>*=Y:^R#JQ ] M/"FIW2*IO*\OTM3Q"A5S8U.CIB][8Q7SM+5EZFJ+K(A.2J9YEKU/%1,Z6<[C
MV=8NYZ;Q4FC<6G"-4LP^KU":=I%,DL/!K2@K'P[2Y;QF)>[0?ZNWEG;I@%(( MA=H)H\'B?I%<3BY6LV ?#7X7V+JC-00E]\8\A,UUL4BR0 @E<8U2
M!B"B\;W'3(:0P?%X?4#_'+63EGOF<&WD'Z+PU2(Y3Z#-/6NDOS7M%^SUG 4\ M;J2+3V@[V[-9
KQQWJC>F1@HH;LW>^KS<.1PGKWAD/<.>>3=!8HL/S'/EG-K M6K#!FM#"(DJ-WD1.Z%"4G;?T59"?7]X8CS"9PCO8-I97I_61BGA*?'>S5-/
M,8)ERGN\58>7OX'W$39&^\K!E2ZP^*=_2MP&@OF!X"H_";C#>@S3; 1YEL]. MX$T'P=.(-STAV($W\%EHIKE@$G:>>7Q3;PQTN],R%JQG'14)-X=
^8K+\ MZ8?)^^S7$V1G-]G9*?3E42F Z8)*H[W0)1)O$O%)."Z-:RS"GW?XY&$E#7_X MZS41)\.\+N+GR?07V'Z[77^YW%W!^K?-YOINR ME19C&@&?
D#<>"Q :OC+=4+>'\N6=Z:6K)(D9$0P?C\!7\%"!@NZ^D(U"I@R3C;(L>R'7(M7FH*.(1A8YTAPJQB&+ = AY;+X+^)Q7@(/H1^-X(1"
MD_C8<6#;D;C'DFI!Z>L#06U-T?#_U3 ;PV;0[2LJ98S*>"7PL4MQW&UW Z#/_+;N:] MF'=_C@VSI:!B2]R3:S;^<):
[:9QM_&FCA/PWGB:IW%9T0\,;3"@[WM#0Z'? MA ##+W'Y-U!+ P04 " !8I6U9B%M4'/D$ !4# &0 'AL+W=O:?
TOC[M]5Q>F\4IJGEAR354)N[ID99;GG4%GO7$C%Z4/&[WQ62T6/&7_I9Y8K'H; ME$)6K)TTFBS/SSL7@]/+43@?#WR5O'1;
[Q28S(RY#8L/Q7FG'PQBQ;D/" (_M=_R&E0I_,.-;B]G9J R"V^]K]'>1.[C,A.,W1OTA"U^>=TXZ5/!<-,K?F.5[ M;OD?M$QGA]"8-\Z;JA7&NI(Z_8K[U@];
B?]1P2R5B"+=B=%TKN[P M=&<]#P7A6"]OP2X36/8(V*_TT6A?.KK2!1>[\CT8MK$N6UMWF3T)..6Z2\/^ M$67];/0$WG##=ACQAD^P=>0-O9-
:Z%P*15,O/%>/\4UPH_UPH6!.72UR/N^@ M(AS;.^Z,7SP;O.R_?L+8T<;8T5/HXQ\"0G]^YGM/E\KDMW_ML_9)O/W6'@Q&
MAS3]FJH5>H4YS1ID5Y)>&%'O/UM'BDW1?/ M3K)L\/J0'"(2-/I2^!WLI7"DC2>I*<>6D@@AHUY\&8_-C4*+"9)ST]BUKM]: M^V\:Q>Z4#@:'-
!=2106&0MOR^"-!N3(N[,YD0;4-7,T#;K]/ M-:B[4MB@T"(Y88MVG#>ANY"WH@@@A5BY(SK( AMP+8TJX(A-7P8-%E>B$>R M<9\!7?
J0W,&AGG>L*0RGY'X$4J))Q>05,X,\@R5P5\N5[VN9?+_VW)8TPB)- ML4N]$BMD&BTL' 9/(K5%4<@ (?^Z)-]1(]PC<_^QM4:ON9L??JL$\R_9YK] M-
TR7R.IU3Z(E,MZS#LKE7.8))P:\#5;L.!*-UCV41RCT+:K%NB%VH4/?@;B< M*:8)4*1SQJXHW3%;??)D7Y^$5]C"]RBL1.T=>A;87Z#0<7?2]>0BN>-&S
6K-M(ZJW$GQ9RKS<@8/N)D:R((=>$]K9EG7U@W4ZW/=M4<*UN -KQ%Q4IFG[RS"4 M;2Q=*$K*NX'--8)1!3JO?HZ.G/\?V&3[V&"A%I@H
6W<&D8)0N16MEZ&G&;::1+^T:( MWM:D5[%=Q'G6-0V$T]"WV=V,S!=I4GPXGN9MW P+B6ZM> [1?O?5<8=LFF'3 MPILZSHTSXS&%QM<2A-F&
_@^-V#9+H*"S3\2XW\ 4$L#!!0 ( %BE;5D- M AYMS@( "X* 9 >&PO=V]R:W-H965TB@KF^YTW<@N;<"6?
UV+4,9Z+2+.=P+8FJBH+*WTM@8CMWALY^X"9/ M,VT&W'!6TA1N07\OKR7VW-8ES@O@*A><2$CFSF)XOIJ:^#K@1PY;== FAF0C
MQ(/IK..YXYD% 8-(&P>*?T^P L:,$2[C<>?IM%,:X6%[[WY9LR/+ABI8"?8S MCW4V=Z8.B2&A%=,W8OL9=CQCXQ<)INI?
LFUBQSAC5"DMBIT8^T7.FW_ZO,O# M@0!]N@7^3N#_(YAZ1P3!3A#4H,W*:JP+JFDXDV)+I(E&-].HITN,;]B$&2.TGCG*=D(27E*>_^:35S-
$O?:G@+Y8 $W@GQ/7_4M9[>\A?+"=IL![5? M\/ILDR\80]8:BLY\-WZC;C]SQ<]522.8.WB'%<@G<,+W[X83[V,7['\R>X$^ M:M%'-O?
PBFJ0.67D#F2AB$BZCARYOX-G399,1 ^_NM)AG>.MZ>AA9O:)C ?D MF\YP&]>\>8V:]]%%)0T,CI,D5Q&"/E94(C,!DMN
MQVUNQ];9GPZ?)'112QPXIC<7S*:=N;4[IU0IJ K>U99S\,T M:8$GUD7UA[7['H6URGK"GK6P9[U@S47*.;7SVJV/\EIE/7FG+>^T]VE^%;/= M_BBS5?
969O?@DUR 3.M*19%(5%PW7^=VM"V&%G4-X/X-;RJI*RK3G"O"($&I M-SC#FR>;ZJ3I:%'6'_B-T%@NU,T,"SJ0)@"?)T+H?<=,T):(X1]02P,$% M @
6*5M6:Z0YMZ0'P 2V, !D !X;"]W;W)K&ULQ5UM<]NVLO[N7X%Q>UIK1E8DV8GCI,V,["BMSW%LU[+3<^?,_0"1D,2$ M(E2"M*/^^KLO
A*%&/W3.=.)XTMDO/BA8D6:BE-3Z]4!M_,=+Z4!?R:SU^85:YD3"\MTQ?#?O_5BZ5,LOUW M/]%G-
_F[GW19I$FF;G)ARN52YNLSE>K'G_<'^^Z#VV2^*/"#%^]^6LFYFJCB M?G63PV\O_"AQLE29270F7\T>',VI!?HB4^)>C3!SP*7,M7Z"_YR$?^\
MWT>*5*JB H>0\->#.E=IBB,!'7_80??]G/AB^+,;_0,M'A8SE4:=Z_3W)"X6 M/^^_WA>QFLDR+6[UXZ_*+N@ECA?IU-#_Q:-
]MK\OHM(4>FE?!@J62<9_RZ^6 M$4]Y86A?&!+=/!%1^5X6\MU/N7X4.3X-H^$/M%1Z&XA+,I3*I,CAVP3>*]Y-MDGF6S))
(9H4819$NLR+)YN)&ITF4*",.W$^=GUX4,!^^]2*R8Y_QV,,=8Y^* MCSHK%D:,LUC%]?=? )V>V*$C]FS8.N!$K7KBJ-\5P_[PN&6\([_X(QKO:,=X
M30O^SVAJBAR4Y7^;%LSC'3>/ASOHC5G)2/V\#UO$J/Q![;_[X;O!J_[;%FJ/ M/;7';:._.Y,F,4+/ CEUF>ZU^(_]^TY]+<19JJ,OC>2W3M!,_H'LB+/1Y&(B
MKC^(F]OQ9'QU-[J[N+[ZX;O7P\'@K?WK;J%$I$'.F5$Q_F2 H%@6\,LLR606 M)3(5IH /8$L71B19E):Q$@6\=ZZ7*YFMA^&!H(9)@925O?
B(5\4&*J5"94FL N(KJ2+* 3 M'NL)7 2-F"R?M1B02;@.NS::H5B S'XK90ZCPIINU4KGA0!SA#9%#/J'OW7M M\ZB%,
(I1(M.%,ETA=%1O=$GMB4D:+VLQ(-HPM81E@ M-=,NV.ZHS'-<'O"]S!7S^1GS=EF@(6\J2F!-*YB2F(T*D,?PO@(K6BS$7&4J MEZA+\(U:X?
BRVO(KH"E*5JEBA8DU#H[4%!)50^7T=Y*QZT.6U07K!4Y;X.2M M$:,L*X'R;2'_BZ2 K\P2$\$C:R5SH= LBO<@J>54Y>)H0(;MZ-G\$6:ARS0& M?
@ATS%:Q/Y<9.SYB1;&010M]/?C0@",SGE"W#U;P?QT;ISO(PIS$X%4L25'E M8]B0Z&"=7N5V/)IXB;X1Z5-?5^".
<1UV&A@RR6MLZ8D66_G2V\J7K;;R7)H% M295^&/]1)@\R95UZGL5LG^9@VA'GH\FO8G3UGG\8_W9_\6ET"49R4C>0GJ(( M?U 5123?
Q!3(N,@]A&9D 4P#UJ8)/(M"?5!NBY%$)6SA/)F#/J1B5>;10]*R M+'&+)<6:Q9 K)9;L@X'?H.F&E48>1)PZ]'M%E%H MT)$4<:R8Y7HI
%S#&QEYC*E,T=Z!7,\)+ (WK8GS7[&Z@/[H!']C.Z(?X,G3 M/ORV!IFEO*M)$T&N\/U* HUQJ>KZ$FL8 /<^S)&7UDC@:L"6N#>\&PY(6LEU MY1Q
:W1$1,#"<,$&5HD.O:(1B "[,$N04%:AR [E;6VN0-T*LO4R?H"W0,-! MX6;( X5JLTJ6:"A2*U9;:2O*5H.FMP99ZO22)>6V6#6!/\+2XC&'2*
MD(66\TATH$V+X,ND$*DV1EGC!V$&RLX$_MJO8HKDP)\$]BV93F\@:P/5I9"K M!PQ.A)+@>AUCG+@!/2EFLB#'CZ8^#"4O,CV#5P.?C-ZC?
P!@%IJU:%D1J (PR>+M;0TZ.$X8^M:23 M5.';[N8:B+N/":P457*JW"XAP<.TCV (%5JD62! )!O8 N8RGRNG%VTR!'YF M9,D:Q&?
I92(+U(U5KJ>D)T0<.\)0=VCEVX8X5K"1 )B2I6@G1_(.K+_]_.'U MRN&8J+08&S=6]X#M]#R7*R &IB*#-M0A#^NLS%'R6$!DG!<&0G P)E0YX&$BB-
Q>)BJ8J%CEF6I2&@*.0 S:FCY^T^MT+P#L9D+-^+F)K'_8@[HB+JT^ MSZYO_X=AV_7DCF/;Z_?
WY^#D)]>7[^ONW=/BL!K!G&@=I3H&8L"/X[X'IV!C M3TR=D5YB9)JJKR#)"J$AMT ( /YPST&\4GE^8"CP'(?6X!8.9DEN"D ,7<$__M@=_OH-
@RA4X%5.M/LBJ (]%/GVO&D)X2@V[=[E,VJ#("*&E(>7@**\KZ*VQ$ MK*-W^YRUV^TS?#')IN-<8]*CLN"?9SEEP:QU-5V*"W($+H@W%AB)D-E-
DM@A7@%W!N#-XB?@) MDG@";./EQ=7%^>A2C/]],[Z:C#=B6D=5!_.3 MO7/[-
HQIT7=P[EVLP"PL83K8Y!%%EW/T&LJE[*P[DH]>/JQV.,+&JW%>SL4=_M^/\5[*T?OAN<'+\5YVB/@;+CU\.WE9;P/B9M!\'@4)[:@E0 E > Q+)FC%%S
M*.,F8Q9J%S6%G)T/99"RN<;4"/R O*/(!3^=E9CF(AL@\X@#>@O1""P3-V!8 MQ?&0SRI)P]FL)H[VQ&YFXR#V%QIDY\2T(?
)U$^FG:U>"M+!J,\F9=P&\JO" MIT#Q$0M@SF\W*9ML+Q+P4FAHU%JCA,&N4.K+AQL.RW,)"H,.CD13""XX "2\ MFQWZ>_( !L:6+9OJU&^JTV]L*MS-
!2*,5-I0!5-%*TZI/@]VM$ZU8Z?_.N+#_M_>W5Q=W][9BP"&:/;CX".*GOLP]EGB6D4TBBX( >'*7<0>A-\5\U*P.&@1SX=SI(2 M!U46EA-
2,S0%!M02["3\:1'DH%]5L?JMHKR$-2O5%9?@_)YN'=L'W2&T>4=< MCD=;MC#$!RE3 8$G1M(4BGJL0P/N@!.&(UV0:X[XGV2<((JA 5'"8"O4BN5X
MKC.J4QF7LJ; M8(J8X9ACJ__198QR6*Q7BN ; T#K*6&*;XZ+B9P0'B7L1V'37WLZ+8MK]A/L M>T[*JF>'R.J#_=OK^_V.8PFK(TJ#/T@3.07S1'9XA^/?
D82O&:V-2-Z4T[KX M2>_0W\4([3.TU. 8*SZ H918)8SH,EMD8:AN8\7=9 M6Q&G7J*JH$M/ &,<0W)E4_O-T(?P/ :HA--Y'2GGR?!]G\BWJP$Y[6!Q^SQZ
MFB9S5DF8;"F_N!&#U&%"!LJ[#OI^2R?"I1$A 0G.7LXS$E:K[XF1:5RAU0I;9B+(2G&52"!&3"((GF$9JIX/HYP#_M9^4AP,8YP=E.=0[V$1>
<;Q$<5JOD@TQ23D4W+114QQD>E^[XQG)9T3>XS#D/ M'V9Z\U\>F.6]V$CO5EG&.]\2G*X4%2O;/9#PXC@01BVV-R2 M"L2!F3N;E@N"(E?
8\S&18S;%,1"LYU%B;,BDK:TEM^)0#JG\QAII"J]8R/P- MUSGEXGV3OGP"S28Q;2E\'=;!^A$#Q6W&/2#G),:0C"4]
M+R4XG$(IPK+A4P"1&;I'0#H8<%0"@,76I:#>1-X-U:-'P@!K3H'-UIQT)1KK M&EXERUSVR5!!V=@1_(,+-'U37(IM"B@PO<7%7+!/D_7;
1EO#U7SJ]1KK64D_F>>< M2JA5YCAOKFQUE/*VUB>B"FS-UQ._!^1C*8=7-=.83G6&F"%RH59BJ2$Z(\,< MYP/C@_[IV_$
M0=)Q!;:UW[X'IF/+RIZ1;^')\%'R$!P$$OJI7+8)< B-1J_"NY4]P&^#EAP, M,R*%CSUT?$&P^2&WF9\\->ZO QBV@$63LH1@-CF-:E8;#+F3<_"%K?
MI?RL79D=E<]^B7Y@+O-,V8:4*ZSVB!$P$_8F(Q=N5DJ4)WPK*1(#__-UE90$ MDDHTCF5N 3JB/:"($(
+]4EV2,D,N>T3T"ZS2U:;D2,I#G93=8D#"HTG)EA< M#C@( #6U8G&NVN=GT497V1I"KH>$7.LI7/PHH^*/W[FT_HU$9L-F#LL]39LY MH-
8E]S1$NTA6007/A!K#!,2FZ&S6*^0$+*=/8Q]+M_+,S[CX74LM75:%:BO%:[W[6M?"[.HP=28%_E:$$B'.076GV+(;>M1QV9 M87=+"1I/ GOT(]?
```

~~6MS%RMTX+JQ?*R_D"6C5;$EHTJN<.6_(!38]-*=)>K]"Z MSD)# IMSQ8B..KJN-%C'HZ[?2EVKON99?6+MB&!8(8+ADQ !;6>7A6#YG7N>~~
~~M34+5^]6IW@>EGMV!U4[-#D0!OF?RZ\7-S<75+Y18^Q7^=XF_?!AO)FXFC9MD M1I3"3H;@,>5\IE>U[E;:H6;4>J)Y2)=]-1JS;VCMN"^'2V=D4C?~~
~~K:+M" %MM MKPCP+V WD9O=E\;:Q%[U2@]:FYO?C;!44G ,3K7&I\KO+_1,'WSNB-'[3^/; MNXL)2&VCV2H@Q/(4,\94#E;_[%C5:GV-GY5W=J#~~
~~M]G;MVS +_S[(PML:SK/WP5]IWOZ"R'HR'MV>X#9E]>48J;"]V039+=7 M#IX2D5;%UR4W3]E>*U]!L>[$(F((BQC(9-QX1M[%E4'(/?KV7^^?~~
~~FQ"#&RXQ M8:7B"0NJ\ Y"LYS"!&JN=B6HW;4CM-)@#W26J?30%4VJL@RE/*@C)MU=D_&/ M^[W-"#_(1O7PNN2A 3>7)SLL8B?0N=S0)A_!F5*=~~
~~UE6G#\/K*EX(S624UD MG%^D]#_!D\T8?8DMUM;_U=(ZF(/! 1SW;5HK=_"JJA!0F0VA2Z$?):H']T:$ MO6F.@_#H9T!.X"Y=0\IFJJ;*&B2N~~
~~[QJGZ]JW.$A@ZRD5E-$$, 86H'*%I: I&PWF47/6,,&V7MBW4)GH'(,%#%?!QXRUKDO M~~

~~$$$3@'65F25F)-9B+/=E* MK?&T8+VXWW4/#P_;,K=ED"#@;! &]-SCDU,Z)*$#TH3NCY X;,BH#3[#H1/J M!CF"3'9~~
~~^(@&7\F$"I]8M&)/!"=C&-)3L(GO\ =:M=08I"%*M$$,4%HD<3'U?CG7=]E;AGBR0_UI @XQXJ ML4_IY=,:C&<^MA+?A!P?~~
~~ZG%5N)=2C@OT;>H$0GJ<-0R='W^J63I;)OVU@A + MOJ=B3TL*8!<[6$WOC-^MI'-*+Y]6-W3.*Z]J;EE'/1F6QP5%PBPK*7^+50R_M+(*H)-~~
~~&R:E:$1QH65$-'3(X/Z_B\-/:JYO)B3OOIN7@[BN%\BJ M9%J2ZOO,'7IQ$B1BN'24!+RW=&C(.J(< OYE(=9;9][/N4! ZMF8F99P9C3~~
~~MX7$+YS!F$AS][9#!'L1P"22\O >RIA(.;-:-*^J M,A_^U.ET#-,XC7EE'_NN;9Q)ML;%C.W']ARO!3%"0>UK]Y-\GNL=<>&8HJQ@~~
~~M'H'5R\U;65TR3DW,6LW:EN?:$"B BX8GX3G,EOYZ0!PY8Q-C2@-A1A%M8 *: MF6>;H4M"F\G18"TPK,E<%U:Z)"[1"AX/DG$PJ=4+.-~~
~~S))9Q)\4RWIQ$8/J8!@T81+PJN>5ET8:VG&6O&FYN]1U10;DPZ8\0 MPQ?4Q6+!\^*IFB"Z~~
~~/9V%8#=943\MW$F933>G$9"_K(#765;6T2,S:'C/3ZS MSU+RU06I@U4@=0(2&>A M8"X5ZT94=;GI@LH[G, Q83F>"#F%'U]!$ .C]NN,* :~~
~~(8IS.1$&\?(Y%V7*$ M]$P13B:$3^7(P48N Q],S&-6"D5K\=*'DO1(E,MZ.A)%C MTDP8HY*8]S$PFPY3O9-~~
~~3A^H&^I!0:8V73;^H+0QAK^W,:LMM^!;F3*<$-8.R?D,A#B/#IDX]1MA9/4)65+D!TE8# Z# >RH5Q$\DA74(_DL,X~~
~~MB^78L"0$\)@/>11TAXR\04"5MN] ^F0XFF M[I[6IT.DW4]&.A<02PYV.DPI+IB759]J[0J1G/Q$N!] MANN6F[C;,9D+]J)F0)[T]-+Y*G69]4"]"~~
~~(-!VH7D9]PCOVTW:#?I6TR&J.R! MFKY#UCTU45ZW+A,7K+-U9UWW(F%LW #C;;=USW1I8$)K"=P^-L68<&IJL;2Z~~
~~M9EUV5J^4R>CJ*PV,2V"+&\W&';+==B/OFW[(K3$T'02XDPD+Y&:$%BL75*W+ MS.K%,AEUW<1\(6Y.^6Z[H=^:~~
~~(AP(\+"8A*N)FJRLJE>7B=5K9#($NTN9&F)IGQYE[*M>T(FNUO:<3'8J4:K:\._++;9SO;UEK:UFCXFAPUHD(=~~
~~M)U9>5M]!9ND"N$:85."B$1KJ^+)TP7T'A[(YO#X@E-:O#P+OU;NP!8L%.^/7 M/20'Z0%A#OAU^A2$Q'G>(WH+W#4"1[U;6^?~~
~~4'AX6EN(9]Y%XVPZK6I.'#0!K M+?X:H:7>!ZX[B]F!:W7C#@GCY@-QPIFAGQU@*ADT@DR].UT39*9Q#E(:?T@I M4\CMH%;#S-~~
~~\I;GCY8?!R2%.(H!%HZ@WSVD#[#\7].11RA[-5C&R-B3N"_\S- M>!8L&$VR7@I[%<72B$?U3G]M/)Y$@AO,S?A +!I-%W<875CPVT#$5E*~~
~~[1L2H M5Y7SZXJ[:*O(,.G#8&KZW+-#*]#I;2IRT@B'"LO,F.Y>RX@X"OL#+#AT91)26A&\ M^OX(Q$VQ)AC]E):YG&FRS<3I7K-)NP M?~~
~~C5&&J&@7@(ON,JSPT7%^QH;V?*MRDLC.M3KUL77178 J72$@Q+NHM$S21K# MDMH\-0*FX I9P5$20%$L5?9\R2[(2/J[PHP$.IO-G%!V?~~
~~T&MD$>3XD?*1F-\ MOQ>!V(V,:$0N3"\,Y->'<,-!)\8V)IQ&,)9<=E."L9\1W[A+Q3?^C,4W^I'X~~
~~M40%A7,_$WZ&V_;31@;$BJPT(JK@6EW1?:O=<%CAIM1&H%&%CT9<%-S#4U[2 MVBI0?&S/?~~
~~^HA3LE_$D)^$"+^"I;$#;XU_^_^S<7)%>4CRF^I17P6$"<^4G@M M#Q)"[,EQOGKN\1-/!$#DC2(%6_*C%\>MM6I@CH.K'L>M@(?~~
~~X02PP9,""$'._M<"_TCUOR>V%'#)#7,J+W\$61[$\+<>>76U^)'2'R'/LTI,)_:3-G%&$QK M@S.K2,1Y-54Y+ZG#3.;X*D/?^A$R(8.'*P).~~
~~M*YS<4C89A%S(M=#C#!$JD_=4HT=U!2:? W10-?#/PGG4%ST0?![#X8K"C-K~~
~~M?,%W22M4*;MZ6T0+#V4V7U'E>\HGS)5H.:>T1+\%PL8:%AL;/0K\P\7>!^)@ M (R"?'-A; 9P@YJ?X$NE&A;I\#KUAJ7CFII'1?8H-~~
~~8V':RAM#S(>^'B*5YY MB!?]3KH++#>!;Y+W2,9:URGQ>H+1$V_BAS!2"K#H'W3,+(?.#42E%(T8D#)V M.*6#X HFN"&7-~~
~~/+NP$R1962KF\VF%D3MC@95! R!7SS/QN:^H_R!653<>0Y, M:BTGQ-6@4\:I%?0Q3+7EXS5H-:;$AJ3?('J%6>(H-_)JKO,ENO1JT,[&@8AB~~
~~MF)K<"[D\;)Z>-<]WJI+\9G0K+GF#\?\Z]27D >0,43 B/3V4HF:BZ:N'&SC90(?0,UVZY M2ABA91NA1IG&!=^I\LGNRRF-_M]PZA.6+NR?~~
~~I=\QB/2N3MXXE0N]TN^A,UU< MN%Q(;63@]7OH4I7L&T^EW,./S(??)>9A(M$7Z].,BR_7*4#90 MOP?9;Q8'=V5.~~
~~(UQBLFV4]W*IW$6YJ[<]U5&(]W:]7#(M+"J#I3D-%!F- $\^PKO%V?3U\!O$?GWX"^*UC=R"8JT2C9U]9M_2!P%!YAU] MU\-~~
~~DZW(ACJA;Z(7CB)FRCQ#4B3'S;RC'.RMDE"Y'JK/6$]R/JEIW(3*>Y":3 MV_B06[I3$6=?N!"]~~
~~(2(2C>H7:^JRY)PF\NU#TP50+J5J"@J38^*S4^)R)RI) MMD]#'-)O9+6I"5-YCP H.-N[S@,V61KX"Q>&\Q#9TK4386UGWDY%G:~~
~~NO5L01K3A=E5J.U^.WFLUJ';$8S M-7CT2G%5F-V(N"[QRP4A>7%V4\/K1.)[+SL+CL?AO&FJD3;#3![_CF=(H^M[MIW3(+)9N&A1E-~~
~~FR%IM!DF<\E/ML;+:*6>Q'.C=N^*6Z%VB^C6=:L]2M\[:V5 M?-UH99)"[^>5MC(^_67--YF>/ZD;:[\3(O.!E8S^$E;4_4E$IV-J:S_)VW+~~
~~MBJYRM3I?3YM5_0S DF:J7,VK;)F*6%&5>#WZ/L_;VYEI*X\NWES2B3DX_1_M61%^E*EY%BRR+!)*'LB:I4<>SM4GT_C,$\83 S_\#~~
~~M4$L#!!0 (%BE;5F\=+EI#PH !." 5 8W1D:"TR,#(T,#DS,%]C M86PN>&UL[5U14^,X$G[?JOL/N=RS"8'=N65JV"T(,)QMU=0 3K?~~
~~<7ZO5ZFZUG4_SZ=QZQ&$I)R=MKL' MA^T6L)!'E#V-T*6H<_?NP>W7QIW=_U6D>'1]\'W6[0/0Z"GS[% ME/WV4?TW(A):* 23^L_3]B1)9A\~~
~~[G:>GIX/Y2,0'7#QTC@X/CSM+ZG9.KCZ- MDA7#2^(?.MF'*](W0S\=:]KNR:F6J$SR&(8Q; MZN?]L/_JGF$2!1,>JSF4!R&?~~
~~=I3J#T^.#SN*NH.2)S %E@0AQPEC$B+UF^0Q MC=1%+D(2AVFL=7^-?^?D"FN3:LG$A7D".%H^=TN)8QZ6 M*$]=^?5&P(S0Z'(^4^+~~
~~(7G;'RWD8IPI%_G&?R53DQIB-3D809X/6'2(3/E86 MS46N;)/P2L5RN0#'1(ZT-:"!DII7<@3B1RRL:I\:87_CU+ QYRA)Y0Q9D~~
~~M%,,9B_"*2"&ZIF1$8YK0E>!K$+<8H1&$0PB!/BH1OT)B!ZF(Q2V&",T;EQB) M;[3%],B,)B0VB5],[59R*7'!F@1]]6$#)3TBQ~~
~~)=R']G*Z[GEJ\;E'QZ92SVX2'OQ4",) YEI5AA)90Y0-X DLO M5VPX=DQ.B6.-V3#[@*)T):[X&T0SI MPR09C.\EZ/W4"HF!QRD*#,_'@$J,2C>J~~
~~DK7$K_(-TJ-IXR\"=E-^509F6-9 M.5IKLKC!G#3!+4=M,S.5O9KW5AL6IQB&D!#*(+HD@JFD'%.>=*H2>8@N8$Q#~~
~~M:D)BS^@4CW6T4"\^>%'F.!-ABPMD/VT?MEM/H%Q57KW+QB$B?%/_>%UHRBDZ M,IU.]9@!36"ZY!\+/BU+0OA6<3[>WPI?~~
~~UP=\]LFX+:PC'V"9HVU;&,<^P"AV MR+90OF\2RO:U.EN8[OS%IJFJ$&+YYR~~
~~*;*\D@/'/*VST$IK1WXM.+L(%D=/_FTJ=G!JIKX^K2VK$ODW$HKWJVU.OAVY?\=~~
~~M;W5U\)6[_T^==837^+>CGI<5@0SX..#9%H8$.VQWL;]%TYTN527=JLFEQR7F M@)\YC[1=@7BD(2:2SE@O0EA#]!G5X0*O?\/~~
~~MQB\B\@L8K5=B:_/O0.RARKB%FLPO* !:GJGWJ9#0\0D^&H]*2//2CO',?C.9 M4UDO8(9+@.H5CTY[)GB4ANH/@]"E]$ZE?[;)"RIG7.HH<#~~
~~N; &RXG&+0J X M-X*/C4<@&R@<]W+@O@)*:U<8)>!BQX0O1?3E/!,& MA3(B%GW<8'1,@)RX*2D/V\D5*;*:!T*W$R 5%5Z79,~~
~~[G'<@G;&V;,DL2J.1E/*J$R4E(\V MH*J-X+I/8PQ2ZE)4P:(VD3GNQY" Z;@ZR;^ 1XBY/CLIUK\5CV,4C\!26 8) M@H3)-YI,>JE,T-~~
~~H%&GV6]*GP#O]%N*<:L=4>R6W?"8F)R,HRW\B#T<9,9'[V MG&P*>Y6A?X5"BS54G). MY&7/34CD)!C'_&E_/3=%M_"KYZ9GRJ1E]F-(~~
~~FQA=OSP(J7I?=S"^8M2UIZ MQ#0]$33$Q9L_(?GZP@O*&_T6J74K796Q+^>A7FA#=!*7XS&$QM=^-")$8PU* M^'L,>B-FT=F4H]?~~
~~Y@UCV*I6Q_MVV5*>E9\;#&8)[B?'QBNC/(M M:\.8ED\+5YFR#3P-H] %D>0 Q!/SJER]CVIE9S%-=M1R% M*R-~~
~~M%.1S%3@:0]"7,E6N2>66JTNE3OCKTX';OO5CLYA\ZG5R;R_5$W:?6J;VI:]:==X:W5?OS_,X M.OW^\)YU5+]P5*,1[*^D'F,IJD8GV?~~
~~O32_U#,%OUG+QCEUS_?, Z(OQ+A,I5 MJX>>=91L@7Q_IY,^]25MIZ." M\[,(2BTAVO7KK(\W8'N:SHZ%.VM@_4QJJQ5]G8ELBW.~~
~~+!AX#D67>@<]J?E-E@G_\BG"]%1.[ECNS899*BSDPTSJ5^CR5E(&4&.V-<*M6/BM[G.0! M)<+?)&Y#(G=E5E_NM?V~~
~~KOMIU:&G);@2:O>O#ZJZ^.V8_'PI2AW'97X/O??? M';]W#(7XU.IHB;:2MW6*'>"U"DM\JE)L:=%6SK=&<<)7O+O:26N<#/NJ~~
~~MDBK;ET5*G'^@_E/="'CE3U!+ P04 " !8I6U93 YI#TM #O6@4 %0 M &-T9&@M,C R-# Y,S!?9&5F+GAM;.U]6W/CN)+F^T;L?ZBM?~~
~~697NZIO=>+T M3,BW;L^X+*_MZI[=EQ,T"5FWGVV!R>W)Q\?9- M7H19'*8T([^^S>C;?_^W__D__OF_@N WDA$6%B1^<[]ZV*);_>/?~~
~~NZ]>OWSW=L_0[RA[>O?_^^P_O-M1OU^3BKW&Q;;!+ M_..[^H];TE==?_U0T1Y]_/CQ7?77+6F>-!'R3H_>_=>GR]MH3A9AD&1B1"+!~~
~~M2Y[\(Z]^>4FCL*B&42O"&RF%^%>P(0O$KX*C]\&'H^^>\O@M'_4W;^JA"UG$ M:$INR.S-^L?/-~~
~~Q>OQR+)BG=QLGBWIGD7IBEGN>IASLA,RNIF 4'/XIO_^^= MEL5JR=4@3Q;+E+Q]UYVIF"[") L69'%/6$OV&ONPSFBR()E8*4']N;:\2KJQ~~
~~MS>Z<]\>B\IX$VR^VY%C14X]C3&9AF1;=!_EE/U*&-]SNLRJ^%15Q,*>I,(OY M=Q%=O!/6[/N/'[Y_5S'-C4%!^/>*(*,%"8Z^YP:"4Y&@")]~~
~~(_E("WM4\V#2O M6(6UEO+-Y4NR1%B>2_[/-;5@R[X$-0_DJ2# MZ..[F"35A\4/U2#4N+HD#V%:?WORE.0-C$DH6O,T"_/[:HV5>?~~
~~0ALN:,9(6^>8WSQRN?_&O MTR2/4IJ7C-QQ33GF_7^9W.<%"Z-BCV.#%DXEN*A4_RY\:F!,(@*DB5,9;C<+ MFAL%$P_-Z%]RG1\?~~
~~J"2,7GLW&(?8JI(M_.O;@I7;[M8[44N_9<;H C2XM(7^\R^[E$_BI]0BJLP-U1EMMX(HW!?)=+W4 M+PHPKD")CJQ/S/-DM,~~
~~M93DE^:#B5:6F=\BC&".)K$,2-YOOX?L3J/I%$D!:TK/L4.-V5W]*L\UB6E=,7C->5^5OK_ MDJ5DE]83N^*T.EI,V36CCTF-~~
~~KU+R*B'OG=N3ZHB07G ?].D_R4K*IH2N?_Z> M/=/;>\=LMJ"\@_+&:XT>6 D.,(N=-)!\97WR5@UJ9XQ-:.<^81@5R2/AGFNXMB4*IE7DO7-[~~
~~M0QX2$;?*BJMP(1_:9K+>N;N=DS35+>XFHOXY6X1I>ESFW#G,Y1M)(U7OO-V% M3Q>Q"';-DAH\KC$^&OJ#2I\">*~~
~~(B)#*GF=QFRTAZY.J61"7C@W#T_OXN*1K/ M]C(2!UR=/47S,'L@$ANB(NN1.W[T%5[F[6IQ3],&MAK_[C8QGX9Y/IU5WG&C MGZ4G'~~
~~N_UCS$=@ (=2A>2S=,HGUW%!OL(YA^L/3[H:2GU8+ YX'"5S2R_#LH M>-R4S57K)+K$KF):*-A.H$(:6-+.?A~~
~~(CN>O7K4C*U"!0N@]HI5.D9H&R_8!6-G6^ M%"C>C^C$4X>9@6+]A%0L5702*-K/2$4SB&D#)?T%J:2@*"10QH](9=0B"Z![M>?~~
~~\'HDX"RD)4/'P^2IP@ !41GS."Q2P 940GP,C!XY"9<+GN*B3$5"Y\'DL MZG0&5"Y\+HLBZP 5"I^SHL_P0&7#ZIY ,$%0&;&Z)Q L~~
~~O1HCM5#40!:H*)A M]4X4: .H:%B=$@" "RHB/J]$!V.!2H;/-S&%@$(EQ>>M)"Y4.'PN2RP6TU0 M^?!Y+Z"+1E#Q\#DPP-M>4~~
~~'Q>2^*ZXG/0CFY1QM1OO0S/BCBIYRF22P*V0;W M82H*NP;YG) B#Z)Z/07+:BJ",@O+..%T&];UUVSM?,?5+5R;W':ZI'O-R#), MXK.GI6~~
~~G7]LU?FA)2R'%^L\765ZR\/5%D2Y=X(#IX^+&U^G9 WY-HD@$]_/K M<"72O),LYK_AMC6^3,+[).4+Q)TZ&$0"6](1))'P>(5*6 BJ9JXE2&.~~
~~M*]/(M])JI9^$RZ0(]P&F0&JWG.7PRRD-40)GZ1VH9 MRZ1VIH%R]8_3 LO5/:4-E+E_Q);Y&I1GE(!"]8_4:J&@T%,34,;^T5K&,AH$~~
~~M/H!"]H_9:FMI-*$&H'S]0[9:KC[D>QW,+8-&U]'Y9@#&IG7C&MDB7<,)LCA2\ZRU2Q\UR$*,$$QB0#,5LCF!" M@I$ZZ(Y;L"6J~~
~~IB@6Y,29IMKH8TA1*,72)N;1+?$]#*!4*CHMCR]7*:I-70F M0R^B+DN$+@"C%\D,!#:J*SS!,A2_GY,BB<)T:__[OM$C^>PX+O@HF?=/6_LK~~
~~M,S 8]77(IJQRP>)JT[XFK+INO,=YBY9#253?EIZ4Q9RRY._GFW!R260MAI7@ M(L]+./P_(M>B&.!V1Y0!:B4%Z;[1)=]*B-~~
~~J.J=%%T@J;V(74L580L^&Y]ZT(67C.6THJON MH#XMY>NJJ.YP/BT%;#H6X@@-;@GR@,X"6B1A',EK5.NGZWW:9(O:?U"U'M0U:W(9~~
~~MU/3#5#C1ZHR"TBW'Q9RPF@>^98FH2,G(]J!JW"3C]NZE,U4I6"/W7-=.F9$\K]";"I,E(W-<(R4G(8O$1>Y3 M\DA26MT]5(_J(UC*1Y)5I*-~~
~~"R36Z)]),3\I\X)KNUC3=?!'.*__V+N,4AE M:]W3$!+K3GXR,K=I_# -60T=_3-\D*X'&9F'2!Q C9T_J]@FB2>/W%P_K%\^ MF\Y>I4)4Y^E6?~~

7@@B->">""(!X+LB:3>&-'=ZI*R^UJD]JX+NJE42=USO@\=_MZ->B_=+P)SHH)-"2-
X"W6+5LDVA3B^Z%6DBFL$Q$9U^0N2$YIW1@>M,)E$=_MI$"J3,1K748"1W"SD1JHT Y.JR=B:3 Q#$ZN!W8]N@ 0T#)W-72,ID]@_0S
M4$YW-;5,Y%3C2: . $[G1IL80K^);DUWFFN["N[.$>XDM#-0$3I/VL*P:=!(Z%SJ;LM##A="YU=W M$A2 Y43G;G<2N$.R#>,EGWRG9E%
JJ)%(G$C"D[U=NO'Z)NHK@&UX+S3O:#) M]<7))\(>"+LA45WI+/F[VFFF2_%?KL1,.%WGE(GS!R>B#_68;)C8O0O2O3<+ M-
U5T4\8[*.=K6P&P4I&4?%MBO[O'5-_A.2R:*REV1-A49*_JE'2H8?^6*]<;-RP-\A?MG$LQ:XI:F:O6@/WW+#&7(&$!UQ9IQNQ?^1\
MPUBG9^L)VC&ZJF<'77UVJ*)52BV0TKF]\51M_V)H:<;GH?%R(8AV7%Q;NQ_9 M[J83MUN$B&ADF3?M%#-&,
<=GOTJOTHSIR9VBZ9='^U) M?!VNQ*XS$1[$0W4PX@=GP@]G=$6(4IQ6?;B7$E#"#EG1NCTSK;*+H#8>5WX MN'+E<:S^/3_F;Y"!4CG:=
()'SNJ/=6Q#>EKJWA$&>2NGO>.TJOM (Z6%2=7W MXU[:<;ZS;.$21(N]"1U@0'V^:RX&UN3H.!9,?=_#;&)>O0L#.C>B T" 9](@ M%(4._@
6$G($<3N%%@V.)DB SLBH@@34RCD+I?F13Y-L+A$9'.5E1[L&%K^< M;6?2KI+Z&X3]@D#M5''%=N7*TN-56!"[5O$ Z$!^$-
D[00C0X?,,E+AE/ <= M/J^3R)!8!SJ@'DQBMZEA=. ^V"!UQV>ZNS4#L&;V4$3X+M:T%]\J3%_3?GKE-2_R_?M);<>SOA+<6[LI)"[&V:VD"J-
KJ2.X'&9I0M MN!6.5P%P<>/?*%"A<,6!)8N2E+QP\N_H"3+=^GNG6&1&Z^9Q"^NN0(2Y.F \MTP8\) M&?^RR90UM!E8BNW.O(X@:SP
\PZ&ED_<"7]V/U0&Q*SQP'*M#X 765ZRAC?B MS!LZEJ>NCB&2%]Q]E#+?2.7Z_DF30WN>B,*'D/.%>0=(Y=-8AO8=89 7?EXT
M[P"I?.WF$]M);ASWP]:(O7PZV\ 14A$UK6K+P4U)RUY5R6:-NPU1X#N(X]1[QW^U^G0@NYN4 >!K*(BL0'$^L]$HE.%7D66/", 2PJA,Q:N
MALI^S7YWZ\S5&$$\?W27;/H>G%98*737<9R,T@$59H=M;6U3;.@VK!:"*(=!
MEPE&MPW9'@!I]AC=YM).\O9(5W1+W?;4JI.VZ'8&V^+K$_'H;F[V9?W@.!]T M-SN[#4E_0%UT%T*[#53;##4Z*](IY@,&'J#SFSH(]/(A2W
.#YWGU.<02#.R MZ+PH2Z/0!36 SK&RKQGV[I.ZLXSV1T&=4D;G7=D? !NA!'>NE!WYVV(3T3E,
M=H9CR,LBP"%U5V\#P9!VNN6$SF0!D[)MOOTQW9A<5YEGPZ.U[+?<=%/4Y?(T+;=V"!\9MP%I+T M]_4T1'6-
;:'MXD>^+I7OS(#;'88T@[ZA MT\2=_"T1#;7;N\W;9URWIE*#(P6T<"J!#W*00*>[^MU0+N)HM-:&=]!)6RW!@OQ=Y1[O
M*DLE.K2[RNZ,"^3<2[NG"8=(AK\/G*Q"-E*Y'_SY"%+9DD4\K^&-3R=]Q(L M:9!$.Y@A8#]\3==.$^+M&>R4$A>7
\N"L)RKQQ]DGD0IR>4Y73VUA1SSIS": M<\UD*_Z1\Y+Q@>:ZKLC5Z\DM,+6!-M_1ZY)%\S#??
2)&SIQ!,QPI:%S.U7@BPA&\"IW/;%22I8AV;-1Y*KNT#QB=IF*O,$JC-4%)\(J'0>7'&/F=5_#%2H>,,
M6@XCT47&/9"\4I(CY7H!M!A<@@_&$GS (,%./82UDL33[$:X%^*-R>,P3_+/
M&;W/":MJR%3L;\H)U%7/]E>*THEQ]ET_FC:^.ZA/N96NR7K!QD7?\G D0C=7
M^6N'P%A&;1^'+26^.=T:%=AV!VCJ%MA.LX>"L(4XN&DPORK207E60_"5Q&/C M>U#]W]'=:L,4Q=3$O>O31-
SQSF)Q.5VY"LP[0"'?'9^&5G*];CBH/-"*RVVOL%8^1]VUZ$967T*V1=2G)=9W Q>@!$[Y?N:T25AQ>HZ#;-BDL4B
MJK\4@WN\TBP#@Y8X)-*JED'+PY%HT%7SJDS.7F*I^;?*M66CRV]Y#(:][/L, M.)ML\6;7:[B9K!))N\;^$K/[2\Q#X^']A4[T%SJ;$5)4
U7").%&CUQ@>:CN MO#:/LAOEX:B7\CG$@ CVH>SAW$LE*%L:A8\QB@?#+71 MI.MNTM 8QTP;?*+FH1Z,HP&_(J26A$Z&
(.P9<.1UMYP=F- M�&QOA 3]M>\D1ED)"&39#;OS;*LFD#O,XPNC(8!J$$G"O?2E1C]QP(2#>C MM 7N@D&=EKFE)Y$LJGZ;ZSWHED&
[R&;3*.CNGZ!4?D1ZL7J-=]: HEMZ[\UF*4DMQ!_=HM:D:':] M5OTU=90+MUNRJM/BM/0$GT4-A4&$T6DI(&&D$%*-Y4:IM':R:2/96;K-
KNZV MB-L(8^_B0J];N(V.]"XVX *-VT.Q,[W6W>X"BFWI[=)^3D2ZVACH-B1W@(]F M#TQ7:@?EIH8/5M-I@_R(9D7Y^LK&$MW[^LK]UE?
N<922%>%9DK'@6. MZ"0)H[ONE9[:(WBR:JQ_#,I MYB=E7M %8;H;GJ;-_1U/?\?3W_%$)XAV\Z5&^YY;T2S!W/7.!YH3*6PJ*/3$
M@"I(TED5D>=^VLV=Y*B%)L5C)I7]#(TF?0,6R=RW^1.7*:S%PQ(8^=:VG%P:S_2[S,^ M/N-C^EY?#8,0=V!(\JA]8$U'[I1W?K2(B#A="
(=90%&/21;-%R'[HBSW"FUV M"+(,^V[B*^966_94KR<"FPTMRSX,7B]&\P6'H21XC0#622 KC35&"89=&6M' MX!5_ZM !T@HP: M#Z
731%[H$;'?DR"F?B"M(7C-1)9F]UWE<#*(]GHH"S&1P)T^3^(1M*6GBJJ M/+7]%8L!^]*O#BM.Y_@5669IJ)&W/!8=
[FR).VDSGL*9D&P'&MV%.3_4+&&) M2F,[.H 83*RU^8-E[M$(U\6PPK()J "5!NL0DJG'/XUJ1\\D#N861>H1Z&J\
MKP6,%;HMQ&/4J3$B#2@@GNJM'O=L+)''/?>,>^X*9QP"^?Q3$*[=KV!9U^ZI M@,'\EWPLXX \+;E>&Q>@,.S5*1*Z%6\P1+3'4AX2EK(%?
FI=_HJO^DFM3CM5 MHO1P:$N]^E-B(,?>.^0$ZYE8WUB&\])^#Z+G09O6KK?-J
MZ)D#>G+JC8/YZ58\KGS@)S)1H511/DY"8^%FUW^4Z4K]\68**Y_.B.[33106 M/GU%'ZLNU9^74UE@81H55,N!E,@" S?
A+"3I[^OE<)%%"KW7D0_.^Z7PM)KOLIHV.P19!ET=X@V@N\T;0)K MH9+6S_'BU^Q>%+3+OP =G MW0=G[?-9WN?
5BW_%V2/_C_J:F(IV2*XU5V\UU$-SKC0S6OIQ-% =):GIPPRA?BTV:PETLC!)KCTBT[5$$H[2ZG8H:;PRC2QMV]4?1I:84
MJXZ:1'Q1I4O[,D@84+GMEJ_C@(R MG2BUM)M?B\&HVIT^>8XTP8ZG4L .WMZ5LRJ7-(KN]8BH M#%-ASE0H+0WYX+RK,4W:!F/E?
U@T%LES0J;T65K8WHCNS .8%PISEE&=Q.VJ*(:T@0^F^&#*(0=3#!S" M(:(J'P/R5\F5+2AVL!V&
(19E'T[C+0!.NCUX2D,6UYN$ZC53*96%FYUG?"#I MBH@;
[3O?:6)#38DC]H*+FV\C$J1YXNXN*5(RG5UD&^IX#,KMGZ^BYY5N[K(_L)+JQFW M]]$C'SWJ^*:1>D^D%C:>T<61@*X"FG->EQFBP ,
JGA$7WJ+(;C4\SQ#3E@^ MFN:C:3Z:9BF:UM*G&R*P=G2TB44EU5,9R2,)EFFX78[V)JN&Z?A-1@SG2)L M=W/R_ONCC]-
%EMR7XIY1_9EK_A5YI OQZFO/)S0O\MMYR,AQF(M;T"NQEVI! M9)9Z]7%<(PDVA[G*QYPNQ8 K:R5IZ9UR+YP)<8%&L5R:2
;A48D&;2;"SN>@ MMO+9%NQ:BPECPI97MN%X]5,;SV8)F,4CJ/C_EQPS^J6'US6>\$(1.?$X(M0X9$GQ-Z?>:@&NU&*%>*_)UHYL-
>LDX>LV$LD<=L.,)L6,UF#(+D>!]D MI BX#'G 5VJ0"V:##5]0'(>R$[XN/% M"+YIWW*W-F0)_9SE2Q(ELX3$TFLP6MIQ<&L_U*_C>F,N-
BQ)P!1*.K=@ :Z(M<9*6XL!S2Z*25<_[GCU%:A ,%IZ#P[Q"=N!KRC^&8JXH_I)M48: MGU;V:64;25D'7@AMN]MC&C"]NTJ-
S@RC2]T"_74TL2;87%!H) %5^+.[,F((MO-M,XKHZ3*%1;V.+>BCI75P;%H9UU).6*-S.T:5^??;+6"*?W7*4W0*&*0;) M6WT(EB6+YF%.
DZ\2(HJLV::N%+WXC9S!>&E6^H]GZ=A%K]ZW_!%WDI"@R-- MA(L;G[3B?OP)+;D=9DQQ"*KDCI:.K/];H62SLB8/C%1K;I\?:>K*N.UA2#-H
M0N#DV?Q-LEA4=^8FE&01=PSA)=+:=>(3'V:W"=?:]#S8]7E'5 .FV0/7]\7S MGU37-]OV@U=:]07+]CU].Q(/:H->\ZO,A.C(?
4K,WV'TR29T@FA=4]K)"\0D M:O>MEEKDT?VH!W6A@^X>(3+C[AHDNX=(E9#9*%^2'(R_N<_%6*7Y''-BD811=N\R]:
M1CHE7Z[H8Z4GHJ:O//TBI[)0W74:%53+@93(@,WX2PDZ>_K*5'FH32D.!) MN+CY-
M)1)N%UH%#RP7F_%/LM4S^P#FQV"++XPHC#)Q7L\[EU.L\>=5DF)>V07&N* M66NHA^9<7>%41S].[H>U)2^YTA8-U]+[-*!/ UK(C2D.
M34\<8HG];AHVT= M*XS2ZG8=:FSD1Y>U--J T45/];,B%W$TZ1P;6GI@.4O8N12=NH(M)C4) DOG:H#Z9[Y/YNF0^
M,&CA.&^?)P]9,DNBD/\<1I& P/$VP9*FB8 9;'_8,*E/XYOVZ"JKWXZO3DG^ M:T:681*?/8E"L"2_%E]8R8);!BULY-
X%HJ$D=1F"K%):\2#X29D7="'N]R;+ M)1^>21;_'F8Q[^_AG&SX <+!?G'%K9:[7 MMD63/]8W<,M__$A8D>2&(F*B><7NG MTEUDW-
\B=^$33!@=N6/>A1-.&7 B=.1NX20DSPFYY"JA]RD-6CB5X(I\W3&G MC&;\QZA^TLAD>;3MQNW-X9<\;%P
#;5;SAE=\JU\)=Y5*OA6(;:)Y;,)TLV. M:7.GLMV0B/][SZ%+B%] \?\YR1DD=C!3_E9*Z7+^M).=6ZL&90* F[I6*+] MR,C'F3[4QW[HQ #;N86T-
+[=5IO* P , !'[.R71V MEA>BY"N1C6DST>AA4*#=$!/69$00*)]N\>F6,:5;=+: FL?1T,D(8)QV"TRA M2U:;B=PB:.46.6)=8NBYPVVNWKJ8L
+4,@?D EIG-H#RODC,CF[G?R!0O^$ M5&APC THY\](Y30\;P.E_069M/UFL8&#\A'9H+1*\4$]#JQ>EG&\#"HP5A\+
MEJ>!2HG5KS)*%T*%Q>I==8XA0@< F^?5,9$*%1NK(Z8*"T)EP^IO=4O^0:7'
MYH7!P6F.@:15T:3W05XN%B%;!72F!5P6U:%VPS2P/E2'+S@M']693QCPU&,+ MOU%LX79#F_!39U4>[C()
[\5E*]Y0ZTTNGF8WX@DM5I]1KFC&-O^L0H>B?>4(MW)%HGB5_E22O L%@5)*+;P\Y]@VR5,P;#A"XFV%D54]>Q>GGC-[GA%5AR(ML
M61;B])^)NWOK.02.1P^?\CGN \AQ@\R.N7T818Y;)99/;?O4MD]M'WQJ6V(" MFN(7K3P*=$E?
8X%=^)CH$L4&H]2;8S5$%.%#P.K$2\L8@;2]TPB A@M_OO?G M>W7QV?#A@7%.ZN?!UZE(D*-LU-:?G_SYR9^?
_/G)GY_\^>EPST\MML0A/-^? M-NFA/%B&*\%<$&:Q^"4?N3@@:^Q@.[>X7>=.?>8N+'J'VCO4*E))K5\
[AVB00V6C2^]^>_?;N]_>_?;NMW>_#]?]MK=3#N&5_QQP MK:@0[\(A%;]Z=D];>>+P#IUZWZ9L>8_;>]RJXF3/RB0J$H.<)% ;[S-[G]G[MS-
YG]CZS]YD/UV\" M>Q<8%G3FC,1)6HI;EK<"EU6==,^>HK3DZE/?,%\LRV*=G]J_G6H0BK;\H8'& M:Y\O
6&+Q!5L(1]]#>/SK7KSQPQ_S/#'#'_,\,<,?\PXW&.&E4URA!<,^O:8 M!CF3!7RXPBSYNV*U@L[$)(]84A7Z$#?1[\N MV#I_R.UYSA*
[G1Z#.EY_8A+]529Y)>&G\"E9E(L;DBSN2Y97'$]G54FE/4^E M0P\F[A:<]:M2++[I;%.*8B+6&ZV+%1)1GA$H +B??L2X(VR19)5:G)-]-]:L
MD04&/Q'V0-CD@9%J(E\^R;C+E)+0 B.:EVA?O/0%>;2V$S-_4O9%5!H+ETD1 MIJ?D(<$1)_4C7V>- VK<[C"DL:8WMJ1ZK5% M:K<)\
<;BQ9/BA.]]*VZXJIN?XH(])C[@+PW/=$.D*'Q M9?<#D&70M7Y)LP?A;8D$F(S_!A*G/%Z10]S*:T8?$WXV.%Y]YB?;BVRZ)"P4
M9;XF$3]85D=*B03F;B6KZX(>DESA0BO:9QR>2/.;1F)-Z?S2125BS+EQ\"X MV6,T;^CS 0>0#]A[A;OQ7 .B'9+K._YMQ1:KH1Z.<^5VI*4?)_
O& HQX!1](U=VB (W? &[5(EE ;C>,WJ0&@S?Y%7A)H B MNGM?"+8V%8%OH$3NG@Z"260:#P>*Z>X5(?#$M4JZ ,5U]VP03-P6Z6.@I.X>
M;@08'0 """B6NZ<781,H3W,. 30U>MVH&]34QJ><@DWM,=P);EICE@D3I=/_ M(/;D2D5I\NVE*!E1@!SUY#;0A6N7\XY>ERR:
MASGA8[&@V6U!HR]RY@R:X<#ZX>+FVT >YJS8R3+R?SUSQO_QK[7_WZADTK_W MSQ6WB$JNFO[>.U:I"G]&F81.:?LE);W MQ:Q,-
Q7!ZM.^ CUBUMBM7-VN$$T60@B9V#;['M.H'*^:.U @7QQ\$<$(7H4+ M-0P%VNP09!G4GATFHON,GY/HBI#*EZT?"5?
BY+3T3KF_R$06A[+5]OFG&R+> M/9+B;_4-G/)_S>B2L&(EWF(ON(((Y5B*X^7Q2H/[,VB)0R(MGLZ@Y>%(-*A% MD_+W.2?
71XJ_[B'=CQXA.@L3 M%CP*H[-%1&XDZ ,EJO@<7J2HENEN:-'&'>$W1O/\<\9(F"9_D_BWUVFM=HTM MP#9!WVRH6-2NL06&SY.,[T-
)F%YD.;#>^1$D4*:#&X!!^, M)?B 08(FS5"B% U:'HY$@^(NF_C+7YLI8QFU?1RVE/CF]$;$]!CW+&&F!-#4
MJ4R?:$96GT+VA13G918W7RF&$3OE^X9P#R:)"A(W^Y7-OU5*9Z/+;WD,!EV; M'A6^%[;VJ/".$&'#XP6ULF]C' A
'(+V844QCH7)\4RC$4K_>[2X<6C0"AT> MSHK>4C-?"152R/URQP!^LZCZ;>1Z)9!N[VK:11T81^4RN]HTS^PNLG&0[FPFL8<[
||8!PAW;IDS'RGB M&994'QG>V1;X:V3P9UM0.:#8V,I1@T 60-FPU)YN@[T$BHBJZ'0[&"Q04BQU MJ-TQR5!/P>&K-
WKQ6N+8H;)B<8NZ0.#17R7Y0E9!4IVI7-PDD7\-[T42'<|= MJXYOMVFQI>TUH2D3,^3<1K35E\ MP]T?-?+0N ,4\HD7?
EK)];KAH/)_5UQ'T=\6^VCG@WTZ>+;Z'#Z743%QH@ M0@?8ZR8V(.2'#L5G1Z]U\6@/__;P;S.)/?Q](Y(YN@0]NBFJ@+%YP,?EN1ZL
M:"BZ9NA2M%=)N%] MY9"=I&&NJCP):C.,%!M^$O$P6V7[XVFVO7%Y'.9)_CFC]Z)0OACXV@LG?#..
M>*NJQOJ^3+#B5'U_UX^FC>^B*P_V9U+,7TF2OQ3EI=Q;L0OP70"V+[+ZJ8"+ M,/,V@&YT77U_S*-[D>>E] 7Q7K\UBE'+):*H"LOV^BT/'/#
>DY'G]:&N91 M-144<.-XC#;%;>"JHLG-N)_CYK2Y[H2"*K2'=R5AR#WY2*^/]!Y.I->A1XDN MX=COR!B<4-#E) <9&>@I>(A4PX>
D4>2[;P@%PA#5(9;.P+,&.@[__>^S\|[Q]H MCP?VO+8_W*^"):-Q&14M<1MFG0[ED8%9ZU1W9O)7&7+!GAJ3[0H*DRU/\ND[

```
M%BZ7.4U/5GP9R+^O(+/(Q._7QWH67A'A<$AQ:>BC7]8*=LEM^$DXB M6>D8%9DK'O-)%J\_WPPJ -
&.@]M!80MKKIZ9FA9SPI0H)T@3IS+T0>%^ C@SXRV"TRV-E)'R)F^$.P"/^;LB!:;E MG481._'8*9PHK3S1.9@F)*_\H%M]@2=;\1'+W
MCBS$!5]T?T+%M#T1!;\0>@MLG=.2?1)SNUF""I9TM!;8V60.7GZFB1DUI8U M+O\K@0Z-
EM@&0U\IF!TU*8ZX+BYN?)2Y*F>RJS22&+.CN9+B4!)<$R9^$3Z0 M(Z@(#4V&E>%U12B="+*"LF.48-
C5O79F7O&G+L8!:S5$MMU,$%@CM_G<,"7Y M.@YW1=1OUBAI?=;<9\VW 5Z?-43LI&=NQ=B\*.VBI+:!@UQ\Y
MX93"S[HA.>&+9JYG2],"!PH5%S??!B:V!0YN77J7^X]KY=JI4-NLB1UZ&%)" M(V$&YKNV/5F9 ^9
3NN4Z^,RYWY#GO.3Q7V25>Z!N!;%]Q+.$?\I3V)2>PW/ MY8N5HG7OT*G\IV1)\Z0 "J>A=LIY=4O4=/'#&GE+_C$Q\$P<7*.(OR$1L?8 ?
(K3["L6 M+RT?RKP0KS,IRM]*:"S$1O^C3%?JCS=36/ET1G2?;J*P43."/E9=JC\OI[+ MPC0JJ)8#*9$-
!KYFA.7S9/F<66ID04YF@8F;F48W%2FS45R3)L=@BR#KH8;DE8V,602
MWT!/.!9^T8SS'0NS/(RJES"/5[M_4:QJ\PY\AM%]AM$^G^5]3OXJ.0]GC_P_ MZCH.*MHAN=94Q]%0#\VYTLQHZX8'0 1+)H&J^!VSBQ:?E!
"9WYUY^(Y"*.9B>P<4+LM!^X MP\F"EZ$.M.36P/C['_[^Q^'<_X !XM!Y75",/02W@\[U:B,<';:#SAV#B:L%
MFV!#EN\6K]"BL#>B6,"=M_HN&E1Z!^X[8=9/YF'V0"ZR\S!A?X1I*0)!SY\7 MGL?FKL/FHR^>*31N/5J@L9M
W&RO^@\;%]8UXE[R0B*&E]3,S'Q,8<$],9 M1VINBL8;#0/M%/BB8?IYH3!?$57@Q*Z*^MB7CWWYV)?U^$F7H_'(XF&=CK0C
MBXT9N+Y#1,(^!N2ODIN-H-BY^]DQ+&;4I],860O..@7,JM+=M7N0R\-.WUX4)F"?+.ZJ8^ X]')YD@T:;)FGU(1+?SD-&
MCOE6&HOG:OEF6G&K#C^9-79<5W)&&'O)SX0QD5(3VY>8D>?Y@4MLJUL?FSN$ M2FH%C;Y_6W<^+MFK(/H]EUK8V$87
MH02Z(FA"DUUFB (/&*@B77WI+8:P9<_S##G!^3BMC]/Z.&W'MY%:G"-&%J+M MYP
QTMBM'4]WB/#NT=$FXIEDXJYX\DB"91IF'2.\IMTZ#?*V8ZY3G/=N3MY_ M?_1QNLB2^U)\V_*H^W@AM9B )7WWI_=%:-
BPE_@#8X8K&XN/&18>[. M?@J?DD6Y:-0PZ=_[YXH;'"5737_OG:L;L:-*(N>O_N:&&^D(-?P5#T?#1J>_ M\E/7?
D6O_2!T$XU3+C?'Q,JMJ9$%RE<5M/1N[V/S#4B4$E,,<1/)(#PJ\;S- M1-CY"1]-?O:.^>1X]4SR76XJFJMBO6V<6(VQ93RZ@7?
NWFX1M;DO_$N"NZ$ MU9Z]+.+M^//C&-OMA:\)/R$M:GG$Z2_B!^13<3+D?K4H6F5[4$V_.][1O$GR M+^>,D-
T28"Y&4_7=\8[FGT1@S4@\>20L?"!_4!%?%1>\70TKB(%QC.]5*?R MZ:P.A4S*8DY9\C>Q;D!UWQGE:#V&22IBHN>45?:_YT&3?
6X<8]>X42K3T_U] M.<0CMF=[JC^>$U4A!X3T%%L>*#N\[T00<%VSO>;G) M6P('Q]VCEST/3B M\G#I87E0_]!AH&N
S=\0%S'(C;+W04:*@ ]^'O 37Y +Z0(2LDRTW_E5NW,\B-_*$7MZ\AP7)#"Q8V_KL6*?]U&) NY%?JB-0[$$EM M&:G1]C0Z[
IP:T"52M3/!84ZK:CR/]V5$4/FT:?M?-KN\-)V"M=NI"FW#N[( M2--J@,/$(/&OHZ;83\A-1IRD955L*"=1R3@7) ^^KJIE<&Z<[.C;
[5;=SIZBM.1*4[_:NUB61>6@3F?[ M%FJRH*7T%J_5OLKY@Y4)7+Z_R*"$=1>>(0V.P19!KV(.>Z"2#Z*V%,4 M,119W$*I"8TT/@KHYC*?
@UV"MK7&HPLM.M][T00IC2?X4&XIX5H_&**A/6F) M8I?PT5X?[?71WH[E^.T?K0>)+'X(EB6+YF%. DZ\2(H*W]VU5+M9KVZC?FUX
MZP:?R^=IF,476:3 SDEH+)1AOUY+>[(5]C=*XWSSZQ>O"S2QUJ8]CE@C+FZ^ MC8&*E,QSX_4M2?<=O#D&;02-IK M U5OP^+=:YH]
<&X7SW]25?!NVP]>:=4UMMOW].U(C$RSE8%!'?G O-\0,:!\ MK-?5'&H?N/Y[(2W?V[H?'P_WA>]&&&G6NC^TDZ>!2=3N&R^UN)N-+GH.
JT^?2& M\2+VZ8U^TAL=([XC!;IW/&,.DKCY(=>"J'7D8^1]T*"^\$2FLQ-& MXD2H0E7!2Z'Q.O+!>;\4.RU3S@.TV2'(,NSK3CX-T0^?6_?
S[%&7A5/2#LGU M_N, :KZ;GX88CG/U,VTZ^G%R;V)+?.K-6CY*X6124\<(HWQ:EX*VW;HQ2JNS M:]38C(PN4VADXM'E5_2S(A=Q-
"D4&UIZ8'E"V,D'G;J"+28U":"A5%J;&\F! MY/*@@2IT:JMU9R@L[(Q24;MY=!CLJLT9U*4N@)+Y1YQ\ MTGT"4BP4+^^LSQ M^O?B/^*E$?
Z;_P]02P,$% @ 6*5M6?Z7D7(/4 /3D$ !4 !C=&1H M+3(P,C0P.3,P7VQA8BYX;6SE?6MS(S>2X/>+N/^ \VV$VQ&2W;+/,^N)V=V@ M)*K-&
[6HE=CVS'5<3)2J0*G&Q0)=550WY]-Z#C)Z#CX@] Q_\< M@E9MUU0VRG2USO!7WQE3>H^+E"33W#+)PV"=T/Y8147E@OICP);I7Y
JRNQ2 M?@S2-LUT"\.6:3X":9GF.VQ9/@X!VJ-7@]#JF$A)ZC)H=4L_-0T!H&!39?B: M+;P'&'^N,#V/FEVS@TWBO4'$5?)R#D?
3VY]^>,O(A&_^?DWBS0KGU22GFT65 M5MM9OB3%BNWO+1I&9@U!JGU-5@:G!"F: >\-61'N>=;GIA23CME?X))LBK@^ M5"EJ./9Q?
O[A\:M_;W$CBAS5V%$/_9^_VU%[/)9)T?(Y*N(1VIH6W\6$GJCK M:G]MHK&,RBTFQ_G8@8=K]%25.
M&8]K"01"$*,$]4@Y0S49Z&/S+]"#&$'_UZM0ZL\+,6:V-Z%]?(D*?$F5T>2* MK-8X+]D*FA0%G2A&
[.5VU^0^VK(U]RDJDFY@D[+>,1M0?!^H-!&[. M_7;-8! ;S1GJ;8&]$9VA=DRH'10:9[6C[<_?2B7!!$1VN^6HDW>DP@MRD^91
M'J=11F]P%2/R&E=1FI6PQV^B;$BQ5.NIHV+*87"]&P$5:$%01P?J"$$-):@A MQ;_BJ3@)Q("S_L[U*(N*%)=4/_XU>L8E[QCF--,]-0_ N1:K>
[HDSS'?H5F ME'E$EB.&^T[9BMQY[U/ZG*?+-([HYRB.R8;>CO+G\S5HFY2.[L/0;F0#GLX> M98+7M8@][NA DXZ.^HY"T?O?
K:Q,$K'.>0>BG-,-]OS[TZ6HZ15 MT5,F+]JF\&V)NBX=7@[M[]$Y>JPI0V2)OHCE8#RQHN5A9[:^S O^0UK^=E-@
M/,OI=0F7E:\+O@CO*5SPA^C[(B_X0P,)?L&WP]W3NN##F! ,"K6C^B]RPQ_'!>X%><;_24#VYOJZK%$18OBL,/5'%X:/">D%K 9_GHH3_"
M1U &5&BX$L@BEEG@:@3$FO-F1R5>9/I<;4@_GA.V?2*BRH% MG%7!'T?K1=C_2(7]:D<(@B\[J3\A
5>8I5&A5F6]*T&^^/X<'&DR4E+\N#@O MF1ZI(<(R@*P*KPBA%[&] +O$':[0+24!W>.B5L)/2&"EYF145.49[(]N9Y/+
MV>UL,9L^!KG%R;&8:/'MR[16_8K3YY<*)Q.ZU4?/^!>246ATP%M?9BLI D[! M?B4D](LT9 E"%-RB99G?IV7::@>'FM&AW?#^B]BXY-
:U*V.7@O"JIAVE>5]!IEUKP^H7OZ(59DQ5>1)^OTS+."$3[C(5\R731M ^(0+M>.35N1)&C'7;T,70@ MEQ2WB0X+/7@7=!^>MN?K@B2;N-
(Z,-1 NO)#$*#V[IS0__BT1?Y4RM. MGHI'@_2,A'9S@&PX5[&SYO]A3Y9">(WTJ>>WTME$K&/UYH.B1%UX5Y6#+8#?[A37O'TI M,?
*!,9AZP]7[:P1O(E6Y(/=4$EZB$E^1U8KDCQ75N=_CU1,NAI:?0C>=]2,! MWO4":$F (-J6"%13@1@9Z&--R,C5RM?
HDB8_RT"*',$H'_":_HIAG)_: 9-- M54)Z.K"S5 2MV\"]>!+H/);_VM91>2(+J<#^UTH^4@X\6<(ZWM@ST_ SYL^ MB-'Y$WNKCZ6'X?7!7?YQ/-
!"N-R4:8[+DI+RE.:,$JI*@!62[DKT4YDFD!*3 M?MW>([97M><49[&8 ]1<4/J(72^Z][AXQ@7JW02"2*B%F2'VV>W7UQA'14Y)
M['^E<\O1!>[!)YE/1$@_9?KEM"&L]^4I7DVTIU;3M5EVOD*X.XMW>GY#<\=F
M3SLS'[..*F2#_HJ3658P"):,%C7^S,%/&8%4#/MB&YT*%B\"K1OBSDGQCN1X MM<[(%N/!J[@1#.-
K@P0NY[EBAIQE=_2W8GKJU$\;GQHG[?.H]M*NFY?G/6N6GJ;MF@J[*KDK:OWH[A<\W7W2 M&P%Z[$9P'/K .I1HWK-AGJ22[URJQF\#?
D3%V^%S7^!UE";-"_4NP(YS\HPU MUSQV>&"=KY_YW?G5AX>'Z=T"W3],[R>S:W1U.[N;74UNT?2O]].[QT!ADJ., M)JKHL@S9^+!";E6[&57
M7'R%70O%!GULR?"KV:IR?ER2 D=C]YPHKO%3M8!G_[$KE%0?S=-,"-NUR/4] M2@ [^LCP![]'R3&<:"1K]GI:3Q
]DDEW_L"%ZL+D8W**4(3@Y83PKR^I3L9 M@?9[_(GP\[3B]+L:$S":<%9(MXOPT&3I01*\;9KM"^(]+ACA_I?U>;U60%?N#U[W2M M\$P?
NG!T;2*J^'P=G,J$Z9R"D:O<V""A+15E33*M>DJ <7P&=;0I")XIP&/&VGG^-L R\=MW3**:FKW4^3SRFO
MXI,V'&NG[0@^YS6CAHZ:CB8$1)V#5M_['7T$PL*HB_KS)3QME";!\+29)/_8 ME QTN2"3^]E5[0#\@.-HG591N\%T?K%#9Y
N#)V32167:XG=T0,!,*O:>[HX MH*9S=-LJGU_NQZMWJC7:'CMWX(BB:_9-@NM/W\#9!;2BF'>7T4*(HEXZI
M[Z/X)7BT)3.9Z1+2ISTY.;U*9%6+ ZM,O23.EIW&UG>5P?#(3SIQN M%,7B)W/@U,H8AZR(,L!R7&$Q-N>A/#"7.T$*<*
M&6RC*5A[L'P=CWM(=&L,'O*/E#$&I"L1*580)$%*>"F+, M7].@QPU8).;+]]$_2'&U*2NRHIKED!E-W%(KN'$0HFOQ$:!6-J/9&H&&-E^C
M!CL80X["#\**73[OAK5BPXI;>@(8^48DGBCP+[ -I;X\T-UE1D><0XJ'>SH) MI=#H9P#)JF5#B#%PGJF3L06:3-;HO55A!OS).63@?
2%90I=:?6F&V&[Y>E#* M_75E6A:/\]>CVG03O#24.N.),3=#A/&S5 --)03Q%56NDWD@_P!PGY'\D'L( M-14-0H?OB_@\'+\_RKS3?R49M"
>E+AF/UY'%>[N';8?2\RH\/UFHD?MR3^= MZ W+ZPN*+\Z'>4CA/I6<'6>V8TT0#+.78."$M$SWB][&RXH->?)GV4[8N5.F
M^?,5*2O)G*J2O72MWV+H[D-S.O0(\)_,U4N6ZT23E1Z5UZY"CNCDYS735E#W MP3EWJ.:?,PE1_2^IZ1F=4)6U,QNA?
OGW[]NT%^*2ALDYH\>,9_0;^7W]1HFA3 MO9 B_2?$_+[M%TP*I-%RIH+(\M>;GHP&,:N7 +1#O\:MI<&,&M0H\
CT7HL6+Q@EZ9*>X!@29SSAZA/&36J- M/7^#^H'XN#))'8N1EG6X1D3;H667V'2%JR*-61H-B :)H*84[?S[)DW"A#6+ MEP^1GQ'C+#9E-
5^^(R2!W>FQB81Y)%G2Q8U>,V]\]DA0.^;/J8[[@J.$?O4S
MG8RL57:'M@D7\/4RY=BCP[UMM601^Q"@5**2THC>8*"RA%3Y77P$6PAI0RLB M#;'LVY>&7!0#O2-
9\D^.6_H;2/3\7.!GL*>P@:,"9U%51WW5S&QBOYJX+^#L M7@ 8W5,2##>()PB00_D5FU1LBE8X52*H,"0>P?
^6C=&'=S%E"O.2I#1B0$[7IO^0O>4ND$K5UC4[!,N=XZKV\A M+*$)Q=I%=:YJ^76Y[V\9-@7_? MT&O45I##3J&GJ>&+C\%YNH.>K:I#'#
(3G0K7A^Q(LJST+X!#= G35"GT-!5 M/H9 A@RT90*WX=$4):9AEK[/*[($R[ .X>? (+;2$UHP!LL@-+-
%P4BQZB@6V;9/0$(DZ"I=+6X:1ZB\/?:! G,&]1A MTZ,I<7YDVQ2STW#??*0#85#%.Z>@F<[>.0#.N0-_B])P_[1"NI4==#>B0'NH
M2"B(++M">+74)6(GG0O'N(,+KX>YK\LA9 ^9^"EJ]%C[O#3%_5\ MR7W:TH.@L[NJ8?+R9JY&DO*F['K$&J_L+4FH1],9:JA">V2!=?
HTQVV:1'S5 M#+O.(U!*(39H.^%\|N4\2G=MQ1,^ZB&3=[P3QY;4-^*0MT#L6I
M"7?]GI7E1O[JO=_:UK6[AAKBRGV&:MRG=]\^X+3HKCW$/M/"5?5Y?$5;IG&4 MM3EJAW52A1Y:1:F$D#WHG$S?
BAOTJ&CPJQ>;LCP.TUMAQ!O9V4'Z[\9M.T09 M*3FA(AHS<8,/H_74.EE2$O>!A]((]ZFPH?>8CLN:KMR-
M'_@,:&2$QWAQ!>T?)K2:"EB9@=0B6[CXIY\5B!]SM[ M?FS+GH^K9V,]S54U'@:_:ANE NI4U'0TL8U=Q7NFQ24DRZ*BW(4-!U?H1N=F
M6+F38[AIODGR*O'NS&^EE6?R")IK&6HQ&CXZVR#2"2O#+; M7LNBZFVM]*_=MDK_^/L#9!\9%&?.KXIB? #%N=,$2$M9,26]
[YL8Q".1QT$R MPA:G$]X\|7"G?/!WC4G?@^.^[%O];!?$A8K/-3+*"K=332]WPJD>^EUGJOMP MG$]UC2S@5 ]RC8RRPIN6?$LU=XR[6(Y;*
(5=CF4:D>NDJ1N+@;N6F!H[9"YK M X%J L)G%)5D.M'C9*@W>J7G>"V4_A@5G^+=E!+M"1\^B>!:=7]*I6 M!T\/1&^--=,XG8; N4_5Q7 R-
X0&;8BHK%%N$ED6^9"+?EC]8&255%M]"3F& M&41,0MU4QCE+E-CE_MK*V3^.?M.]LOK8*;@7UC"[Q3'OB) AID%P>XK, Z0T
MG2\_4!6'Y1,3%&73[*T5-B>-QJ\9!TH*^?(4;1.5F>?R@Q M8C2=H9,=L/&;_O'[]O&:>V:!C_V,AO3[;
(7<_C#6PJ(SDA3)3UNOKU@W_YP!CX]:PQY3W"V M#2+2HCDG"A/I39Q9A5_5< RY3H"+@;N/-\!8 \B.I),)7J<\B90LYRJB;BL
M[J,TN<,\">*TTA29 VC.]T1P[%Y37"Q7:]H@#R(T/#X22>;X.S;WBPR,)%L; M::U[? Y#]54OAX->)X++VD@TKG2-"1K.9D9&&B@J:TQ&B"*[
FF0DFD!Y#I9 MT2M])P?8U<0XV?P DMSG:GAVL@18.)M?J6) BJWH8#YNHGTJ[T"YEJ$.UQDD MCPQT% ]PCLBPP]O\:Y>O:N.[&CE^C=
(,S%[65YN*!6Q MP+PWV$Q?!]L#YT'K8E?8M$6X5V4@E)8US%$BRZ9 .KQB((M:9RLZ?:APEB/= M_HN):%&<)*[J;S>NQ5AP'S#50C?
XAH[UBN3L&OQK6KU<;,UH(W3](FJG M0#Q8Y[E[AIX+J!^QR0L<9>5FYX;@V1/(%9\@L.<(]_ZGGZ\*]M_3XSGZ0RSC/[V&:
M:/X8LL_\|C7V,\3PHQ].),N\@-M#R>7'6!BVMD'WY<\I+B"-CGIAF%$8-JL= M\'#Y$TO486:6H[O)+Z=7,V9\2L;*(,CQV7&T]S](T5Y72D[
!+^15MSW(3#G M6GV#+%3,A(!]1(XG?A_QGL:M[4^'UO;IYW5:L,;WK"ZLZ-7.)GR39SH;='A] ME[-!L/9#7!ANA7EYV]&-9+CF\IG-ZF(Y?
%>S/Z=!-?D+94W^PIDF?Q%:D[\X M/4W^D-LCFOP@"YUJ0W?1"L^7>ZP)Y.WEQ!G1$>TK?)@'NGXM0DR<<3]V42.NPZGFUO>QWSG,(8/
```

~~XV MPRDX)%I][C<#$%WO& U*5.,,:X$2,90H<"F,K CJL'/;V9 3'^:E0RD)5UR= MST]>A 0T-~~
~~37>+;LD,2SB4'B#D^FB[='&!QT@R|98OC#7N&DV$UT>.C?2G"Y M/3:VLTNF8&=2ZVQJ.Q B"?OR$FY'4YR"(8." E|-G;': D4'$8%#~~
~~[E8C374< MJC@@74M.5YGK8XT82>?,=#D&_=I;25K&&8$G.A9D KY_H^ZR=$8$%_&YA];5B%E33IU:B3/%Y-; M-'E|G"[""..W!Q!(Q%_P]~~
~~[6S6ZXS99Z,,|O+<9.33+*?*WZJVWXHW.<7>NL|P MSQZO;^>.'ARF:WZ"KR>//Z.9V_BN:W=W,']Y/~~
~~M%K/Y71A;O^*,$$,V^[2EK:E&L+VGHI@:-C]*=.5%:U(@!=_VM M.DH1>",(3(A#373740^4$1F&F"8=_Y33Q?>2KN|Q90_= M|9|'2]~~
~~*FFFE$3|&YR=?^#%>]3S9-FC7R0#>XD6AB='NZZGNQV[_#>ESP.'@P!X@DE-%X35-<'*Y MI9I!,LN[-/$32-K,;!PC-~~
~~S9]0)I2I8[0N1FKO:P]HIN'^7LTOY|^T O;W3LT MN5K,?@EGUS*8&V*/X?Y29^_5.)C6Y1TX8BML[YLH>PBFKWO:('*=FYFE4=BH~~
~~M32(U"D=K1RP@1(E?AKJU^#F#/6(TY>>&5&[UWCJ:N#P6+PJZ/#G*]]_+D6HL MFBO. Q|06_[W)|7$9];Y,#+?0V2/V M(;G>!P~~
~~;6P62#H$."+;RGL_& 8(=0)XY M'@%T_D[98D0? 2=B2,/(D(";1)Y%_CPSFNK05'QQ^@]'-URFI4IYB[KH>G$(~~
~~M0+N6H:ZL=]$A9Y4!6%7&+".?('=P"7_]RUOV"/1&X|K.."HT1)EWQK>;;#MVNQEJH7>[Z4-R?[O)ML:W&S."+=UNLFVXV|W@~~
~~MW!,)_AC*Y63SO"DKL63RVNC(YB$LYZ<]PV-EIP>P'(NIS4^2 ,4?VL@]<9D&TOJWD@"B"E/"(@4B_Q=~~
~~MR)*$&1&B[)X5+;F*UFD590=R+=E:]QHV#-6YK'=H6:G4|S1'<8TYS*UJA+=$ MD6&^[8UC?~~
~~A&|9F;61&|^#0_37Z9W"P+Y+7!Y=VP8#.US<-V%OL)[S2Y/S0/. MH,+,%2FK|BA-33EFF[8$55/6#+$[-T<.)4KJY5+Z&-K0;6OVB*,I,50*;](|~~
~~MRN,TRF8Y77L,;7D'8;8?NBC;6U;F8TA95.VKHT3*XG MIZQBC[TB*.Z&9?HR MSQDA(CE:MD1#6;N&ZA#QQX-5+6[[7~~
~~FSR^B(|$^S3OI];R7 M*D^.3 #0:;R>LB1'=R0GK?67W@O):LQE4Z]3KN^F$+AKP82:+V7%M!>02<+R M6*6,~~
~~O0&US1|$ZZ2MB3GB1X[[:LC)3V;B@HV9U",)/60X4Z6%)!]X)XTCZC% MB6**U(;"83H,4TUC?T3PS0DK&!R!$F@6(O;Z>RM6W)9=[BNV-~~
~~M1B=9!2L>>FK'BM*)8ODP<:=Y7VX7E 91?+-|3]OZ]@Z#ZT5T2_+G|]OTE6[5 M"_H]||YF>4F"1D:Q,[P0 EWB0$_YGK:%<(A=Q8D.+-~~
~~J!>3X&^V07,K$'!)#E/=3X-S?E8 M; 1*,X>;_CS!Q^H4E+Q"!>P_[3)$ZGH?)>H=+W1'9#D_"4<,"- '?8<<#]= M*I4TC.?(TV@VUTSY$^~~
~~M+)_Z3CCCRS#[B!1/O,D!)+J!_|/=FEZ8, OCHH=8&H.7#?V!*D+[7_1:4BG. M-DF:/U^GY9]44?:N()LU[0'>.P2*(6QPT@2|D)PG9B%~~
~~(T)1BGZ3ZLOK[')/. M^7+:/%^S|L:/5514:D<8RZ$UN;NN,Q]/__/#[)?)+55Z'|_0$WY.|QS"V|@2 MK;4+_@&T8'~~
~~GD&.9HQP^RDY%3F"%OYQ4XCN1TS][*^7N--=<| M!WA@?;C-,+PGY[LURFBBRKTO0P6JR]O3M5-_,K1K7/_;K:7IYSJ+TP.]XTR7~~
~~M2|RUW80A(H0:I$SL%Z$(*8_*^XGN@>^:=1+9W=7#=/(X16^NI_6G;^AWB'O4 M?WEGN_X"M76Z&|Y^Z#2]S3-8/_I[@DAZY98ICB E-~~
~~6QJC[ND2=(S#]BE*(BF;,FSS!!<(=3TC# MDS1'7]_G?|O?Y]>+_&?ZS^/7]"Y#=L;*$N//T6H-">F^OK_XVX_O+WZX_IK"~~
~~M[')KT(^DH#HD6D8Q"SH@.49;'!6T=_J*T8IN%"_E&=OSJI>4-L4Y2J)MB#@$ MS8V!6! PTUQ|8F|C_Y!BJM-~~
~~69$572/|E#,C376V.0Y(Y_Z%GPAB>%&'6#|- MC;4Q&&>C27=5_L 744IL]]7!%5TP"LVX+BE,L J&1,@HL)1?U&3^_$/ J|6 M04O=^,ACB-~~
~~XK6^Q0&]6U|.SZ FXO>W5AYG=A+F$BH1BJ9Q'<*4.^|(R:|4, MP*[Q8P!18./' $46C1]6QFMB_/CP.+T&6ZEZ!:8 X]3S2P-Z4$L0>MJB-T 3~~
~~M/7&_Z=T.9&?7K[E'M.ZTZDT%VI>F]+) MA@_5B3^K5:*!W55Z?::NPX7;N_, M3&?-9512DW4DA.-<)|]L]"9BOT; SDHH5H-M-~~
~~$5I#Y9K|6F0A16/8>X1*9;X MBRV*7W"RR?!|.3!?|3QIF ;X/0S/%CAY(8.#6([-O65;;Z<1@7< MN."=BRW6,~~
~~<<0=XATXXJL$^1|4VPH!@-1GV:T(QJU5".01=2C&SJUE$-=7L1H M1Q|7S($[M#>+0^D@_J;;<;9ZSB$/ZT'N8 M9Q)@|KPM39:~~
~~[C]XLEBG/|VR@A:;H]R#YNO7W4.I<=XTHUKBWOWL V|C]P_QF MM@BRGH8FFTCP(_!1,AHH+MO-ZJ;N,8![>&<^.X'R[]*~~
~~<']UFW<1:ET75DSOZ MUT[FZ!]_OX),:[A81T6U!0(&=(ZQ9HHRQ0/GWEEEA[.1&__G^B@OB2R#G$K% M UY3+KY$)9X|%YC9>~~
~~XI&MR.M/IJR(|TC@!"%6(STN,[,6*F/^OK[YNTVH[D M?AANI&MGW0/FW(ZPF%_]Y>?Y[?7TX?%KYN>]^%L8_^HP#XD<8T[!^7*7-7_,~~
~~M_J4'Q+Z+Y@"RH%Z;:$=0^+H*FI,DY^_YROGP2?WN,&^[D^EB.XT?!>U:-&|^ M/-S-%A|>IBSN!;;"^_?3NP75|Z=A[HM2?)9)V7?$/'].1)~~
~~$MG;MV(E|/[G] MR,FJW%_7X4@6CVLAG"]^GCY 4-;|_12]F?[U?GKW./TF7!YV)=X?IF179ZBA M5^?D?G;U'A?/N'C~~
~~3;FQ])^UO9"]LK8A6#>D@)S7O3KO!_)G"9]..Z@^5B_N M|/KDJ15W_J85/<.[YL MR=Z5~~
~~)./"]6$HJM$JF'S]5RB2);.DXJ[D5O8)A5W15=*M:8H$DM<]K9R(1UY MA8O5-7ZJ1G+-B9IJKL$AD%X2L+/P+TM99:RX7J_/VNQHR>~~
~~#7"ZE55K--O7)AH:$1G*,ZBLDR7*?TE M*E%<4Q="7QH7(*+(U6"[IO#A6]S8TL[IL7C%T=X9|FU[A+F"_=-!=0KFJ3TK~~
~~M2RJKUYN""N]U2A=6":!QW2VGGW$1IR5.AC95+0 Z^ZP2(M=2U2*"3>M3@UQY MYW4|(KW-F&&'895~~
~~'4H9>;#M1O3&6FXRMD]7+YCNSL?R5)BMO!(+%IC]+=$Q41U:IU 1Y?$ OV7-HH^WQ4Q8--]-^!-|'YRVMX0%>K<2#~~
~~MQK1KUW#$4F0[>X#GB "1Y8WAV5-;=SJ_)'Z&$&%#G9-D$*!KF6W,=!U6_=0@ MEL@W3@P"FWKSC!"UQ~~
~~38UL7B0>29YL|1//G']JX07BX(/$+D<9KAO=(9"V*6 M+<$%"ET'IS_DY1K'[)F%&X8R MVE8C[(0+TWVJ@1IQN.B2<782)1X9W@O?~~
~~48!PDL[S*Y.W?99W58'GRRN2O^*B M@NK?|!XQ=%W4Z.]SBU3!X|5W4(4@Y4NGV]']I-&EQ"#P=6'D0%K876'OVNVM~~
~~MHPFVZE5:E]38HIQ4Z]_3C@:_[_6S^/^2!V,)A%|PBKIW^V=*(7]3L9]9DDQ) M*+$!3!9:6Q0QGH@@ZF*C2[2&<1EED=?%@JIX"-J;=Z*~~
~~!BU71*MCTMA^U=^> M/>B|7,'A:+QBSGE;+@|8DBKCI,VY(LP4)VZLN42&@;I>'"W67;:LH%GD1CA+ MU-~~
~~CE+X9:,3V9:"QS>]I0L[=1RGO6WR%X23:XCB'(_"P?Y(/P0 MI_D@(:9'NJ71&9[KM?-5'384_G 72Q3GA)=@I$?3^YYN+CSEA6VUC>X#,-UG~~
~~M)-C=M@!KV"->S%:BQ"M_J?,)/1WH4L9EU3P'7*<%CNG8GR]?KI=NDGPQ M=-=2Q3S:88MJL:(EQ??;B<#'%$WI$*E_?1%I(FRQZ5_#~~
~~[F1^8Q;)|')..&O0G MD3XR*M("'U+$_2US391-FO:?7"HDM!.WQ)UPLRS:NTVG(? M'C4A:#Q'*F)R+8J,'';|WI.RSBP0[+E2=Q*(!GQ..V+]?~~
~~$=7@7- MM&)#C|$Y#PKMH]3W=+5"N:Z?*XLZ9UDW^E2$"/@4B .1Y93?G963:E;8SL8N MZ2,.?F@O#)-~~
~~M5LQ.WG[G.=_L(UUXS.6Z]1[AR(:PG8Y#SQ |?|X|821"S$0B MS1EO"G^;D><:U__.|DD)76[;Y*Z-?~~
~~C#WO/E&$ZTN.@UH71CTAHQ(G':&:2%WH/G M(_,SU409QM#V(1XKB31_?.H?9(47T>?&_'Z)<|RO)S326E^#&(+]6F+N'^;_~~
~~MS!YG|SMT,^]RXBXF?PT4'3/&6Z+(,&|BU*G3=09]]*)%6F*U'-32$~~
~~MO/*:;FW1I.WBB,M0$X.T:BTH7W?;/DZ=&ZL9S5HA*_TL<,'2OAU-.9'AB6>5 M#"(+5"NAJ!ICH=CFHD6KB%*IN74ZJR3]%):O!N ME]'1+~~
~~<##3(;V?E'S>W'C|>(OH]<@>KW$7I9&4B>LHW>#HE);JY=1!HY5)T#| M-%=,*B]%NE|'(P77(JM.&U?;.",)_DRWAC0'W3[#="OA>V_(M-~~
~~=QXQ#!=6Y= M[.-&'7)]SPZ[@S%.99;F]*1HO%6@R!>]MK&TE03MCSQN*0W@!B(E5T29OX:K~~
~~MXS(JT_@NJC9%E$$9OA>|2N,HR[;O2<(R1.Q1(E@V1H!TUI,60N>.[4 4:JB] M2SAV=*&6L'VA-%B%GEC@<'D^,7[E/7[%.WZM6G[%>|,(L';-~~
~~A)O8FRY_NFQ4 MO@"-]!^PBKU&&;.C5E=146SIY+%|!3S-5]6OKIXK@|/YL4]QUT(+'_".#BV5 MTO$++_(>LGQ:&=4CJX9#=. M*~~
~~"X8DR)]YA2=DSH6HO|)H4D*XR7+)V/;$EYA/C[82DE$3/SP4D?X("A@:B>4WUN!KP4CMG&[X#GJ*776]=B30N(M7;04-5J)H!V-4T.K8Q2<~~
~~M,Q)04Z,132!_TC-SF3A#4L-TY:RH)G3$C,.F%L5!+?)=0VNG8-5#HW[K*RU M@87E-VHI09|H*9T]-7Q^3>4Y(:;,#OQR=D^R--~~
~~Z.B:I27ZLO9PY4*|XDF M1QU)VX1NG@ELH#=]#P@5X._:TC0'ASG&3):9 BP>1>'89Z144;X>ZZM,[U M27K8X-+1]H[C'72?9;F~~
~~GH%!$EICJVP2R***^SCHX: M87A-#:PPAR!]FF$.<>O:8>-..F7_"?'F@%FWES(1[MG36U8SDD/@(:2W@>W]%Q;J0IF*.[I"[RLT!,6.M-)N_PI]~~
~~[!?Y"=O2&4[S3=V(=->WO_WQ!=S9AT3D<&_G,L]0FBF'HI1EZW@?057L M'#)0#LFSL*&.1 |"=.]8R9 R+_;5#JVR3%LBWEBJ(7$,*~~
~~[Z.BEWMS&)XD $D M7"PT1)Z9I@D3H71]O7I$V1"YK;12'1Y!]3WQ*%]WR#L91_DROP>@||UL@X M@?1;H!C7!+-SHB49 L&P)!D,^ U1;;~~
~~[YN*K?|C M87U35I$2E6VU|9;,$,|'+A8H<2T^KH+..A>-&RI"4?8W'!73/+FF%^#%'#WSBB:H]"MZB&-R)<^*D^1CD[J]K]"Z~~
~~M05^KFVE9;MAK*=5?XATQ*!_-8>YAS.'=XY3F-1*VSWSYIBAWQW: MYJ3:&B0Q.8+I6G*ZY!^-~~
~~BEVC1@QWL/0??,X2)79Y$1;0|.5$Y:BEL:!T$'V+ M";N)G8*0'/-T4$0XC#*-<:"_8MF,8*.-M>(=>$"=/VL"8GM)P2R.PV%6L(H-~~
~~M.GQ:L'%1(FI|=;Q1WK?^D1R+E;"=P2:Y!|]G/K]Q+K)P RI-|D$UF@!P4QM M8H$@TGSR>/=8DS*MNJ)0PP&>DJVU[QZ#4)T[KFZ>SC-~~
~~X$41)30#*6@H"W3C$ MS"6*";.%WR39OAN,Z RB)HQ__N0/F+^=WAU(OS-;%9/[87L"(9LIV%|PY, M.Y'ABU-QG5(%XIDJ0^|*|JEZ@5]T4;~~
~~[E2JZPM;80#T+U5!*@Q8UJY*C!'DA$ MQ/PEBDP+9]>+<5VH3M)0=]CM"/T!:O#!0[WYBY+)H&R|'P%^ M5!-~~
~~P$K;'(|D1&!^'.>]7|V291,NWI-CDP:;R=$UJ+5* GR*+4N M|Q[W9_@PU_$1*PRM5|SE'YZA<'*]@;JV]46*&=U[L3>3/($H@4V>X.37]"BB~~
~~M_,ACU18X'0N8 5KG-Z,H:Y[W6&A6"70H6|:|CD_/=M;5D^X/E+FJK5N2T*>& M)O:.2_].V%A0'3D;P(1F0UJ)[2ERJKL_KJ(LN]R4:8Z/BD2/M-~~
~~+6U?>@>=+1 M&4[4(@VDF@^SD4CRQJT,'^&ASY6/=.#&=WZQ@>&-_#= M3H(Z!'#+_?_,+2 M3":JG/,G0~~
~~NPL,D)SUY3.X+#0(81&H;Z).1EGZ]|61E@5L!XW7N6)3"9Y>6F M&,CYJ-[16ISN(8)P.;J'E-B)SS48GTEL;H,6I2W>.MX=%Z]IC/U>)S6$2QBP~~
~~M*^:HMT76>?:^IV1M"A9F"+%W'W+R!'R&]3_+UYNJ?,# G31+V<8 ?VX*T%A8 M.:/NU5[DY>T4E^92=D*3K]7OA'B=#>-~~
~~$N&B:O?"+'[INUL,@.ZG;[8!XG2+G M?DG%%3T]GTG!MQ(.MC+R3NJ@>3(6,YRH11K0U>>8C4?>/AS>!/+;F'Q.>8EK M^ VM^&H~~
~~0.>7]7U?!O01D(8IZR/@)M=_X9A%3G>+QF^RKL%+]RZ(11V,AY%I MKKU_#/(/U]^ PC%_OZ<'66/0?(=K4"QT)2&8|SO;~~
~~($9DAJLP+M&M"]MQK M4& MI/;.X^96=M =6,_[Z!E+:HP^ULA/83|=X#!W5*9<6Q[>1OSAREDCT"| YQI[@| MWYR%-+E> OU_ZM3"/1W.~~
~~[,6+D$*TV7XU'Q/Y^PE*IF73EH!?>|(2S[76*#&>%F]*P83JO$F:;:"87Y/$.<7E M]'.=V:].S[*BFRR;^_ER&A40SES>0Y*~~
~~[J!#'7EB%K7GH6Z'!];.;8)Q+MJ#3- M?!]H[!I;)(|!+:UMSM".6MA'6GIATZP3ZI^%C!>Q*^W$Z32:IM:-EA'.?B89 M)~~
~~XM9WG,SULQTE0KY>TP2.?I:QE:U.*%!'?QM_HY*ZR-POAT'AQ8@'RM(Y)" M5!CG[_Q,_K$IV=%>+L@D25*8A2B[9R_E5]$ZK:*,+~~
~~<,G./!AH>*|;.XIOV_2 M,JWHFF;> ;4: '>9YYQ!$;U,^T*K>^HZ)L^Y@RNX,)XSXD A[:@+<[#XFFL2 M:@(#>FA-~~
~~F@35E$"ETM>:E=8PBG)_6,2UV/+6,QFCBJ]4B1D6'^0SE M.(SV]"1>0C^M,7YZ6VQ7,&I(CLZVA;3|;9<>]X*SR&2Z:"XN$6A?BTI$@|YB~~
~~MLCLFC7O;'@$(*#@+G>%92H2(#@^=/H(OHL^SA*+M"C>,Y/49::_]#,Z!Z|FA MAF)'^^C#IM$9XS)19IU;3PHFR-DL3_#GOV"^YQ6GG;~~
~~[OQ#X|3|+28$4,+:)X M0SD7<+A)I%GD[4B^K54$*-+".8$'6F@>N#U(K@6"H6J*SP0Y=(:X1B18X70W M>,#/:5E!Y!VG[K6HF?9>L~~
~~_.G__4/EX]ORE3VO7]I?7:8PQ3N%HH"D>61H5EY M7CQ'>?J/=G9.|N0:EW&1KFNK=IOJ0B330N C@E:"9'K-= GAH4;]>&CH#6+?~~
~~U1).8,]^_>]GE=I<2%6K1"7R] MI?J8NGL-P7:ND;08$4,9T@-0@MN|? M=C@JH4.M-[RF0NZ*/M<+!0: V C0TQ8=+9N0KK[^YGYH|?~~
~~F94&|+^+X@R2:N MCJQM@YX#:ITTEXX8N&NY;["C8PNJI$N!(Z&79#G1XZ/3^^[@1L[[6?M^ZV=; M;*Z%0?~~
~~8_+LO(&!_|/2TUY4C4MA/)7KH/3&+HSC-#-^A/;D>1Y3K19*6C/>46 M/T=9+>H#%QA!"XV=Y0"2>W,I18?:+~~
~~<;_S43$/"+!$5,STW*9QIC99/E^B]Q& M6N:B0V#.34(,(;KMXMHNBA;(MEI.]Z!"421U(7M$ZB&RVC$A[#E<^2!RW/-V M5K+2Q"P%N,"~~
~~[:;B1YDFX#|R]KUZ#+4BZLA$&$CFN.-6+)TE"V5=9^0(_;+FS2/|CB-LGLH>P66 MZ"=X"(IYX3|J74UW&@$*?_L/6:*."M22016LAI# &Y/,+~~
~~QM5]*L_1*-P;SG M1!^HPIM|O3U1[JR|9ZA'-FKIAAC0CG+$2#]#?>(1HQ[MD]|<^$CZ6?/T#<6# M3X#^9M[;$OX5I|(O%4XFK[B(GIM2=/-~~
~~EG49ZOJG**LJ39BPQ9VUJP=!<=$JX~~

```
M7*^F7Z>S=S\OIM=H\LOT8?)NBNX^O+^IH_HPX,H2F&\VEA]5YU'0;O]'0Q3P^&LKV3IF>EXB\"XRK8"[# M&226I\7HYHGCI%D#<;(3??
K'W^](_K#)\,7;IQ\O)D6Q*%9YE=QDT?.!8$NU M511;(4S70DD1GP-F!*C/+] $2A\|U_>#!2Y65)6F.Q;Z"+3XE4 Y5A,E_OFP M6US1C_-
B03[QG_:X+4UM%CN(OBT6@!F1 @'NL-:* :X.V2IXK#+-L51G'9]^ MA@!37-Z3+(VW0B=0N1Y:>92$D-U[#-2IY5OTZ&--@/SUQ\.0C-
TXR1)%];G& M"OS5(P3?SG4S?-R0&B(7D)QD$0W>.CJ&I<]@ZP=PF-/W=$]>N6/7^9DK)RJ3 MA*PIKR1D9:"EH;#T((:2EH:$4Q"5(?X.R
J7:3X4M'M"+]K9_TG75R3AAQF) M&INJ:7M ?6MJ-7)$L2- 'U99&V;OD+XFX)DWX\AAJBJ1M4_85M.P,0C3M?P< M&^7NI@MT.W]\1/?
3AST+'C/1)23+HJ*$%(BUN2Z,M4[,?Z+$5&\"UL;&3.(Z M*0V\7?&C449::PH9!ZIS,6NCOGIX0X:AC#&7*'+,Q\G&WD#GQ7U!7M/CZFVR
MS4U/MP.POL\WAAY,$2T!84\X'I.'SC@AYX)N0O"QP.)D_M+]+&Y,>_!#;%%G MJ*4A;/"///-'-BX!1\-E8KK<+BANP5$HT<-6'J8=9.>\8
ZY*DHPV=1 MLB(>\_P\ZXCM!..-S1]V/%H+1"\[@2T&$IP>?M>Q:S?0>A_/,O()"ESPZX*G"2 M5NB6E&&JZBJ*'C'C'C471<0BE_I:0S!G
M)$F.$S4VAHA)N(K*EQNZGY;RL0C<+N8Q"$>@O<8> ';$T)]0S &?V\.Q!B,L M=)L^DZQ6)&>YWX]\2+FV/YE.^HDU!<#]I=834:%9H-3JN
S*E#(Z$"/DK*XA M4Z(>+<%\I!7EB^@QU]N.?0T!O7$=>D"OH.LZ94C/1>A@3QUMK[E7<^&Z7DQ] MQ('JEHYQE"BS*
<2!S\3ZA60)7?/3WS=@ZY<^^=8$^&5^CFI 3 MT@HD9F)8/9!EK]^,RO2JQ6C81$Q1%MZ7QSN8Y%L>!.PG_7(/-;OVA+TL2[#Y
M,$&S!.^"BI7@N6:LN461\I.@9EB@PKW3C#)X1)@"ILZL\XYW>^C(<3G26E.0 M.%!=RU&-%O4RA(0]
<>82Q0YYD\!BS)_CK[F%#*#MCS0T#6_!>HM0W2$.*T.C_!T( M+Q4SS6<"V24N2U:&\ 9CGB;$:Z:?)'8/G(>TL!T^M*0(0R6!'68BD>6,8=3?
M<&G).Y+CU3HCV^/I5^RE$_TW#MVU<$B2H1P$Z&)D&C99=K??*[>**H+R4QN9 M7HCCX@6CZ/FY8(4J4<1JL[NSX V? 8,,6.)$K=\
M7J(/RJS./,8+14_$34?ZWRV5@>S^A5[QN77K>4TTM,!#4#Y<(0]QJCH^FM.L
M85)C2!'#BF3(=J#%=R/#%VT[YCJX4""::Y]=IN6[RG%,5HRQQQ3N?I?IH M[I%"V+XN^$(B="[XMD9E3(Z+%1H\^ MFE2_GI4E5;^O-
Y"&_!X7*4EJ#V3VXYP5+"ZGGW$1IR5.>%= ;4#:WINJ")VG MX&@0@6B6[%6$U!0$S]EM,#G$'L>]";64S<*J%<*O76$8J\[.;DJWAG)S1RI<
M(H8XS#/YN*WB)*P/G-7&*DE8V)C'X=C=E_GX@FW+I[052TS'^$XLRV-O,OR M,]#T[J.BVBZ**"\C%H]27F[[OPAL:>H -*56'I%
[_T6&C]F'[TA>-'\"?F8> M#F=ATY@,8LYA0Y^DQ0NF7U[442\Q=>)X';I7<[0$UZ2 J,;4BQQ6D%UB],VWTA(NK01
M1W;*O.T9S5]R4ZN!L$QH0-'<&!4RN M-X.FDCP<6@2H"B*V.IPG%MCISS%YY[!"50.HXTDW$(X8"MOJ.B8/P?1US@PB MUSE$+
(VB(E64J9T0"^B",O"TKL#3.MM1$L;'6B@C1(EEWA9!5]ZV?L?B5;:5 M+MFL"$9SZ:BB<[VJ^J66:Y)$599/Q4E0>]*&RB-
KS80W,;_#%20Y8TGI$YQ< M;C]0+6F6-T76\^=)3,\CMB)'0O7U 6F*NCI"YYY?T3NRLH;CRY6LQ^F2UFT\<@\FPP-\0>P_U=R ?5_=YEZ'*
[:]+T895.IG)2K,"1<D M>,3%:QIS0]BU8#AP]SK"Y3Z9*KAWI0RM6A:2 -Y>_)F0]/0:86]HD:V?E QE M=@2(BS?
_$3:DBPZZMK=V26G'5[@STIIUTI M&2-Z[/7HMEO1>RU.IE&14S6LG,1TSC;_G6-EVF<\IXLY3MJN_6.(?"0\[?% MB)(:I4'L6N.JJ/)
HOF9,E:5%6@NR/T62_MO?PYFSN]#,HIPU)Z$W2$/4-2I@I MB*E]E$!2L >PYJTLS=GWNW3+I%?;;T5RO!U^GCOD7?U4]\00'3_409>]-[HR
M@':INIB)R2Q[.Q+?PQR]CXK?<'6SR9-26#U"W%CS$!P&ZGK#8EA1C18QO&$+ M1XRPEJCQRY_XU#Z@L-G,\O6F8J;B^R*-
Q65(9+OIBM0(>.?"M<./& %-+!-B M- 06-%G6$UU^^DN^&)6@_\$_8()XC3*P3XCR?8YVT$VXR 7LW$$7:E*#!L\^ M]) '3? YSF>BSCR?
U\2*"C?5#(=)&_Y6N.'9 *E_R=1&'5!ZPT9K6Y@MXF(* M@AWL;+?_A63T2@'O=TJGN["OI2-^$$> <[X^X7>$G-9A+YX)P8DOP5Z/I4(J
M3">E-?9 ]1*.( I::I<%.8+HKQC($6J]$B 61J#AR]_B10WB,S0^ D>K0B06 M1(%3 8OCS%M/Y*MHG591-EYT5A& M;
(Y/$2NETU+";APM[8LE.9_.I&",Z/\ M%U:?D6.J7[="&2<:ZVXSX1QE[+C&A'*&8>'T90_YUTU]/##\RCPXNAM.;>%]
MK**B4AO4992!@3DLW=-<\3E!BFJ7'J.CSD6VW(FLWTF@%L--@7%[4#]$E9K9 M<1R I=L)'U& *PJKQP'4H$XG WI.ZZ8B,36"ZXHLO[V)
[G5:QAD!&KOL"",J MFT0/3>$40/9U> I(T-F^K8Y(.U%V15"3.(">K?3\JI@\AHEFD9$>HL% ?]G$ M6@WW%C3>UK]U.YJ\2;J?;N:P,?CN
P#@(M/+?\3*:,+3>T, 8D_T) ^32$R: M_42;I_ZN-9NGDFK%X%<$Q3Z%JH6PK>[E9@BF\Q"G#BEB6,.J!6*V$B5>!=-3 MP8 $QO_K%
+1\T193QT'8$E/Y2,*H*>VQ*"6FA-44R5F1J"FRK+;HR>5JN MLJ@LYTMV]1,\J(^VUS;K<. Z?Y $?'"8UI&> =_0QUE+E/D5? >$:O-:.]]Q
M1\L[W@Y!R)T.J#C-#6Y@ B0V-AY7_;D(]=:#N"(KMZ&N2] 10-][5] ZJWQV M$GD>^3OWNI+7;13A1 MRFJ/R#.6)35F/D -
>:>2,=5T%@7*I='ERH_%Y6K?K@*" MG!T:84[)V'+(\W%+RR C0YE9%A2OZ,HA;FW'U-)"]6YL <1!;QTCW.5;7(99 M%E*(A/K>:'M[@N1'^^.
(4D@E<)S'8G$*JQ+NTS.:%7^TO1V!\I?G_E"@()5] M:)5LE,=\@0J>EG[_['U(GU^J^?)#62?3E]*J.'VL*%4'L)T'G\_>_;PXG]_0
M/Z;H=CJA_YT\/DX7CV?H;KHX 6V*QVNN,B5D8###VX@R-=;MODI:3_ M-:U>9GD"#V*;*.LW$J=IL056UZ?
*$+TWQRM#.K6\L[SS1L.%JR627V<"LL6C M':%G^RVE^./*VW[ M[][@/"9)FM_]^MV7ZVAV?7)^_MT;5J \01G)\:_?Y>2[?
_^W__D__O&_HN@W MG&.*"IR\N=V\N5F6>8+I1[+";_[K^.KB3?3F^U_^?O3N\M.;+S8K-X* MZ+__\/[[MT+Z+=>\P"N<%U%."AP=?<]
[PZ5P5* 'S'B/JAZ#WFF+&&U= 7?!?;.6%8OWWH=8"/Q28#\PM M?#M%,A)K>BI^\|_/_/'LAIRE.?_<*AZN]S,:OR&4FPB_?L?-#/Z7!:84)Q?U
M.Z1;8K7@5XKP%U;;^M_%%\;)K]\5M-QK@6C\8A=Y^J"MQ-LUHF+GB)=IENQ: M+RA9F2_>! 8-?_%
L!3<%=2N/#D<5E=\*,%M>I.FT_6QIM\#1UYB M\+ F:"($#RMX6,'#"AY6\+!L>ECFEI1U3RLA<5G]@/(DPM5 CM)\0>BJ>B7<
MR0(^R)Y_9:10)]?J3T0IXKOH#;DL:;Q$#)^0U8KDUP7_OI_PZA;3)M_*H-F M[LR,8Y0(G,XR=-?@S#3^?4!]3L122C$Z(ZJ5M::GP
BFY0M)"SJ> M/RX6,E<'*FY7VR9'!R)J0_/_*1'ESD>VN<)K0I^[Y0I) MJUK>\)V#I959H5/SN:A=/?
DK5+KQ/UO19VNB)PFW,MCV/V*6'DGCB0I96WJ* MO6Y.;\@W>=13*FE+QTO"+:[L_Z5KR7ZM%[:E:>6CS.DE)?=I32%3ZBH1'US;
MD\IAR,ZY-?KPGW@C55,B-[Q^CS;J]9([3&Q>%A5-D1OD51O^YTA>D=A^$W2KX52_Y)URB7CT^E]."ZGJ49_EPV M>%Y-
(A:_J'@I/>$KRQVA2#*1_JE6%8+7\GI.2+S$:YM(-:6="= M6V(H+M)[S"U&M)VY"J6;Q"V.@RM\EXJX45Y\1BLYN$_%+.IWO<19HOBAT(V
M=5NA+#LN&3?)F'SQ;I0:7+<;]'">B(JU9Z9I%2"/O51H;H!,1 8DER>5K M]W,1*^/N&L<>K#!CJ;M$;N MU,>*"1#P-
)87I"]PEXD^8S'>XB,+BD)!N<' MC\#1Q:7!H/SH'2CJ0"@8F)\FM4]K,#&(O(,!^MDG@$#!53 TO_@$C9;= (;E M@X>PR.@4<$-
O6G$&&"I*1@0M@_'Q!.C%W9B$@Z+)_8OZ.PC'!5/@KK >\4(^M2W4ZV"2XK7*$U.']9"';9=@+FCG96B%]L_G^>LI.CE*;DNCW@U
MIZ6F42!N%L$5CG%Z M+U3\C M8EU1-[/8A22J6!-_OJCEU@M9I@9[SZ8'2=C5GC"]I,D6K/T;O'6JF M&0B',F/04U,F4"EK]Y0"8DN^%
(C_G/Y5\DF485%@KCA!E&[X]O 'RLKGVTJK MMM;/7J1%72N/*TAR$7C%>9QBV1 'M'!U>D3Y"21BMHN7WF-:I&+]%34+MSN,
M>LK"&EGMAQC$?
(M73]UF(]N4KOEL5\|87ARIH$]432QFHO+G''3B+G2718AT8I9U)7RT%IO+#/'U+T_$EK\6)KG_28$R.Z12\T5&E84%0S)24F"+R00-
38"A&2DST!@:@Z D&)N1L@/;KL&: MZ"$8%N.S,.-?8%JO+",WYF > #1/YXL; .BO=&51YZ!\&3=F")GP+GSQ!ART=!I?E@\]%*"3%[ZL%7HX
M3+DGPT6"'6S%>GCT= 6OXKUZ0$Q9VA,[UQK5&"UQD<8HV^^L0Q]SE;QV*J=> ME>K##L&&;RVT5-
FCCDHQM."K/&#OL%G!JP1L[[H1]FP%;3 M[TD/-^H%7GC@A4\^#A18UH%EK1X8@64=6-:PN'D;J\Z[L6* D-I.'"ZL;+'" M9G=X^BBN.?)
($"/9;;A+_"><[!5-5.139/".->XV^$)%4Z"]/[-,;L MFJN_/^[Q,:4X%BS^TR7&"7\5[_SF<9?\SP*,MCS30(-DFZ? M42R8]T*E9;I>OXQ
::1Z4.$W[G5>$,;F^4EU<\AY?H926NUW\|4!4_4COGT> MG3%NWRY0)E'\2I#TJ?B4K;>1T?E"6?A5V2;*?
W'3$W]3W0GG0\RL4#1\J#,Y9]50!0GLWN^7-]M M[P>?+UZD7E1A@5;/\(^TI7/: D\K\+0"3ROPM"0)7K5)X L6TEZ^1**]K>?+ M%%*!-7
R=D">F_U#H)!!IPBS^S*5@QN QC;QR)$!I)I] M,?]@/E3+C+4O3I5Y]Y]C!TR-^^)S=0),2F+RZJQB*X@Z\^J'\] <+.F=1AF8
M"#6<"S6*5'50!C7!=!C2IB\<.=H35Z)TC.]/:0O=.AUQGE^U/#4DZU7RWR6K"[_?$+E2^\L% M&OO2\AD]J%^=3:]/I7\LJ;A6KBJJ6J\"!\?
79WDBJF:4XNO_B2A%>?-)XSZ> M-W2W=N\[?< T3MF+4H0=GC"_PL@ M[+S656U:Y2B0RMD]4UQ9
):DO/OT'AP'R1K^2@NG_FX(O"6K.%DOU;.G;9* MA!62XS[LZ$3+Y]='**>;6MCN@8.M@XJ32[2I^.=B)[NK;'3NQV'N*9 -QLKN
MM'J&_5X"Z@R_K%+WP\3T_=&-OCNW[MFRK%H/06W"82%8/>>7]X_"SKKVX8C M4(UZ*MRS^O?<\]^1JZ7]:/.0\?2S^F,=[I!Z3]T?-
(;^5D9\Q\^J?L9H>MG# M1]4_QWYOGRQQJNX\O; M*Z8V>2R^<(>,<3&(%'K'VH-B!''LO1M TM5&$_'R9861=Y/T$B/QY;B/\6P"
MQ'A]F4R@,:2-R'JW[HZP!D!]Y2=_/RWLDK9@%')M!'.X&3-V9+2NW0#3Q^59 M'C4L?5-8O-NE%*AU(LOXG3?%1>(YAX! ?&V'@?-
S#:=.PXCR[%B"VC M14:^#7?9GNH5(SN8I%>UTSDDJU>^Y1^>:M[I%,4N(/01U__EIMR:^UTGO&4:
MHTQR:YA)TW[/1C7[@0<)E^83*]I6[2[2>\(*"??7Z73J?'I$>/9YG&;XB5M[ M0T[X]+ZDY#[E$_AX\X5_Y_-\7XQF%A?I?
5JD4G)7GZ]P=+5*GUW0$$V'?)7= MLS1<1_'_8E>_1YGHT!7F^J0QWQS$'[AG^_07!Y+[XL-UJ2R4_49)N1;U+U,6
MUQ4>7AO*;OCZG;I8>T?/M_-]QT\?XLHHN>(&U>EB@>6W M<5I5PM%*>UA7D?^W"QH][ >#,E^>\ZW:,PGF?SH!:3I>#
[H.7>&YZSDC;%FWR)LU2448RW0AZ(RFS9-;(63],SI5JV[E:% [TV@*[ M4PGR59XW<=2+Q],HAPD.B?[-PJXTGVZ-
!K$WGXF<(KPT@[1)J,C0I&>Y7F>5 M#BC;(7>>+PA=U:0##>QFK;T^6RT?=Z_D2'6XC59Y#"O<1CN"DVACXM'UY8(.
MAY:#NR2^#+;!T4*Z,IU)V(P=Y5CU#:$FT3Y -8""[W MKQ8P*$$$<$$\LP#Z1E#%/O&L0D4[Z#J=)AA@^YX>@AT8)X-OS=/&#T1$&JZN
MA0,37\W4#=,C#*<.5PI@^J+ MHI+!Z95]W0]V[<\)>&5%]P.FVY.@X ]B7-C.647<$7R6CL?-P1_%N'">H_)!
M$_PD;4LZ^5&XM@T=U!=WU;3S3R)ZBE. C_A8JGV5DP)'1Q&' .5;.DJ$\B1* M,(MI6AG;HM[3;-7RP?;J7'52L%-UJ]H[G-U17&G2>'6H7K"'
MXD^?.03LAFR76)3M)[Z,@6_8J@<5YP>?1RS$CQ]GOCC>?IH;_C6.LY<'F-H__MH ?%K]
"X>SW[4CD.XO\,VM$0P&M4170V@V:65S7RA;C2OS()ZGRNFAP.^>] MD5I)JY&V6SB&VV1\ER\IWD]?S0$60(OI]L#1<3-
A(LX7)]Q*2XLS%%?7.2@& MD$[X78ENGRHD,;1:._7EQ9.Z6X;]*KL/IOW\)**#C DL=&&PC4X]8!'.:0+,5M+:2O<%(:U=1MK:/[X@ MI-LDB?
&>Y TRVB/ (+?1%SX.8+&!!O=\@40_0F!^H2]X0%9;>&30NV-)\E(" M$$?%ET'2?L-Y%7=D#UAR8RKIV5=?
<@,2T"7=\T!NDK+O(E:N5HAN1!:2I7=Y MNDACQ/^*Z@,@XDZI-%?DC/7BKR-SO&/]WY#+DL9+Q XO MV93C9] L)&:'3\PR6AR$C?
F_'C7C_^"C_2%=E:O&SRG]^_!:I;E:JZ:_#Z[5 ME6!Y-GR_QK_9T4:*4,-?[=[_Q(=RDF9ED=[C:QR7M"(>GCX(?B!.:CZX6/M1 M;4"
<(K[0\GWM$M.Z2,JF^0&*)(R%-XX P<]HI<[G0)M9OPV(;Z?/V***CZEO M8%?
_IV<7E$E,I:PKK2O#87O@&:J]O,UT21[3[X$CFLKIMI+2P1DRY3C2REO5 M?
E^CZ'BS__'W%%/NF"XW%_@>9XJUR*RQJW[MBA=L3C+$5$LKJ(VK7GS"2(QZ MX=*^,>O!]##P[*>FP'23+/
MKX1I)&YB/T8L95]RKOZEK4=2>?SQ2E 6;MO6[0;)IG,#ST+9WW MB+UMG0:7\N:1KC/TC&]Q.Q
MC1AU2=G6::^N4O:5[R%X=Q30>!3J'^"T?U5$JH+?J%>R9D[[HEFA=>+.=5>N
MU/H&=O4G.=Y\0O0K+L[*/&G.O,&$K>I]2E$%X%EPMOFWRA'8QR/M'JYXS*//]FGTRVT677:*MEWC M/@MD\][RX+
OA(D"\@Z3<4:VS[J:\SEJ,O[8Y@^3)N+8>X M@"1G_X^.&P0DO)K49@$82,+]]9RQ;T.K]V7<]!#UU/'$P5"_"(:HX$$.P3@
MX2CJ&B91\WI],0_ZG7:-AQO 4!E?9#2V::>G5OLRSZ!I L#)3S DQE&PY']=5YK1Q$C$V;J<,#(T7K#
```

```
M<^IQ0,BP@'ER4\]D&2,A<2BGGJT"XZ *?TP]#04!P=Q:G_IB83,@/M)5(L3# M.\;#V_F";B+B/T0K]-^$1O%6.1:A/(E8N5YG*?
^789@<^#3+L7,CK3H%U,41 MX?@S*DJ*,L&J7N)5&J,LVWPB2;I(<5*9%HEX!TUSQ;5"G1[40]CYR>/%B0.^ M"2JO00+
(]Z#6&2GI)_$M=W-)H9).M@=UGCY>[(Z[,=6P8C3IV.H!KR3[PO^* MH=]:*]R'0M\
(6!VU:,C*.,_*/)MXS3D9N=#@^HDB0_/%$P6D&1FM;,AQ33K' MM>54B ,..+W7WG^C$[>J.[=_8RQ,8&'1"8+G,
<[CY0K1K\H*HM!FCONRV:NE MN@@*V,QU7S1E:@$MW/9 6Y86T,)N#[:+]0N]U-=;P5I--X<]_1ZXS<*;#2=8
M([O97Y1AMHVA?,;JJ^J4LB'''G+L(<<>I@F+@* MI(5=[C$^S1ZA"B2E1^P+4H!Z/5"WU)?$M.GD,G$7?<&HU;!1!&5\P:7-P@/P ML/PG/$"R
5,?)'I3QB35-O4Q 40#EF2>.AA=U@]8.L('1B%D\D 2PQZ/%I6E M8A*)G/IP"=1L0R)N#WRHJ4\K,%9P+M;4*+$VXTI\49BJNB\8IQKQ-
WKON%,+N: MSQ";-K/;%Y+?W>QN+M)$7I6REHN)9MS>22X1E>PT>D%G^MY0E#,^\;B#P(XW
MAW]1C'_S!X0(J_T(:_]ZEK>LNJNO.+WG_Z,^JJ>2=:FUYN"S1MJUYLKE12L? MXO$A'O\"#& M>[4WR&A38&U]"E^2A.W6('B(UQ><.!
<]@Z(SON !694'&"4CI]ILHB\# @2#/)_KRQ$D SJG+HOAT@ 0&@3EKZ<)@%@H4EF^S(] $PM M2'S0E[VCO3_3:9#\-&Y4 --%QS[Q914-
1_$"N;,MN1.0OW5#W?PERC R/U;W MO)EE4F;SZ[TY&"=CXBT6:8PO1,\53#R94."=C8MW%KA08^!"B7FRN\FH1)E8 MHU5<*
(VX<]W5+"AM \OZ,X;Q?(U%093\KM*.:8E0H$:!@1/.. 9.1>!4!$[% M #D8W1Y(S'<<7[ !Y.M %H0O,37(6(%X+;[@$:Y>#2&DUB$D
\O732SI0X3_ M*OG@C8H#2H=A8$GY#,M1)H NW:Y4)8@F]7*GNB]5*M5#2.F40TDV6)PV/WA/ MDQIJ2<].XX;XUR 7%=ZD18;GB_,\2>_3A-
L#DML4E7+VM10W7%>\-#'_E^GZ MAB@^>(A/I8?IW>*OBW%3L]WS1/JTU<;!3P2G?&[4-D+$3&0F3L M=4;&]"8+Z<$NF#I*^@ T/2;>C
(-%Q KM_48T)P)"#>Y]3'10@2AB!AUR!A M2[O53;SPZ&@78$NKBU'2>QRM,[3?]X A0]UC+$<-8>KXSE6[6>)WWQ]]F*_R M]+84!
[!J)"XY$/(8([A17PJ^.ZHGB8E^@#8AU.@\U/@)/:2KSM=B MT"@+:FGEK6HO-GA1%48QY9M$G.BH) W"]D-S._7A\,59$:I6->K]>)X\V(-
MJ1;4QU4U3T"]'?)5(4D4",8AC1+2*"&-TF\T^*6[031V_]1[K78:B,WMS!X7E/"UT4D#>7KQ,*) MH9#&UR>#K[FYB6A*ON1LC>-
TD>)$>NI&*SN\MKNAM%-%DE17RME-9_-/FJ19 M*4SZ:QR7M+IF]O0ASDJ^-)SQC4&LZ66]/LT7IXCF8@6ZQ+1>TS?-#U EQX=_
MXP@0U":GH,VFFVJ>?@]<)GTCD*=2WJ#7*A(1P M2 C+7S5U/& ) ( 'YT,R0#LP8%&>J4-A MD#RUY=WZ JGEM?
V5)78MHZNPX'U!U$:J;++9PI J4Z;*@($:1TFP]]&ZI/$2 M,1QQX55:5&ZI:19,_13;:3"(-MWR8&R9H3QY<<'@DR281"9DP$(&3)]3.B%E
M7F"Z%A>B2@XAZ<2&/[*)=]-L=D=Q-92>ZR/-VAFWM1JW/'E<-69Y(BH9\Y4' M\UF#&;R86+N'3#=O,OT>.,K\7&YGPN.
J4UU4>Z7Y'=\3JP>_Z0ZC=CV.>/M MK?I<8_LG.>ZQ,B&B$P^9L7 (,>2<0LXIY)SZC7HK;6G2R6R=.CS=+0S2X[;M M"YKJ7)/>M9MZ,@
RZ0"AE*G#8'!VLYN![PM0 ZU"(7\1\A&S^Z81+#Q;7&>\SE3:L*[*$&T=I<8;B-&N>H%!QY[I?B,V7JN]@!S8+L7T/3KU<
M[ZVUTWM=LD4"1VLL,B_4_3SXV)+/&4.EX4)X]A(OTC.Z6CV_;# M)/%LT%O^CW^^>+DL/ T3[IQ@E&OZJ:#9#:8K-E_V)ZF-
W25%T!%7\H.J"<<3G=8@H%LC^*T M]A7@BD',9NS4[7$S5*"KP]1MTADB\K43?9.4TK4-
!)2UR7!,HKQ^K/M%B>E*P@*U&O)%VOQ:#.D]]1 MGO#GW9WAG3Z ?@SP^!XZO:U7!/D0&M$>E#D8F:W'Z*'&?3PO,$1'Q1"=[3_9 MY?
9#:2A_^@9V]4_N,2U2QO6I[@51SSO#5E9[W6.T%L M*/V M5GMWGG.##=^@!UAG=.*6=1>19D*!'T(G;I?+C!G#^((/"9U1:M#":@\^XV\'
MRRDE.?\QK@/5)M.C[6/L5I%YJH/&!-!(3T]S5[69*%ES,V0C+KXL^#8GMKCU MX_*I&UFFS:WV[0K'F._7MQET^NL;6-:?
841C87U\Y(YF1M;U6?#*::X5E'8$ MW-)RCRI_F>-,N,5U^>5:5<\#[2V69\GMU>%(X4>/! MB9HO#,\7IZP0Q>9?A#W40OXDK_H+
[X1S$K)S$D#C8^K\FG!&PA+3;*09W\ T M>U%32.,O$?/HJB_0 /I+ND4Y?9E.9DBU")Q.G5/1#BBHVSEU>D4[=& AQ:D3
M+^W]AECN*HSR2GNW]6:031OH7-SA>YNE?)695H@I,=[7Q M;I>H-O2E4MX0(/!CW/15_?$J3;_DY)9A6B4)SO-U68A 5"Y*#FV_(1"/ 5X5
M"$@>$)! R\X(UH<6>L*(M=-*70]G9 3JE(PZI1Y54R=#!,948$P%QM0A$I+= MKBFZU\K*]&7$&.-DPUWQA4AD .Y@IKV;8-G[B-
8)Y9:A,&E[RX$NC1[#A+&D M+P4%J30JAQ#42$)0'U.&[NXHUZ3*QBVV# R0CV34-KCXP<4?LYZOS\67+]'! M@0\.?'#@@P,?''B]
[]3"''+C#/VT"]VR:(TV0KT(Y8GX)</1P9?+OAR8];S]?ER+5?[X.@%1R\X>L'1"XZ>WM'KSW!RX__]',4DK\X# MBMU!_.IQKVCE\\$?:-
G/,U5L&-\.K@7(GS/M5/#A1N+#G3Q^-G&%(%[!\PJ>E][S,K"&W+A61^^B'!<1!XJO]YA& M3)0Z:.=401YEV9V"JS2,(P5Y/\B%@G1(=
TGAKG"5D\+ M#FIP4,>LY^MS4$$[8'!-@VL:7-/@F@;7U"0IV,%"\F7@&.50![&R';G_$0<+ MY>F_JM=4Q)L$LYBF56U#44#AMF1\IO!--
\$%2C,6%5S_$F6FP8'.+[(=.NA) MX4Z!A>/M*V;Q7V7*JKK+G]!#NBI75SA=W9;I"Z_I-N6"4=[\^ M,T0!A_#M&Y:!ZD<^_QJ!-&
[GO#JSO/Y&E,DZJ+-8N[45.Z,I_P!_2Q);7L M8EWO_X(P12\>9:+\%R>*7@F[)L?)SC^M71Q?$-*:X*2MJ>L+0KJM@!BOO-
X@H\UO@7QN7[(V@,4&&O3T!1+]"(&% M 'S! [+:PD.\8%1&7E<5D">'F..^#)+V&TZG03+R._)L\$E&?MW=F/DDHZ.:
M]9:L'6Y9F0QF!CGZX?:DR:"E3JP/L!Y_J '*1>F\K>Q(((*%N =8G\W>LCP@-$ROJ-TM&BU2@V#<3*^EG1T.!E05L"H_#)Y5" 983=\ M4*.
[L[HQ0OMXE65.:'\J=V*%UO1B/JCYRO,'7J9Q)NX\D7'7]-)]\ \1GPPY MIAO^DK.2[Z]%2;&"A:@7?UU(@O4_GUXK=)!_/GB8NQYOF!RCH.1;>.
($/Z.5FND#;1:XS3WTZY2;]62#<67-S*MS5TKJ MFU;>JO;GN4@0$;K9W]UXA<7M@U)NK;R!(_PO*5EC6FPN,VYC\D$B!LA:F,''
M&PV9SZ#E.'JDI?@9M!Q'C[XPS'?RBW0AF_F EH[&7: 1J\)?(Z4H!6)H((8V M=;[982,:SVGJO;9I-I.VYJDO()M8&Z3#ENX+7GI6B[']Y@L3S'
H&078?<%( M/GP4P;FI=UZYC2E"I%-GC*K[+0]83[W?718$<';+%Y#T&XJU\.'4UQG+AF.[ M+*(OX]:R=0Z,3P;^>."/6_Y1LN*&I93-
WW.>+?,[2NBBYLG5H9;>D<+3HLT MP'"K\VA1&H0L, &*YP*E-+H7"^Z>T+CKPQ T3\7KQDSUU*K=C>[9N!_^1@EC
M7W**49;^"R>_O4Q=MFO< YD1],Z&\DSM&O>@\#YA=9XSOLZ(47#&/VD3;P(L M/XQ:#3@TWR1CVG88=1E?^&@AWB:.K@'U;&
[4@X)BF%=+]5($M,[S_3<3)^OV M]S3Q#7&5,L;-!9'-; 2WTX-ZZ(CX=+UTI-.#>NB(]+:'OI;?P\X._K) L1Z>
M8CTF6MR8>B7G8ND;C$#__<+S,67"XB^IV9=1M+?:.W&2Z] HB-4<9)VX4]V; M#2"@M%7-]V\_WNQ__#W%E#M8R\T%OL>98GZ8-
7;5KT\8B4%=84VK B2QJLZO M04LW/3K/N;?,*GB/E*1>0 OG/7AOW(/W8^A!T\A0DF -6CKO$7LYF8W[IGV& M^UY>B6 4Y18);
@"FEKMTR>2X\TG1+_BXJS,D^9CK#!AR\6;^]?'(P--.]"T 33MX3WAP.SVG]G=TH FO>RYOH '\,[)$'N$+_B9.#J: MD:>T9'W!2\](@<:+?
&':F[J0AB\\2Z.!!(M7 M>3B*NNY?:H?>E['4[[1KC,,% FX@X/IK^+WLIRGWUL^5N M VO2C+ZLO#"18 M6M.[9;81D[X(0]ZMR'*T>F
E@=$R+MP\)K2,-^0"(3NN.Y;[W-H_8Z \B/E4@8_>F)XD8Q/L_Y-,&L,!Z%^@>_2% MY0&=.X @@"^0Z(<'S'3U!8\N2XG:,?&.!10J@(<*X+
[VNX_E0!(_H'H;T16,J&'3("B%%=$81:E^4%1 M M%0/,H*;@+SD8%@'2.R-03B:T'GX'+Z0M& M-B+;(\|_CCFRO<8T)0E_/RTN1A3DMFK]>S?
5!H'4P WU;N+:!!0:(1DN]5FO M":=Y\GI6A!]EV-K,F+V/*+['^4$U[JC #T6),L/$E_Y!EO-74(4ZI:&$175# M]N4_]L/I8_W&FZ^J>D&2N(M4
M_OGEKB&X%8);RN"6X;(1PE*O)RQEP^N=BC4@S?//Z$ MB_W@!7Z0N1[4.N,E/23^+:[B:A022?;@SIC9(+(5-TF?)XBTJA:HV2[B(\L
M]L[_BJ'?42OX]/L-ZA 4OI-OB"ESUZ!G1=?UFTKFM;5AQ/_DL.7!+AAS7.&681BY0&;*EDFU-KO6K?2!O5;C@FBR6FMVTE)Q=1XELH#2O=
M,-R^Y(1+"JOEBG\E/G&6>K4T+8:L0V#SJX.J&-@?AH''.9+B:[L8PK:0,7< MMO/CH+IV\V1J\83H_1CZ:-2=#LM"'WK7"VA>,L!7D,M:U?JX9-
P$8HR[1[=I M7FV8XJ0/WQ"Y1OPGEB:8;O?17Z/]!J_S_B-6%I >R<1MJJYM6A1=/I M#VL46%&!%=6EFH55"R60K?
PG6]F,;XTT0CR%^)8C))1!'(B%Z-W8T"&B,SZG MGB(PB'Y"XQ[>9=JTD(!B+MYE3I13!V3_>Y=)44+2E[\'1NTG'U S\/B>M&%5Z*]5KGY
HM$,Y^WRXHYWDL1T,CVH,RUWA= :& M0BSDQ$:5$_N(;XOSG':PGBN/];6D)]*5QOP!H^BA.+&H+%:@$[>J^P[.;2!#Z"91NT'2$=["$9@O
M3KC/DHKA77F(BEFL$W>N^X6P:9M+&9DVLUQ)/ZOF'Z*2'4@OZ$S?&XIRAN+J MXLGCS>%?%"/)_$A+VH_+]J_GN4MPW^57(?
3>_X_ZMHA*EF76FLJ&6FD76NN M7%ZT\IYET4-MD9#NE@1+%1X+,;5 ?<&DQ:Y-X+:++RAIK632UAKU!2'=%DF, M=R1OD-$R3-
I:SK[P+-JM0? IR\XZ4<2S)OW!0_(JCS *)D*24TZ;V?!D0(!CDR55?F%H &-0);E^X60 @M.DZ7TA9 "PT&65?I@> " V) M@OFR=[3W9SH-
DI&S\0#314R2T8(%(&&,C\Y\>&A32_S==:8'LG.K]XZ("MU!_TY$Z9,ERN_P
M>7Z&4OH'RDH1@7I\O;!Z=C3[W4L/>9#PUOY21J7GG'O_W*#Z+P,-LD!H'0FA M%38[-
=+1#Q/6_4#Y5+NUL$0DX@"XR!+#!R5&Q$L4>>'A]S%'N-:4H2_GY:C#'@ M!G267F%(V\"$?D51[8XAL.%"VO4\.\V3,:%EZ-:["6W_$F48L<
M8SGP#%.G4QSY C.&\7Q=5?/)[R[$^T[% QGOR7Q=UK8Y48
MEJC>*!L"GB'@&WKO9;)0TIRJ1YB2J<<6K+!HI+SP7N:U%!+>AH*#$&M=@X_H\6!
ML\__]:B9N"7Z)BTR/%^(+5@,LLJUZ$D^LEW]&.^1Z4B"NY^2Y4::F.=,$:.RL86ML'AQK-*!5)0[$Z MB&_Q^&7@?>[ZV!
(]*ML84'BK^>,E3CY6%)N:%S65 LQ(5CSM/B-$B9'O]WC M8*-J6B&=$ 8-8="FSNM- ]+#_CMUE/31'J")-?7('VBX@%RMJ0< X4A O+VI
MCXL0$0X1X2Z1NW;.SRL*!@_E,;W"*'%?;H&;0/+1T2ZRFN:BRD1ZCZ-UAO*. ML633QUH.)[=3KU-$>8PQ5(FJ-TO\[ONC#_-5GMZ6XG1,C=
E!T@>A 8WZDO! M=T>GU2@/Z&'=%6N&K^E]._#:Y7F:JV:_CZX5E=BJY;$Z%_\ MS8XV4H0:_FHWGOZ-NTN::T :9:QJN?/O*KNB)C
H+US1RMNM1, 75'&?@@+B M)A$G.BI)SLU"=N/7C<;C@7E^O'D4N42;JEZC&+^[36Y74XQ5=R??+-&6$,-^
MXX\H^"9=FZJR>+>EU[O*NK3MWOY0VXP;_:NZ1\(=BKF_^5&X2MQ(%-7;^H85 M^EX?\+Q*V=#:]UP<\_\2"ZH63V3VFZ
[_042@71R/MP6L4H&I M(?RY%/OK?%'[^+.R6!*:_@OWOI#*WC-QO.ZYVRJ"F6>$5CO!P+ ]?]W4T&O< M-)6)ZO[?Y 5FS]:@ZH\?^?
*S7Z^LX*G58JQ8,UDW'WVF/ '9UD.^RCYFM_J1 M^8* GQL@#S;[PHV3CH$U&UA=,].-" MD>/Q!03M6@O,&OG"HM-/%# UP!=
(U.1C2>YXZO-#:8$I,OA3_^CJ?LOY%.!^ M3_;FP_Z(Q).]S"X0B>7DSJ%3-Z^01"P. :7WT\;G!MLH[ &/\<,.Y,0 *#_4L NRTM$8SQ
MAX!Q/T021R?,WD4Y+J),F)9K3",F>AAA1'/1_N!7[>Z_;?MXVR?..JG9Z>39 M;+VFY"%=(>E1 IU8#T>VI'?
$M07F4/7>'QX.@3D_!'8=XQSQ9>Y+SOA>DBY2 MOIO(BGEI98?7=C?N=JI(CF0IY>P>,]I. KZ7[/:<-'ZF,4C6JM:?<7&>\|46
M7\CIKXTR@;3E04&O9Q;/TVC+O"SXZI^+_5@UEEL]PS-J6O_[96"OO0[VFGK_ M(D;;\=3Q@"72 3N^#TEU[<" ^1A3A\)FOGFD5(,IY)L=
(:$,#BG,5N]FA1*( M#A::=W-'"13 +7,4\CMJ,B,17_"2-"NK:DL,QR5-BQ2SZ-OV>T>H_N"U.(O(
MXZ=N&QL<6@_[9:ML]*=3M%'N6PRM/"PB: ?"$#H[W_L*+ZFS%2FE!]1[??:44#G>-#] 55=I^#>. $'MR6=HLU!Q
M*@1;70=;D=R^LG.+EM%5[.>^C-<0F0^1>=/;)/KW\QW%9=]'ZY+&2\1PQ(57:5&=I.A:
MZ]_LJ;9CIFVTZ\:W9,N,&_3G>:P@6TID>F!:3NBB@Q\]'5/>@[@S^2^V@#%B^7I#[E4#RK,XX)H-9 *]:# %5H@G/V^'4W*/)!&-*0J1D4F
M_XAOB\<*=(K(N%S0H;YG*%;SV67BCD*C3]714JMUXE9U%UO\?''"K9%4 %D5 M&E.,%YVX<]TOQ.9%E?A#FX7PN@?D\.N]]7-
ZK\LO*65=:OW\?@2UWLT71KC3 M7'W#GDX^)&-",L;O9 S %B.FUH,OF&CM#=)V7_<%(=WB3XS76F^0T4= (1NG
M+VF$]@/E=6>A8"Z/+WA %EQX0,C_?!(TD.++^% ;*9"(I2]C H"$+GKL?ZXQ M7%H5TJWR%"(TC@O)%&[_(OY'W!/"?_/_5!+ P4 "
!8I6U94;5?>5$& M 0 *P0X % &-T9&@R,#(T,#DS,%\Q,'$N:'1M['UK=^(XUN[GMWZ%3J9G MNFHMD_*%:ZHZ9Q%"JG@[
09(]_3Y,LO82O"TL6G;I,+\^B/)YAJ;<#%8MG?/ M="?AXBUI/_LN;7W]OZ]C$[U@QS5LZY>?I4OQ9X0MS=8-Z_F7G^O]1JOU\_^]
M_O!UY)&/D8]:[B\7(\^;7'W^_./'C\L?RJ7M/'^6:K7:YU?ZF0O_0U<.?EK[ MX.O0,=E'95$L?R;OSC](W]"-Q6?7/^>_.?
^HI1J:N_Y)%VN7S_;+9_86^8Y< M7'VN$3D$Y;-AN9YJ:7CQ>5B?T0M*WUTA&3Z;;?1D ML2#*!4F>/V3J%KS9!"\7\4EUA^PI\W?
```

~~HEY3YQUW'B_K|XJVU+TP]!S]'+GKM M,WE_.9^HSTG*RIQ61N[89L3(V3OTFY6"**TLK^M-G'"\T'?6X/*&$>MHH6\/~~
~~M57>!%L.UB(}4V88O_Q-K,/="85[R8>XMD6B\C\3")GZ]T=32L:/;8[SV[=[M MMSN##/_9O=3L\0JC=F/3:ZB\OS,6'1OART[>6%MU;$W'*~~
~~(QL4Y]/EQ$3:\KB&TX$'AQG$_BAD%; MO#9U"(J9^%/G+^[JA77T"+P:&CK"_.JC<(_2=]9'X8]M3PG:A3^F^O/UO2(~~
~~M1VOZV@>)9#VKZB14Y.@;:Q_6/6=#5ZSABKS[F;X=*"6I($L7UU]'6-6O/_S/ M5_P3'Q-V3EGV+\E\:]+8E"^?O;?^_ _]'|?~~
~~_T^A@+YABX(!ZV@X0P,?]K<$ M[JAK.YYJH@*2I,]$B=!'H?*5)%])9=1]0(4"L6-C[*F(#K"_YH:+[]<-&R+ MX,PK#,C@+I#F__7+A4?~~
~~@]YD9M,_77S_[X_PZM/49%\1>>%+'ACF[0Q_X:VI[7P;&&+NHC7^@GCU6+?_%+VBBZA2A5T@T+"1>~~
~~M2H;U!1&XN+9SA=2I9W\A*Z,;+W-*NN%.3)4\U+(M3-\S7]_H@+#C_VKH.K,(MZ,COY!-~~
~~M*BJ&YL_DU>M1.ZS_FZX%7751"GZM%:A06"K5%D0JKVYMC7S1\NX, M5U/-+GF$K=^1U]P+9!"X&*\OA5*M7+VX_J?~~
~~R]?,:I7@I_X%5YRW=VL4U_7+, ME!M,1%<(-RW]E@!KE71%O+@N$ M*K$K,U.MDTCJ;N*D^KY$DDO&DFBZ.F6#3 M(J(T:Q"*CFJVB-~~
~~2_HIG:X3EBVN1_%.39;E8.81Z)9PZ42Q7;=OJ34TLB<.2 M5'><@3.V/'TY=:TJ$NWK^RYT/-[5D_&*]0);B"/68\N(WAF.G.!PZKH](0IN~~
~~M,3S2F<>SP;"P(8F'#NG.435JS?T'56K*Q=KHC)4A_;M!31AV)]KCS=ID=/57 MPRW4W9&I6GK+TA[P>(B=?W>GCC8B#EK#'H\-~~
~~CXI5\U4SIU3/WMO6,WG >/D6 M>\3;;_B/ND!3R_#'\=B_G:](8/*NWGZK1SP@PR)T'LA_Q]-Q?4P'[+]/%NP"~~
~~M4>U"GK"Q6,2E*>BV5]"Q9HQ5$C<%OQ#[65"(';Z7;KY446NG%"]VX>R_NV2]~~
~~M%LLW&&'REM0D)M";D44DTS!>,/W(FS7HCU0';ZX">_&&+(-.YCDA;AKSS0A* M5.L9TT6YF2T_TE5G;-%_J(X^I^AZ#E/Z;L<;868=SW;.U/?~~
~~[!SZ.VWLB$K.7Q_)8=O M5O)U8O@N\7RI CRL+Q4-4Z_T]3,CYNWB6A*/M"D*L8-'+(Q4ZXPM8SAUDU@9~~
~~MN7+0RFS(&_%;WRZ2LI0W)9"W 75;.T_$SAHOACY5S;7%JEOZC4W&NJ.XT:5M MN>X4Z[=3AZ@:?V+LLVZX+'YS;-~~
~~<]M>Z1Q?"UD'*X%E+M73W,?LW%6E3#UV+# M.C(TS-Y>UXXT1KZZQZZ+ M<6?"S&VQIH['J_.E[ML#7%;>QE<['*N]G6+"^6O/-~~
~~B13C^FTHVXY)8W'F]PC37(>N58G#MO%@[>#.9 M7ZQ=U5:ILEL('C'RN0,S'_S"K/?Q,PN1#QV_M)>+LI9SZ3HV&84WH]&91_PP~~
~~M&LY._)AKP:<'51L9%G9FY/V[J4.F1B85\+='8[3@4Z\T*1(>XD62>73QT]2\ M-YZ"7*Q6E)78PMI3S=1/_QP_4WG+3/?~~
~~*RNX]4>H<3STB,N3]W_#(T(CLGHZC MTI9YECB89US\W):0V='M+F[J8\-WAUA=8GO"LF41W>O9SNPWU9SZNA2[V'G!~~
~~MIXX"BYM1H!&N"_D:<_G0,==-T_Y!B^!WMG-K3X<>@<%;S^K$XZ^&)=)#84*B MX]~~
~~PFN:M;8L%TUW5Z3A]CU9:*1_P\BN'V2/Q4A3%:*.T,1-Y5T;P/I-*Z5B>~~
~~M=!W\A!T'ZQQ,IG@L6Q*9#'MAM5#.!D$<5>R2O^GFGBN7;64AHT=LV]75B.U@ MHVYE8;XGX?+5U2^"M^E>AE\N7&,|~~
~~(4+]V2>P]E#VMVM/'?]/MAWM*E@ZMI91 M%=OKX+.8E6OG?QDZ_?O)P YB(\6A>\|:K5_72[B;7[Z>O[3^] G+E.7_K7CGONE.CMKG:P2ZV~~
~~M*_+>W@L=Z :) ?P6#[UEV8\Y6&W[A?E6;=N;>]/WQ,WN/#6(=C"\.U4S3+)6 M[+,]]4G%YO=@:]>R[-N?#EW\UY26>ZG+L/#P-~~
~~EX/G+@3LSC@E!^V^7_JA-@K MQ;(1C 'IQMC/TRY5XMNUN;CVX]DW*_3U<^A3]R 6M<0!R8B%/IYN!*LE*A=,#-~~
~~[946+"0"X6Q&H8R#N:9P/&MV#\S0(!Q.." M.,5D?!!/:#<.9WAV'>|J; T";&VNQ/&@VGLIEW"+6M.3(6[-#3D"<2%%,K;Q M!, 'X(MTF)7= Y4 3\~~
~~9V?69@_#X %PBA>K%/I$Y M%7:":$&3?K3M]PRQ%QS;LZ;]YOOTQ5MLV6/#"GML,/UW\WYKC_B\/OI#TX-L~~
~~M!PUE7U_#EDI6T<^,3R:_6KXW8#XE V:T0X=_#RE_78*^? -@:-9<[Z HUGS M;H"C:7(?=K"CO.T!3,XBO=5?*Y-#AG@[ML]:.^*2~~
~~6:OC33^S%@$=.PX9'D]-R*_;HJFW#_N#':S:>-C4 2Q-RT[/L-+827]O< MD\I-"Y0XT?UGZ_D'N.,0=P'+=\'=QD>/M4ISL&4"1/Q8I0TNG<~~
~~J[=G0,F4< MVS:7#&K_\S4VY10'_*C_%"#OB/,BF_I?]M%+8.1:1F"4-%.7%F"^L"%9@&.[M^G+&,)I!#!U_P+7P662PE'=LAV+@*Y]%]V.[+0-?~~
~~X\OBK7[T!#4!G M*NQG2.T:^)G.:O5;?PCT;1+^4%SZ=JW)ZXEYLU^59&..;?4%XVN.)^U$M>_% M/9Q)Y]))7L0,YFWY-N?!AWRRU8]+/N=&~~
~~<]^.C-RR--Z^AT?EXL^P1PC8EAU_M=M5> F-/(8_QV?VHV /8EIUX9&D?Q5I86^,^GGAL?DH[:83)[C-~~
~~+.3_/>,%RU['U]>9%7%3Z[^#MCM/"SHNA!5KWJV,&&EX?Q6;AP^"%K*"&-E M("?;&,I)SO3$Y^E!LD"R,B-97.V&XT2R;E37T-JJ-~~
~~W54LV[I#2(IAJ::YNS! MUJD Z&N< I%+K\@=Q&FPO98^Q$R>.#^A_; MF7_(#0[M.1BOOYX5B8M:PC,)W3O,.$[JWG)R<7~~
~~Q@I\9M'&\R!6(2D*BDFKH M;AXTX<I HD M):4&@:L^$]P8A QGAU**\[0EB)+K]W&>72;@9:4\D@ 7*TWR!#("SM6IG2NH~~
~~MN^4/X>!6I4JB0$A2:@9XZ/T7W#83MO\[>+%NZ<&K'6^$'3XQ%[W!>6-K=>AL M,EA<#;M2")B<,8!B%NSBP%$G$]LL4.JN;DR~~
~~["9P,^,V4W@9[9L)_"36_NY=D_/G6HXOZGF%-_,[@UU MR#H0-TS5]?>K-&SK!3N>,319VV.WJ\Z6>V9YX^L\H[YU2BOU\&USBY/C9[W~~
~~M!_AYQA9TR;T"]W1BVG2E^?[S#$JCMU M,)U'RYI,EQ_??*/Y.L&:A_5;>FLD 5Y/[3B'0-@JA')^N1R1'-^9:-1Z+@GO MOK#9TCB1]U,!6~~
~~&LO#FXY]2L78=$#[_9INHQ*Q5\O:=:S\'GU5=C/!T#?F/ M;^A:'SX0&@_U7N%6-C4X%T)A6" 4Z1&*56YE4RC.X=: I M8#A2)QX09X#U /%~~
~~(W'ID.^(ZY%1\8#8(\[BVX \%ZS&"<7B[4*GTUID.];8 M+@Y@)5(C#A!;@'4 <8!8 JP#B /$#]<1A_Y(=3"K,H%M.*$P;"YS.BU#MN.& M;:(~~
~~=B$EH@ Q U@%$ 6(%\ J@"CD(5:(.E:XLKYW#OYKBBUMQD"[^,S*)^C5 M.E/',:QGOK&\P_R6"-MEHG%BX20'#M?~~
~~8VU#=4=W2Z8_F7U/C137IE'Q59%MX M]J Z?V+O;FKI05/[54 L?OU.6* ZVFAVCU^PN8X))HHN>T-Z^XA,8BIZ45>4 M5>CJ'J\F=V-/"*3?~~
~~\BG6P>1)N$(.X6<2YVEA;WSM%]+8NZ\F5'*B">/01DK> MM-%9NX, <@&Y:4]CK6EE\&C!HP6/-F8;$M+&KTX&HAOFU#->)<)_.R? ,[#9? M-~~
~~7.J8_W.L<<->TP8P.Z7ZCPU5<MWWW:$2]VZ3_0TO?,U1CGN+FV_Y^R3* M9R"D1M";48-G6XN:8]~~
~~[*L&Q/D\!\"UT6^>RU)'ADSJ1^,4,S=W85M=UIG)4 MLZL:>LMJJ!/#4\U,<&_KW++$Q-2D$W=DW$DS@"=A5E1I#73F"70F)W6LO=D-~~
~~MNC;'S <=G0DF?Z/%*HSI(DU]QQ]%+M7%>E>=T1G6:4'KF2UAFZS<>&+:,\SY MC3MOIK62)]AG?@"'"18I4U[!R9$#_DE:@)M*_R9U^~~
~~5/Z\0P3HVGECKH9MQG M7,T(9\K&89-;LFU,]N/W:!K<\Q\T-&98#)D2Q/;A)\9$&3**TA= MR)YG_P2RI>G'+WA:D"U-~~
~~*70S[C/.VR:4>6P]4XZW-409LAMG:QAT[=EW=:2%^:"C,\%DR @GMG\V M,R#(HIE(778"#!8DUE(*W8R;WOG!4?X2:\5X@_LB)-~~
~~;.=3#]_&Q+I17GS78F MS<34V# >+,#-&,1UU<2[!W(;IN]ZG2?&-X;+%%_T%SFIO%[3MS_W ML\#K#!ZI^?~~
~~K9>+URL&L3W&*7\)K^/<*JSD:O&R_D)?K??_Q-*HM?@E?82TBC MZ_/+A34US0OR]0ERO9E)V/5$'EUX4L>&.;OZ>4 6V$5M_/U[+%J_?~~
~~R%O>L: M_\57DCCQ_#]?5,<@XG-EV?9L*[HVQ<+PA-*-I3&!HE=*-"I%U33 M>+:N-,(+[*S3_#]\?FRW!LU;U!_4!\T^^OIY2%YT/I-~~
~~I#J_[S<9CKS5HD=?K M[5O4_%?C>[W]K8D:G8>'5K_?ZK39Q\|]XM]5=T2\4L^V!'1[V;A$LE@]UMX; M2FH9=-?~~
~~I/:"O!*R6;:6G8X)N#06@[N&G2 UU@2R5ZA0=&U>WMC:E8DEO?[I@ M:DTCYEH2"_]D4K!\|'5&5S&6U?OGE.@D[)BS'I[8CA*1~~
~~CXHWHUPNZ.BO,L.H4L'5QW<<3SS=/ MBB@@2NHM'L^)$]M)(RX'Q"/S+PQ; V9I-V 6WP!S^;Q3 M-;4@F0^>388_1O M\@\E0W]F3Q%1?~~
~~\PJ1N&G@P3(VM*T7^L-#:9DW5"MAFSPL 4":.8T$N%[-6[S<=![]$74*O=N$Q6 M5WULOJI$MN@DJ(YB\$CU47N!<.M"182'#_!. HF?~~
~~O*NU*EGSU]P MC.=1\ KQW?_GP__\SU>B_'02DG@.^9O^J<\IOV#',S35#%8=C0U=-_$7Y)-! MUY]O@*29-7Y-JFH2/G>?~~
~~B1F#'Z_T^,&'EXBN#?LC3;(>I> MI3]9Q88->VIYSJQAZW-I]+ZU*2[]Y,2Q7^CSJ%%OXQ=55T.%@Z[(9T]_9\V# M9?~~
~~=77;PL_WT%6>]^^0W3BI>5##-MH+ZV@E2 QABW9@%J],-0;Y4G'>E?O(X$G]#YNX$@[Z#W$[7-WP'1/[R7CDKR#';TS;<>~~
~~(TY"6P)"^RZ^N3?A@_C]CLN+T2,K%M2*72Z>RH$F8A&"Z M-'*8. 29QD0U$7XE ;QGO-" @A@&[!YL(H,H<=$$HXCRG+>:."9YK\,?7]V~~
~~MD8=-/!G9UCP](9 @4C.GU.PBU<$]$3 ='YNSH%]Y3AZV*F=%(F?5-\F*PG&$ M[FT"LRZ=SIIK+)4NKHM2M5 5RV(&TB-K%%;R<'Y:~~
~~#M81Y.P))[\<;A(W]4U M[PKR [N[=YX]"2@H-6H;SVSTAM=?R>I8&9+$^$56WD%S2_?]9?~~
~~7U9\=E/SRTG+DA\'<3QI1V5*]S\;#VWS(S5GQTU9 MJ5Y6^9YR.T@',C;C>1*>2/J/D4%>6:]#+4NQNQMS8@E8K@.;_ULZT.';:[_&~~
~~MBO4(5.E,DH=,A.;6H^SG\LG"LB*:*(ZZ$4UIQC]="F*HD2+&LBE&Y2/<. 3 M%K:SK7(@J+Z89=X'WV-9OB0$=T!,ZOF!.B^\K90PI)"L+54-~~
~~BX2MZNKJ M7V_*TXP0>E"=/[&'[N\;.5<3NVSJVT%QU"ZNYT^BCM@D>!9:U2:@,0Y8\# = M(HN^#OD=E,B1, Y1*~~
~~[)T2K6R<\!]W)K_9^IZQM/LO!%X*-&6I=-A(-4WR)MVJ02.^OZ8&C?>(=AGB MX /DF8?OVT Z>9>XT?2C$P=KF#G5DHS8KAX7?23/(T!~~
~~[H1XF.[(IH7F^9X. M;Z1ZFV/_H:Z/DNV$8%\.YO!)0*JEHX^R/\?91\B4ZBN Y~~
~~M%.HN&P0;I.IZ]"8B79VYESXS]_\OV[,52RJX,74<,CY_+PU54>PHVUR*Y(OK M/["[*29OQE+\@MIV"A,3\<*>PH$@86QX'L$.-@DB'-~~
~~NBVMJ<(4PT]PRUJ!)5 M-9;&O%4]%=%],9M2L7S&:E:D-R6?+(HE"OP>?IZ:?FFL7QB@CW1Q*E]D1;X, M/N"-~~
~~#+:M8D*W59Q:1/SQ+I"/W4\E"!S"?XUH)Q34","^83/"C(I-\ M'R-5TPB8241/V$WYZU -&/HJ(HM9"'W#)2,DOP9*E.)/L\EK[,/_;N!Z+' M-O\@5?~~
~~C!AR/&.?^D8?F"2CSK@CPW8:MVZ_)]WD,J,\K)W:](N/R>))\@W%A; M\?MP+![DRE?\8FCT8.,_2+"Y]H#AG7XQZ[$LX_OC/-DZ'I)]V+:;I^-'~~
~~M7!N G09AZ;/MS.9FN'@2I+%/,ZYKP:=9O!9F6&()G-]=O9A04CY,VD[.W"Z4 M]>-U->- (YOTS=2E^VP6P"I;A0OR3^.;I4-D,=~~
~~[.RC,GYE+^Q&3?\ M"<^Q63[TO,S!&2PV>\2FCU87"_WCKZGM?=E8,O_%+RA8%91DG/.T)9Z@VT5"~~
~~MPR#C*2R<9T$\,3>6S6+PJ8O9I\@(V$FUL'-"))RAM,P9)?[#(*0)6621&=I4 MR;X8+C-?EFHAFI2EY%N9*V"V]?0)#]6($"M&9[NA*"J'*HH_R~~
~~3G M"9CM^8^CW7L6Q+?M%_]TI20+/I;H5(-?*7."B1$YU)$]]9AT4#$)5NZ.97>(M//CSKEZLK>%:~~
~~[P\TM0S_9=:4*R0)NJPRL$^XG24]$@\3HX)99+QZ=-2:C@NZ MS78[&&2*%RCXQ?WEHM6^N[B6]T*E7!7$4FF^TO,17_NE=[8*~~
~~[/B37UUS*?F# M,V=G3BJL=![H?KOY=9$T"/;CLE0 6LT%,*V!UI(!]*6+ZXUGW0UZBX>MB! * M9 BM$-CX[NBI0%3]VQ=I>@-~~
~~UO[4?'Y9S\#LJK/WX\'7DS EWZ]^:A9M>L_YK MH7XW:/:ND&K^4&?N?(?Q%4UTX,7!?$$C[,]*GKQ^(3PU;?*QOXGL'_(]5?N3 M6**II1?~~
~~6W[KXO+D"WV_#5X NX\'S'W0:]X,UY]856"Q$*(#0&P0)B+TB()#WN,;SNJL_XN*V+<0+FT.\>QYO-KZ[,??Z$MR:1LDT6~~
~~MBP*2E2KY3ZFT8-X>*W52W'?KO0%]'0/Y:OR[=-[8C%:[WFZTZO?$;%'[41^L M-D,ZNYB>5_ZD+5+W#O)*)08Z#I'7\O~~
~~829>\8NYND,63@='AJVI6.+YKG(;\PBLYK-C6H2F'V%,PEZ5!(.1 M@SMNP,'KPMT$U649W@4=_^@M0TD_G#'LRZ+7]L,?T&FG+~~
~~<@$0(8#4@%E>&Y @H+<@L*]C68)CS,+6L4*#S"HI(EA;*H'_%>0.K0S0_'%(_. MA(Y]YI0&OS6>>_Q,_!*F+=CY42[5Q0& X%==^("HWC~~
~~MA+8SP)9A.RN0R0@\.-?,%$D*U%M1F#!N=8H<0N+#CL"U++\~~
~~M$QF&;64$$)SKB3*W@&B^CHRAD7!"/P('M715:P[NPG^B]8M[)S'Y#&TO^\N% M?,&!7-&K3%O?VO7!8Z_9YS/1HFSF]9-J.~~
~~^GSN#4V2E.G9TVW7N)MN_(3U>; ML<8/SYUF=)WV:;/=;][2 M4WS]SGWKMDYOUKZIWQ-D-E'_>[,9?K!O39S>"-N:K&~~
~~[K'A#"]0-.]@7ZY+Z.?*&?]_S,+B#X'0KL8O+FRC=LW-EW=6. M1_ULC"0XP[IRK&2I^HW+RO_3A<[*)1?DB]WU_XWUEWNQ)R+X$&-~~
~~S1BRX.?3T;S$A-E$W! XRCA/'4H$)*HWL5" MQ[<"-$'VV.LUVP.4H"4^Q;3.XZ!EE10P*592'*F6=QR+V",7OQQ96^8]PLM=~~
~~MQY!:*PR@H#*PT;67';ZENS U^@N]Q.=%-6FI9EL>:EE=/DM>YB3D?MH&2=ZH M?+-*~~
~~<9S40WO6*]70GK5!L!]%S]K'_NV\8^W4+3RKZN2**Z)E<%41+?]*Q]AU%OB^ZI10H 4RF' %,I2')!D9(# MIB 7RT*I)O,+38[,VYD\9]~~
~~[,6]WOID_OI[,P@=_0Q *R,&N$0CN@_Z -R-C9 MA)]$9@9_DD1!KL@"^8([P>RZ.'/K+1-94#GODTM([U0.-8ASOO<6;&]C;W'G~~
~~MWR'J1]I6A'*58V7# 4KR ->*+H>',IR*Y51K2H98KX&=KSLX#O=M*1:@J M97X5!P?(R <0Y4.M5SQ 5*I%H5]%,~~

```
O"K'+)JYO=M_9&JJ6E'WMH^;IH[E.:@8 "1) S5?-G%+.Q60[A8I<%FH5
MCF(_+J#)PQCR(A[%?:WV^<1#%A1)%,3BV[M8^18/C@Q],J&J5$W:T@]LCYAW MS8(!,# M#B5JS*H$C!5^@1C; 8\,0S=KDK+3C$$7
HNT6[A;'&,LU_M/K:Z#\WV0$#MYB!J7S\(P F=@8-WK74=>T( .^N:)/ZH6SK=,CNAC9,.KKU* M-:%6!0>5(W()8?+@36OQ8Y*H145)UW8
\%4S+C2<>3(<+#EP&'S5^'W57NO; M]T&AHE42A#'OY.!Q#7D3AV!WX.XO"D_&*]<)_L6-O2$$A9>@'KYP[.7Q>^6#SH"XW]L[HW_O
3!RHEQ1!+E:$DL+1-J&= M(,>1[>/ @P<:0 -H<*LASG5:+NH^F?M6_:9UWQJTFGW__LE!I_'K]\[];;/7 M_YEM&A[\@3[>-
N]:C=;@4TX:J8==D75&\JDD!8R#KO@IA170 !K9H,&1ACA; MVN]#N=H 3_, MYP:9' TEFT(2=OSF@),.\0B)1*_Z$LJ*E$XY@;
H.=MO6VRI::W3LCV,)NJ, MWG "G=%XT33EL#-5N]TNN.1MF[#6[?JL/;9IE52I"J*X]Z;F,YM=P&H26 W; M>;_;A8,'836^3<>Y-
'9GJQ)P8NP6MPH&1H[=5J%JFC/%>E*-O^'@P\Z2=-Q1 MB'+848B]+B4,=%+=TNL^9NZ7^9&CC&I9*,F24*LJB6FML(,1>3.T.1:-L&V[
M>UV->#+1J C%$OGWO0P0=Z+!D97/3T@;-!E?[_3]7A(;]%?Z]5?8!NR=3'M< M:DJJ"A59%,3:WNU&P(2#",0A F$=]7X!]>T *F
2'%S*GY.XW-]@)R,(>W7JGK>_& M@WM(\Q3%'7P%1<2NHF-;F%4$J9A<5>+MZO* 3A[&D%\).?A"C!-)B"P+Q6HQ M92+"D;'/?
$2SL0?!+TZ8-N&0AYTQE"=RH+,.;M6_DIM-MR6'XD2>!:!R\+4 M,0I PH8:BA.\&VJV&WX\-CQZ2YK+]@92T!*F84LC $0?ZI)1T=9 170
!JYJ@CGP2W[.KS>I>]=5IRRI$N!J2<%3,IJ:3A?V6(_QV-8 M.J:?+O@)Y*Z#G[#C8#II6_M30!/502^J.<7HIZ_N1+7F@RZX6"L8KX61H9,'
M7&F5(N'OU@^4+JXO15&4OGZF'[L.?J ))GP?J0X64+B_7M[)7^_31X1<,^// MID\GPS[BUJ?>R';(JND'9'I:[;NH+%18]2,\]OA7O50J"V(E[,:O
M".@;C"+CP8H7CU0/]?'$P^,A45&*2&P"@1+[U"W6@EF=OB5"M)'?N%6(!?K%Y<"P0)S9+R75/25-0'MX_+%:05H6R) I59>^+@'-
I[O*5!F/=/Z?CJ.EZ M) S4\9.A&5ZV[5PN#AQ\#-=(!W<$ZV%/-2RL-U7',JQG=P4UMSYH#E).R"7K
M]LM%X>):$A5!E!2A5N1(346<&OP$@I$UP3BX3]C)!:.JT$A5*%??N<6")[G@ MR)SG+7KU#]*R"M;(-HE(N#^CM>
(4$TO/42V7@O%J.IE@1U-=3+Z+_YH:W@Q] M#-R 3XMR%;@#V=1ZNY6U0K1>?P5?38::8\V_(A0KBJ 4.;I ZQ_YN0@7 QV
MVP%Y.C&X+@J54D4016@2RG_8GLVC.T #:&3\2%CF(P'_H,J@,ZC?HY4&H:C> MOD5A!\4"3NT2'! /\DU0L/UL608_:86-49W7O)+GI$GHT:-
MV= M[F*=_L;"65:DNS,LU=(,U41]C[S VGIU'Q_"'Q:VKN$LB>+@Q74!2:BP6*?1PD'MUK\U M"S>]9OW70OUNT.Q=
(=7\H<[ZMM\,\ZND[[MMGN-V\1^:W?N6_= MU@=-ZFR3'P_-]J"/.G>HTR6#'[3(!Q(9X\='2YWJ!M$%^2_Y[X)M%>\
[=F^Q$NCP=2P*2TD0(FI8 4 M,"E64AQY"WGK#]-U;'VJ>G-"H%$1I MCQ8O+]B:XCO''M,K BF%WPUOU)BZ1*ZPT[(T3_^D!]/;#UHJ(( ME=
FM9QTHP)4\X'J8@BJE26J%:Y07:R5A"*TNP54OX?J4KBNEKC4U:5235!D MCAOE JKY0'4Y7%=+7.KJ2IG>,<8QJCF*=S)_;'Z7:V%<#]E/Z-
FV=9=6PW7T M$;\2,+K&"Z9OZ(:#28A$[T<@7_7_L G#1ECU[U88D?^8]'"?1A[E?LIX&!5; M)Z&SJ[?C&@E)8N6(.$SS]-
$5A5KGZ1L%&CT2C)T70\-NGT"N^1IHOUN&+_)N M*X!:)T :>>E[@#/Z&/? X\-EH5+CY^CP;HV(0( R(D#5(T(^3@1(H90UY"
M^ENOT^^C;J]SUQI .)I172;%4!;\YMBNVW7LIP,[V5_+)**L58HI4T<@ QF1 M 3F&(N+1,E LE86*E%QOM_H7#TIEH525!#G!>XX!I_SB-
&SK\KX5NMAP*I>%BLC19?20 M4>0F7NAA%ZN.-F(G^W3\@DU[0F_A@_"!%U4BAVWBWK\?BL]FHDINETQNOD[H
MG8R'WEQ;K,E"M9C*(:CLOBCK%J$/S2F\ QQ!W=CD M%J5A'>CV:K(1(TJK1?#0^"'#T8C"L"[][&($:.2(E1EZ%?+#SE^8!I1 =Z]
M6T2,,*T)4IECE'(4..2M8D&/K&'7)7!03?2$L][''/54:)*(ZOU>I8I6_=_C0 MJJJ3L2#TU*M(H@0VG)$CAN4*A&%W[W*$?&@
ME&I249#+'*=RDP=.;G$:4>O=JP 1F]6O%06%9ZO/4>20MY)#Y^G)T#"K.-C> M"#L0.'"C0B(J[WL%#AW*TSXV:"[
<12@Y*VT<6.KCD[O8/)[JML.JV^P M@(7=M00!"S>Z)HXSW6W;HE52![OSG99SOKM'I$ D29#!0')$CA_0QG'$^R2@ MK96$4AD":W[(\8/9.
Y\GP2SBEP1Q#(H6G[(\0/:.$Y_GP2T,FT 4^2XC,=1 M])&W\L@MGA!\&2H%!$0:O.B28AS'OU=92_3*Q+'U*2-R:!I.JD 6F1]R_( U
MCF/?,8.U*%2E&H"5&W+\@#6.X]XQ@[4LE!0(*?@AQP]8XSCE'3-8I:)0Y+F9 M)$>Q1-XJ&7<.II+"2A?
NR)A,#.L98@INE,G11[L#_M([@0/N'NB<%<':\4.. M'X >?:H[+H!*@ESCV,0ECYG<0O3H0]WQ0521X 1/^3X@>C1![KC@J@LE'C. MP7
4*.2MZ'!ONRXBB-4-=V*[JDEW/^&_ID8236A#;Q0]LW[)[Z6VQ3@.CW]3 M#8M"JF/=,D 9E$#GJ>ZZV(LLF3X9KU@O_!
<[]KK:0BY9N%\N"A?7!7YT%Q<@ MY6$,^164.$ZO@Z" H&1=4$IQ'*_2%"V>L-+::&-?26.-N-P 5<>QI!?D8GC M+#_8%MZBROR4G^0*&\?
]D@LB?U]DQD_-Y-C;15'VX &/5E5M_1@D^VA=]8) M);$L%*7D:@5A*BEOV=D"#')0DF01$4HEY.[V/ HCCM;=3!:$( &T : M0 -H
(U=:7!D03.?":6NX/#ZOM/OH[M>YP%UNLU>?=#JM/M?/P^O(1.:=C__
M8X2C'T=#HLX$TPYGUG/+TNPQIC6<(RN<54&NUH0B3QT'(FHWGT DLB82<;0[ MBE\DBD*E7!&*/+4[BA"):!.V0??+D@2CL&:D
AL5F"A?!#Z!'1).1B@0;0 !I M VBDB 9'%C0GN=C.X'NSAUKM1N>AB3XV_]5MMOO-3^]E8].%,3+-.9EAJ/<( MI(!)J2<%3$H!*6!2K*0X\A?
RUANA9;U@UZ.-$)9W5B*#I7_0Q^!LRR\SOJWJE2L2:49>BVQ@^Y!# ;D: NAYVC M.NCVRGA!N\Q5*T*UQM$>@LQ6:?
B$;01JPXX\'71E9=RJMD9;LG%\Q5_R(,H^ M9J-4;=CAI(,NJ3R5JJT(2HFK7FT\%O\RG[K<;-.&51<'L0<$&]Q8P+#37?L&
M&XRUO@(Y\"*T"O'.*LF=Z@)SQR] PW8E[QM8[ #0J.8Q//6,X0\FN45EV,;@ M?0.'H]6F)!0K):$LY@ECD12PB]FGL M56[,R89$:%&RCYP"#:
!-( &T :T**$OS3JEV6[Z)OF7:?71-U>Y[=6O]5I M(_+GO&W)H/ZO9@X:2//HVT<[[1';6/?*>RZ["=XY]KA!'F=84^+=!NT&;&Q2SQ_.A#'-
DWF^WO8P>ZQM=*J4%5D MH5;DJ#MA9D/?=.$^8F_L7HE-?G%?%"H5B82\'*5'H15T3B0K8M?F7ME1?B5+ MJ@E2J2+(98[*<6!2>
!^-6+'Y5[Y3XZ!7Q2*Y%^N2FZ0,%_Q]LC[C!%GXRTK0['NZ4 MS\=NH0@AB*-;) @!"$&JA2".YI,@!" $J1:".)I9YE4(.(K9(.L)-( &T : M0"-%-
#BRH#G)>K:; T3WBN8@Q_FNKZP07UFWI[35W8:S_!//+G[TL*/V1L31 M9+J-
O=CNK>9P8^B;$$#)]$%)D(VY;,31WSI.V>!P\RC(1DYE(XXNVW'*!H_; M/T$X.@>8OF.574;?987G5XC1J=AX=.&_6_UWM-R+7F*"PXY-
J,+G;Z M(]7!F^%!4W4LXCV[\_=O5-?0#@@36NV[E4!!O%0@?@9!25A0:H=HQS"TJY H("@I*PH!QR%<9Y!46ZY/KB&,C.9C1+ #2 !M M&D
#LK-9SL0T2N"QQVT=OD[V=QT%_0%YHM;_E(*^[LT_._\FXZ+%'A!-[7TH5&DC\ MCNE$L5XG@J\^X_9T/,1.YXE]UNU,/==3+>J$'Q-
@7,M5H2+7A'(QN<1N6"R1 M]W.DN1*7O2^K2DY^2%,7F0>[EM(C$O%N$+TDS5)=CK?KOY M]6(35*+X]S!I#%YA8L]>
(F'[^K/N!KW%PT*6"JT0V/CNZ*G@V#_>OJAATT3= M;R3@WOK@<%[.8;"Q>F0Y"DA&A0"@ZS\^?!TMLBY=$NL7;GK-^J^%^MV@V;M"
MJOE#G;ESQ41!8N&U:7U!(^ROCTRE)\BE_$UD_X2E68*W+CYOKN7WV_"UI PY M>"4'G<:]8?VYQ$/("FR76_0&BSOJ]1
)HE/928XW&;BK[(9!Y@+M+'C)4O@]!]O^JW;5KW76NGP&#',S5'N(*,K PS&MR:U M='2=]FVSW6_>(O);OW/?NJW3A%)_0'X\--
N#/LU"]0E??_W>N;]M]M@H__&W MJBQ5OM MALXD>.NW!]SYJDHF1 MB32[9"(TFZ808TY]6$2L*?U%262H'Q\M=:H;1$V_NU3Q:^5UL?
1?^O"5V=- MY3"_@HIR8*P7?[L355O\[0O]DV$-Z%?#]?MVE;F''[&6-!59,9BX ]1;\?T!
MSUD9T'>LTF$OAG3JQ/;)4M9S#:R4_GZ6(@%:>GRAY(@Y(1"P?KDHOV\HD^PI MMIA'\>_G3OOO9@WL\9@$$'W/UOY\+U5_+MYFB-
S7X8+B,#2P.2EH%PIPIZ$D MLP# 9>#R"_I0?,J4 MGQ@]FTP=PFD>Q@!HBP5M7=7Y.G0^LY']HI3#, #X)T#>'6R\K0^L^H_\#?*
MKFKHA9:U$)&&.C&(RP-" D)R%B'1M.EX:M*RUP*"M_C)T P/( @0/(L[2E-Y M(]LD,W'GA1%^]77SKZGAS3@>X,= ?
#_Q*K\);)_/3MB29Q]&YQC-U!EAWWY(ZXTA(WZBF:FE80/\[M?!BIU6VCR'N M0DX\]Y;VR*WJ&QW@C. X1[F@B/]>
[!+V@\.&/9[8%MTT7'\UW(*_8X5%N0^8 M;DU_;S_[FXWKQQSQJ)4%4:[RTYZ$0Y"=>+[;^O%P W!9%$\"\)#VZ*OY'O]Y M!_5(OY:%:H6COCL
;$Z!+1T,[&4%B59I6E90FSDGR*LU02R5!*4*2 >D+\83 MWBN-X/I@J/>PIQH6UN<=TLZ(\64CM5I1D*JB4*MQY:_DIL5@>G"N1./\S) M
M"9(L"Y4BGXCE**(_4Z20'S$LQ.6!>BLDESSR.W+>\%60> ML/.,'>1@S<_Y&/]560#B.:KE!L&(9KN>"S6:!.+" N2^\L3NB"Q 1+.UC5:>
M\10O-$\?7=6[K8:O&'H;>J$SH?]M69J#51??V4Z#Z ;R(?O98AGDJ"S#D_&* M]<)_L6-')1@*/"46N -C]K$?E0(+:YVV-_@/*'"
<2!"V5T$D0:F5>1*$C.:$ M.96!"!&(N,A^/Q'8I_!1H!+1&9? **,0-AM]>]=2PF*'$HE4"K)O6"R4 WNP([.-=S/=<.^&3)
(C/%$CA^@2XD61V("_3NGGZ2B M()5K@']^R/&#?SF9R@AH>T![ FC?^TI7T-C;;@KC(8:&$DB:R26?#@)RP+P\ MD@/FI9@<,"_%Y))G'D?
N6]Y*("P;B@S7G6*=%D'HM:/CB6G/,(8#(AQ%BL7= M\B+?',)KC&EZ9.KG0EA+KAO5Q7I7G=% L>Z0SSRSY$E[R6P_11)[/S#ZT18#
MU^W4,:SG+ED(6_?;A/FOW]E.'SLOAH;=0YN%561!E"O\1J<< #FW$@G^"G&E9:9["LPXDV M/T,N+>UJKK0EER;'92E6HRB5^3S4T
N]F@X>S/.!SE@7HK) M ?-23"YYYG'DT>6M3-/&'C)M%P[<0%DF?^P^W?J&("DRE;#C^:I8"S5$[%N6 M9H_Q/9%]R(FE'B,":*
Z/\_G3UCP^.P.&$8#V/@B#O;"R8\C90S'O(P!@ZY Z#A M?0P<<@= P_L8..1.ND'#4:20MZ+6C6JJEH8%U,<3CV5:D$* 0J/9,]>YWB!%
M>4>T3S&DB0T"Z/1V:>']&O&45,);SK'>+!(G5LZ[H8Q*M:$TI*1:CP='B "WSS M,(86 M%D4H5A1!*8KI$9:0U%$Z:L"P>2,+^\$2'T JYIO
!N(4K$H>40"Z % * 4 M J@YIE\S?-_IQ:>ESL5.-;'36#HBLD!\U),+GGF<>31Y:U&TR=A K*?Z'U8 M8Q**N#24@ H-
/WF^:D@K'&79"D>)]]B8YNFCJ#N6_0+.RJ/JEMYU\!.1(*S__MKM(KG;U#&NVPHDY1$$61_LM3Q,D=+//:CU()NS@L5BE8R:ILDP%VAT7\(B
2 M 0#H\T2.&P-0#+LI;&_H'U#S24@,A%JM)I1!&'@BQX\PA-T!MK0S:$ ."DE #IB7=G+ O!23 M2YYY''ET>2LD-
5^QHQDN*R:Q*A*R)]3=AVN\. HCE;-6D];V)T85E-B;'1\J M&A1F6=ESXJ5' #WL K-3%8S>@3E+L>R%\B.3@V=F->CP\^KP ML"O-
SE$0BAWF[QV$*U:JZ5#E( 'GE8"PZ\].6@7B3<,#XK.'>$G>!OFP&]%V MK?^ XN8T10!%GS232S[;!>2@Z
/D@'EI)P?,2S&YY)G'D4>7MZ(/"QN0P6(* MY-GD4Q8>3TQ[AC'4?3C*F.QXBN@;W>^',4V<3/TL":O1W*@D&.RJ,YI+J=,]
M@<\LK=)>,MM/GIRU;N2_?F<[?>R\&!H^^.@1"<"*52@:98G<@46C'4\9)2R9UXA 1\>*Z#%6G7%B0TA8+4MKQ&-)I9>-$5:N8Y*1"#$FIF
Y# N)S5@>L MM./!I=.*3]PEKYWE!LI=("W[2,MNIYV.E18N#$89SD=!J2RK<1@_.4(@!Z4R M(
?,2SLY8%Z*R27//(X\NER6R@I#&IO09GL3;+DJ=?>A3)9 W%G@)L;*DG[C MQ#&-2"HD<22HKO]GZGKT:>[ CLA>LYP%TPN-
%;70PX2\:W@X2#'XV8<>UNQG MBSV%)2+@!!&HN?UK.4F?($I**M[9MRZ7A5*5XW1<%G3W;N1.*2;\..,"7'EP8'>9QY-'EK:K0
MQAXR;1<.VT 5(7_L/MWZ[G$W3>GD-S2%I!Z(V+R+[L.LV[4#FHRP0 MRR5+1Y0% -0 ZL.7/.)6]7(L]R<="%[4:A4)$$I*3R!_!-'@,LO
MOG<[6010Y2Y4S7[Q 4U4X@U8SP5_2SCV%H.SIV5H> 7-LT=,8$44#T M_Y_.GK'A<5B<,(R',7#$G>T%$YY&RAD/>1@#A]P!T/ ^!@ZY
Z#A?0P<M&-55+PP+JXXG',BU((4"AT>R9ZUQOD**\(]JG&,.&#)$A(-V> M#DV\NQ EEK?8?? 1Z8V-5A#&*:\I8GWE.E//]52+S$[5X47)
(PO"2M'2]B9A442Q)(LE"LKC]\",^J_+PQO)^_+(?"1K*6.0D2)T'>9'W;PB22QK:%."A7 MLP9LC>A9[-!6)Q@C5:--3E1K1E8*M6V/$/1LU+
M'5NT!0KYC24"B;K6T9UA MJ99FJ"9:Z&_WDF:I+P-?]=O/KQ1L1IC+\%@C!*TR@V4L7UQO/
MNAOT%@\+62JT0F#CNZ.G@F/_>/NBADT3=;^U'Q^V/CBWLWZKX7ZW:#9NT*J^4.=N7.5<\4N@%B;UA
9O77S>7,OOM^%K21ER\$H..HU[P_ISB8>0%=@NM^@- M%G=4*2$21*>RBQQO\F\'\*^0"3"R)@Y?A]>-/QKW'33XWNS5N\W'0:O1%U"K
MW;A$]?8MZC_>]%NWK7JOU>Q__3R\/O_H.NW;9KO?O$7DMW[GOG5;'Y_^@/R MXZ'9'O11YX[\U6G\^KUS?]OLL5'^XV]56:I\
(5]'S7\^M@9_H(^WS;M6HS7X ME,@D[CH]NL"HW6HWT4.G/?C>1TTR+S*/9I?,XZ;9FV>ZBTBU]"#EG* M>W@); $-:LN8XG]E]1)6+/)-
ON>L#.@[5H-L\GG*2%G<2A9*CE@, @'B*);? MMX5G\;0CRIN+>13/7E@+6X_U8AO5K2R=BYCSOI#VB"+;N7B;(7)?APN*P]"P MY:2@76^-
]MY0DED X#)P^01F04[*+*P.D#]U/[ ]$FESH.A7M]B NQ1_%I5N M:^)?6/;TH?B4*7_OR-EDZA!.\S &0%LL:.NJSM>A\YF-C+6* ^ !\,X!O.4N
```

```
MA:7_P-\HZ0Z*0LM:B$BPEP*$!(3D+$*B:=/QU*25K04$;_&3H1D>0! @>!9W M=*4.'Q1!>%;8_E8!GD<8R.\G7@4X@=,JV8F;\Y&*3KY/()
#YN61'# OQ>2 M>2DFESSSX!AQ\L>(;[$6G"*6$CE%# W,HKM.EFNA>\TEN:!(W![PE:M"J506 M1)Z.<' (LA//EZ_CN%$ KX@G ?
@)SP'*0K54!F!S#&PN-'=%.AC8'!QVK5:% MLB0*5054."#]O2:KE? N)+M G8LCIU6%JG2A7)5X GM&^P>G >=%H5*J"*)8
MX4;7<10G9[\Q;Y;))9_R 7+',"\TM,KNC+--#H0QQ>2 >2DFESSS./+H\E;Y
M>,#.,W:0@S4_L6+\5V71K.>HEAM$MIKM>G!M(%P;F#]V\U$6*(7/KNK=5L-7#+T-O="9T/^V+,W!JHOO;*=!= /YD/ULL33MOG>Q M+1-
/<"D;1^0XRJ>6XP#_ 56$$PG"]E)#K234),B\\D&.G_)9)0X9V*>\ %: M2T1F7P"BK$#8SZB=U_3]3UZ-!-VU:/HZHIB&.C1,$I-#%06J*+EC-
Q=5E*IX]BK* M0C6X SLZ_W__UPW[9LT@6<83.6ZRQ54IT8I)3*!_Y]R15!2D,D=W9G((R-SB M7TZF6@+:'M">-
J5HRLCH+$YBZ&A*I)F31Y:TJPA*DR'#=*=9I783>]3F>F/8,8SA(PE'P6-PM5?+-(;S&F&9,IGYZ MA/7'NE%=K'?
5&8T=ZP[YS#/+I[27S/:S)K$WYZ(?;3%PW4X=PWKNDH6P=;]G ME__ZG>WTL?-B:-@]N'.7) FUJL)OQ,H!DG-;3-
KQ2$YR@A/5*^:MV+!;8>*0 M&I;E 7'AAQP_=F;'0SRG%9=C6XF=6'2J%4&IB"__)#C1WYV/ !T6ODYN#_9 ML8(#)3&0EGVD9;?
#0L=*"Q\6H\:QQ\51 @9*:FDFEWPN$1QY=+DMJA2$-3DAT,YY@RV7[\J"*,J+?.'%,P[,*M7.>'YIG
M$=;WYH;GKUG2@NF%QHI:Z&%"WC4\'.08_/3#2EL3EHDX4<;MS,@ -1>[JBEM MR:_5DCI@E+14;$_'E61)D,LE?M-Q'&
XRR*S+25=._N9I*1E!6HV("#[",@Q MQYB2QGK*[0)'03V4:=),+OG\%)"#,@V0 V%,.SE@7HK))<\\CCRZO)5IVMA#
MINW"*2>\+F>>>B!BW[(T>XSOB>Q#3BSM0.:CSI+4U3< M:@#U\4L><95'[>R7V>P%YZVYW.4]-5)-D$H502YSM?T>+FOB
>#'W%630ZQR M%*QFM?PP48D38#T7_'4DKTY>SYX=&=J.CIW5(2#7-@V=K;PH(/K_3[R/ZERI
M'1X8QL,8L@*:I"HK//"0AS%D!4>Y81@/8P#0I(QA/(P!0',ZAG$4*>2MK'6C MFJJE80'U\<1CN1:D$-#0Y>^E2$<63B%94>YJ1;9()N/[S#NQ!
(U0K%1"I7(E4FJR5(DH' MB]2Q_0)C$*]J32@I%:$B@]D"&>-@W.$E+T64#Q:R@YL*'B]=*Q4R41%$21%J M19E[.3M7C1=$C"\14Z)%[-
S2H@C%BB(H18Z:U;XG+"&IHW34@&'W1A9VA"4^ M@%3,-X$MQ"E8E3RB '0!H !0 "@ %$#-,_F:YRW6@I*GQ$J>,ASNXZ5QC"(6
M0^)BN2#)!47BMAI9%8I52:@6J_P$T!QB[,3S3;)TN$=)L'02?)^R9E'D^)9W M@#4G:KM\,*PY*,N5BT))402Q4@2D
]*WGP=3Q,K!4.>B.%96A$JM)B@5KM1Z M1H\ZI@'G$3"O1L/\/%JYHA"U7.18)7,4RW-6Y8J;'G282O/TLDT.&BUFBQP( M8XK) ?
-23"YYYG'DT>6M.M,G 0*RG^A=6&,2A+@TB$"JI2-5H]=CJ=:,1,SH MATIO\/4(+0M[4+;A)UJLA33)499-
/D@^["XV+BLDESSR./+H\UWO\8T7VA+K[4/3A*&0\[_FAM585474?]F;' MATH,M1^)I[NJLJSL.?'2PX$NG_.
(T#LP9^F4O5!^9"+PS*P&'1Z[[BAMT>%R M4D> 8H?Y.YE#H5CA.'?( 22S+ ';O!CY[,=^>-/P@/B<(?Z8\SZ@MSG-$$#- M)\WDDD]V 3FH^0
Y$,:TDP/FI9A<\LSCR*/+6\V'A0W(8#$%\FSR*0N/)Z8] MPQC*/AR%CSN>]?E&=_QA3/,F4S])PDHT-RH)!KOJC*92ZG17X#/+JK27S/9S
M)V%DA.'$M0W5 MG[@+8SL+#A3%0%KVD9;=SC\=*RU<6(R*Q+'%X"@! R6U-)-+/I<(Y*"D!N1 M&--.#IB78G+),X\CCRZ7);7"D
8G])*F";9*8 MAF<5E"1.#M7U_TQ=CS[-'=@1^6N6M&!ZH;&B%GJ8D'<-#P ')1I@!P(8]K) ?-23"YYYG'DT>6M3-/&'C)M%TXY M05DF?
^P^W?KN4Z@YYT4^\]0#$?N6I=EC?$]D'W)B:0Y9/%^N2A<7$M%H4C^K=84GE#^B2/$Y1?@QUR_DT.L MLYX*_I.2UR>O9QS"T'1T[JT-
KFT:.F."*"#Z_T_GSWYS M."Q.&,;#&#CDSNZ@2;ZRP@4/>1A#JG&41X;Q, 8.N0.@X7T,''(GW:#A*%+( M6UGK1C552\,"ZN.)QW(M2"%
H>'LF2M=;Y"BO"/:IQC#A@R1(2#=G@Y-O+L0 M)9:XV'WP$?F-C;NBC%-
>$,5:^G6FGNNI%N7ZXL_[]!+'6H\MQ<)5Z0,+XD3(F6L#,+BR2()5DH5S@ZT?:>K 2)HP_DY]#69W2@*EG[ M:_*";KQ6-X/W]9#H6-
9"US$B1.@KS)^KZ%222-;0MQ4*YF#=@: MT;/8H=UC,$:J1OO&J-;,K!1JVQXAZ-FH85LZMFA7&?(;2P02=:VC.\-2+ K_OMYM>+-R),9?
@M$()7F$"SERZN-YYU-^@M M'A:R5&B%P,9W1T\%Q_[Q]D4-FR;J?FL_/FQ]<#@OYS#86#VZF1D542$ Z/J/ M#U]'BP1HM_ZM6;CI-
>N_%NIW@V;O"JGF#W7FSE7.%;M[8VU:7] (^^LC$S%! M05KS;R+[)RSC&;QU\7ES+;_?]D(9L\?"7<2>SHQ<^Q_!K(=$&6[(3##X6NVR
M1I9'-]R)J9)A&)9)?)/"T"0J= 6@Z[S8%2N/>L/X,Q0A%<&Q#VAQ@N-YY M(Z\[JMT0+4-'OXNNV\3X#@IBA4S RS65\75XW?
BC<=]!@^_-7KW;?!RT>! MM=J-2U1OWZ+^XTV_==NJ]UK-_M?/P^OSCZ[3OFVV^\U;1'[K=^Y;M_4!^;_
M(#\>FNU!'W7N4*/>_X[N[CN_)S/&CX^6.B6A+M8_O4<_?B6_CF#_I0]?F7D. M-!CS/J@$!49^\;<[4;7%W[ZL/1G6@'XUW%QLU\!
[Z!RVI@:UF\S(O++:#"M, M^>Z%YZP,Z#M6@\SU>4I6)RM&G:,D&$J#F"'":^)]EM\WL&=QWR-KID2:_/^W MB9)&#^3!(Q\YG?
V+LJ)5_[."IBPOLXJ$NZ\#;17:_S@#I= MXCH/6NUOJ-X8M'YK#59]Y8A]'6G2PFS2 MXM_:)#_M&<+.6VTMB,C$IG3W@&$A>X(=U:.
["ZB=>3$\ [M7V4DC V@D2NM=S:_*'&M)U79 M.&[QA*@Z0V5NO6KI2!W;9.G_J\)%6PD%6^&Q5BGL+J9]DP2KS":_FYC^4K?T
M^@K/#]NU7O9*"E?9 NZ0E%O@[G9U4E+ I2F#$D?'N3BVC?F)" +;2#-2B "9 M[D2T7=5$]A.BMZ9,:)0 MI$?%1-
VU=2^MO&;:EB4X1WKEK&;G8/K/-5=%WM' MYR4EH2IQE9/D#DRYQ6X9"J\C2-K52 MC,$DLE8D-YL7QQWF9Y=D29!Y.M/-(7RRC-:M-
G"WZPO.!U:XOQ"BPNWF;\WP ML'QQ+1G&&=\IU6Z5$O8A1*[VD'-TT=7X;>GME?8?:".J58$I08Y4X[( M\8/:W2Z,2 *U4DVH2$5^4^.@?
8RBV4:\?:T3B@#(E6B#0/LJ&0[5#@ M^+^3S\+^0J !-&!_(=M["\X?N+>P)"@B5[LG,GH4,66H#=OULV_5Z'2HE8M5 MH5+FZ.Z%B(.
(0:.CO^2_7&QBS<,Z[;9G>'A\MHY'^SK\.PPY>X:T16)-R[.= M6;3YW&%=SJ4UTCD4;A(7Y;!=8<=;Y#F&C /3_RL[&JN"7'RG=7@R&-@Q(9=.
M@'(T%'YD)6RKT_%^0'RR4BP*%:6<3EF!T#DYB]]U\$0U*#8,BRXXPJ^TD@O[ M2[B*0L+VKNU5+=M4/0';&P'7FP'3#[VL2BE7A%*-
JXV7$#[S -RPG5%[U<9. M"MQJD4"WQ%59E\<^/OFIB6T81<-RIPZ]GY4=6B>/?S$TL(P\N>5Q=+5[ZY8' M_&_-
V7^D;UXN"26)*RW#':*R#^ H"QE'>[L3(?BZ6!.D*E?GUGDTC[F+&3O> M"#M@!?FQ@F$[T(ZW@HS-G7GOL0R?\^4 2WF%;B6LX]#QYF\?
Z.Y\/6.URM7^ M &YSJ+D+%Q?;CR;JC%VPQ5J<:9HSQ7I.\JD[WY?"H6[:>>P1+GSEM#N;NCZH M:",J'U+WACHT3-8%]-
C[F=EY>8X.6D5<SYGVP?@4D]%*J X-C^MM/,>V+UY M,^^URR8&=D-U1UW'?C%TK-_,'EVLD_AD$9HL&GH?H9J2E$HU2"WS!$Y?B >
MQYZEY"$N"R6Y*%2*7.URYM;(GBWXYNF:U[@)'^^79W$HB;$#<,#54. J6K[# M#GI->G. V'VTC_WF+6JU#[J,-OWN6BX2+%%9R6/VC*
[G'61_J(ZC0K66JU+6,>UBYP%:-^#V'6%VRW6G]%Q$ MY^GW@-O[[FR&#,'J<=T@ST.J>^546M212A5.4JP00B0!G/HTJM(P!9R
MHV&J<5S2'*YA&O9X;%OL[ADPAP#6., :Q\7,!X/UG;US@BS7!$6L\HM+8J%LB_C=7OG=&Z]B< C@"OW%0X '8)& &L<8(WCJN:#P?
I>K\MB!0)& M"!C?L8-00^1/JQQS2W.85@GJ,7.V0P41YL3O;OYL+XM(!=9D8NX-P0= M>2%T@EYGZCL8Y2>D#3E*W.UU?FO=-
F_1S1\''15(OQ;C4CU%Z9U:'-N$(LXT MQE<5%6K$7Q:K'/=VX0!3N85P')N'3@UA21:D8E4H)=@9,$TF]&SA,2>-4++> M#
(:CH4!_(L#!KNS@2"-F/JA8QA&M=J/7K/>;Z.-MT__M$VU.Q,*+>OO6_Z7Y MS\?6;_7[9GL (05GVRUK<6RWI-X8_;?YU]1X(?Z6Y;D]
['J.02^DI6_4+7W] MA95/=LD<;/UMXV?-G%*9;[YJ(]5ZQCW5P\VG)ZP=EC9<;GFK"HI$G+OJ.[=0 MP\[-[,I"A"C$L7,S!:)P+9>
(#-2XVKG,K2G/4' #-(!&5FAPI"%RXNQO]>@% M-,3DXQ8Q4G2'P(39,7#S^7%M-O:*&[X_(\D%13JA/[/P7&X-=V*[JOF-B,^$ M?
(/\38=C6%.L!]T4;>O@@H-<+ NE&E?^/'=0S"WR2R'(E[.!?$DH%16A*,$N MOIQY\I">YFLH4*8 '$"9(J61"[;TO,0L[^^$5(CTZ/:4;NW>$)^?
N'+W=A]W MA%M8#G$+3U_K.$] )%<%4>)G=[22Q]W1:_-5Y)2*VIX#CY"U2FCR(1.R)@E5 MD?Z;W&['PZ2-(R\D0W$9T :6:'!D8;(29S2?
^QV[YL/)#*IWZ/;5K]QW^D_ M]IJH_FU%BDHB94Q4K*I"(PYA_(SZ&MS^AH5;+TU^0%W7BY_O#A*_TQ_T[P MTMZ&\"#7?
PV&&J8<(L/O8XQ43;/'$]6:T5U5;=LC!#T;-6Q+QY:+=?H;*W31 MSK H./RHFJCOD1=8]]A+9C(C)O+SQA1^_K("8_]X M^Z*&31-
UO[4?'[8^.)R7N_ M%NIW@V;O"JGF#W7FSA4$!8F%UZ;U!8VPOSXR!7O@&?Y-9/^$.8W!6Q>?-]?R M^VTOE#'[+-
R@T[@WK#]#EXXR=@/= 9E:[;)&)J(;[L14R?(9EFE8N# T;>W/ M%2BMK]J.0[J(W6&-A,./@!%#V]0/FFCC#Q+5H\'W9J_>;3X.6HV^0(]07;+Z
M9/_QIM^Z;=5[K/5"YM>BW1DT^P1/J-%IWS;;]%I[\EN_<]^ZK0_('T%'BOH] MZ@_("P]^R3;SR_+QT5*GND&4^J=0;?*.?7JCUW?
T54*L$17G#34?2G-3%^Y@ M2%;(_&?J>L;3;-VV#$:8K(OOE% G:$+<%KK*.M&%#C8LI+JT:-_'$V+KAMCQ M!ZD0'XI&"$BU_-
C1(X_Q1@XUIN05BRPS&I/1C%Q:]2&FMEN@Y#N!FJ>/KCK.LVH9_V6+2DMAV-4< M@W71[3S=3%VR0*X[(_^\,=D=+
('O*5T@\D%U0M6],\54QLX%!,**C](GU.E] MJ[=;_X_E/9FNO&WV&[U6E_W=N4,WC_U6N]GO7RV2HN=AT+F6H3'33!L1J7 (
M%Z:>H1%Y;ED:69U+.F/TD2+]'W^KRK+XI>%[C0+[4_HR?_D'WGS%GCKS5XBL
M!"].W>"U3^@'$3+#TFQG8CO,R21R5Y\^D_$AJ583J0RJZ(ZX',0'1?./46DE MO@CVA8]"#['!ZV2&#GG &LCB_@ISP99HUO\@DU[0KU5-
I]+HB.]$;(75=F5 M4M'Q)/DRQ_Y^IY0=)[&LJHL&-,]6\J1-\0Z:MXM /C/R3BGA]@C]H ,YLG$FL<> MI$T=ATP2#0,9H_I(0&3@;?
O%_W*9J1Y_L%3#K2P[Z\!(5Y.Y]E3OS1>=$%M[ MO8U?5%T]IX8ZEP!T+ (6+5CG"ELK16"3#^".:+!D8KI>*AD37;EGIB#'0Q(:
M^49D^O_9^]*FQK%SX<\WOT+%S;R!*L%8MO'2,Y W+MW8& M=[]Y 'R18_K:#;8[@DG"Y;/O[O2^W9PG@TVIO
[BD>*D$YXR/AJ<7&*>B\0! MCA6'T/DS_!5VX-_9=[8\&#D T0W>Z/ZC&\4_:&5R4K7 M0/YG JXJO:?%K$4 MK.>\@4"&\'J JH)HB"X'6(!Y*[2!
[86*?C+$XQD1+%M,2@-MF**V^P,3+05P ME190Q2"1B7QAA@3P<-RNB.![<2M!Y\"UM)N_,#V&$9J=^B_:[GAF^=[##'8Y MG3E(?
PQP"5[QIDN; %WYNY?V<,?O+5CM>UXE1=7QS&T:? 'BH' 8^AF M4, T0[@8,PJ] .[? :H]!,J.YX='"4PB'A#84N2$DB7!AWXT19(R!!00>(Z> M
Z@1FJ RV,&$K].&J\4;PW,=^$"D=,V)B$\Y, -0)5 >A' 9YSUX"@X/9;N M6",S,OE6S(9800)A(GH99:#B_.$ED#@5, "(PY-@>C@&T44H=2)Y\-
<8C M/4]0 [0HET$;+\>UO F@('!7:5X=P'/PU]3T3<<1CH:V$D3HR *Z'2*S@(N! MYQ)4 RD?+RH&:51&U*S\'K!9)R*V@ \%YDB$S
2F8Q.0?.C]L D"B&!D?X1SA(W94VR%H!D=;29,7@[2)P)&!X0_/C2X6!(B M80)@)G!:@YFZVSG)J:5++J+]W70CY
3P83M^_!;KG:.=$P@/+AFP%L ":"CO M Q:V;!^%=$]"KQVBU70*X^#GPH5#=^B1- ADKQ\(+SPQ9(DXLXMVO(MOYHP$ M.D0+
(#1>1,^'WE1#;1^%"H"\L7>/U[=LZ7A^]VAX"P$F8C$\' ,MHL5L.Q\< M ^0"F@1>1L"3]_'S^7F:11)*IV#M%!C;5 Y\L4MB$*A!U U\"S4/
CEXE>! M3<"_;,<)XHMW4=W7_@$W!#1%U_KWPE(4]SSP3>%D2 .N93%UT.7]#6S'EK1" MC$8P^7#V&!*&8Z!8MV.F;K=
<@ETMW(M".!:T[M@JW)7Y.2I80QTYS]3V:>>\ M\ DPI,AG_\"32,T!^1N @=QDCT;QI0,_
MH"NCE4D"B@B(]*/9D4/OUILP,HA'>\3\OID^\"@X),!V(X?M."!:V"G!1"T5 M)-\4+#-90O#;[>)UXJ-&?0\% (9C#S7)"4@
*">3VXIOLM/]"6^,!I!@H&Z7 M=A^B) 7$$L\$]@T#!$JX-MK[_F=88!GAT!)WD"2^4#LPM+^J&*CX)@@W+E<
M:YHV,L&#&P2YS1>D?'C\-1$Y;Q#RXDF-37'PG^/1S('OF4@<01&8DJ:";RLJ
MJ^AUZM6B=6PS'00P.Q,#7[)%9BIC$PGAR!R*_=#;QY_*A,/BK#+M3(0@T3,M M6?$?2!S00"&M"#:Q0B46X&E/[3L/9=SDU',4\Q'*Q=J'!
(;XU2Q4P.0HXA]H MO9#Q1:Z7Y$FB^R P#Z, 1\IL 73&B1V&+/[$\F4O+5]>G/3VI#&J+]A0=%@[
MW!WLH4E1XL(9$'60#$EOT6D,1J]C+YB0$-\;A@OE!X2_J0#%%5,0V I@@:2? MPG5<\9(C@FT#B03X,1'+_XR
%!/!D9OC\TD33]""+1"_7("T'J@9P#V4%'WZ M+:-39> %C?_B!QY5,,2%V2-D-@ 6: ))XZ?<16)QB8#D!V M!(EAR5P,%S
_+Y@HY.4P]%@^8LA%1\S M7M$B"$8-T$- 6;2P1,:,7)&FV8E$EQ4 8]L)7#9:3N8Q@GG%(XBP3/Y4DF*3 M()ZGEWS!0?
JM:':MF>)VZBE)_W++64H+W\ XER&.]L,G\8"RB#AZNZB M/,^ M,]CK>/);L2>_\MU7OOO*=U_Y[E_3=T_!=G !@ M-
```

```
^<7WT]/]IZUC[<\Q+4Y"% ^%@]3= =*'TO$W4K3!O#8HI$1/WK._P%OFK!' MQ6C_$BAS-0DE*2-<1X^%+C,*QS#5_[&3C95\93E#8Q\LQ:3
"G.(MG 4R,BV MC%[/Y6:N0@EIR1(_IU4+TBB&*!$-4_Y2.XC7QE[ M 9!K\0:*:G!(#G92#;N M49 44]/G7JAN24BSI[;%D/0(9&H6+K,SL*
<.AVA/Z/J>^[; 0.PZY^V?ISS$\DSTC+:!"Q\Z<']9 M]88<#:;CL"DV8B,W:R$R&B%E=WB!N+\$F,F,@I:RQ$/"\]P+1')L9T+W(:W] M]+U VXPV-
IV1W&U=^ET5S%L> 64F@((NU/9!J_@38">,3ZJQ=NO)&W"9/V*[ M,2?[X\5R9(F0CL9;M+Z.T!P_'(L)J8DJ0$/'UU 7EB4MV9+K%-!6Q!I?.'1!
ML:-5*:3L#J*0$=0^W0C>89=8VG-GNU:$50R0^@ ZPB[@2 @4D)J3S]"\=;V M/$KX&FJ]H,Z&,W*4!@?:%^]>D%N0@DT\@)HXT@0@%P
1U%B:F+'(7.!)3D\^ MC-(4-@G4R9_OC3SP(C9[2YP-RO\)P0TDW42NJ-1:R"$FUH)DC_'(5 V XSH M2$<3J0/?
1O@%*>E*&31ZPS\CFV\0'1O7Y@@MZ"IXJ0Q!;Z^2&+&"Y',9QZ#) M")QF-@R(Y'EAQ>QJ66Q/)FQ.?A0_GW5)YTY78RMOE2(/
MCRX%CS.WG#XSJOGU'&A7F7@L(!/"G\0^BOQUZ*G!=2V_25I:&@SN;0=#03CD MR,I%*:DEIFX_/6!RC[&XJ(;-QC-]6RV>B:
<#"64R(5NQ(/JJ) Z205*SZ_/[ MH$WD]D!Q?_FSS6PI\ZW<$W.=T+L5Q'@2@_K< C)848@+ Q$+(_&IH&TYC$$A MLP)VEE)$I?HZ?
NV47U.7ID(P%T1> KBNG=Z_%[GK25^8P])0Z1KTA\JDW(@8'X&X""A[&*50X+ NEHSBC<"R9 MGC9U,()HXD7H@W \T^4P"
[DT"4EJ4P,1WJ,D1P0"0'P.?'.L>0F8.R@?QJM3 M%QKK42JX6C$L6W 4'*:*(@ME@D;'PL?% &G^$%)* %"-7#[84<2(E U#C:=*
M1Z;'&^=8DJ2',WJM,%E3QFW(3>G()Q)?)EPDYG1JNVV \1ZJ9$>& M*8$4G5E"-)5J M=I;/'6C'DN:-*:B2IN4S4>M$(BX-A'B*"VH'-
(J+G7;VZ\:_5=972L/L/=C! M/D-Q#,3?R+"6*B_0Q_5G.-=LXB!95Z>48+@_.)L MY^A0;W8[>M=HSA4BR!Z0O"^=PP@S@HYP9.2
DGB&7'9FIGS_>('$ZY"9FC%_ M^^R@-;1/<7/:[XK]DNG=5?=L:1@S("-IX"O;3R KL5FS< $*YI,S-33BH+
M&AQ;1/@IKW$AHBR!Q6VD/E_RZ' 5#1Q[J"DP8UQ7]RH/)_\,G&XLR4E#%5Q3 MX7A5/,4+XRG:53Q%%4]1Q5-4\115/$4IXBG08;"[:?
$4;U1F8LX8@:(R1QLV6$9C;@HR1YL?;!'S/A'C>U31KQ5>3P8V1H$.7N+2%2@S2'@*?( L_ MCQ(6F1*G\MR6&E13!"!@>)E,'17;XXO!3$=?
U7]2,?0!'"\PDK#FH=Z*^<:D MJ<(N8//^C-*"'"!HR>6>D70N&%+4^C*B8I??QMR"UD[\%K*,J\X9:M:#FUC O M!09@;BEF\"59JX$J<XAL
MZD;*!XF); 'H@)B5$G'45IRBER>5"0,XGXQB"C18QA1\XJ0H%+5_T7:.?O/8&04'['.\P5<; MT!A0?/;KSSC,VH-
+W@"2SYY2'DQ3E<&R7!MH'[J>,"C"%:$&5(!(SR*6W2HN M;-Q^2F'C"Q&>NYCK^14F>Q;[)6?<_^SL[QQU]$ZCKG>;!494/(]%VVB_0GWF
MU]R&T=6-P[9>;QES^]!5AACP$F?&=#Q-M4SR4T<3Z;:VQ,@>VN&R.^P\MV_8 MM>"$QU/31UBF-NR%%XD1,'5Z/'@=*>$4[2L8'(%=U
QK%B+&(V3):GSL3*R@B^ M5#0D%Z)QE*\5HTKDJ&EI [X,D&T[R9PX! ODF-H8H$<0I$BN8C/ Q.0[#OR,
M7R#FD0X/A>%]"DZDH@N9KU0J=#:A4(9C8@I\JL9 +/NH $@9E/_H813%Z6-L M.A5V6A@_O&[J_%ZQ,(IDKUS'42_4V5(^?
IQ783JKU&''N@OVNLT160(0MUP Z][S28D? MFE,[Y#SW19LTGKI)TJS_X F.>?Q78@"'>K/5T)O=>1 @$DC4SA6LLO@FNJ-5 MA
P6/Y%;55D"'M)X06+U* JQJ 2\A=$Q1?'@2%6I9)>BYG'IKG08C,K_3Q=] M!$(1H;8IZQ@AI*&1Q,? (UFG],/0MUB]#SA4PLH<^7%<[H
ML(6^9"2=*UH>(^3K,LC+1'L6!4JX5-T,M7_%U.(%)6D5&(26+G%)-BS\T!*# MD#_Q!HXL"T:CPT X/%4OL2*A)X$DZ8+LF1^J,G483$5# ?
<%QJ\,;ZEH M>5;ZL,@(ZI^!C%J5"^9(101"$#E4QD>FP,W2F.388)'$RB'>##%M'\2G.YNS MO<@H8:5C9P\8Z+1>.B*,4IK@$-
MY0HQF1M_W[A?S*J->2(4,8]^H__LK7,?E MZ!B68(=GYI!"NLDT@C[-!\-_]:!!@+0HW/+V#?["<"#V?^WR9^5!1
M\J^>>XLFPQ.X_V=VV#Q$6V&QO9!D415]*-$BS@HSZE+ _2CDXP\A[2M27(U% M5X:>PM-Z%:JAH'DEPSKEY!6ODWD2T1_%C=+K5.E7*
(5@M:(XDE7F\MEGU&*D \#_&.EPX0. ZDC='-EL1>.!DX9<0MU M2YE,#*-;PH'!*=6M0!NCE2?GO$@YPW&\>Q=1CX92:B=7\4FJ)-Y1)7K?
5)6E MN?S6S[!N&MET9%7-N[C\%MDWS3O/IKI8GG.'=7K4(<\)7GRR"M"EK.5A43** MN<[$")V7\J2C== T)
<&;0*I9(1[+W)0@$/RQAQJ.:3A&4312XE1^0?:67X?,A43GV7_A89V62[_12?. MOC(V_:L@.0Z7+-CXAR'JE[1QU?)GF&
[YDP@=L3\DE7+Y]*X'.J<;Q[GO\@[( M,LY.F%LR%_94)S2TQQTP#F<9"M>6?:CAHAX2=P<,0DY+$2 Z!( M?@#. 1#5-)U-L=(#[?
I4H8"V23IM1LI*=M&'Y,:L3BE&_8X@Q!X M[Q4PUR%PN[DF2D;C[9HHS06#UO< 9;]]ZUW_"^,^^^>_79R?G1_W+FZTWO'Q MY7>,^_Q-
NP)X/@:$YG#0QT7>#77TWY U6V7;4PL',G9SXK<3?SG ?T9-X'*4 _89_YL'^'JW6>\T M6BVC43MLM=;70&S7W-,^]_KG?<2$J^O3/A!KBI
F5=?X1?[(2LJ/2\E*/,Z' MZ-EZ0Q4UVG5=79JGD;)*5Q.IV0.C+R0>IM,GH]3I=/=U',7NR\9[SGNICH.'_)_XCM"B,;C?C4]4-:
M$U2XHS0FR+983SXD;(8A#4D^5I*W"QJ\$=%=O,@#^! UTL0*HI"!2_FG:^GA M+>-Q*3C#2E,V:.!#MN1)X/+E>"FE%]87AWZJ:3#
[UL^*PK,YD^J^JI*N28%)61\$J#9,>4M M8)TN6>=%?<78"^CLV?@7\R:TUVK=&OPU"["7E<9%W( P6!3@/D7GOA6)+/I: MGN#H!)@#
[D&+=X,1"/*-6+Y++4F6&PAD-5^X:%7(B)QDG 0V3-9H6]R](=56 M0PX5,W%?8+54-B]SAP?/!_P?X9FKI#*=^[ E,Z'W!U89N5.3*1Q-
MW8ORQNI M@T-)DE+DT"P 5#N0'DN+>WQRE5BN'@M$?$@1%2IFED0$V?(U2(FV2:H8'K"J M5<6.9BE&9 ;*PA4&D8C[@#."U%7'L7?
WE"-!I5101L[6G(B?0E8A0/A10!W; MZ^4UR_XKF8K*>(.@+)!.,J;J5VRWY@91&QL!]=*-LAV9F> MHXIF2(Q0F!#K\_.#4\2>
[&&K"@+G&%\)# M@ MQXG7,>57-F:PDC<0*,.;/".L5!3^P&C7E$)/HK\@M%M?T)BQG*M=Q/(XD MDY(AL:O=-9KMPQI H7'8G5--
WU$DM_:T\XO?0>6]O/X7 M:\*7_1LV?%Z>?#\&0;U_^?4D*Z+'NU/J;Y"O\)V4-2>M695*YQZ&#[")1.D= M4;="BJO#='??2J1W@ V91^R!
(+1+9>CWL:\Q_P:R^QY"(";2<;0(\5$JV(B] M)UDMCU<2H&@N24X@+?!)T._02QIG95]A>BB"^1@'1Y$,;ID[0+\UH404\N\C
MGQQH4IZ@N#O.VB:=88Q&JR11"6L_CST,N9*Q+G"0 PZ]2AZBD).IC[7793K_1!?%DSB'E(64]%K5"E*+1LK[N!S#'<;S/D ^,<4*+N=D7^3
M,2FQ*IOY3YT>%6R1F$&A_AR^GP50MHP61<5'+5FI"3CT$N"QO MZB4":(IVY =1<^;00QFR1")^/!Z:]U1-
R5@I2U:36F:ZUP/54\D&0KJ910?(5A!+9U*G6+!9IJO=8Z;-5;W2:H MJ^U6?8V:JMC#8)RKWCF@_-?S"[BVK]KI_UXA$A"Y1OY-
^1%P@_E8E""[.ES+BR "E_<>@' M=Q0L/M$#;?%AXR#R#QIDX<1<9Y!3>^7:6?MTL)"8()V:C>4L1\>[PJ=D<@0& MYBQ>2O[80]NAEI0#,
<-V,R ]<7Q*[.A07H1@+$3(E;?)JX<<@IUIE.KA[L>> M#$I365\0Q\MM5M@Y3/CA#!M>A3W70I<\W<^":+V6T>@V:JUVI],X;'17) QO
MV>%T=[2GG7V_OCB_^7Y]2L(1!G1_:A L(B4+MDVXXCVZRE4BV MYD]B@#G03M+F&#L@&U<4QA;@Q A-[MG0-Y'5[SN48L668?(?IY5A?
%>,(DSF MO$OB2&4BU&X2XK7[CMDQI8GFK4R2%^E\O?&W7+DPQE+^9!2M09HP3]'+Z1F
M@YYN^RJ%.7&]J[:BWJU+.6WL/%#!8(G1(=,")^]SCFL=QF!"(8YWZ88"M,J# M=X[,?GU:]!5P3HBO6*MH46R7T:P9-
:/;;1T:G?:JY.WK:6].''$D; M2!W:B )4\C['QEX \^$B>VK SFV-F@K)WRB#."BRU++^][HWT\
MZMV=Z\OO.WOJ2)+$4OX@G52ZP/"V(#HU(RWDG/=!-,A>/UTXEU,DP2.N'L"K MH%ZKX=CV+2[4C/"&/ )U6I[((!-T?+(4HAK"\G?NLA#G;
!W8CK<1BLX7+6Z MXKCA3;$Q5;5W8=>++'0YB^LYQ&1:W@] W@*@63Y/4L8&)YM@+S$>(A7190=Q MKG \XQR4:ZFMT4)22U B#/$9*
<1@!>DA$P\29#.6?K7BF(ODUA0+)\GN#[ ( M3=$.)9S+L')9ED>R18?*)&(%G6Q0#WG$.79UZ-,BL0 PE1_!#?MS"TY'I\N\ M;$<4;Y2J;S
I5<[X1[;+J)L[9?;(QY[#F* GAS0Q+2E+/LB'8H1%"> N%Z.5 M/3!9, @%"^5=3'4E R@7[%6,"Z*DK@/#CV1L4? FV;K0 HS+F/]N[94&IX[BJV+
[/-I*A0 M(/O...1D-.-8.#KU+,XFP2DJVH-+T@1*>DX7HN*B-3*M258G<&8<@BA3)K@] M@HRVFR._JLX)X5: %HH9!?W95#-.B1-
A4C,SEH/1G2AKZV.$EW3(44F$L7>O M@@\!B0 /I&/E9Y3+RLW8J0*(XNW=">++\AX>[DE!&.L^RT/WG-E MO YW"4PG=?TGLF[?M_'?
Z\OLUZCF1>*:B01NMUAR;QIMHUNKMVJ=1JW=7&$2"' M8JI-/$LXQ"UEITJ65Y-$3JV/8?-8.??[E)BMZM[=ZW^/>S]?> =:O68@P'S2
M=NT]I1'/8@JT&^RI-B?J('^!)]./$MM.54!)EP-,Q%T:C5Z%=Q.21H5M4F7X MJ3P0/G:W%P?/%S^DZ-
'*4R.)V(5A"TZ9@&675*,]O$;NF+!L:]O(@ZYDR(@Z MEBW<(HHM$_,_GLKBXNIDM%T4H&Y-WY4]#P W0!O7>D1N31;Y.:LW5=-HSC%A
MP:2^2B7W1:X6JN>KFM,D.BMS.^$7KF2$&!$'XZDH-W(HL!))R.U313"$4D$= M5_TD'BYES/2X53#%
[<6Q:IZ?]IB0$KO/W88RX6SX$58(J^K[K"_NQ*A5@2=5 MX$D5>%(%GE2!)U7@25F[+<;:%\E'N9CC H4LG>53I)"EI!D5A^L-AY%/26R8
M#FES17-9$7@VE?Y#J@0IXQ%F2C-0$Y%NI2QG:3-FW#^15\+^&*4PL)M$KCMN M"R1M#'&\0B:VGUV:61-
'7#XS"2=.'0H:Y%1L@RPBH((II.J);LJ)LH<=:'SE M?\B&(AH6<9VJU&I0,BV'S4>XKSCP0C-'V$S-7'KRJ;P*MBN-(F=D.TX< $*G
M2.O/9"PO4I#BJ)G8E$5B;ISBI5+,6)V.KRX5N8X%E5/Z>Z!J4M\4:H-9\R<6 M6HA OJ#+NX_'S^PR-
[Z>71&#&MZ=TNUI[ZP9TM815#^,;HB-6E(5CM-&?L]- MJU' :9L"*::+U3^OJ%KU_&WC)S!DRK);*+9C6+XY+;/@#HJ]^\?@ :J6$!?
MHF_/M;Y(Y#T3RJ.^P*]^V*YWV@;\Z'8ZC3>L0/>H=+R13V,F)+,4#H#.R[:)"=GW.4YQA+@=:\9 J4BWP,.)'=6A0 MJ5^D^N9SOQ;Y.&2R:[*
^ 6L8J%F5^E<&PB@<:XVIK2$Y-FDYKR+ DV[#<-H MM6NMUF&]\Y:E#Q\%O/_L:;V3WT^O;\[[ &ZYZB3)9A0P^$+F]UE)7Q.R$&8X M.
[$W^D-#=^1$Y?K(L>)XR@V^Z&MI< )JDE!@Y0*V\^[ Y;'L*[BT$S2,67+'%E! M)8[EE>*2M-
W+_C,^UD[S>5@S#L@E(5!/0L.D%%HD%ZOA[" =,[O"AA*K'QHH M?7)H4"T^%0R].(H9N;7JNK>OPGK-KH"$".U2$,]P"YQ?+\..\R54=!
MNEU3[4ND>PL!OUA$Y&Y001(/0F&Y@LLZR;B1$*M@WO+VY 5A9Q1>!H-B?!6Q METZUEBIHO83,*$93<^ M& +I
C7DHO2)D'TRJN5&.ODY'8A8V\K-SAYT;%#B M^8@=Z5-1_#V52R*CP#E+!=8:.K)T;9*C0WM36)LB"%2UD5A0JEI
M"YM(!7Q1#6K9[HD2T3$6BDT+LJ9%0DH#&8-#=BSQ8,8E=&3"/9UT!#OGAD"R
MQBU^FJPQ&&/,CHVA'1S!XW),#_=WXYY3\97(9!Z'ZEZ$J:HJ;-@KC7F+B1H M;E(9]8>UGWAC]MAC>Y<2@20!HVT
N^9:,GSHDVP3OM2&9M0-GJ@_&6U^N-X] M7-)M+&C%!R:3]9-*-@'%.CZAGL1\([XDH81G3X*!DN(WYBV:RT+9]W .^C=9 M*5#-
JZ_0&@$0O8 <-QK-5JN.6H%1KZ^U^/=D3[LXO=&^7O;[VM7I-2@!W[Y= M7FC]+[WK7*5*K'\GBU;AS$@3/];I"I56E%2IZ;KU2L4U1XZN%
[$I59X%&%=[3BDFSUYDHMC/_=7+:]'Y.H9Y>/.+\[B(L?YDSTL/MEV=;(KGZQQJ+SJ^-70 MVXV&;ACMM>&7DJ\:
('G%RKZ#Y5U3#"V5'_$8OG76S\].@;][,R$("BYIZ1L M"PO.L[M^+K:9YVGH[797!_EV[:C55(ZJ9^ 3"OCKYE^;>?\+SM-8/]?:S/-L
M=VMZMWFX=FQJQ-X77V I<\X6E+%2UB:K[@PY:&3&:Q1NP/=( -)SK7.5W(@% M0X*L?
Z]>KQN@2S;:S6;K$!N$K$V==_>T_LWE\3_V/_X]U=H8=R?K^6/HB#+-LCTXWE[:JL4^#G4B MPQ1LQ/N@]- _XQY@G!JZM,+HV(;A?"ZB)*?
-#JW:ZO%1DT]-3I 4R)IRS*J. M+5[2KV1> L^N J[G%DV_4I(^+A**YRJHS%<$S-50H5(1@1TFP7LJ^BS.)4BJ M >(+V&8R"5+;9.7S#
Z;^C]^XY""I!#E@G*4=>.PW:DWVH>M3J/16:/&Z>UI M9[WS:^WWWM?OI]JWTU[_^S5S6PXP/>^#S(*?Y4)]"FHK! !(5E*;;7>GUS^.
MBRMTZC5M!X])HW/24@?%2N:)': >")\%\B55>R1(I9IG*L"D0#Q7)I @7A":6*)TE)GL\QK:BZ8B;-2-4$DA$\,ZYR!N?V \/G,&!S:,-Z0A#<
M^L>T,]"7QV9 .AU-FUH9U87C=_=YE9-DZSKW5'2IPVXXVX\;GJ2>V42B.4'"-%>6D3@A6S+CUL$C M^S6B_\NO'*/&.AV9"E$,G6*
(E7L;_XV5]=3?10HSH:Z-64&D'3^@HO9??_FO M__HU''C6[.C7,%8K*3 ?F(Z2T$)O2@_CLU9^[ XME[Y\GJB8EQ17.)INJ]WE ML\%I?
PZM!8LSH]![^\4]1A._8CBW9GS2_@G* .*K1'P_+H7#L8#\N>SM0EF M: ^2((WYBPE$'^0W#S]]^OFB6U1 ]X(#?8D:E"UHG,*
5]]H!:Z/@6O]DW8Y M0+F+2$^&W]CN-&*(C%PO>49^'%=G&6(90Z!97"-TIL >1$2S M\*?-\6?!N? MM._+@),K)SX90$'4E]SR9^+)
[ZD8KD4;_3I7+SP3>YX5],CO@6T!?'2'^MQ5 M'%4ZE8.1RFI)O9;NZZGRM3A:5&#ZB##V_'"?*NR27,I> M6UFZ2J8@8*"T'Q7VD1V:
:>/T2\H%L/Q\H-%S;KI3M3G4W.&'\J /AI684E2 M;#E]U[I64*,]2/<]3M\P-G-G1YZ=V:9K8FJ&3+=YYZ2;][O;13'T.OK614QW
M1I%K251!DP&Q!;PHN 01WQ#[[2E_"1,B"@$CA9X4T9^T=,CC:AY/7U;W^]O\ M;FBU\0HP/P'[\2X"5,H23JEDLL+@@I.@S E)[=,[2ZFZ-
```

OE9\X;O+C&(^;7 MF:/\0,\5R5%A%8%,'#4I](%(XP;12 M;L,"RB4;Z;)+3+W"A:)Y1)79F7BS2970M3L/GW:H1&RZ.B/YT1'?8K_O@C/5
MJ7LRYN(+[D2-V2N<4<3],=%C2YO9PK%D5>=4#4VZ%AF('RP"[D^9OZ?.M_.3/.K-73G]:R):6E*76OSH/.3DE3V^2#AT^F#1F*D
MYM\.=D'#Q/_OO9VQ,X-TA7T*U8EDS:*)RY;%S'*M[HO2+,JX.-)UE]EAWQ3F M0:S%GH3_LU-_/-
+U;>!_0R&^QT5,A55&F,*:=.\!4IKD8^G;6TI;*U@N(RS_ MYGM!4$8X_NZJ\BAE7-UO6."D0K,*S2HT>U,!R4.G685G%9X]3QDI]"L$"#R
MVKIS@?$:KZU>:^I:O=&!?PX/]]Y.PU9Z;:-]4/_IO6$D"P"^_#H[FW;1HPUJ; MUK61<\ QJFGPZ*JIJDO:PJFJ2]J
J;I+>M6I2B2='!Z28/+6TLE:Y9'C7(#4 MITH.J>98IUKY=BKD6O$,H()JC:4Q[AM_F]4))(YWLH>LE1(6Q'#; M+N;5?.W K%'_^RH
CEH5'/%]&TTY5<40+ON1;^.$WD<"H<2:CR MC3#E#!&%]T;^.XX(^SR+?XW#2@@2Z.WXNW,*ZJ/\F'KBW86G@LDWIH]$7U*4?
V@[#V_T_X7KHT96WG:+^@).7: MX&\[6>(BRLI@_B[THYJCNJ(/R[7>\$*+EK. :S4JKI5L+1XWJ?JS39RK1$K0
MNYE=MY\Q5'-4MV6Q*])R;!/93#,;;;JL<)T:] >UJY- ME>T.UK[?"@@](*B H *""@@^IF%CG?%D"^LN[5[GUI[K_+B/N+%;6RY%W?5 M3)
[R$;>5E[[H'ZXQ*#^ O-XXUW-XR=B$)['5FVCT P&T!Z M+"]"<],F4V-;: 1B67? 0TVZ_@ MJX*O=R?C=:-
T9)S*PB4EV+C0CU'^I*LY5,C&$#>IN+<5K*-HB2%]KK<0@OX&YJ[5Z\N5R]* M*VCL&_7]AO'QZO2L6%UNN6F]J;>[=;W1Z)2W8$^%?
4HDE4ORAC88N0C7U;Q MOG^8TQ$V*"\@@KA-H3;M2N$*T8X#-:H$&Z;$*X<'*XH/G^+$>[5RD!NO(A9
M(C/%NSE&WMX85*QB;Z>AJYJCFJ.:HYJCFJ-R,&RQ@R%; [-R&:3@<9L]!F4L M4?2.N4P?3(&O;KNZ[>JVRW/\U6VOU1*T;D/-.B-
87U3C\IV\*+G@C49Y,.DM MBTDNS@HL'X*_XMI+D-17P54%5Q5<57!5P54%5Q\9KC;]%J50-M7!4 M2J.Y)"IE46^TNR+EI6
M1C^2ZI'4CK++F;[9##=C@$KL7:!Y(^V'F&DVA6[CY6HA?/?9 35UOS\<>P[, M$JB3R*$LV_B!<.P+H9FNI;FV*
[0)3#@.-.%:PM+Z8AK*$F8U*F'6U+5[X/PEL^.-_RQHXA 9T<3@&M36 @H0 =_5<" M/DE=" .'PG$D9,=_!U-S&/_MF
%@X,AV:9*=/(;5:C\5X,ISD8Z(K T7[Q(Z M/9!=@8PJC#RAGUK0%V'BLG?>R]SR9DY-31YFJ_/3^T2B)^1Q>:T4T+5]0##Z
MW8C/^7V;]:G%TMF\JY'I\;Y]OPZ ^"M2I.L]RJQ^-@M5D!36]"YR+.Y$L!, MVGZ]Y31VY<8U)8NM!,)@HYZHJ M2-
U22"UJ;55B+^X[151FE8\U>G'[(>BNVA5HUJ)$XO-ZT-THH=SZ>&;U>/VY]+ MJ]] 0B\;;0C-HLU;<*+2=:Q3ZU7-
O8<<3;.9W,YL*,H&FHGWQJ&\2[20>NG)?!2+R>\F]KA1?CH-YZ7W@IEVFC8@5; MP H:J_6,KEC!NZ'VH@3BE:92F1V&RM3WP]?
9B*82@LA(P2L0+5F5E@[:#3* U3E(XL?E@IWURKM'8CL"!L'$N0>,:(./M M^>5^?
67:UM@Y:AZ4B+!M&+=LEAVT7IMK/@VT#@^:Z^L=7ZDNY27):S1Z5R1Y MNTERN^R@59'DC=!C/IJKY7+D%TZ HE0LL@YT;-XF
M_E/)6.2RDA?K88ZM-<8I/@I/:^2+QLZ182CN5A.[#O;$JZES6SA6)5Z\OZ\<=W5E8K3E(L)[!IM\L]# MK0
V,0"]!35]G>)@;\T&U]X$MVSH6U&+,E&+-7HB*FI1>FKQXJI]?\LM[&\E MK*OV*Y8>R"2? 7QX/M7^^@20: G?L5WQBY;M3'-!G6FNN#/-
KS_C($?+EEG2 MHT@1B_]$06B/9O-5Y[@ G.W>:ES7#&NJ(7*%8\W4@F@"+\RP*!T6F1N.49* M--NE/T>F[6MW6(H-'_ B'\G-@NX^0R
MYZ/94%!]@[',(1LK],&3XTV5CW- MEY:E>^5#?[W"=,OKT5$!NN^N-P#,O<.S8?\:@*4[A+=D6;I<';I6ZPWKT$E2 M02SNDW;X4ZP==0_?
N3#=QU(^.!TU*Y^?3<=TAU0'$I#P1 QE@1&#"HPTMEL; M+>*0RPK8&HWW[V*W0+#KK%:95M&AV3$B?
EZL(QXG6=RR8K1SY"TEEOT!E'R. ME 596A9D*5^\J*6%;$M8"J3K&A;WS@Z_J]+RS@/@H@H&9"Q.3ENN\G8*M.5 MAW*MF-
=3.B*V@(8AW"VN<+^\&K=1TVLU^J\B:>61S4I#THY)UT)5*ZMF?0"2 M]@KU$-=&^59>>S&!;"^(8ME4
OF;:;O8!N3<'3]1):QS]]3T77CLF42SKAOM MSEH9E$%Q(TBI%LO&\XIMD6E,[>:?CZ?*I5+ 7XI,34*].324M!GZL)7-8UZ EUN^OP?B27!D\
%U6D+1&1Y"; $L(]>#9@Z'P]#]'9, =.&]A3;Z=P* M5_BFX\SP>^05EO)P? <\QP8Z."BQDAZ=D:EAHR?;A_@#LQ;FE +/?CKAX!M
MRH.@=CQ 4:+)E!!X MX@!>F'I^:FE/.0E:!VQ],C7=&G:O>G[.*NCR!^]5#B(?#1YEXX:9G82_XO.>T<7%PD$V"YIZ O+AAFH M.]V!UG/"L1?
=CM-7B3N <6'L9/< @&,;-HCW[VCB80J0($C(R-ZRO$%?: /A MV.(.%@0G-A!P?&;@N>2T(<1[$QPA2 '<09Z*O*_[3#R0D'_TJV7?*6?3U6^?
U'<\&B>VV?] M4/ 1>KDR8YW=7"\M(I^:(/?N>+3O>?S'Z*/3+OZ[>+[M\>KTR]T@N6)\L[1 M/DA+VOZO/\-D2-O3/_[RZSC6 :YZOYWN?
[X^[?UCOW=V-_E*;@*GMJ*R[IU=MR%]9RI8?N MY44,/,=ZUD:/_W7\]5*[^7)ZW;LZ_7YS?MS7M?.+8Z!)%R=;__OG_OG)>>_Z M_+3_
<[BXA+X/\"3=GQY<7)ZT3\]P=_ZEU_/3T R.-'.SB]Z%\?GO:]_P8^ M^'9Z^!PCS[5OO^E\H4/;/?[LX/SL_[EW<:+WCX\OO%S?G%[]I5P!-
MQX!.GS3LG;$+\ 4??S\]V7O6LE^3@68G?[E$#HOJQ;+NE>^Y\.N0I<$KD!6' M,_XW'V?2:!]U>KU]V&K6ZH=&0>_#]]))=O_0&_'S/V9Y6%
M+0S/.G>3F ST\.LD,<9]8;7DAE%#<2U0* +MLP<_M-VS7O_SGI2,M5[_.PT ML*)K.^50]L8,AB,P1 MB*8'.Z0YN+#7VPCT#A2"
[8!J1%&_47A1N&/ZF%]3@I0>@!*'C7%)6$8;18 * M712(4>2X(B#=RN;)0IC,2B;3!C.I;>$^X0OS]A:5)U:%V!;"8YD#+P*Q6^I) M^"QL
O2'OX$,3]J4?<=C8P4K>"IM>J%5I0=#$U*\&HIBLRU6EP#+7(MT!#L] M,.H5(QMM-!I5] 5Y'^X1#=V@RP$[2"[2.
(Q;L*)&"@^CWFEYI#QHH%2 M@I[MR\\6C$D5 #7"G$Y!K;!PC29HL5XPE6L8H-E(#NN+,/4-O3(TBV:0ZA_?'UT7 M##F4-R*D[H7!@?"-
#8^25FI*U52M&A7C!,1@!2 9CDV8&,^1U)BGZ:JL:%H M,#C83OR^0&S+X#>O!-&7?V,4YM^30V[K&M*]>NV7OK@E +F.X5ZB=+U3B-+\
M'&FAZM44:NLTJ@'2R=@>CO-8;?-8$L=DN"B/D5R5LHW0C#K:66#3<(+8HICT M;+0((MC O>-E3SQXQQ*A:3M+43H]'2+U
UH7E!4C38=>@)4-79("^-*>(*[8 M'M!4&;#Z+ 1?C(GRG"R:RI#F"AU71L>_1Z[
MRZM+5@M8F.:A%]X!?;M?:\3XA^9^C6ST6LK@KY"P4Z_M?=(6/-D\Q1 ()P! M)L*UDL%*ZT>#_]]>AC)%/K2(M0W ?
JO11""0$AF)H6HNSN2*N"JY(=[$GU! M[0%9'D>-@8%0(C&C3;++,5U-\(H"7A'\DJS')$E4K2C %?G)BAB, \13.Q@+ M!L(%9(&6$42PQ.QT-
AGDDOT\$YT9?!1.T\+PW05H'8Z]0&0&7HDW*YRD[Y$^ MYD4B=C[^W70CTY_))2G20%0&[::%]D_&3E-#(YZ/""@Y[=/Q]:#0F?!\?8+2
MV"S@6,=ZP:9V0#6W.(* WCI*+|*" ML[\M&A'>5B-*63DY#K51./BQH-/.G.-$"!9@+0$X9"L1UDPY'::1CQ&E1/:2 MP]!PK22SX
@FL%5YQ'.T39(U=8N2X[/9/[_WQ"E4N%KT)Q /+8&&!S\:[M1U?79.*Y[(&ALT//2S":I<4M)"0V.RD6+O) 4^B>.#(*P1*_D.P#_@C37 7^
M$N9PG-+%D&(A8"%F^$HL 1(;CN(5Y+.B 1G6LHZH!&Q2QQ/?WSW@/-+X MF+C#Z<01*4S$5%@*W=M<&D8Q35^75QK-
C1D#_2M8JZ[%G7 C<08T1,D\&#%Q M#!08='_+ANJO2]7>0W+8@.M4;^?7GP_[7^*6^YN%U=+\RY& 4:<3/;D/LAH M^_;#_MBV0!KY!+?
0W#GR7)4>]0VBP"93CM31="F$)@K@R!M& 7M2F?K>"<>;@ M$NXAX",%$SX*-/;_Q0Y_D.||Y@C:< :B)-!!$#A=Z6,&==2*AI+FLJU)F*'"
MYJGPIHXD-&C5]B+F*HX]$ON@C<*C@]1''VD9B*J"W+Y,X"UR\R84\T#[XMW# MBGV=J$P(QVMSS$#"!O)TV6>X9AJ.C!>=PG8Q/N
MG]7@0QGH#34O61!;DDYLQ]N?X!@., ^V4++7I>&NLOLRY,VRK"4"A2?#XH7(/\MAD3]W2!Q%;]33LBHZ/OKS1'C3[W"GZ?B M#V>FE
A)*JC9#*AI5%!304U%:RJH^7"TID1YM>]\B%/=4M'Z.1>I7T MUT=\.>?*V=DC=ZVP;LR'YR6W-EIZNUZB7F(EK/M303] ?U&?H48"_8T-A?YF
M73I8/W0U"\&H<5O)=FNO+_^XK]#S<*WAM8H[A3 MP7MYIBL/O!>UHWNJ*^WVGJCT2DOO)=(M=KZFMPP=>_/R)PZXH%5]TJ9
M*@WQ6=#=;B5E2EUJJ2A/M[+FEV>Z\L!YZP5*5"GAO%7BAA?K![P/"^<+HA16
M4I[*">>')98BUP]Y'Q;0%P0DK*0UE1+0NWJW7OFB*E\43WV).2'V@N&K5NM7IQAJHWZ-$!1:E65Z$ MU:6>T,5R[;1P\;(7$,,%447M?-
VNH+?JS;N&WKS-JC=OU9NWZLU; MJ>9=0V_>=^_'^]9=/*A'U#?S/YZOQ(L C>\1]:GT@Z2[8+YFO();L56+/K6BR(;"@*)0*1%3.96
M/==V\./S[+-PAV/8XP_R 6&WO$#*P!\N%H@HOG9MU1NO&SM'(R_R7W3A18Z^ L]Z.2[\+#'9;@ON&<^_.IU 4WG=/ M-:+SQ5#8=]2)0[;*"
<3R$]@KK-+.H^$6E7,_B5!PQ*@K=(I^<=8\^'@DHNH8;- MCX!Z"^22>^]%3*HH,ZD@WK(<3.KFWBL!K#^!1SU!)GG\MCNK2:'8]&W)A1?
% MLQ>$'Y7DPLO#Y#KS=N!W$$L:*\9#EX8?E0-%42A9>E]/8D>-%PLE#2.'NT^C MTHT58P;+
P7EP=ON?'S!\^%@"\62='_4:>0/Q]0GU':!GH6>/TLWV?2]B8:B MM0;?69X?_**-5=O05(=0;2 <6V"7:SO4AH 4$].&&[3=U/!PQ($-.S)]S<%.
MJ=B/V?>BV['L\NECKRKL/WIGPD-X*7)*U;H8(5J$4\<C59$+\Q@"$U M"V PH(!.'!4;U*.QU#6YP:@SV\:;?8I!A,Z$I1!JOBJ[B$[L!VH='?
E)OU=J M0!X@P8)O%M"K%8N%O8&0(2.D%]&JPJCJSV9@#R_,,/)-I^=:JKBH,_OF6=3P
M^EAUL178QG9=E&S!6:]8J*HZZR=QC6Z!UW^.C0QP,[8V@WW>8[W QC'&RKH M@;S@)E_+]O_^-YFY*"2_CG@094..U>)-
JB,M.M*B"O1S*) &;NQRSDM.--]E MUHZ7<1_8G.T+0#1XY!F(^X<_XU=E LA8(ESLK%FY^3A'CK9CT\O;JY[-^>7
M%WWM\DP[OCX].;_1KL_[__BTL[)/GP#L A2<8A7G-Q7@% \]{4%,K,/=T?* M($"O-K)=4#)M@&J 6;BJB4!MQ;MW 9X'LXS *<4>H\>?3(P[
M8_MV#.,Z-GQKD7(5A+S<>QNTDPD2+CNT!:VM6],LJU6.]!Z,#M0/=04AY&/#R$F:: I M_L 'X>9PHW!,002S\A[@,AT+UGP'"
2*:8*CI@7:+6S5AET!0Y+'5@2" $1P ME+ ?':XBB)R0#M.;"@ET>G(C(T1/."X/G@0^!Z,CK. EFD'@P6AXCP07M&G0 M@&&O.!JON/ 0LQJX@
N/8)B /L45N+>/W"UP;[X'.,^QY\"A6 +P!Y;&1PH@ M"HP)WJ*S)20+.VHWWA3LU@:Q22@M?12%N/3T\;KQF8K12/"9XO[-@>W8X0PO
M9@ICX4?QX<&L.+:+E@,/H>*D'8">'02(R6NP4=P]T5F;3#DQ+OC8Z8+@_X M=41+[<_(I)F+#P:P#*'(#9U9]HQMQ.\[6]SCV>+0].5:
(COC>TI'2J%4](2 M #IN$87CVX8/!<$Q'R=^3C0+/X'1";89?!E."+EQ"6>,!]H]WY!VCJ,@EL'B
M_*G'AX925"A8&*:AWE'B68_U"N5FPF8FBT@)8RNK!$@>%0$2(1 %QR@@R@?7 MO)1'$#H"8D\19&'D(KNA>$
N(N]H%#D.KXCHDSGAQR5#$)9:$=(-A&R+V!"F MD1/Z)\8A/ ! 7F6PEH>G*7KA3'(#X'O(Y*.V2I(W"/#P)GA@B:!7QKBV' M#.1&KI>A[-
YHM"]YDQ:,A9#W3"26A"A?P-/(?<:F>TOW1)D&0&F]*2%5^A-? M$11AW2(],'T?W^)KV[9@^'3,>F:P5PI@/XP#V*N0]2IDO0I9KT+6WSUD?
1/M M/\]W>V7.D*?W7 L^\2-A?;59N ;U+FR+:$WE3,T#CK+ M>XH_0P29,VNU]K3'.L@O7&"\OS=<8._X^/([$
/MJO>OWN>OIT0\X7D8G^$(34R!&7HU4(Q@U^,TI0;UCW:7'B^YO. 1(V M1CZA8^G1?->W*ED^..JXGIC.O?,Y?)"S?M?]8D6;RV:EP]6?
B*&\>4-_C$F_ MU>VDZ\Q5Q&6+ '[EFI#EPPN4%-X+'YY<>;2"FO)"3:-44//Q2G@]L;CUB&+[M]ET$N8);3%*5'])E%RG2,\ZIU2]1V MHGP-
G2] 18!MU0H MK%OU/<;QOL!;%/O'+;TPT:),_N5B/E]A"Y0TDP&9^I& M 06]"C>@N('M9GVK3%<>XF&\@-
OA]7[&VQ7!BVA'RSC4.]U&>2E'"2#FPP)H M_07<[;4 U- /NS6]79 L6QH0+1%S^PC-&1+F9OJQ&ZSB:^4A&XVG\C6J81?3
M#+C54[[4EQ$.Y&R')28;)8"9#PNBS:=RMC, MX=S"](?CBKF5AW(@F#>U4P M-1IMO=4L,9B6B,M]!/6M'PW@,LQ J/P]S9'1?
+.*SY6'@+2?:YR4.7\]1'/V M,AYGZ)V"^EBEH1TE)D/"Z&=YUHG7Q5"Z\V&WJ]86Z7$RY.!S57YL+67[=X"Y3C&# Q+U@)X';+2;>F=1J>\
M5*4$4/51@;C][*"3]P;B9]>M-VL5;ZQ4/YJZ$DL0;#<[7#EBNH0$9^6U+Z!+
MSXYG(;B83^U[&0/MZ+7Z^DA/443X1^.J'QD7GATZ\Q:XT.SJ=:.Y8;A0(M[\ M$?
36FVRU^649YUO.P=^H%?;Z:=A3>V&WGQS(\Y1*R\+6]4/ZX;>[:PO<+6H MT?6'8_5JBA4>7) T;NA"JC@A_"?L;Y(N.>ARO.
[Q&]PB:2OGGM[(_S)B1B$ M^GUS?G6/OH@JJHR4I(KU+TZ!D+?*R*Y.6K
M_3URA688]G%MILXO9F=3+5$L2.I=>*'0KF1Y.*UWZPNJ0*GMXCL[YT FL:#H MQ57O__UWIUXW?MGCLJ;7YL@4CO;%/?UUS)^LKTP]F-;
[H! MOQI\GJ6_H7X)O!*U<%CVTE8)%(-S>>|*'ZOS)OT1GM,>H;%SU# .YG-8?U(- M"X;>9.)A0S"@,#K6[XB+#L*]Q27T$Z5$Y0 4!E)1@^
4/A_$J0\ MP%Y,+EZP+!P[]6UW:$]1]Z#:LE0%>\%Q%_ERU7$C+3R/ZZ?3L2+$(2S)5A5? M;5=[A]'PPGNC1^I_I'\:BW_C?W$U(J"?
LP#%;.\;K6)L<6;;@RT .Q*6WK1+7RC MU5?AKWT&MV=@3>[-YR)/ZGV-ZX1GD/WE"!6.;?^U\:E3Y% %?.KLUPNY#]_(

```
MAF!4XS&,DO#UH7 JJ;+770&K;@CFGH%4V1>?BU/SJ"E1*T<97HYI3]&,>Q%ABRIAPB.R*FXL:NM:+$?H6HH TKJR]X6KB"LS*E3[
MB%>6(XIG3"N>015S;SZ7+,X15TD5YVC[*]!%>_3Z9+'(0]S<-VH@=Q2117DW M+R"*_^Y'@T#\&<&(I]@[.6X$F?N\A"14 >:'(J 7WAW#
<7L5="00?0XV9EY\ M+C+.X[3$QAQ)>06-&L#IU7&QV-%ID+&^ !?5S6PE,CZJ@L=P2>Q3@@M=4>C=
M"NHR%/>&>Y3CZGEVB^.DT9VA?HXZ3 MTU #85('+L0H6!>V9\2>=&)Q__!.D;]/M3]^@;1:U#@W>[WG#+
M[,3UG:,B(_$4SLATX3T]#@6)IK!])6!5/:,6U_C/LP/J&=6J>D95/:.JGE%5
MSZAWZ1F5)IEO3J*?//D;R,O2M[_(T=0B%*4A[%$+*^'^GD6"M8@'M8.,<$[J23 V2?XJ=#S[ MMN>KGJ2X$NJ7&S<39A%0]O*5?
2WA.Y:D0!",0C@7"M? ILNC>14I4!K2/[&+ M[L@&;>*,6Y>ZM]JNB5V$1X!OUAZ'NA9/A".;6A]D*RWE\,^^[@V'H,HD^UFX M%SY3J:(,6>*5?
9MAO1-N%1QW:PZ YH0HS(%$#5<2#_0+ZCUW-FA;NC;V[@6<
MN,YM>N62\7:Q^ZIP9$=8>2TJ#,,>Z5K<)HK'Y2<"ZA$M1[FW8;D#X<(NL=DK MMAZ_!RG0XY[ KM9$ZJ7L:UX4@D[HHG2;N67UO;R8
^W[5&Z8#LVGCLP8F>%J MI/3@[R=B9$9.F#UCD&I(+E6*! BH ].EVM$G>NNC V;LSHAW%$L[^='O1\+ M5[,BJ7IX P?;
(JN>N^F1^4611RCLX.U@(ITHZ#D>!5*?Q>FQ&3 L#SZ3R_.P ME7@\#RD]9,6\]_P?=*KFU*8X;1C@%F[%IU[!'/LB4)?&CO);V4?Y)!*22F!G
M;E";+#0TC(34[5#CE(J_- YG* 'B +>GEA'N=*K)&9/V.BX:&+O"F[:O8<-R M@7\!!
DB#P=:HJMKW(27VCBG'_>1I@U1E+>P::])M9A!HF<8YY:\,* W$=HN M]BW?>Z3K!$%IET M);5D61P0-?
=G%DVJ=_7FX7SZ&@'JHBVWBK=L;,B66PV]VYX/Z(\Q-1S[@KFE M"SL 'N2&8[0D6AFC?Z.6,NS8@60123OS%':FJ>PV(M!-
NA&DQI'"LKU[D*9] M1$OF3_#3)C6-3#D**7:ZL"MDUWC#KI 9$\UR ]$3-,T5FD!^C,1UI2YW#M?<
M3.BSZ9@HKS+:I)OV:=QSZF,EQSV2R5,O2]6,;I&/1V;HO#)+3-$BHK RM6<1 M6QS9#\+:_S_A>SF.N%\5SJB2(_:6L,*9-W
M)UHO+&_276!=>1O:1FEQ#&CG[AF V>\(93#NT^2LQ\)>C'9GK62N*I-2=MHW MI_W-&TVVG.0]GY"42TM\*?TK*J__-@+=JQ(Y8\.IW
@%#XTSP.6(7?F,ZVJ\PAZO.:#\0PWW[87]L6Y9P/P'8='>.R*/RZ\_X MW)$VPR#8 ZT7:':(CA.,'?!A23#6P)EI0R!"IO2AJ-.@X
#Q(/RA+3W8^66Q M&S:U*';BT%RP[3M!TPR$<.<<-2N(,>X.1Q&DXAJ M:6"0$;"__S-51$ZQ][-
=6Y#$^TACIBQUI55>CK[#RGJXNEYJ[N=QW$ZGIM\]5:,MEXO:'20%X49O#)NV#DGB8[9(U,! ]P)!Q"% M5AS[^1'E&$1D!%6
Z(8P#+W9:.M& M=[YHV>.@\^3;;2R]W2(S;B.YW<8[GTQ;;QE/B@MIUXJ,-8WD;M][!_6ZWC[L M/G:Q;\>?9'SVFO--SFZN"Y,F5/1X:H*GY&-
D$UE>*7>E'>>NY /NJTR6*I.E MRF2I,EG>+I.EV,P[IP6M: *4"\[C]CJL.WV,C.>JA,'IGY$=4HVN$SL8.EX0 M^7/1:^U::[V&GNZ>=OK/[^P^G
!]$ F,V (-T@_ MK)#&L#,AH\P'V#Q7< M?8:"F\V72.G:Q=">KZ*Z2/7HK!.%?V.'CK@/=_'@ (D"7_8X3B9X=4. MK5LOKJ+!]DWJJ%%
5A>$%0+V_)5W)N>Z)>>_0)8^<(M%<9)%'X@]&'Z@?( \+PAU@)MNC*5C^0 O\I'<^[::KO9/\Z MI[3W&_-AB+DBZGG4^ %16-@58*GN547
M 7 &OVUWZ'/8#):#M"0GU4+S@>-"*)- LB[,8*:@6]^D@@E4>"26(#%H1Y90 MP+>Y5DFX=>B28 D&OB>47K:<.49#7\(+KF3@Q#Q&-
=\.H^;1QXA-QH!%IQQ?;BD>I=@U4?-CH9M0>-%4:[5^D(5G:_MF2=B<+J>:?Q#&TRXEK M#Z) 8SQ4]F$T14Y7+"/5"R*DC2[U5.C^&X>^
.@F>0AFQ:_D'N/Y\9D5 MQ:-""2@EB'^>S2%&[Q[D%5[64IK(6D2_KQV '+ L+WJ2D#CTQR<-S5NP8\$:Z*B\51$YH M4B4(;
[XV.Q+E(!H$MF4#!HC@0+N4T](J 5BY]E$X#S)8!$G8M+*!D%6..#KR M3ZK -4-=Q([?R6XJ/6HH?
(P8O19WPHUP>19!G='MM'3]_V=*!TR61'QY1 IL[QS!/C*ALMK(]R9<9QY61<=" MT;.+8^%T[5YH8]/B&UNH<-47&,WS9JN28)$$C-_P
&!BUDU>I'\|$8\P>)I0 M8"%,RK!IUULTA"\FINTB')AWINT0L"#%&T58!.JQX;?1B:3:^B'4 LP9O]I' MN@972VIP;_E_$N"-T&WXF#J[[=F9(A6.
\1,2Z>KWB;6L++6%R\D14Y'2@>K\#I MXFVMQ/ :"SQ7>89'3X=^+-=N: 7MQOS(> O$L\.M).\I?71F)=':&$3;;^*%!9A4&:5]\(7,;Y1
MD%*RGJ>'X#P#<5CGYX8F7R]!!Y5% ]@C4JY\=$R;M#T&\Q<5P]B26A<8')B H.*F'DUJ.E*_( M"_JD[=I[Y#?G"K>8/IJT+7F"P?'?UWAE!!3? -
DFT41!0,&-#QZ_\4'^QN/* M';UD]:=RW=CSWE VRD8K<\>(EY_@N%$6 3GU(!%1ETVZL9F!XI"W-LS&_Z%BN80]G
ML(5T=YOG=+,!BMT\*$#WG^BLTHARYSFP8*S-L.2@5@S@6X@Y[W> ?U!TOK!Z M(/^;M^+W>'+POJ>@GD;?F"&D4+6-/"A.+!KW^UI
M% J ^?HS6SC68M!KKJ83O>>)*=)U(K?PW(/:;^PRXO9-_EF MI%V!&WK.%6]6;%F&L.1Z6#R52=.Y6*SO+@@Q:JZH'CU.$[[W3T"V>0=U* ?
J M].4)'&=\R<\5KFH'1=&'B\.SFJME&:] 'C;_[(R#VGQR,[5=(\GT#?-?"^V] MV]=PK5,U7*O25*LTU2I-=7UIJIL89W1J^FAI"Q1[G8L@:KYA!-
%*,7GU/>WB M]$;[>MGO:U>GUUK_2^_Z]).VI2%%14T\J&X2MP3C7D&3:13&!9*P%,Z0#9"V
M$Z&N*^2=DGBAS%V/2AEE:_'1'XZ%%6%$=1Y&/^..>RYH)K3?PN8?[59!^O3F M-_]
(%O1%F+CL>$EO707V#>N[+JYI^J9S@/B&IO[_V6D]7D#EC>J:OVMEVZ+- M9:O= KV](4_*-U:<3U%QC@GM@C*W%1QL(QQR"\#Y*L?
J,5*&TF*#4J4*I MJ:)*%2B5"I3*1952HN%;]]X]K/^T/N7D'>=( X(RRK^B$+W]!UA=4C5'=4F; M,L?675*)>B*^4S_8+
(=>8W]$\N^:H>=OM:%T6Q%G&^>H+FD#YJ@N:0/FV+I+ M*I&<\!%Z)U_(BKPFU3
M;\)_G6XYZ6V)E(QW,D:N5D&\9J13,+*RH]DR8EGIG:0:-42D_E2RP;M"_HI)SO+;TA MT%Z?;VE107L%[3&TK]C8;T.@O35?&KZ"]@K:8VA?
$)9G;")M-PX*&N.5 =JE M;O47^,DU(7^FFI:%Y6+75A9U6^;(35&ZSNO:7--UZBGE"QA%<'NI^>*P[IRZ M2$T%\>$ ,$NS7?
K=%]ABFCH=JO:" S$THX ?M=VA$P6R NW4"[&/E.GDW&OW M7N18VMB\HZ;M<$KV/JT"!Q6C$0Q_H%W%[R[HT!2.L>$UM3VDZLNR74-
!(5RU MP[F.$O/>/AK0Q./&2KO!I\VLB]N#@U,'VA?#R+=#6P2G\IS.X)B.DQ.:+Z,[
M5S*W4ZM*YE;UTY;-454,K$KF5G!0E*)6K.&4%2AL,2A55JD!I*ZG2K^4IF;OY'LIR1G:NW4E; MMCNHKKRZ\NK*-
WH!Y9NNNO*/%]M>FE+#?0H'\*;HS-[RFH+E1,7BN*_.:KFY M_WYAL,+G6?$ %#UV.IDZWDP( I'+:6$,66'TV L7U9L 5H;/SN71V^VN;I2K
M_E;9X/S#HM5JB<(56LVA5;M;T[O-PPJI2C-=>9!JM9SE"JDJ7E6AU1/0:K4$ MZ@JM-H]7E4C?_1#UJDS?AZ\K];8\M&W%!.VWI&T2*C:
GAF'>JO3TKM&J[PD M;?W_6%Q:<7T[PJ7")<:>KO1T VC5'FW90/N#XM+*R:75[A4\:4*EQ[!I153 MURM$2MP?"C\TX24X(!&$GBN" PT+
M)8QL/PB33[5[,] F(M0L('CN+2V$'_D3]A0*'\?B*@A8\."OQ<2^6^2OSA+[ MQG[#^/#<,K?&G^5=^P\-6'ULG=!Y75*;A68B4'6>U"OAC?-
%_@0-P" M' /HR8FTJ>]9T?#1^V\>:-]BF.%"&CBK.1S;XH[!DTMLV'Y^L5Q)8V2[ +=3 M_??Y'<1V'^;!U^0G) M2Z<,NYLQF/]GWO?
OY#++&AW5P>?[7='X7I"'C^65.RVD>W>X!BMF4' M4\>$$[-=QW;%_@"Y<^KVZ;CB4UMQ23NO;B)?" 'W\B(&GF,]:Z/'_SK^>JG= M?#F]
[EV=?K\Y/^X#P[LX/M!Z%R=:__OG_OG)>>_Z_+3_<[BXO+FM _P!,+1 MQ]B^/SWE>M?P,?D/#T 8YE][MK N,&<6$$LP=BO?
S0GSS/87XYAZAY>D_OP/X::>_ MDP2_H0)\?G<79F"9?VHGPK$#U)^T"R\$>6A#=_>8A"I:I?#T$,AI\DR3E8B M5&*D%MY[P,E W_
#KO&%.H \*P[^_6;Z/T#^W]WA3__??W?J=>.7/=B(&;)$ M:(9STJ;KA2CRDJ3R7_CFR(M\-==7>2O7$0B1G[1=8T\;F;9#
M$W@:2F^DK9@:JKOXZ<"V0#:%&T21SL5-! &NQ=7^BH4$4Y764.!MU! ] ]3) M4*@-?:I0H%D@C.C.;GV/ZYZ-@8S!0> 6C?8O&F"F'
016L'!'J8H+%H-^IU>#$O[*[P:+)6S-Q330"$,(G@>+R!,<"<#SUG< Y5$,SH D* R MNA:
<*$(A7U0.9[5=4(=M1^L!H#M:G3X\W&/M[-9<@%]%"XBU18%L)K,:RQ., MK@N&!-X\(70T!QZI@S;JC[Q7\3"U_;@4H*H.*-
_F"H;9K4_,&>".=HM65U)H M-)&(3G;@ R;&R4DWO'&Y:&/="UQ>7H&/9LAV?F$!A;.*-'>8-?8-7H M4DDL@3GY^68V99-A[O-
EQCXEBF<7"+,_WV-3^__M?6ESV\B9\.?D5Z!4F7VE M+$7QTC7CN$J6I7>4V);&\NQL/FV!0)/$&@08')*87[_/U8T&>.L6S:I4QI* M1O?
3SWUNO6^C5)WNW8.[X>/4'4" +\!JR!=UN!P&!+U7C "'TQ& C* I"*#/ MOI88T%H* \Y!Q%@B,(CX R1G"/ZIFG=)H%F
FH4!@D2Y/C%+1"2;EQ(#=:[< M,<;B:B+/>%5?1>A61L48FURXK*Y%(-.H-;#N&6[4MND6\-,[+\^_?9W;$,3Z
MP"K.O;)7]'$OT"TZZ"+W#Z1U_]+'8SBYBEU]D;F? *L8)P&9*&=&WH\U3HN M/?-5I7G(0A=0#_?"<^"7 >9J@ %[O E\E988*; \4-]#5/G1
MX9 4D+.,81V"8E@;>P(@&LB9Y>3!^W_&N9,.J,TZ,/N862^NG&M?YBK,E;X, M+#E(F*-SEW=?A\S@4" CAH#EN[^QT8]?LKZSXNJT
O:K+X'(_B:N?Q)%.:SS ME9KEHR32>_B'"1^2+X#5D(]@YG \K4E*3'L:U+[A4;C[/IF!J"C@E+]W8V ')".0/@,XEN 1E(3!8$AAQ!%FYF-8)H_;M
M4+GL0!)@C^EV$,CV]5T4YCVB[MB^/[)X$]53B= G@(Y)L894_+^<6)&BMXFW M[ U<5*" 9?^[\%])P)=L?7K6"Q(O'^+$ 4],Z#GX-
15+\>BSWZE:Y3B\A$QZ M4(R3(/T.N\|C\4JP%6]@WH/=QPD\P(HYT0"-=H#?([%IOH2V?M!#P !QPG'=
M,!SK\0MQJO2=$;'6R!N'C@C"=GUUJYWY[,Y3HPS)0Y8.Q]J=221$3EL%>@ER MEL(_$;JW>!@%!_;QP-\149RX"VS<\-
U1#C]ZL%X^0AZ%NTW438"'!G28 V;R M_/1"A#)?;JURM;"2#W\)XQ&_$'NPL8314&O^VGG38P\I.6Y*[,+XS'ZO7]=M
M9RO>&H!EX$9],I]0Y\8C;>/#94*[/CLMD]D.[@VY)!Z1KQXD1"JB:EP(#R0K M(%./()BC"B_^)*/YKW:/EESR $U[>4@7>1. *,9/H[
>F7VC1(XSE.2I)Q MEE8\==])%C'(A&]K\:-/A;],$;PX $3#$@ B\T,RV.R(;L'UZ=(#,F?)LXTI M/N+6ILDG2]$.KXN4X]
(D$]I,%UA2!%A;IXM91^VG^_X2^#+=XVM0\"8,GV7+ M[FRU7)^T6HO'@W$PS!-$6/"(. \TV U >_$&$1@W?8XN()(2.@@;2!UO#)CL MPS>
#>QRUILD+UDC?H 4,QVDB50.?U=]%9$:"'(-J &M:<"E/Y3@M>N@3\&Y MN' ^)GD?]/84,Y?.X6\5]G$>Q^Q;H>=.? SMI)DXC;>%89Q_/#$!-
""N5J/9 MH;TA(H>H1_KXLH<#=7YQ3/".LT#EJ_>)L#\9^$M^- MX92C<>AT5>:6@+"#/-VUSHQ?^A(HN+-
H]RKPOO/13O6QS2Z_7)WJ7=8=^,$) M<)V$;@;U9#=#=U">Q6D\=-G-G9)>@* $;6">!L2K4_VY_J++1X,-!ID 1;2. ):,EP1=Q5SWBC)!+PK2
M(!V/10U<3N3'0R!!O^;X<4[S@^ Y^ DX+:@0*G3008 $G?O /X$].QA'A><* M4@L*MQ^A-
!I=^JO\GKIQPYRL#9Y=U5/9F&YB!.K9T/503B$&$&.?"]0P!JR@ M0P\Q]IGP$*KIB($?L)Y"C)1T1-=IMG9OE?IN71"'8T@[C8#^0'U
0>>6"7+! M]E 1'E.0$QL@?R)DQ. Q PTNEM,?<<+>3:%&P=TB M@(L,1$8@?+N4)]P\-(_K6-DY,![<,E MH 7P4*-DS3O'5+XGV!O0!# P; )*
M6(X Z"$]8J- ^?HQ.5E%'AN*I5,UA%^M^AS+&+:S(O'P9Y8#O((-W0P%,%T5]_'WL6%+2*) MI"U<.P/!-
@(;#4.=>>AFZ"_NQCXJ541RYM4L(7<'^3M3<_$1.1?^ 3<$/*7F M7-^"]B\<]R)-R'%ML0;C47H8L863\|;!9$4M5ZR%%5A-'3UO*>9C
M8%ZRYM*:[3 ,&%D8"-O"5G^_)H:ZPQ$=?2-[#$!]9\*4*,@S#Q06)P.E'H@> M>:"0;CK!K2BUA*7 KDB!0C[PG== ;\
[$T)2+ES0>WIDPT5N7!4SG2);>;G5@ M95"1=D@ ?G83D%.(23$>TOM ]2+;#)UXF/ENB.Y"]FKS1V9Z<(.N3P8)7:KV2/,1F5F27D"<5O-
LZ]5I^UAG7@AH=JZZB2ZA(<$R M<)$9@EFH=K-X%__KB$[%*JVH58 3BM1/6[OB'V36IO81!"0.M6J T!X%-S'J MN074*UQS ?[.YC,
([1P+FX=M%UJM :3UVF<#DF1 M/_&RF3H$XM](^0"U1,:=NCYH^Q:MXX[G@ B.;3R1Z' "=DP,1P['\+&9I_,9 M/N>AM>^<8 '
M7#!FW"DL3 " ASRE?(-+[FR\@._SAHE#Z@P/C;DF\]+5&'M-#!?5IBO^B$;> MR72A>1B,5F",B#)K8X6>F4?*YMF%5E=6
N'JHA0Y$EPVO#R%(EA6+""$>3JH MUA8[A/"\>9$+(?)OS;,;'4O:Z:>$_U6V\YR\)1F/I%^)E.)TX=V(4;$BN3+%WM@2+Q;23])9^/Q/1' MRWY?
Y'PRPL0<'A-+)\YN-@E['W(NN88%*K?%UBV#4&]>KZQ5?OQ %V&9<7@7 M@-ALR?+Y".,8'@:,2$Z*7T/$;_/PE]2Y,BK!J90R*Z-
2F3\%MIN,'%G.]M7% MU0X@S3".V$NC:POF(H_O4S",_87%^J-XA,?$"#YFV6G/2I-RJ!%5;4ELN59* M5V-
)7'$W1D6LNZE7FH+NB#VN\Q7]I04T/K)/=*U5=>V^1]3'G(O8U QCH!.M M;LL];?P-)7[S=)$3:BISF+/%#
[;23[J^A[J*EVD3D/Q7>F^@>'6).Q@& M1J\86Y$,5-!I L61UE&B1F["IQQ'\0A37CC2Z !UAF,)EAB%=O'Y)OP*=-#9 M)V2*1"4=
(\4JLI1T\6WJ&Q+]DBQJ0VD]T&Y1<)>UV5B[]?29@H*9@G;!6JL' M$B).C'/)K$2IL>AXAWMF5[BQUED[7>T*%QHM @$U::4(
$Q&+Q__PN(9 I,R M]\&->R'<7]GP8*:CV7;.+FBV#WB/MD?@ 8KX'&0F!P?ZL(KX&7^'^A)@-NL- MW8?
5&D":"@SG!8Y+V]4X[TOYE@*V$4ED:&93B1=GED^@+_UA18N"4F0* M1N0!Z(*BQSB6& M"I2SO?7[]=6W2^/BP0]NA)PQQ
7Y3=O[]26N@T6RUSHZKC7;A\[6N^#]9P5* M@B^!2<7ZI=F;3N&!_<&C]5;6\-=U[8Y!]2,/&4XSP80U &E)>S3.*]FF' F0 MD4)
[Z%>9A&1Q0"K+E*W/D<^RX9H1:0H0X:2&BCS"BXB[P,&.*WF$DU/WB@V M_V$B9E3P2E!F_J@DQ:*/<:<>!B*]@1]2)E"?8.0M!Y,,!$M+L0-
6!4P0AZRHY)4H!D;C] M*$XIEDX5.\#$ C=$_@XV9%IW?M7IFG@PT(Z4.0A5F&;HO*,/,^=S9^30V!_W M306XW)?-!!?XK_H-](1_!.*_1;5
M6R5P2;^PZ$)#D[HH@").5)'J+F\8]+EQ?==^B<,F&!4-P_%N?$MQSKR;!D#^ MB6D[(-LS262D*LN)KO.NWMF<'7SZ=&IM( R&%.$/
QV6U]S@/MNY9IU_=S3%IZ4;%25HA,K,NUF*1&D+E(1LI\$50E>QV4@R9! MI E:WB4F$T]- :=S4A+>2(>&/VCA)1_@LA]YLE-3]W-
J5^8415S718J[%,!@ MU"U,U>U )GUK33O*FN1&^)**KD/[6+"Q7YBCL"G@$C"55>O.LO&+?X#.L.
M4N>,\,;48/$[M.7N>]W7GO$E85_+4LOHEOCM'Z'2F O8X?AHPH"EE[+E0WEQ M=\&077E_.:H=M8E*>,!%\[C6W#^DGTVLPT
V0L@.&;*J#%D^K;Z9&GM&A,^N#/I #(G!".F5>"O1!KT-+$@K#K7:;?ISVN(L:79 M)O0P7*5$AG[F7!^LF?W%
>26O"X9=;+"FYP)MOI[S]]7'_1;+\2C$>$8GR8S MVV!W%N)WQU02>'^:GR2)]N$BHFEW6E/X\%+LUUGI:)W#G^[/':;PK_V#A?SK
MJ,P/EAQ)B7'3)3&+@)S[G"AI]>QD$D?71R?E*+) *" MBU8D^EX*RQ$^(MP37DHXPY1=D' PZMB#B1^SP&SG1KY!YG)?
3G))L<$7X",U,96X! Q!#)/2_92082M1^8OS>.%5-CH5\$.]0AEBH MM\*7%R#?%%/MH%&ANQD?69FNHWNX&#UTRU-
65,.UR1"WD35GCFJUMY$U7[D MJ-HWJH1/^M@;P8,'XB$E3YB6<7/RF4M9T&Q%.X, EDBX>Y@8[(0A%-1/L#,M
MZ@#8E1)_P\PI\'@'_*1IW2H%8%1Q5S1!Y2P(\0FXW$:8N1(H_OE0U9V/1;70 M"NXR7(Y2.":!X7H>C8WET:;'W'
FUFSX%R>S0%A^MKU/S[)S]]I8FS?&0F/1 MSHX.EM]9IV7O[%=S:^&8OYBG!-@A=G:SY U:CM0)%3:/R2@)YUAA:1_W4L(>
M,_A52]ZP)8#!&^NH09*;+N;F&4;'IS#1MM)SDJG,"DMZ"DN:R\8D M!55^B,%D'V ,AXWUR*?
L'UP\W7D#8/+%@XM;6M#GRJL=7=Q7EH7\;+RGU@EN3;4]:SO->6:H/&FJ< TI1P=!&A7"0EJ M><9]V(U;A;+BJ9 +]"Z >HJID/J7>K2"]3-
E..O[X\!WD&!*>I8$W9PP(U(@ M(Y/OG-3*2,4#X1&CRA1=_%Y_"6XI"L?F6Y,8B3AD4H#,]B9P,XBZJ/]3!_X\ MXW^#0D%]5;.9?
Y^;+U:Q%M$O2JEA 3 M4#A25@A*!RP>HC[NH$IZTGQ-_L*' M5* WQ&,LP=4-3UC%H YI<$4C[FM6?$I3>#H(1]-
*!BK7UK'NH@$3ESX2E(=O MP*N@+$0]+&]*QA'0-:+R,^O3O3R2&08TE<*>L,$5H$4QH%Y_#(1\]7 ?@4D1-#\-
)9(;6(XOWN@495,E[(,=XU)2,)&0M,#5=;8U MYY^*JS;^F;L1]Y51A5OKNS?]X6NECI!Z,R063,'E9/$G:[1WB,"G=I3C*^BW MU!'S/]SAZ!?
GHU5"^IM8Q )&?L]T7YCA>@A'1;ES)@"PO6N N=R#)<%Y \0]5UBY2 MU8O]V+4Y1"X@IL12L&14.HB3;!=K=LKB"<:>F&Q4P
M&)"W:7Z=N#A\@(/4!-HT1PH,Q#*R(<-2>EA2S2%MT M%IVA-?4,K=K^4?->,8O.W$!(;^U="C$.@32L-[U5,E%L]VHKQ;>0 U(BK>H
M*H6V!Z]4I/$?NHW&!+F$R..0>11RU"Z/9SDIC"="KP.2^CI*.L/[2=NQ./4 MQ-H_FI]G4^L-.YAZK+ /3A8T=8EPD?-&XT+FY23!6<4?YDR
M/51!V8E\=J39A@FW&>=N:=0F,&1UH)2B8;U2X2B3L%I'PK]*XAX/40/TH(9! M%E&TIV;D-
6N=YCU#^_.I8O]X6FKJ8BDXYP@'TW,@:YVG(6O@@9U[4/7D"?20 M01T!L1&3O!L\.TYDH=2)%SQ '"VR@K&*M>_(([IUQ.G+&29]";C_1P[]
M_Z$L'H4**$_7H;XDIAD?ABV88+.*$8AO^#A@E;B0>X=\ !XSS66QZ*10T+#\ M1/RTOM2&>G$_@@.(4H=.[:Z*5"_E
%VR*:EIG_$D.&'%0,\'$:7808!2-67 MG^ST-)V]/@7_R@-?#T$Z=4=!1C.64[@-]$]M>\45A2WVL;C!0N>L M8D15).9QZX@+H,CC?
A^9>UQK=0ZM-;0@E"7TW&KG#QXM$ZD^#X3$, R%W^2V MIJ3%@=5^ ;V<7.5[8UB=(PN]8%V[6B?-6TWFS)]&Q )()E+,R,KWF'FSUE[
M/:]U6NVGT-K!RC]N+(Q%KS-V?ZLT-M"FA\_%^_ RL%(I\F,>;*ZJ]IS0?$VR MR;6W@;N;< &OE+]&_;1<)'PK4^(090N?-
M,6^NF4XA&Y<=2/K6B8#B<+(3+B MD08(W EM(JN_#&Q.&H*1XQ_;:-&)>GFE'9L>UD9- MQ$1U'$A@(-=&AL]*SH MRQ6S/S"(IOVQ:-
I%H1ET9U#A,GEHI(-"1+-',7RB$<]LJ&C]B5$5DQ5'&0#P MIWSB@KJ.G)!;<$8CA:F-YP$,ZYE!\ A3STM5W,HI[4K(+C86\5-
^6(A)0Y/&;5^VN68&]2-\*E M?!>K4133'-DXW,R=%%)04*7;-_>_BE+7,R%(LDOL>7=36%1L JT"1HK8XCESFSW(P M>*@2)#-
I&\@!9=U:,]-38(2%3<*9:B,.OJ,H[99ZG>@I[3+_W!YV24 3UZ_A M;0 \:M5 [6%D#DS1$L,;,[>V!CP-)Z+AZ CD/'V(F&? =AB_V. 76A9PV
M=OJY2PUKU"07U,T=X8P(_EY.<]"0QUH?8TPSZ"77(XXX<_/"%.T;T]/Y;EZ! M!]GYCW_ENF+$E MTED:FSKS,@X3/7S6
W:A!Q$AT6,T4:B1$Y$U@IF@OJA49-5JTS7EQ"33V)83 ML!@8!'E8.T\X>4L3S02U&IY#<:#2#I&5^@H5)<1*&H:$:[LW;A#]%3 4*KW\
M$E(P"O7-X5DM-G,4LAL[W,<0F[I@TR52"0GL\HM:E1<\ BN@K2_%"H1RL?%M M!GB,.('C93"%@]:V+@U ]CE.Q2P_GDQ(\Y$V^,\\'I.RST11-
AWV]0!8%H^P M3QQ 2_VP$ %>G&$\15;5%$NP9N:B5EM1U(X:A[KQ(GI]".A,PS+_L^('\MPD M&0/VW(+NFG+++Y,51/Q"B\@6AF
M3/Q+IUGK-#C4S(1+B@9GI0:8,T._%8F2 MB[4O#BP2\93UPQJLR(7,O2.:M_I,D#W-U6WKDA*0TZ7[=XM6S2"W/
N*",QQZY8LD944:Q7$PI)L'(9DN M/D+3:&AHZ>>99BWZ HP34$_N,=9(=?LRU%8/,:#T-$=H/-/C:>;04+:G'@8CV&7"0584>X]N:0609NDE
M:YOFI7UB1*B[73=T.6\/O0N 7WCAMFXP0\=81S;\KON>O&_GV*#F-;AO']Q& M(GA_:3C(B;&KN
WAFSO:HNO[HL175O&>HEU7V)2K^E&7+/ZI[O]:O)$ION=) MM^MJ^7BP2.[:L[!]LI[7!:M3V6]T6['JW?!%$H8V0>==I[6_"3K_
MR$%GD 7-)N7])NU%P'EJ TI.88!&]VS2Z:\YHRWV4\+S]2=YQ@ M_;GQAJP]=GV9ADJ%-VB^DG%<.V[,RH1\B(ZQ<"]3](Q6K=DY?
KB>8=*&;3UC MX7ZF)+O)(-RT\ 'I^,0M623B$.2*!G^IO@XFU4Y\%#H/AMLIK+9&9T8SB1F@ M[#S+.
(1MQ5V6KHO(:DA:87QJ!0ESR#OR.J MO@H3[#G# T6DF7MN:+>*!+@*-ZMQ_(KKS'2=ML-MB2J]2E8(/FC//7EK9)BC M^/S)#O!
+2SF"TBK$^HPPSW)L62NKR)R88]I2OO(*DZ@XD/D'[RH'0M=K66X M3FQ(99XV=@H!^/I].832B,29:90X.V+H$$]PN=*1"_"E=
[1.24"N680B[ "$ M=K7C;85QFG-_'':2]\G9.>,]_I(>WYK->''6XZX1TO0K&CC=V+T^!4!1.M@$C$OC;SF,1)3-8"-Z,;$Z/78>JT
M5G;0%9&:4OS5*L\L=3K0[CD='L&J8Q4&ZH9=J"AWP+!$OFC-I8;C!HF7#S&J MX>GQ)!9Y,%:CXU**/2.W;\9'TMQ=CF6A5
1DPO,8,$ELA#Z";EC\HZEGGG'E MC&6)D@Q,UT?K&H2Q2TYQ3ANB4TK.8!UU]R:2/.>]>XT #1-[)'9Q47P_'!^ M0E#/H'BX%\.877DUB\
MZ5=H+/K(FM:5$;FE?AQG13 8\_H+"7LV5-8W"?VRI*36B@@I)O($./Q) T]Z MHCQR+":J7(AG7\C( M7(BS[:8<^^%=74QS#U*Q
MG/1"!0)^!%AL[=2=#]K"H&,I\T#M,,MD9*[M'/V,"B7)]%*6Z2IAA0.I!I8GBK[R.(BFU$ MJ/IB7.9^83R\F#
(?"^N)W#%\@Y*Z&10W"#;VM,]@+AI% M/Q%5DM9T#1AJ )9'*8G%E4Q.>BD\^ZF^)?V0\M>1W7R%*_&E+>)5Z$9K>,3/ MTW05I(F4$GU-
K?))[@<9G#( MF?DVIUHND4!HLY6B+;BD>M\.%#DUF2M+]2J[;3-VJM+KO3RD!N#S;V\&_Y_) M:1V>+(V+:%FP[Y M4)=<*KD***V\AU-
Z49.EBUS?K%A/CG8]KF. GTD/%]/SQ6GYV6*10KYN) &4 M0G"-0'!9Q:12RW*+&.B3&]XKX+<:W:+9.,M2[.V43,6>;2K:AM^.K4WR^/1(
M,O^-."JK+#.D"A(B90H@M4F$@-N)IYDXV4VT@!X>4 DS$R'&>(C6D4\ DV'" M(G--U+VQ+@^DH&7EK=J,3YB1F'3O=0R!-'];Y*(KLI
MSZDP@YL]]LQ)#;K'JL+TZ^?K-N;BH.Y?? M?CW[ZEQ\.;_|^OGDV\7EES?]JJT><(41=.2\;M;-#+]57M:'X7=7>M7YI/K
M@:XXIPI[:MA;>'M7L(BWG5,: .JG:(+#?TVC;)>\PERQ&;K!4-(1"#RC CP. M#LT15DWF&?:SP/+Z6:6TE@ZL'<2I3NU@_R([
S!WI_BN_46<*G 3^)R$PL,Q MV#CH[&AAA0ORK@"S$*Q5. XTOFXHQA[9]"XT,/5(UUCEDFO#R?H.0$U2&!W
M"ALF.EV"OTGY/7A*TR(KZ%7^@C_17ZG+\97GL-$6[ [U'K?OH]?*R25UQ:J$92E]&^>A7]-B M6>>F%"DP5EJ"M4FI9V9HX-
ID"%D.)M='&UU56K\7\IW;&W'#]JG99B^N&K\$ MLSNI4X* <\XI2NO-=RXB0Y;:^<>I2S;*44,ZT 0'3.& Z[^925_EW!70$G9_ MJSGC.,>)
8#4F%2EV"5 #7*T>I\@A'426*F+S16L[%S4'+P,284YT2K]U'P9 M9T]JS-P2WUJANA.YB2?Q*--7LK@16U>E<;7@\&7]G'CV(E]">M
M')EXP8*F-C6W%;XD5;W"PO8+A4CAO^!* MI;X"%<..+#MB?LE=<;AM1?& KX '8#<@Y03#@I.B0P?W8Q^8N>N#CLXCH;BE M
MU^AKFNN#UR@5Z%/<;P-J[U-$F) M9EJQ=22"WUGG$P5ZS:789>3\/8^4TYY6H!&D:2X-#8QB"I Y;M8..AUQ5V.M
MF/*YUQH!%5LB8<>H6_/T)"Y<-SE!50_E5.($]ME[/$$I4O MV;V< WWE[&K0BB7-WS-)[-7$@Q(TXC+ M1H+W_A+L]XZ0@\1[ZB4!$1;+F!<
M6E%N2720&6 6B08Z+OH1G2;<'ZR5P;8IRP&,(A7Y9K"INH,E)#S%A",QB&%+]+2&?;W=ENF38B%D$5.2IM.T>%_VT'CI!'8B-
>/$PBC7+0DB#GG3/* MNV'@898(M6%;7Z_[/?AI^P7XZ4?5;9WZ)H[4<97G0'1;B>H_,,X]==3@I4(59;_YG]\%=[!2]"4?@B#PN)/> M7?95]?
ZVY?\/"M3=1A/^)_]]WFTWMIP(A,[?MI3G_PY2)O6*-UV?N6^"=) M\@U>_A""%-UR O]O6]A\=&6H\"0&R$>)KG"(,
<3X=$]R&W_!YV!X'O]^AG[ZC1V'J_X(GFPB=:"Y]H;[W' MD)>YIRG_X=V:%&:M)6(3&T[$3:OA9ZWJ-0^F:'F+4I)WP.2/1Y)H5[3])?-:
M)Q;5)"?1T_;^;8*Y4!)A-QF4>0*?2FD.PXR6O>R9<%-I5LRJ,9H':8^G!KMP M1,)E[&6M>C07QNH<"2NRCMSH[N\VM[T=[FHYUKWL4,.V'D
EEAM@%ZW":KJ_ M71F&+#(;1Z MTU=4/Y<1K]>[_RCI^\](6,!0>8*W>O]V0\-'ZQ8:?K=GW C8.;IS*+/=2?
K=;9!T^+\=^A*L_%2H'9]^O7BJI1- M84$$_DM7?]^;7P5 #P-OY6T$;_7U!Y[DZ2ZA56_^Y_,A8A;/*F!ZU),M] 8L MSY'?NW@GH:]@^=D_Y?3?
9\]W,W3MNM5]=PST0F\U. M^_"P<]SJ-%J'^X>M/77W/X=-^,5A?9 -MTHJ+DZ@!S41A"*Q?6P279H'@A4$ MJ%7Q=(B:PZG.7+YUDO?
AB$ZKJ;W<74Z[<(>QZ/KBLZV9T3/GY$"641/7>5<: MF:&>;/WVW9Y;-JZVL8EP,HHYH[J+T2/]1,&3S$1D.8!(VE];=1:?2H/H2]CQ
M"'.-0:C'F9#^?7:*?]9GD\$C.V^4+TQB^QMA"NUZ\|?A"0\F]$:CU6X?M)'0 M6\UV\V Y0D<@2,SNPM"7)"R?8]2?)GGH4'\-
'ZJ#_0F'OW%]K%HS;R#!.LL1 M:?M1B+0<6S2&,I7Z<,>3;;$K@9[%;-S!%8N10NQB:+Q5RG[+$K]=;ST?<4\%
MU!NC[V:CN7^PWR'ZWC\^6(Z^3Q$05 I)_IP3=!]17 ?RNR?M,QE2I!7E/=!/ M\]E)G^4S[V&?]["AX9>@X?:&AE>AX7:CL7]X?
(@TW#G:W^_LOP@-"SE1E3S. MYL/]A0\(O0<*=#0D_1,T^6H:$/XQ#]S9]8IVZ]6A4N5&07P%E M-AO/:?ZN VEV&]W6<8,TY(/CX_V#XV5(K,
!QZ/JGESAV_;F?7&*7IC\S[(>;V4L%V!HHEB M0"I_BKWON[^/BL'%J4RQ)>FUXW[>;TH=F/A/HAB'UL&:XK]KY@'S3V<8!]/
MP&X(]C40[,.>?0#![C<:3T2PU_F(R.@1*+:]H=BUHMC]#<4^A&);SV[F5I(^
MYAJZ*]+V_H:VUXJV#WXHVG[FQ*ZCP\X!L8%6J]%-1=V>2&ME^$MH\VM'U_VCYX],A3*>=C#]&GI=SL*KW/2LVFWSZ4 SR>4;[A M *^!
QQO.,"*'*#3:#:) W0ZG8/F,AS@/.@!ZI_(<"&B0D7MKGP6VU>Z)+>H MQ[#IVZ1I'*Y"X$MGE#(%QJ,*NZUPU5OTQ&26-
#U@\AZT;T9VO<73G.M:L/VG:<;/> M_.L/*8I(DK0?/SF1^Z;@#!-L&;A'XTLZ+O9#*>H'=%W (% ]$!]Z@N0E-Z:Q M;+\?
2SD#EH8G_]M6:^O54$?K(=3!!Z^BW.%CA_971KESTWYX&LK]"*CV.M"K M!F KM]PXHD M8+_ZGGS:8"5B MY:E,;\!_HT<.1S9L?
L2VP,$&15\?BGXZ^;!!4<)+MZO" M#7:^+NR\^G]VP4[$SJM$I8"-&RG_ZI"T\S $?=;=KMY=^H6IXI0FS5^Y?>5< M8'S>Y0%>']W,=A]
05)Z:,EPQ2 MQQ<>QE.)NTI%3CS$61@^CK](&H$SO=71)NW&NHTV>6-(;!U0;K$ZF.'ZXO]_.?GV M^]>SZS6=B75E\6\>D$QSC66 ,G-
QFW77Y"D>'$]"#*0:-O;RW!RGIY*82SC; MDR=&I_!Q'JN*?+RK!F[8PUQ27(BB=_( #B-3>00OT7ING@WB! [WK.S^[>?1
MV4KL_OX,2V6)C"-[G7)W]_NWB]+KF7'PYK3]P M',I2P%@6 /=[M=-Z-(N/3_!T]P"6AO]9=\K_7_3AE)G&][6FGAB!/HQ_ON_.
M\'I>P1"@O71/4"1X_Z7N7'NP%4Q54._V@AF6[.LG@\J\)::$IX-A!6X;:,V% MULR0%(["!E8& M_@0;+6W-
M;2_Q^D@=YW/]8V:MAH0JX#;@&L)/6U*UO);@]L+Z6D] SE]3>!Y M<1Y1Z]Y7]K99[MA/)]??=@MW\-2ZX1>N!VXW9]0#:X770G97[_G
MVA7("QIHL2*K2(A0]K5];9_C-^EYC_W>Z_).]U9-6(]V@8"AR(^WQ5F&CZN];96DJ$GF\%>D\$;8:
```

```
M2BL#JW2Z18%.K4QA;64LLZ%.Y7&JMT[>M6K>Z59?AQ,R=A*[Y]FM&O4?B6$S MVW2/D4A4/&F\[ZE$&KJ08[K2B4C?-S,1ABH=-
/942KMUE3:YUVRNJ[+M0M/F MJF%&(E7'5[W]DMLQI'%\ZV?&H_XOD%(BY7A:S.G!4;A0N=?G!N MNKJ52T!+:U
A5U(A(W,5S:P(/6U)ZKMN.7C$F@T?<$L45K^^7]^%#@W%2%(N M1TJ.(0AVJ S]58@<)(LG="4S2 +IE,[0'X:I_D4ZHM-)$&LH!U0DDP5V
CYU MTV"WN3AO?.:|>?AD9,S!L/2#V!%:G O-K<0OWPIMFPO+X0LW"%R%P/WU0>!' M88 [("R9T-=4CV,9#G"".2#F'GZAAA.IMBZ2$-
!ZD4ZH2&U>2+B-0";!1C$N M!2'T@&>(82(1H"@GG2B+S?%V2P:I#*0Q(I^P22*^2HP[TZ=!60AG,&3,(0"/ MP0:!RH,B@5F*YN3B)QH/53
D4_"O^_9CF'3N-X-K.L0T@2X?G9@]]Z4+"D#;3[0=10I/&Z;'8?&+HE<.MP#QXIW&_@D:7CGE1ER"S9+ MH&>L:?
P<*H.XRA1HQTJ7Z]@3(,MU($,4&]H&WD,) GE0=VZ1BJ<#26V(R%41 MP\)E9$?;TGOALC)^\H^*DZ?4$X_[)U::&3YZ?K O3QXHFALHPD
\ST66PH(# MS<9SF+?)4UZ9?F)]Z/=)&M0!BR[_^CY1*AS[!:(P3V_"05A? O3E2#ZLTP4V MLX"BC)1Q.@4KF;I^.+F^5[A9E&
(T)T[QH6/3M6TD7#(0D6Y4288<$4L6(PQ+>?$ M?62)%CY.G0VO\5=?LB'T$NUEN-''-T+0_KH2],DZL\33IRO4D^D*BH]4R"P4 M1J<.6,*
P9R],35%'DYI N(JT5>QLA..-5<-RX>&8Y0CB^?[G.E,]N<4_[:< M4%;D&&K8PB_EYF!,"9%?D4 MLG**5_7)U<.0JB(53.^!2NKPO[\-A/
MT7)Q9RTY/XV^?UE"_6GFZTX5Z=<__C2Y\TT4^H:H%*X/E3YYK"YCGB\DRP3)
MU2Q0ZAFBQC&E#H(B9TS/!'!S_27:6)3P=V'HQ6!KZ9N_LZ?M)>,(A(3$+-B5 M;@:@B;LYY4O5M+CS9<=[,A3F+L)E<7($EJ%3;3?
[4E$G%*NO,BZO41?L*S^P M(!NZOC6Z'JT/75]P9^.^#0NG-*_'>@5H$^?+_'-X6!D@![&1W>78N,I?C*X9[/>US MYS(V]]W<])[_610J;S#\
[>H*_1$A&AIY)S\KZ%9F># &5WX7LI&FMT:@-;HN:2-@C'(<\Q7 63I9 B'<5\0E]' M-9:1;3C E 7N1<#&'80\.1:!MHHD5*+OZ.CG1\'W@K?
#YC,4H*?A%\[_OL#& M)GWL;?V@0OQ"YV,4>)?=DKLWIWS0W]ZK
M$/_L-.FQ"1SNO^X,:J;64B5HYU['::]74R0,L>AE\IL1XP0:^K.EK+]W"]ZF7[O%/]>-5I_Y-?:I^IO3P_ZUTME VC:J['RX4LBG1Y?G'SY_UH
ML.!W[U=\P(L:OXN/T\K]4\%_5!+ P04 " !8I6U9^?;,: (( !6, M#0 &5X7S:U<@+VB@Q8JL(B%"V=?VM7V.S[U.T1[9 M)#YICZ0(3]
[]U+;*QO)$WO[[UZ/#XU_K^ZAMUWSANY]0_X]JEV*F(U3)NY&HYL M*Q'Y4*5-ML>4!R?=OS[W/O;Z=-C8/VC7!B?M6G;R[H'Q5WU_@@<+
_Z2#DS6 M>FR,'YMC@"V2^_G%'_NNZT3JAN_ M'1YM_B[]IS!61=/%07L5NMBGZT!;2V=.K@OX[ADZ=VSR40P>RY=FJC0CIK4J-
=_;I&;KL*AA!&IGMTRJW%TX6S+ M9_9CGE\@XG)5R.K,6;%1N-3I;\Y-5[=V"6AE#2KD2BID9*ZBN16AIRU)8]\M M!X]8L^$#;HG"ZM?
WZ[O0H9$82\KE6,D)!,&.E*$_"Y /&4KF0&22"=TAGZ MPS#5/TE'=#H-8@WE@(IDLL!.P*=>&NRWEN>-SYPW#Y^,C 48EGX0.T++L0>+
Y"/PH#' 'A"53^IKJ22S#(4XP!\3\ PQ3"0"%.6D$V6Q.=YNQ2"5@31& MY%,V2<17B7'G^C0H"^$,AHPY!. QV"!0>5
D,$O1G%S\1).1"D9D"OYUWWXB M/XGFTET,W2T"!TJ+CC"EL4,0Q ,9UQ>H)2X_P)A!E1%.N)F?$OET-E;(Z%
M(,&%WF]X69FCD9DYL^+MEDEOA$E'F\.D_@+LWIN2)66@S0>ZCB*%QUVSY]#8 M(Y%+AWO@6/%N Y\D#>^\,B-NP68)]
(PUC9]#91!7F0+M6.ER'7L"9+D.9(AB M0[O >RA!(__J[BU2\70HJ0,1N2IB6+B,['A7>B]<5L9/_E%Q\I1ZXG'_Q$HS MQT?/#_;ER0-%"P-%&
(CGNODKF,A6-1 M&=?=,Z%2*BA7*J@=?#$Z5J&[C3/%P*A0865X LI'GTZW4^ZI,!P1NG/'N/#1
MJ9HV$@Y9J"@WR@0#KH@%BS&FY9RXCRS1PL>I\^$U_AI(-H1>HKT,M_KX1@@Z MV%2"/EEG5GCZ=(5Z,EU!\;$*F87"Z-
0!2Q@PF+,WIJ;(PQE-0%PE!BI6=LJQ MYKIA^=!PC')D\7Q?,)W+_ISBWY83RHH\ UF-BXV# -!V#K@\<.ANY&-P%C4R MX\. 39#C>E[BT%
91'?+S#?"S&!SF-D=B[AP^L*PE5'$W\N, 3BS)I]"8/L$ MI?2/ZY,K1T$TA,H9G\(-=&$?'OLI6B[NK"7GI]'W+TMH,,M\W:DB_1K GQ9W
MOF71VV!1N#DL^N1AN@IWOHLLJR9%>Z&8 A[M*4[U/3XLZ7/>_)2)B[X)9UR7%7 MADZPW>Q+,9U2K+
[*N+Q!7;*O_,"")NIVWSQE>EZO#ET?<%UC?LB+)S1O'*O M("QH\[2[%Q.FSS-"W95L$'X)Y()6Y^8NKG0%Z"Q)E+52KI7H@4;,RC6A@D^N
M^2YH"44TK+CXY%QT=G[(;X6"R^[$*%+W4H;9V][$O"5F;=!-3"=&BH-:!?KP MU1Y?$@9* NQE8'AW(S*1XBM'>C[E<;&>2];HJ/M
TO$9%@IEB==PT2GE?^S7(5IK>&H$VZ*:D@X Q MRG',5P!GZ60)A'#?#I?,J?@(3*5C'8\EAV&I&)9?EDLDDB_54HG8RTEZ[ MQ (OP:,?
C$A7EG3#$/Z,MZX\0!P7O!_56$:VZ0!3%KAW )MW$/+D6 ;:.I)0 MB;[CXY\?!=\+7@Q;S%" GJ9?./_[ AN;#+"WC<,*\;N,[_QU8&V5B?@779+
[LJ<\N%@MUXA_MEKT6,3.#IXW1G43*VM2M NO(G7 MKJF3!UCT,OC,B/&"#7Q9T]=>NJ7EVB[5PTMU.E(RHNZM# J^1*,O/H/9+MIC
MB[9;7IY#V.3=RI6YW]X;$;A0C2F(A3$?=G[O7/>KEYWS;O7C5;?S+WZ??:[V M\ORL?[54-HJJN9ZL%K(HTN7YQU8;6_B
M1A#^?/D54TZ7(Y(--H1+#CM(A) 6M/2M-K*UE!GAGOO/B99R9V(Y7$/3>B).CMO'$54S'MT>6O!_OMSH'=0*W; M+
(4[;U#_DVG"&>54$D4#6*S BW(>4'DB$@I3(16)P03;;N+5LEK[T.[:5K?3 MAND7,,V>FU!%P(^(S*@ZJN4J- ]KE923A![50B$3HLR
*NHK)G@-?,$5Y6BM M:$S32'!ZQ$6MM^,VRZ#=A0A6D*E57#S.E9FQWRFZ3953W(8D8?&J^]YC"G&4=6SL'N9"^5LG5 *';AU"H774G!%
M)"-<=8'KE&('$B(O&.]"8:+H4IDD9AM%L-VVTN M>FXS[>T\$M3]A![*?
AU&%445A%;7>KM\D:7.4SZV7/P9#WZ'0TZ'NCR1BFY[/Y>7_L@3=Y+N,7B<8^A//&O#%HP'PX*"*RVQW+>)58
M^G/HGTRFWO#DU":J0A4Q#+XFA.)-8M7,*,IDAZ@]A2/Q/8WOX(( M8;#R8X'2[D959K0/#T T88WOX0BDX99P:X%.IRV5
MFLLLQY*"$G#;2;MO[0\'3M%'.D 2B%3/B[O&\ZJJ&E_HO@BZ(]6[NZO5<43KM\/#"2*_'R@3W7U=B6Z[X-\QB;
MV,=&C'6[W+20I)UMP]TT6P5>^V-[ MW]%MN%T=_)4:#/BKD?8_K/^9L&[]6+!FO-R?-5;UWDR0K .4%C!=8YXP/;E2 M23,-
;T.K21SC>HK3AN'@046*>,^,:AIQPGTMQP,#5ARMQPI:Y7'9'2+5_P^@
M(EMW1#7:&C\XZO_">E%"H>B/,@XSIJ'J%M"H!,6:W[T!2]DPVY!ZJ'&@PEFG M\^Y)F'W'!K11LQ-$0+TY\%2"^R^<8#-K@LMZ&
[N,VV2]1V#Z?>_G<1Y[S=2WW/NE:@Z8%?@QR3+CFJ?^W//G/;/AN;Q;-C_67^^,$HFOJ;$M)"\7'L#U!+ P04 " !8I6U94"Y% MHZL$ D$P #0
&5X7SB??< MZ;GG&+4CG<2==D1)T-EZU=9,Q[1#%[_M[[;V]IMUM+8;Q>+6*[3_9%EP2CF5 M1-, YDN811D/J#P6"86QD)K$8('C-
/!JVLU=:+F.XSI-&)^!977:"=4$_(A( M1?5A)=.A=5 I5SE)Z&$E%#(AV@JHIKYF@E? %UQ3CMZ:QC2-!*>'7%0Z6^U& M ;H]%\$2E%[&^>-
<6XK]3EUP[%1[D"^$)&'QTH7MRTQH;\82JF!(KV$B$L*+ M10]2$@2,7[A@,PYVW6'< S^32D@72*:%9V*F:X'*?3': MY2:_V--
TH2T2LPON2G81:2\A\H)QU_AC0>:=_NK/=F'?:C;2S M]4C\MQL WOX9!&L!M_ECCZ^0"KO)=GK3V:#DT&O.QN,AC ^GTS/ MN\,9S$;/9?Q-
T#@'<%Z?UGMUF/9[.2*GM6?77@1+=PK=X]%XUC]^\;*LBO'> M?@>C$YA]Z,.T.SGJ#OM3:_3Y8_]7Z/9FQM*T[1^ JE\RI5FX7 \ZX$:&>"%)
M<,UT!#IB"CYE1&+-XB5,:(KJ!V@]P2U1?*Q/($+H+?U8H$BB8*8TT\Q7-1AP MOPY5'5'8?GW0;-I>3R0IXED$ 8I"&\"4IHHF <@X(
MDB+DN\B*K%; $'H-?A8JR@B&$<5H#GTI3KQJDJ)49UA2T@-M6VG[MO-OW
M\D8R"$D@4C,Y[CI/R[(:@F'\'#F1<\*ILD:+F"ZAZVMC,02KH9UH]Q_DF";S MF,)<2!QSAQ4;!Q*-XW)8W-RKE/BK^Q+2-0MT9,:0_<:#G&
,7R!&!#M=F&&" M\Q0'KESY7YE"XOLN>8B527,OXQ1L;GJPAE,'3_OEQ@=K!?>*58-\I0:*2A9Z MFP/UV=I5G9V\<";DX\!6_7;
GNNK;$O5XT;9C%VL8^=&)M^N>DA22\S)FF" M+TX9#J[(ZK2J9 >P49V]:K!SP]O;CKOIMI*\SOO6KF?Z<+,Z^"L-&?#7,.U_M6O\
[:=W\OFC->'&2-EPU)VB"8AW@:D[3%><),Z,KE509>M>,F<0QX&.(!2 XPUXX'3R6X^XT3 M;*@&M%EG_3#3;K#.(SS]NA?TN)"]9.Z;2?_P"?
&S]#V1> M327#G%-,^E:]C683WQ<9UZAR*-1Y->Z-MQ=2Z(!=@1\3I0XK'[O3F37NGO:M MHTF_^XOY_G+'.CX]F4TVUJ+0DN+Z_J)1=1B?
#L_/;J.AA_F(],/HFB8CTHH M!OG7L3\ 4$L! A0#% @ 6*5M6>L[-WA7$ 0[P !$ M ( ! &-T9&@M,C R-# Y,S N>'-D4$L! A0#% @
6*5M6;QTN6D/ M"@ $X( !4 ( !AA &-T9&@M,C R-# Y,S!?8V%L+GAM M;%!+ 0(4 Q0 ( %BE;5E,#FD/2T .]:!0 5 " <@: M
!C=&1H+3(P,C0P.3,P7V1E9BYX;6Q02P$"% ,4 " !8I6U9_I>1<@]0 M ].00 %0 @ %&6P 8W1D:"TR,#(T,#DS,%]L86(N>&UL M4$L! A0#% @
6*5M6;WWVJZL00 T)\% !4 ( !B*L M &-T9&@M,C R-# Y,S!?<')E+GAM;%!+ 0(4 Q0 ( %BE;5E1M5]Y408! M K!#@ 4 " 6?M !C=&1H,C R-#
Y,S!?,3!Q+FAT;5!+ M 0(4 Q0 ( %BE;5GCM1&6 @ %LP - " >KS 0!E M>%\W-#,U-CDN:'1M4$L! A0#% @ 6*5M6?GVS&@"" 5C T M ( !%?P!
&5X7S2;F M3+,$ C$P #0 @ %"! ( 97A?-S0S-3%\W ?-#,U-S(N:'1M4$L%!@ * H >0( /8- @ $! end XML 66 ctdh20240930_10q_htm.xml
IDEA: XBRL DOCUMENT 0000922247 2024-01-01 2024-09-30 0000922247 2024-07-01 2024-09-30 0000922247
ctdh:NovemberNoteMember ctdh:RafaelHoldingsIncMember us-gaap:SubsequentEventMember 2024-11-01 0000922247
ctdh:OctoberNoteMember ctdh:RafaelHoldingsIncMember us-gaap:SubsequentEventMember 2024-10-08 0000922247
ctdh:AshlandIncMember us-gaap:PurchaseCommitmentMember 2024-09-30 0000922247 ctdh:AshlandIncMember us-
gaap:PurchaseCommitmentMember 2023-01-01 2023-03-31 0000922247 us-gaap:WarrantMember 2023-01-01 2023-09-30 0000922247
us-gaap:WarrantMember 2024-01-01 2024-09-30 0000922247 us-gaap:WarrantMember 2023-07-01 2023-09-30 0000922247 us-
gaap:WarrantMember 2024-07-01 2024-09-30 0000922247 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0000922247
us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0000922247 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-
09-30 0000922247 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0000922247 ctdh:ApproximationMember 2023-01-
01 2023-09-30 0000922247 ctdh:ApproximationMember 2024-01-01 2024-09-30 0000922247 ctdh:ApproximationMember 2023-07-01
2023-09-30 0000922247 ctdh:ApproximationMember 2024-07-01 2024-09-30 0000922247 2023-01-01 2023-09-30 0000922247 2023-
07-01 2023-09-30 0000922247 srt:MaximumMember 2024-01-01 2024-09-30 0000922247 srt:MinimumMember 2024-01-01 2024-09-
30 0000922247 ctdh:The2021EquityIncentivePlanMember 2024-01-01 2024-09-30 0000922247
ctdh:The2021EquityIncentivePlanMember 2024-07-01 2024-09-30 0000922247 ctdh:The2021EquityIncentivePlanMember 2024-09-30
0000922247 us-gaap:EmployeeStockOptionMember ctdh:The2021EquityIncentivePlanMember 2024-01-01 2024-09-30 0000922247 us-
gaap:EmployeeStockOptionMember ctdh:The2021EquityIncentivePlanMember 2021-06-24 2021-06-24 0000922247
ctdh:The2021EquityIncentivePlanMember 2021-06-24 0000922247 ctdh:The2019OmnibusIncentivePlanMember 2024-01-01 2024-09-
30 0000922247 us-gaap:EmployeeStockOptionMember ctdh:The2019OmnibusIncentivePlanMember 2024-01-01 2024-03-31
0000922247 ctdh:The2019OmnibusIncentivePlanMember 2019-08-29 0000922247 ctdh:EmployeeAndBoardMember 2023-07-01 2023-
09-30 0000922247 ctdh:EmployeeAndBoardMember 2023-01-01 2023-09-30 0000922247 ctdh:EmployeeAndBoardMember 2024-07-01
2024-07-01 0000922247 ctdh:EmployeeAndBoardMember 2024-01-01 2024-09-30 0000922247 ctdh:BoardMembersMember 2023-01-
01 2023-09-30 0000922247 ctdh:BoardMembersMember 2023-07-01 2023-09-30 0000922247 ctdh:BoardMembersMember 2022-01-01
2022-12-31 0000922247 ctdh:BoardMembersMember 2024-01-01 2024-09-30 0000922247 ctdh:BoardMembersMember 2024-07-01
2024-09-30 0000922247 ctdh:BoardMembersMember 2023-01-01 2023-12-31 0000922247 2023-12-31 0000922247 2024-09-30
0000922247 ctdh:OfficeLeaseMember 2023-01-01 2023-01-31 0000922247 ctdh:RafaelHoldingsIncMember 2024-09-30 0000922247
ctdh:RafaelHoldingsIncMember 2024-01-01 2024-09-30 0000922247 ctdh:RafaelHoldingsIncMember 2023-12-31 0000922247
```

~~ctdh:RafaelHoldingsIncMember 2024-07-01 2024-09-30 0000922247 ctdh:SeptemberNoteMember ctdh:RafaelHoldingsIncMember 2024-09-09 0000922247 ctdh:AugustNoteMember ctdh:RafaelHoldingsIncMember 2024-08-21 0000922247 ctdh:JulyNoteMember ctdh:RafaelHoldingsIncMember 2024-07-16 0000922247 ctdh:JuneNoteMember ctdh:RafaelHoldingsIncMember 2024-06-11 0000922247 ctdh:RafaelHoldingsIncMember 2024-06-11 0000922247 ctdh:CyclodexterinComplexesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0000922247 ctdh:CyclodexterinComplexesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-09-30 0000922247 ctdh:BasicNaturalAndChemicallyModifiedCyclodexterinsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0000922247 ctdh:BasicNaturalAndChemicallyModifiedCyclodexterinsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-09-30 0000922247 ctdh:ThreeMajorCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000922247 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000922247 ctdh:TwoMajorCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000922247 ctdh:ThreeMajorCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000922247 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000922247 ctdh:TwoMajorCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000922247 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000922247 ctdh:FourMajorCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0000922247 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0000922247 ctdh:ThreeMajorCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0000922247 ctdh:FourMajorCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0000922247 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0000922247 ctdh:ThreeMajorCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0000922247 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0000922247 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-09-30 0000922247 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-09-30 0000922247 us-gaap:ProductAndServiceOtherMember 2023-07-01 2023-09-30 0000922247 us-gaap:ProductAndServiceOtherMember 2024-07-01 2024-09-30 0000922247 ctdh:AquaplexMember 2023-01-01 2023-09-30 0000922247 ctdh:AquaplexMember 2024-01-01 2024-09-30 0000922247 ctdh:AquaplexMember 2023-07-01 2023-09-30 0000922247 ctdh:AquaplexMember 2024-07-01 2024-09-30 0000922247 ctdh:TrappsolHPBMember 2023-01-01 2023-09-30 0000922247 ctdh:TrappsolHPBMember 2024-01-01 2024-09-30 0000922247 ctdh:TrappsolHPBMember 2023-07-01 2023-09-30 0000922247 ctdh:TrappsolHPBMember 2024-07-01 2024-09-30 0000922247 ctdh:TrappsolCycloMember 2023-01-01 2023-09-30 0000922247 ctdh:TrappsolCycloMember 2024-01-01 2024-09-30 0000922247 ctdh:TrappsolCycloMember 2023-07-01 2023-09-30 0000922247 ctdh:TrappsolCycloMember 2024-07-01 2024-09-30 0000922247 us-gaap:ConvertibleNotesPayableMember 2024-09-30 0000922247 us-gaap:ConvertibleNotesPayableMember 2024-01-01 2024-09-30 0000922247 us-gaap:ConvertibleNotesPayableMember 2023-12-31 0000922247 us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-01-01 2024-09-30 0000922247 us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-07-01 2024-09-30 0000922247 srt:MaximumMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputPriceVolatilityMember 2024-01-01 2024-09-30 0000922247 srt:MinimumMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputPriceVolatilityMember 2024-01-01 2024-09-30 0000922247 srt:MaximumMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputPriceVolatilityMember 2024-07-01 2024-09-30 0000922247 srt:MinimumMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputPriceVolatilityMember 2024-07-01 2024-09-30 0000922247 srt:MaximumMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-01-01 2024-09-30 0000922247 srt:MinimumMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-01-01 2024-09-30 0000922247 srt:MaximumMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-07-01 2024-09-30 0000922247 srt:MinimumMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-07-01 2024-09-30 0000922247 srt:MaximumMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputExpectedTermMember 2024-01-01 2024-09-30 0000922247 srt:MinimumMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputExpectedTermMember 2024-01-01 2024-09-30 0000922247 srt:MaximumMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputExpectedTermMember 2024-07-01 2024-09-30 0000922247 srt:MinimumMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputExpectedTermMember 2024-07-01 2024-09-30 0000922247 srt:MaximumMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputSharePriceMember 2024-01-01 2024-09-30 0000922247 srt:MinimumMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputSharePriceMember 2024-01-01 2024-09-30 0000922247 srt:MaximumMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputSharePriceMember 2024-07-01 2024-09-30 0000922247 srt:MinimumMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputSharePriceMember 2024-07-01 2024-09-30 0000922247 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000922247 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000922247 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000922247 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000922247 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-01-01 2024-09-30 0000922247 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000922247 ctdh:WarrantsToPurchaseCommonStockMember 2023-07-01 2023-09-30 0000922247 ctdh:WarrantsToPurchaseCommonStockMember 2023-01-01 2023-09-30 0000922247 ctdh:WarrantsToPurchaseCommonStockMember 2024-07-01 2024-09-30 0000922247 ctdh:WarrantsToPurchaseCommonStockMember 2024-01-01 2024-09-30 0000922247 srt:MaximumMember ctdh:MachineryAndFurnitureMember 2024-09-30 0000922247 srt:MinimumMember ctdh:MachineryAndFurnitureMember 2024-09-30 0000922247 srt:MaximumMember ctdh:ComputersAndVehiclesMember 2024-09-30 0000922247 srt:MinimumMember ctdh:ComputersAndVehiclesMember 2024-09-30 0000922247 ctdh:RafaelHoldingsIncMember us-gaap:SubsequentEventMember 2024-11-12 0000922247 ctdh:MergerAgreementMember 2024-08-21 0000922247 2023-09-30 0000922247 2022-12-31 0000922247 us-gaap:RetainedEarningsMember 2023-09-30 0000922247 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000922247 us-gaap:CommonStockMember 2023-09-30 0000922247 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0000922247 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0000922247 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000922247 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-01-01 2023-09-30 0000922247 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0000922247 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0000922247 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000922247 us-gaap:RetainedEarningsMember 2022-12-31 0000922247 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000922247 us-gaap:CommonStockMember 2022-12-31 0000922247 us-gaap:RetainedEarningsMember 2024-09-30 0000922247 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000922247 us-gaap:CommonStockMember 2024-09-30 0000922247 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0000922247 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0000922247 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0000922247 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-01-01 2024-09-30 0000922247 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0000922247 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0000922247 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:CommonStockMember 2024-01-01 2024-09-30 0000922247 us-gaap:RetainedEarningsMember 2023-12-31 0000922247 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000922247 us-gaap:CommonStockMember 2023-12-31 0000922247 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000922247 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000922247 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000922247 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-07-01 2023-09-30 0000922247 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000922247 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30~~

~~0000922247 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000922247 2023-06-30 0000922247 us-gaap:RetainedEarningsMember 2023-06-30 0000922247 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000922247 us-gaap:CommonStockMember 2023-06-30 0000922247 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000922247 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000922247 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000922247 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-07-01 2024-09-30 0000922247 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000922247 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000922247 2024-06-30 0000922247 us-gaap:RetainedEarningsMember 2024-06-30 0000922247 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000922247 us-gaap:CommonStockMember 2024-06-30 0000922247 2024-11-12 0000922247 ctdh:WarrantsToPurchaseCommonStockMember 2024-01-01 2024-09-30 0000922247 us-gaap:CommonStockMember 2024-01-01 2024-09-30 thunderdome:item iso4217:USD shares iso4217:USD shares pure utr:Y Q3 2024 --12-31 false 0000922247 false false false false 0 0 P10Y P10Y 0 0 0 0 P3Y 3 3 2 4 4 3 1 P10Y P7Y P5Y P3Y 0 0 0 0.0001 0.0001 0.0001 0.0001 10-Q true 2024-09-30 false 0-25466 CYCLO THERAPEUTICS, INC. NV 59-3029743 6714 NW 16th Street, Suite B Gainesville FL 32653 386 418-8060 Common Stock, par value $.0001 per share CYTH NASDAQ Warrants to purchase Common Stock CYTHW NASDAQ Yes Yes Non-accelerated Filer true false false 28768055 928010 9246592 187682 122379 236110 254352 177836 384889 1726970 2310045 3256608 12318257 19988 38332 26636 890949 1950670 0 5253902 13247538 20116 1010631 12178000 0 6521983 7457416 18720099 8468047 7143 22484 7143 22484 5000000 5000000 0 0 0 0 250000000 250000000 28768055 28768055 28556072 28556072 2877 2856 89537725 88610832 -103013942 -83856681 -13473340 4757007 5253902 13247538 233772 495477 559326 765006 16798 38767 42002 68872 216974 456710 517324 696134 843157 834878 2581207 2526700 5492844 3469067 11830127 10037433 3495 847 13822 9162 1412432 597095 2430263 1494332 640590 220607 2361381 775922 111281 95560 327061 243143 2177 4819 6531 14457 441 1297 1315 2519 -0 -0 -11813 -0 8506417 5224170 19563520 15103668 -8289443 -4767460 -19046196 -14407534 549621 -3893 591312 -7359 373878 0 1475623 0 -1467000 0 -2178000 0 -543501 -3893 -111065 -7359 -8832944 -4771353 -19157261 -14414893 0 0 0 0 -8832944 -4771353 -19157261 -14414893 -0.31 -0.29 -0.67 -1 28729641 16191723 28674910 14394920 28696028 2870 89055380 -94180998 -5122748 -0 1396 -0 1396 0 214169 0 214169 72027 7 90747 90754 0 178825 0 178825 0 0 -8832944 -8832944 28768055 2877 89537725 -103013942 -13473340 15308449 1531 71956553 -73442919 -1484835 4000000 400 4999600 0 5000000 1155 0 1478 0 1478 55485 6 75454 0 75460 0 126580 126580 0 0 -4771353 -4771353 19365089 1937 77159665 -78214272 -1052670 28556072 2856 88610832 -83856681 -0 95911 -0 95911 0 214169 0 214169 211983 21 287370 0 287391 0 521265 0 521265 0 0 -19157261 -19157261 28768055 2877 89537725 -103013942 -13473340 8481848 849 64533074 -63799379 734544 9007853 900 12145989 0 12146889 1678696 168 0 0 168 1155 0 1478 0 1478 195537 20 219694 0 219714 0 259430 0 259430 0 0 -14414893 -14414893 19365089 1937 77159665 -78214272 -1052670 -19157261 -14414893 6531 14457 -11813 -0 521265 259430 287391 219714 -2178000 -0 65303 248769 -18242 -44736 1367595 841350 -65510 49187 -0 -1883 -721264 3123835 934590 2524749 -18222671 -11890144 0 2917581 0 9229308 95911 -0 0 1478 0 168 10000000 0 9904089 12148535 -8318582 258391 9246592 1543418 928010 1801809 2318 9807 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(1) ORGANIZATION AND DESCRIPTION OF BUSINESS:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Cyclo Therapeutics, Inc. (the “Company,” “we,” “our” or “us”) was incorporated in August 1990 as a Florida corporation under the name Cyclodextrin Technologies Development, Inc. with operations beginning in July 1992. In conjunction with a restructuring in 2000, we changed our name to CTD Holdings, Inc. We changed our name to Cyclo Therapeutics, Inc. in September 2019 to better reflect our current business and, on November 6, 2020, we reincorporated from the State of Florida to the State of Nevada.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On December 27, 2023, the Company completed a strategic combination pursuant to that certain Agreement and Plan of Merger, dated as of September 21, 2023, by and among the Company, Cameo Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company ("Merger Sub"), and Applied Molecular Transport Inc., a Delaware corporation ("AMTI"), providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of the Company (the "AMTI Merger").</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We are a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of neurodegenerative diseases. We filed a Type II Drug Master File with the U.S. Food and Drug Administration (“FDA”) in 2014 for our lead drug candidate, Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin) as a treatment for Niemann-Pick Type C disease (“NPC”). NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. In 2015, we launched an International Clinical Program for Trappsol® Cyclo™ as a treatment for NPC. In 2016, we filed an Investigational New Drug application (“IND”) with the FDA, which described our Phase I clinical plans for a randomized, double blind, parallel group study at a single clinical site in the U.S. The Phase I study evaluated the safety and pharmacokinetics of Trappsol® Cyclo™ along with markers of cholesterol metabolism and markers of NPC during a 12-week treatment period of intravenous administration of Trappsol® Cyclo™ every two weeks to participants 18 years of age and older. The IND was approved by the FDA in September 2016, and in January 2017 the FDA granted Fast Track designation to Trappsol® Cyclo™ for the treatment of NPC. Initial patient enrollment in the U.S. Phase I study commenced in September 2017, and in May 2020 we announced top line data showing Trappsol® Cyclo™ was well tolerated in this study.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We have also completed a Phase I/II clinical study approved by European regulatory bodies with clinical trial centers in the United Kingdom, Sweden, and Israel. The Phase I/II study evaluated the safety, tolerability and efficacy of Trappsol® Cyclo™ through a range of clinical outcomes, including neurologic, respiratory, and measurements of cholesterol metabolism and markers of NPC. Consistent with the 12-week Phase I study (single US site), the European/Israel study administered Trappsol® Cyclo™ intravenously to NPC patients every two weeks in a double-blind, randomized trial, but differs in that the study period was for 48 weeks (24 doses). In March of 2021 we announced that 100% of patients who completed the trial (9 out of 12) improved or remained stable, and 89% met the outcome measure in at least two domains of the 17-domain NPC severity scale. We did not conduct a Phase II trial in the U.S. and instead relied on the data obtained from our Phase I/II trial abroad to support the commencement of our Phase III trial in the U.S.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In February 2020 we had a face-to-face “Type C” meeting with the FDA with respect to the initiation of our pivotal Phase III clinical trial of Trappsol® Cyclo™ based on the clinical data obtained to date. At that meeting, we also discussed with the FDA submitting a New Drug Application (NDA) under Section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for the treatment of NPC in pediatric and adult patients with Trappsol® Cyclo™. A similar request was submitted to the European Medicines Agency (“EMA”) in February 2020, seeking scientific advice and protocol assistance from the EMA for proceeding with a Phase III clinical trial in Europe. In October 2020 we received a “Study May Proceed” notification from the FDA with respect to the proposed Phase III clinical trial, and in June of 2021 we commenced enrollment in TransportNPC, a pivotal Phase III study of Trappsol® Cyclo™ for the treatment of NPC. In May 2024, we enrolled the last of the 104 patients enrolled in the Phase III study.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We are also exploring the use of cyclodextrins in the treatment of Alzheimer’s disease. In January 2018, the FDA authorized a single patient IND expanded access program using Trappsol® Cyclo™ for the treatment of Alzheimer’s disease. Based on the data collected from this patient combined with the data from our NPC studies, we prepared a synopsis for an early-stage protocol using Trappsol® Cyclo™ intravenously to treat Alzheimer’s disease that was presented to the FDA in January of 2021. We received feedback from the FDA on this synopsis in April 2021 and incorporated the feedback into an IND for a Phase II study for the treatment of Alzheimer’s disease with Trappsol® Cyclo™ that we submitted to the FDA in November 2021. In December of 2021, we received IND clearance from the FDA, allowing us to proceed with our Phase II study of Trappsol® Cyclo™ for the treatment of Alzheimer’s disease. U.S. sites for the study were activated during the second half of 2022, with patient dosing beginning in the first quarter of 2023.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We also continue to operate our legacy fine chemical business, consisting of the sale of cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.~~

However, our core business has transitioned to a biotechnology company primarily focused on the development of cyclodextrin- based biopharmaceuticals for the treatment of disease from a business that had been primarily reselling basic cyclodextrin products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Proposed Acquisition by Rafael Holdings</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On August 21, 2024, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Rafael Holdings, Inc. (“Rafael”), a Delaware corporation; and Tandem Therapeutics, Inc., a Nevada corporation and a wholly-owned subsidiary of Rafael (“First Merger Sub”); and Tandem Therapeutics, LLC, a Nevada limited liability company and a wholly-owned subsidiary of the Rafael (“Second Merger Sub”). Pursuant to the terms of the Merger Agreement, the Rafael, First Merger Sub and the Company will be merged with and into Rafael (the “First Merger”), with the Company surviving the Merger as a wholly-owned subsidiary of Rafael. Immediately following the First Merger, the Company will merge with and into the Second Merger Sub (the “Second Merger”, and together with the First Merger, the “Merger”) with Rafael being the surviving entity of the Second Merger. The name of the Surviving Entity will be changed to Cyclo Therapeutics, LLC.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">At the closing of the Merger, each outstanding share of Company common stock will be converted into the right to receive a number of shares of Rafael Class B common stock calculated in accordance with the Merger Agreement (the “Exchange Ratio”). The Exchange Ratio was initially estimated to be 0.3112 shares of Rafael Class B common stock for each share of Company common stock. The actual exchange ratio will be determined at the time of closing based on valuing Company common stock at $0.95 per share and Rafael at the combined value of its cash, cash equivalents, marketable securities, real estate and certain other financial holdings plus amounts loaned by Rafael to the Company between the signing of the Merger Agreement and the closing of the Merger, less certain of Rafael’s current liabilities. In addition, the cash value with take into account the funding of the Company’s operations by Rafael with convertible notes through closing, as discussed at Note (7). Any fractional shares of Rafael Class B common stock will be rounded up to the nearest whole share.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All compensatory options to purchase Company common stock will be converted into an option to acquire Rafael Class B common stock, as described in the Merger Agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Unless otherwise provided for in outstanding warrant agreements, all outstanding warrants to purchase Cyclo common stock (other than those held by Rafael which will be cancelled) will automatically be converted into warrants to purchase a number of shares of Rafael Class B common stock, at an adjusted exercise price per share based upon the Exchange Ratio. Certain holders of Cyclo warrants, representing 5,498,914 Cyclo warrant shares, have the right to elect to receive cash payment in an amount equal to the Black Sholes Value of the unexercised portion of their warrants on the date of consummation of the Merger in lieu of receiving warrants to purchase Rafael Class B common stock.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Holders of Cyclo Public Warrants will receive Rafael Public Warrants in exchange for their Cyclo Public Warrants.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Merger Agreement contains specified termination rights of each of the Company and Rafael. In connection with a termination of the Merger Agreement in specified circumstances, the terminating party will be reimbursed for transaction costs of up to $250,000. If the Merger Agreement is terminated by Company due to the Company’s board of directors making an adverse change recommendation, the Company will be required to pay a $400,000 termination fee to Rafael.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The boards of directors of each of the Company and Rafael have approved the Merger Agreement and the transactions contemplated thereby, subject to the satisfaction or waiver of customary conditions, including the requisite approval by the Company's and Rafael's stockholders and the effectiveness of a registration statement to register the shares of Rafael Class B common stock to be issued in connection with the transaction. The transaction is expected to close in late December.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Although the Company has entered into the Merger Agreement and intends to consummate the proposed Merger, there is no assurance that the Company will be able to successfully consummate the proposed Merger on a timely basis, or at all.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Going Concern and Liquidity</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For the three and nine months ended September 30, 2024, the Company incurred a net loss of $8,832,944 and $19,157,261, respectively. The Company has an accumulated deficit of $103,013,942 at September 30, 2024. Our recent losses have predominantly resulted from research and development expenses for our Trappsol® Cyclo™ product and other general operating expenses, including personnel expenses and board advisory fees. We believe our expenses will continue to increase as we continue to conduct clinical trials and seek regulatory approval for the use of Trappsol® Cyclo™ in the treatment of NPC and Alzheimer’s disease.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">For the nine months ended September 30, 2024, the Company’s operations used $18,222,671 in cash, and at September 30, 2024, the Company had a cash and cash equivalents balance of $928,010 and negative working capital of $15,463,491. We will need to raise additional capital in the foreseeable future to fund the development of our drug product candidates through clinical development, manufacturing and commercialization.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Rafael has agreed to fund the Company through the earlier of the consummation of the Merger or termination of the Merger Agreement in such amounts as may be necessary for the Company to operate its business and pay its debts and obligations as they become due, provided that the Company is not in active discussions regarding an acquisition proposal and is being operated in a manner consistent with the terms of the Merger Agreement and the financial forecast previously shared with Rafael. As discussed in Note 7, the Company has borrowed $15,000,000 from Rafael through November 12, 2024.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We intend to continue to borrow from Rafael through the consummation of the Merger or termination of the Merger Agreement. If the Merger Agreement is terminated, we intend to continue to raise such capital through the sale of equity securities from time to time, the issuance of debt securities, the sale or licensing of existing assets or assets in development, or from other non-dilutive funding mechanisms. Our ability to obtain such additional capital will likely be subject to various factors, including our overall business performance and market conditions. If we cannot raise the additional funds required for our anticipated operations, we may be required to reduce the scope of or eliminate our research and development programs, delay our clinical trials and the ability to seek regulatory approvals, downsize our general and administrative infrastructure, and/or seek alternative measures to avoid insolvency. If we raise additional funds through future offerings of shares of our common stock or other securities, such offerings would cause dilution of current stockholders’ percentage ownership in the Company, which could be substantial. Future offerings also could have a material and adverse effect on the price of our common stock.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Our condensed consolidated financial statements for the three and nine months ended September 30, 2024, were prepared on the basis of a going concern, which contemplates that we will be able to realize assets and discharge liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon the availability of equity or debt financing as noted above, including from Rafael. Various factors including our overall business performance and market conditions raise substantial doubt about our ability to continue as a going concern. The condensed and consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> 5498914 250000 400000 -8832944 -19157261 -103013942 -18222671 928010 -15463491 15000000 <p style="font-

family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following is a summary of the more significant accounting policies of the Company that affect the accompanying condensed consolidated financial statements:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a) BASIS OF PRESENTATION--The condensed consolidated financial statements include the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The interim condensed consolidated financial statements of the Company included in this Quarterly Report on Form 10-Q, including these notes, are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Such adjustments are of a normal, recurring nature. The condensed consolidated financial statements, and these notes, have been prepared in accordance with generally accepted accounting principles and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The condensed consolidated financial statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b) CASH AND CASH EQUIVALENTS--Cash and cash equivalents consist of cash and any highly liquid investments with an original purchased maturity of three months or less. The Company maintains deposits in financial institutions in excess of federally insured limits of $250,000, in the amount of $928,010 at September 30, 2024.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(c) ACCOUNTS RECEIVABLE--Accounts receivable are unsecured and non-interest bearing and stated at the amount we expect to collect from outstanding balances. Customer account balances with invoices dated over 90 days old are considered past due. The Company does not accrue interest on past due accounts. Customer payments are allocated to the specific invoices identified on the customer’s remittance advice or, if unspecified, applied to the oldest unpaid invoices.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The carrying amount of accounts receivable is reduced by an allowance for credit losses that reflects management’s best estimate of expected credit losses. The Company reviews each customer balance where all or a portion of the balance exceeds 90 days from the invoice date. Based on the Company’s assessment of the customer's current and forecasted creditworthiness, the Company estimates the portion, if any, of the balance that will not be collected, and writes off receivables as a charge to the allowance for credit losses when, in management’s estimation, it is probable that the receivable is worthless. The Company determined an allowance for credit losses was not necessary as of September 30, 2024. The allowance for credit losses at December 31, 2023 approximated $10,000.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company develops and documents its allowance for credit losses on its trade receivables based on portfolio segments, which include domestic and international customers. The determination of portfolio segments is based primarily on the customers’ geographical location. Our quantitative allowance for credit loss estimates was determined using the method that uses an aging schedule. The Company also considers qualitative adjustments that may relate to unique risks, changes in current economic conditions that may not be reflected in quantitatively derived results, or other relevant factors to further inform our estimate of the allowance for credit losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(d) INVENTORY AND COST OF PRODUCTS SOLD--Inventory consists of cyclodextrin products and chemical complexes purchased for resale recorded at the lower of cost (first-in, first-out) or net realizable value. Cost of products sold includes the acquisition cost of the products sold and does not include any allocation of inbound or outbound freight charges, indirect overhead expenses, warehouse and distribution expenses, or depreciation and amortization expense. The Company records a specific reserve for inventory items that are determined to be obsolete. The Company determined no reserve for obsolete inventory was necessary as of September 30, 2024 and December 31, 2023.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company’s reserve for obsolete inventory is based on the Company’s best estimates of product sales and customer demands. It is reasonably possible that the estimates used by the Company to determine its provisions for inventory write-downs will be materially different from actual write-downs. These differences could result in materially higher than expected inventory provisions and related costs, which could have a material adverse effect on the Company’s results of operations and financial condition in the near term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(e) PREPAID CLINICAL EXPENSES--Prepaid clinical expenses consist of our active pharmaceutical ingredients and other raw materials for our pharmaceutical drug Trappsol® Cyclo™ expected to be used in our clinical trial program recorded at cost. In addition, advance payments for goods or services for future research and development activities are included as prepaid clinical expenses. Prepaid clinical expenses are expensed as research and development costs as the goods are delivered or the related services are performed. Prepaid clinical expenses expected to be utilized beyond one year from the balance sheet date are classified as non-current assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">(f) FURNITURE AND EQUIPMENT--Furniture and equipment are recorded at cost, less accumulated depreciation. Depreciation is computed using primarily the straight-line method over the estimated useful lives of the assets (generally three to five years for computers and vehicles and seven to ten years for machinery, equipment and office furniture). We periodically review our long-lived assets to determine if the carrying value of assets may not be recoverable. If an impairment is identified, we recognize a loss for the difference between the carrying amount and the estimated fair value of the asset. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(g) LEASES--The Company leases office and warehouse space. The Company determines if an arrangement is a lease at inception. Contracts containing a lease are further evaluated for classification as an operating or finance lease where the Company is a lessee, or as an operating, sales-type or direct financing lease where the Company is a lessor, based on their terms. Operating leases are included in right-of-use ("ROU") lease assets and lease liabilities on the Company’s condensed consolidated balance sheets. The Company subleases office space under one existing lease to a third party. Sublease income is reported as other income in the condensed consolidated statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable lease payments are expensed as incurred. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In evaluating contracts to determine if they qualify as a lease, the Company considers factors such as if the Company has obtained substantially all of the rights to the underlying asset through exclusivity, if it can direct the use of the asset by making decisions about how and for what purpose the asset will be used and if the lessor has substantive substitution rights. This evaluation may require significant judgment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(h) REVENUE RECOGNITION--Revenues are recognized when our customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under Accounting Standard Update (“ASU”) No. 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Product revenues</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The majority of our revenue is garnered in North America from companies in the pharmaceutical industry that are manufacturing or conducting research with our fine chemical products. In other countries, we sell our products primarily to wholesale distributors and other third-party distribution partners.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We treat shipping and handling costs performed after a customer obtains control of the product as a fulfillment cost. We have identified one performance obligation in our contracts with customers which is the delivery of product to our customers. The transaction price is recognized in full when we deliver the product to our customer, which is the point at which we have satisfied our performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For additional information on our revenues, please read Note 3, Revenues, to these condensed consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(i) SHIPPING AND HANDLING FEES--Shipping and handling fees, if billed to customers, are included in product sales. Shipping and handling costs associated with inbound and outbound freight are expensed as incurred and included in freight and shipping expense.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(j) ADVERTISING--Advertising costs are charged to operations when incurred. We incur minimal advertising expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(k) RESEARCH AND DEVELOPMENT COSTS--Research and development costs are expensed as incurred. The Company records amounts paid in advance of the service being rendered as a prepaid asset, and the expense recognized when the service is performed. Research and development costs are primarily comprised of materials used in our clinical trials, personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on our contracts with our vendors and are realized in the ordinary course of business. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(l) INCOME TAXES--Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In addition, tax benefits related to positions considered uncertain are recognized only when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions shall initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts. As of September 30, 2024 and December 31, 2023, the Company has recorded a full valuation allowance against its deferred tax assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(m) NET LOSS PER COMMON SHARE-- Basic and fully diluted net loss per common share is computed using a simple weighted average of common shares outstanding during the periods presented, as outstanding warrants to purchase 15,686,916 shares of common stock were antidilutive for the three and nine months ended September 30, 2024, and warrants to purchase 13,733,117 shares of common stock were antidilutive for the three and nine months ended September 30, 2023. Additionally, outstanding options to purchase 1,779,161 shares of common stock were antidilutive for the three and nine months ended September 30, 2024 and outstanding options to purchase 790,945 shares of common stock were antidilutive for the three and nine months ended September 30, 2023, and therefore also excluded.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(n) STOCK-BASED COMPENSATION--The Company periodically awards stock to employees, directors, and consultants. In the case of employees and consultants, an expense is recognized equal to the fair value of the stock determined using the closing trading price of the stock on the award date. With respect to directors, the Company accrues stock compensation expense on a quarterly basis based on the Company’s historical director compensation policies, and each quarter recognizes such expense based on the trading price of the common stock during such quarter.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This expense is then trued up at the time the shares are issued to directors based on the trading price at the time of issuance.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company periodically issues stock options under its 2021 Equity Incentive Plan. The Company uses the Black-Scholes valuation method to estimate the fair value of stock options at grant date. Compensation expense is recognized on the straight-line basis over the requisite service period, which is generally the vesting period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(o) FAIR VALUE MEASUREMENTS AND DISCLOSURES--Accounting Standards Codification ("ASC”) 820 "Fair Value Measurements and Disclosures” requires companies to determine fair value based on the price that would be received to sell the asset or paid to transfer the liability to a market participant. ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following categories:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Level 1: Quoted market prices in active markets for identical assets or liabilities.</p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Level 3: Unobservable inputs that are not corroborated by market data.</p> </td> </tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-

~~align:justify;margin:0pt;">Long-lived assets are measured at fair value on a non-recurring basis and are subject to fair value adjustments when there is evidence of impairment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For short-term classes of our financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable, and which are not reported at fair value, the carrying amounts approximate fair value due to their short-term nature. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of September 30, 2024, money market funds and a convertible notes payable were the only financial instruments measured and recorded at fair value on a recurring basis on the Company's condensed consolidated balance sheets. Money market funds were recorded within cash and cash equivalents. We classified the convertible notes payable as a Level 3 fair value measurement and used the Black-Scholes model to calculate the fair value as of the date of issuance, and for each reporting period. Key inputs for the simulation are summarized below. The Black-Scholes simulation uses inputs such as the stock price, volatility, the contractual term of the convertible notes payable, risk free interest rates and dividend yields. The following table presents money market funds and the convertible notes payable at their level within the fair value hierarchy for the periods indicated. As of December 31, 2023, money market funds were the only financial instrument measured and recorded at fair value on a recurring basis on the Company's condensed consolidated balance sheets.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14.8%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Fair Value</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Hierarchy</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Level</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Amortized</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Cost</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Gross</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Unrealized</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Gains</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Gross</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Unrealized</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Losses</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Fair Value</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 37.2%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash equivalents:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds invested in U.S. government obligations</p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Level 1</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New~~

```
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times
New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times
New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Liabilities:</td> <td style="text-align: center; font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-
size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-
left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td
style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td>
<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr
style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255,
255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible notes payable (Note 7)
</p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin:
0pt;">Level 3</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0,
0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-
left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,000,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left:
0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid
rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,178,000</td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-
align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0,
0, 0);">12,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-
bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="2" style="font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant:
normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;
border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,000,000</td> <td style="width: 1%; font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width:
1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times
New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width:
9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px
double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-
bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;
border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,178,000</td> <td style="width: 1%; font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width:
1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times
New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width:
9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px
double rgb(0, 0, 0);">12,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal;
margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times
```

~~New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash equivalents:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds invested in U.S. government obligations</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Level 1</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,792,338</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,792,338</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"> </p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible notes payable (Note 7)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">Level 3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New~~

Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,792,338</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,792,338</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The range of key inputs for the Black-Scholes simulation for the three and nine months ended September 30, 2024, were as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Three months ended</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Nine months ended</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Key Inputs</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="4" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> September 30, 2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="4" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30, 2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock Price</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%; text-align: right;">$0.68</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; width: 1%;">-</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6%;">$1.26</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%; text-align: right;">$0.68</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; text-align: center;">-</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6%;">$1.27</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Term (years)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">0.09</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.33</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">0.09</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.37</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin:

~~***0pt;">Risk-Free interest rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.7</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.40</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.7</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.40</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Volatility</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">53%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">110%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">53%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">110%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Convertible Notes Payable</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table sets forth a summary of the changes in the fair value of our convertible notes payable categorized within Level 3 of the fair value hierarchy:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 84%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of Convertible Notes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,000,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Change in fair value of Notes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of September 30, 2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(p) USE OF ESTIMATES--The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions, including regarding contingencies, that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company’s most significant estimates relate to inventory obsolescence, stock-based compensation, fair value of convertible notes issued, warrant liability valuation, fair value of warrants issued, assumed liabilities, and allowance for credit losses. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(q) RECENT ACCOUNTING PRONOUNCEMENTS--</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In December 2023, the Financial Accounting Standards Board (FASB) issued ASU 2023-09, "Income Taxes***~~

~~(Topic 740) - Improvements to Income Tax Disclosures." The new guidance is intended to enhance the transparency and decision usefulness of income tax disclosures by requiring disaggregated information about a reporting entity's effective tax rate reconciliation and information on income taxes paid. The amendment is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis, with retrospective application permitted. The Company is in the process of evaluating the impact that the adoption of ASU 2023-09 will have on its condensed consolidated financial statements and related disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures,” which is intended to improve reportable segment disclosure requirements, primarily through additional and more detailed information about a reportable segment's expenses. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with retrospective application required and early adoption permitted. The Company is currently evaluating the effect this new guidance will have on its condensed consolidated financial statements and related disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In June 2022, the FASB issued ASU No. 2022-03, “Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions” ("ASU 2022-03”) which clarifies guidance for fair value measurement of an equity security subject to a contractual sale restriction and establishes new disclosure requirements for such equity securities. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023 and for interim periods within those fiscal years, with early adoption permitted. The Company adopted the new guidance as of January 1, 2024, and it did not have a material impact on its condensed consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(r) WARRANTS--The Company accounts for its warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants considering the authoritative guidance in ASC 480<i>,</i> “Distinguishing Liabilities from Equity” (“ASC 480”) and ASC 815<i>,</i> “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants meet the definition of a liability pursuant to ASC 480<i> </i>and meet all of the requirements for equity classification under ASC 815<i>,</i> including whether the warrants are indexed to the Company’s own common stock and satisfy additional conditions for equity classification. Warrants that are liability-classified are measured at fair value at each reporting date in accordance with the guidance in ASC 820<i>,</i> “Fair Value Measurement,” with any subsequent changes in fair value recognized in the statement of operations in the period of change. The fair value of liability classified warrants was not material at September 30, 2024 and December 31, 2023.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a) BASIS OF PRESENTATION--The condensed consolidated financial statements include the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The interim condensed consolidated financial statements of the Company included in this Quarterly Report on Form 10-Q, including these notes, are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Such adjustments are of a normal, recurring nature. The condensed consolidated financial statements, and these notes, have been prepared in accordance with generally accepted accounting principles and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The condensed consolidated financial statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> (b) CASH AND CASH EQUIVALENTS--Cash and cash equivalents consist of cash and any highly liquid investments with an original purchased maturity of three months or less. The Company maintains deposits in financial institutions in excess of federally insured limits of $250,000, in the amount of $928,010 at September 30, 2024. 928010 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(c) ACCOUNTS RECEIVABLE--Accounts receivable are unsecured and non-interest bearing and stated at the amount we expect to collect from outstanding balances. Customer account balances with invoices dated over 90 days old are considered past due. The Company does not accrue interest on past due accounts. Customer payments are allocated to the specific invoices identified on the customer’s remittance advice or, if unspecified, applied to the oldest unpaid invoices.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The carrying amount of accounts receivable is reduced by an allowance for credit losses that reflects management’s best estimate of expected credit losses. The Company reviews each customer balance where all or a portion of the balance exceeds 90 days from the invoice date. Based on the Company’s assessment of the customer's current and forecasted creditworthiness, the Company estimates the portion, if any, of the balance that will not be collected, and writes off receivables as a charge to the allowance for credit losses when, in management’s estimation, it is probable that the receivable is worthless. The Company determined an allowance for credit losses was not necessary as of September 30, 2024. The allowance for credit losses at December 31, 2023 approximated $10,000.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company develops and documents its allowance for credit losses on its trade receivables based on portfolio segments, which include domestic and international customers. The determination of portfolio segments is based primarily on the customers’ geographical location. Our quantitative allowance for credit loss estimates was determined using the method that uses an aging schedule. The Company also considers qualitative adjustments that may relate to unique risks, changes in current economic conditions that may not be reflected in quantitatively derived results, or other relevant factors to further inform our estimate of the allowance for credit losses.</p> 10000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(d) INVENTORY AND COST OF PRODUCTS SOLD--Inventory consists of cyclodextrin products and chemical complexes purchased for resale recorded at the lower of cost (first-in, first-out) or net realizable value. Cost of products sold includes the acquisition cost of the products sold and does not include any allocation of inbound or outbound freight charges, indirect overhead expenses, warehouse and distribution expenses, or depreciation and amortization expense. The Company records a specific reserve for inventory items that are determined to be obsolete. The Company determined no reserve for obsolete inventory was necessary as of September 30, 2024 and December 31, 2023.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company’s reserve for obsolete inventory is based on the Company’s best estimates of product sales and customer demands. It is reasonably possible that the estimates used by the Company to determine its provisions for inventory write-downs will be materially different from actual write-downs. These differences could result in materially higher than expected inventory provisions and related costs, which could have a material adverse effect on the Company’s results of operations and financial condition in the near term.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(e) PREPAID CLINICAL EXPENSES--Prepaid clinical expenses consist of our active pharmaceutical ingredients and other raw materials for our pharmaceutical drug Trappsol® Cyclo™ expected to be used in our clinical trial program recorded at cost. In addition, advance payments for goods or services for future research and development activities are included as prepaid clinical expenses. Prepaid clinical expenses are expensed as research and development costs as the goods are delivered or the related services are performed. Prepaid clinical expenses expected to be utilized beyond one year from the balance sheet date are classified as non-current assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">(f) FURNITURE AND EQUIPMENT--Furniture and equipment are recorded at cost, less accumulated depreciation. Depreciation is computed using primarily the straight-line method over the estimated useful lives of the assets (generally three to five years for computers and vehicles and seven to ten years for machinery, equipment and office furniture). We periodically review our long-lived assets to determine if the carrying value of assets may not be recoverable. If an impairment is identified, we recognize a loss for the difference between the carrying amount and the estimated fair value of the asset. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(g) LEASES--The Company leases office and warehouse space. The Company determines if an arrangement~~

~~is a lease at inception. Contracts containing a lease are further evaluated for classification as an operating or finance lease where the Company is a lessee, or as an operating, sales-type or direct financing lease where the Company is a lessor, based on their terms. Operating leases are included in right-of-use ("ROU") lease assets and lease liabilities on the Company’s condensed consolidated balance sheets. The Company subleases office space under one existing lease to a third party. Sublease income is reported as other income in the condensed consolidated statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable lease payments are expensed as incurred. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In evaluating contracts to determine if they qualify as a lease, the Company considers factors such as if the Company has obtained substantially all of the rights to the underlying asset through exclusivity, if it can direct the use of the asset by making decisions about how and for what purpose the asset will be used and if the lessor has substantive substitution rights. This evaluation may require significant judgment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(h) REVENUE RECOGNITION--Revenues are recognized when our customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under Accounting Standard Update (“ASU”) No. 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Product revenues</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The majority of our revenue is garnered in North America from companies in the pharmaceutical industry that are manufacturing or conducting research with our fine chemical products. In other countries, we sell our products primarily to wholesale distributors and other third-party distribution partners.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We treat shipping and handling costs performed after a customer obtains control of the product as a fulfillment cost. We have identified one performance obligation in our contracts with customers which is the delivery of product to our customers. The transaction price is recognized in full when we deliver the product to our customer, which is the point at which we have satisfied our performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For additional information on our revenues, please read Note 3, Revenues, to these condensed consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(i) SHIPPING AND HANDLING FEES--Shipping and handling fees, if billed to customers, are included in product sales. Shipping and handling costs associated with inbound and outbound freight are expensed as incurred and included in freight and shipping expense.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(j) ADVERTISING--Advertising costs are charged to operations when incurred. We incur minimal advertising expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(k) RESEARCH AND DEVELOPMENT COSTS--Research and development costs are expensed as incurred. The Company records amounts paid in advance of the service being rendered as a prepaid asset, and the expense recognized when the service is performed. Research and development costs are primarily comprised of materials used in our clinical trials, personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on our contracts with our vendors and are realized in the ordinary course of business. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(l) INCOME TAXES--Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In addition, tax benefits related to positions considered uncertain are recognized only when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions shall initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts. As of September 30, 2024 and December 31, 2023, the Company has recorded a full valuation allowance against its deferred tax assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(m) NET LOSS PER COMMON SHARE-- Basic and fully diluted net loss per common share is computed using a simple weighted average of common shares outstanding during the periods presented, as outstanding warrants to purchase 15,686,916 shares of common stock were antidilutive for the three and nine months ended September 30, 2024, and warrants to purchase 13,733,117 shares of common stock were antidilutive for the three and nine months ended September 30, 2023. Additionally, outstanding options to purchase 1,779,161 shares of common stock were antidilutive for the three and nine months ended September 30, 2024 and outstanding options to purchase 790,945 shares of common stock were antidilutive for the three and nine months ended September 30, 2023, and therefore also excluded.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 15686916 15686916 13733117 13733117 1779161 1779161 790945 790945 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(n) STOCK-BASED COMPENSATION--The Company periodically awards stock to employees, directors, and consultants. In the case of employees and consultants, an expense is recognized equal to the fair value of the stock determined using the closing trading price of the stock on the award date. With respect to directors, the Company accrues stock compensation expense on a quarterly basis based on the Company’s historical director compensation policies, and each quarter recognizes such expense based on the trading price of the common stock during such quarter.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This expense is then trued up at the time the shares are issued to directors based on the trading price at the time of issuance.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company periodically issues stock options under its 2021 Equity Incentive Plan. The Company uses the Black-Scholes valuation method to estimate the fair value of stock options at grant date. Compensation expense is recognized on the straight-line basis over the requisite service period, which is generally the vesting period.</p> <p style="font-family:'Times New~~

~~Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(o) FAIR VALUE MEASUREMENTS AND DISCLOSURES--Accounting Standards Codification ("ASC") 820 "Fair Value Measurements and Disclosures" requires companies to determine fair value based on the price that would be received to sell the asset or paid to transfer the liability to a market participant. ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following categories:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Level 1: Quoted market prices in active markets for identical assets or liabilities.</p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Level 3: Unobservable inputs that are not corroborated by market data.</p> </td> </tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Long-lived assets are measured at fair value on a non-recurring basis and are subject to fair value adjustments when there is evidence of impairment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For short-term classes of our financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable, and which are not reported at fair value, the carrying amounts approximate fair value due to their short-term nature. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of September 30, 2024, money market funds and a convertible notes payable were the only financial instruments measured and recorded at fair value on a recurring basis on the Company's condensed consolidated balance sheets. Money market funds were recorded within cash and cash equivalents. We classified the convertible notes payable as a Level 3 fair value measurement and used the Black-Scholes model to calculate the fair value as of the date of issuance, and for each reporting period. Key inputs for the simulation are summarized below. The Black-Scholes simulation uses inputs such as the stock price, volatility, the contractual term of the convertible notes payable, risk free interest rates and dividend yields. The following table presents money market funds and the convertible notes payable at their level within the fair value hierarchy for the periods indicated. As of December 31, 2023, money market funds were the only financial instrument measured and recorded at fair value on a recurring basis on the Company's condensed consolidated balance sheets.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14.8%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Fair Value</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Hierarchy</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Level</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Amortized</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Cost</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Gross</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Unrealized</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Gains</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Gross</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Unrealized</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Losses</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Fair Value</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 37.2%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash equivalents:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-~~

~~family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds invested in U.S. government obligations</p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Level 1</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Liabilities:</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible notes payable (Note 7)</p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Level 3</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,000,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,000,000</td> <td style="width: 1%; font-~~

~~family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">December 31, 2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash equivalents:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds invested in U.S. government obligations</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Level 1</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,792,338</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,792,338</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"> </p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif;~~

font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible notes payable (Note 7)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">Level 3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,792,338</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,792,338</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The range of key inputs for the Black-Scholes simulation for the three and nine months ended September 30, 2024, were as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Three months ended</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Nine months ended</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Key Inputs</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="4" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> September 30, 2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="4" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30, 2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock Price</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%; text-align: right;">$0.68</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; width: 1%;">-</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6%;">$1.26</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center;

```
font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> </p> </td> <td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%; text-align:
right;">$0.68</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; text-align:
center;">-</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6%;">$1.27</td> <td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align:
bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times
New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Term (years)</p> </td> <td style="width: 1%;
font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt; margin-left: 0pt; text-align: right;">0.09</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.33</td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt; text-align: right;">0.09</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt; margin-left: 0pt;">0.37</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin:
0pt;">Risk-Free interest rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align:
right;">4.7</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;
text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-
left: 0pt;">5.40</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.7</td> <td style="width: 1%; font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width:
6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.40</td> <td style="width: 1%; font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom;
font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Volatility</p> </td> <td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt; margin-left: 0pt; text-align: right;">53%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">110%</td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt; text-align: right;">53%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt; margin-left: 0pt;">110%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin:
0pt;">Dividend yield</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"> </td>
<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-
</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"> </td> <td style="width: 1%; font-family: &quot;Times
New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times
New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New
Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-
variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Convertible Notes Payable</span></p> <p style="font-
family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-
size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table sets forth a summary of the changes in the fair value
of our convertible notes payable categorized within Level 3 of the fair value hierarchy:</p> <p style="font-family:'Times New
Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable"
style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color:
rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 84%;"> <p
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of
December 31, 2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt
9pt;">Issuance of Convertible Notes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-
size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;">10,000,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt
9pt;">Change in fair value of Notes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-
size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom:
1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-
```

~~size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of September 30, 2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14.8%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Fair Value</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Hierarchy</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Level</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Amortized</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Cost</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Gross</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Unrealized</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Gains</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Gross</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Unrealized</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Losses</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Fair Value</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 37.2%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash equivalents:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds invested in U.S. government obligations</p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Level 1</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td~~

```
style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr
style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255,
255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr
style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;">Liabilities:</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align:
right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times
New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-
size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-
left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible notes
payable (Note 7)</p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-
align: center; margin: 0pt;">Level 3</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-
size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom:
1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-
size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,000,000</td> <td style="width: 1%; font-family: &quot;Times
New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-
align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0,
0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;
margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid
rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,178,000</td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-
align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0,
0, 0);">12,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-
bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="2" style="font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant:
normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;
border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,000,000</td> <td style="width: 1%; font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width:
1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times
New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width:
9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px
double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-
bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;
border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,178,000</td> <td style="width: 1%; font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width:
1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times
New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width:
9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px
double rgb(0, 0, 0);">12,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal;
margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times
New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif;
```

~~font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash equivalents:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds invested in U.S. government obligations</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Level 1</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,792,338</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,792,338</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"> </p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible notes payable (Note 7)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">Level 3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0,~~

0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,792,338</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,792,338</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 0 0 10000000 0 2178000 12178000 10000000 2178000 12178000 4792338 0 0 4792338 4792338 0 4792338 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Three months ended</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Nine months ended</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Key Inputs</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="4" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30, 2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="4" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30, 2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock Price</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%; text-align: right;">$0.68</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; width: 1%;">-</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6%;">$1.26</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%; text-align: right;">$0.68</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; text-align: center;">-</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6%;">$1.27</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Term (years)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">0.09</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.33</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">0.09</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.37</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-Free interest rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.7</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.40</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times,

~~serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.7</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.40</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Volatility</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">53%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">110%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">53%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">110%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> 0.68 1.26 0.68 1.27 0.09 0.33 0.09 0.37 0.047 0.054 0.047 0.054 0.53 1.10 0.53 1.10 0 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 84%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of Convertible Notes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,000,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Change in fair value of Notes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of September 30, 2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> </tbody></table> 0 10000000 2178000 12178000 (p) USE OF ESTIMATES--The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions, including regarding contingencies, that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company’s most significant estimates relate to inventory obsolescence, stock-based compensation, fair value of convertible notes issued, warrant liability valuation, fair value of warrants issued, assumed liabilities, and allowance for credit losses. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates. <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(q) RECENT ACCOUNTING PRONOUNCEMENTS--</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In December 2023, the Financial Accounting Standards Board (FASB) issued ASU 2023-09, "Income Taxes (Topic 740) - Improvements to Income Tax Disclosures." The new guidance is intended to enhance the transparency and decision usefulness of income tax disclosures by requiring disaggregated information about a reporting entity's effective tax rate reconciliation and information on income taxes paid. The amendment is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis, with retrospective application permitted. The Company is in the process of evaluating the impact that the adoption of ASU 2023-09 will have on its condensed consolidated financial statements and related disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures,” which is intended to improve reportable segment disclosure requirements, primarily through additional and more detailed information about a reportable segment's expenses. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with retrospective application required and early adoption permitted. The Company is currently evaluating the effect this new guidance will have on its condensed consolidated financial statements and related disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In June 2022, the FASB issued ASU No. 2022-03, “Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions” ("ASU 2022-03”) which clarifies guidance for fair value~~

measurement of an equity security subject to a contractual sale restriction and establishes new disclosure requirements for such equity securities. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023 and for interim periods within those fiscal years, with early adoption permitted. The Company adopted the new guidance as of January 1, 2024, and it did not have a material impact on its condensed consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(r) WARRANTS--The Company accounts for its warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants considering the authoritative guidance in ASC 480<i>,</i> “Distinguishing Liabilities from Equity” (“ASC 480”) and ASC 815<i>,</i> “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants meet the definition of a liability pursuant to ASC 480<i> </i>and meet all of the requirements for equity classification under ASC 815<i>,</i> including whether the warrants are indexed to the Company’s own common stock and satisfy additional conditions for equity classification. Warrants that are liability-classified are measured at fair value at each reporting date in accordance with the guidance in ASC 820<i>,</i> “Fair Value Measurement,” with any subsequent changes in fair value recognized in the statement of operations in the period of change. The fair value of liability classified warrants was not material at September 30, 2024 and December 31, 2023.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3) REVENUES:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company operates in one business segment, which primarily focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life-threatening rare diseases and medical conditions. However, substantially all of the Company’s revenues are derived from the sale of cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Revenues by product are summarized as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Three Months Ended September 30 </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Nine Months Ended September 30,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Trappsol® HPB</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,727</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">342,184</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">256,331</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">485,412</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Trappsol® Fine Chemical</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">196,146</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">152,135</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">300,085</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">267,338</td> <td style="width: 1%;

font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Aquaplex®</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">94</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">658</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,922</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">805</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,098</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,252</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,334</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total revenues</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">233,772</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">495,477</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">559,326</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">765,006</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Three Months Ended September 30 </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Nine Months Ended September 30,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom:

```
1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2"
style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom:
1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-
align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-
size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal;
margin: 0pt;">Trappsol® HPB</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
margin-left: 0pt;">36,727</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td
style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;">342,184</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td
style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;">256,331</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td
style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;">485,412</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Trappsol® Fine
Chemical</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align:
right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">196,146</td> <td style="width: 1%;
font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">152,135</td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt; margin-left: 0pt;">300,085</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align:
right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">267,338</td> <td style="width: 1%;
font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align:
bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Aquaplex®</p> </td> <td style="width: 1%; font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">94</td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt; margin-left: 0pt;">60</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align:
right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">658</td> <td style="width: 1%;
font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,922</td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times
New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-
size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">805</td> <td style="width: 1%;
font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0,
0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-
left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,098</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0,
0);">2,252</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;
padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-
bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,334</td> <td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-
align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total revenues</p> </td> <td style="width: 1%; font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td
style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-
bottom: 3px double rgb(0, 0, 0);">233,772</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-
size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">495,477</td>
```

<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">559,326</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">765,006</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> 36727 342184 256331 485412 196146 152135 300085 267338 94 60 658 9922 805 1098 2252 2334 233772 495477 559326 765006 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(4) MAJOR CUSTOMERS AND SUPPLIERS: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For the three months ended September 30, 2024, three major customers accounted for 91% of total revenues. For the nine months ended September 30, 2024, four major customers accounted for 90% of total revenues. Accounts receivable for these major customers represent 71% of total accounts receivable at September 30, 2024. Accounts receivable balances for four customers accounted for 92% of total accounts receivable at September 30, 2024.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For the three months ended September 30, 2023, two major customers accounted for 90% of total revenues. For the nine months ended September 30, 2023, three major customers accounting for 86% of total revenues. Accounts receivable for these major customers represent 76% of total accounts receivable at September 30, 2023. Accounts receivable balances for three customers accounted for 97% of total accounts receivable at September 30, 2023.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company purchases inventory primarily from four vendors; however, the Company believes it can maintain purchases at similar levels through other readily available vendors in the marketplace. The Company maintains vendors both domestically and internationally.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For the nine months ended September 30, 2024 and 2023, the product mix of our revenues consisted of 99% basic natural and chemically modified cyclodextrins and 1% cyclodextrin complexes. For the three months ended September 30, 2024 and 2023, the product mix of our revenues consisted entirely of basic natural and chemically modified cyclodextrins.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0.91 0.90 0.71 0.92 0.90 0.86 0.76 0.97 0.99 0.99 0.01 0.01 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(5) CONCENTRATIONS OF CREDIT RISK:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Significant concentrations of credit risk for all financial instruments owned by the Company are as follows: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash equivalents represent highly liquid investments with maturities of 90 days or less at the date of purchase. Credit risk related to cash and cash equivalents is based on the creditworthiness of the financial institutions at which these funds are held. The Company has cash balances at financial institutions which throughout the year may exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows. To reduce its risk associated with the failure of such financial institutions, the Company evaluates the rating of the financial institutions in which it holds deposits. Any material loss that the Company may experience in the future could have an adverse effect on its ability to pay its operational expenses or make other payments and may require the Company to move its cash to other high quality financial institutions. Currently, the Company is reviewing its bank relationships in order to mitigate its risk to ensure that its exposure is limited or reduced to the Federal Deposit Insurance Corporation protection limits.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tbody><tr> <td style="vertical-align:top;width:3.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(6) </p> </td> <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ACCOUNTS PAYABLE AND ACCRUED EXPENSES:</p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accounts payable and accrued expenses consist of the following: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> September 30,</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts payable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:

0pt;">5,023,095</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,856,530</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued bonus compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">615,893</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,590,776</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued board expense</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">115,856</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">92,110</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued clinical research</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">520,382</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">137,642</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sub-lease deposit liability</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">51,897</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">243,742</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Merger liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96,838</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">487,402</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">98,022</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">49,214</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total accounts payable and accrued expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,521,983</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,457,416</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">September 30,</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31,</p> </td>

~~<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts payable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,023,095</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,856,530</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued bonus compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">615,893</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,590,776</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued board expense</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">115,856</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">92,110</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued clinical research</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">520,382</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">137,642</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sub-lease deposit liability</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">51,897</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">243,742</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Merger liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96,838</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">487,402</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">98,022</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">49,214</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total accounts payable and accrued expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%;~~

text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,521,983</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,457,416</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 5023095 4856530 615893 1590776 115856 92110 520382 137642 51897 243742 96838 487402 98022 49214 6521983 7457416 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tbody><tr> <td style="vertical-align:top;width:3.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(7) </p> </td> <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CONVERTIBLE NOTES PAYABLE:</p> </td> </tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On June 11, 2024, the Company entered into a Note Purchase Agreement (the "Initial NPA") with Rafael Holdings, Inc., a Delaware corporation ("Rafael"), the holder of approximately 31.5% of our common stock, pursuant to which the Company issued and sold a convertible promissory note in the principal amount of $2,000,000 (the "June Note") to Rafael.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On July 16, 2024, the Company entered into an Amended and Restated Note Purchase Agreement (the "Amended NPA") with Rafael, which amended and restated the Initial NPA in its entirety, pursuant to which the Company issued and sold a second convertible promissory note in the principal amount of $2,000,000 (the "July Note") to Rafael.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On August 21, 2024, the Company entered into a Second Amended and Restated Note Purchase Agreement (the "Second Amended NPA") with Rafael, which amended and restated the Amended NPA dated July 16, 2024 in its entirety, pursuant to which the Company issued and sold a third convertible promissory note in the principal amount of $3,000,000 (the "August Note") to Rafael.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On September 9, 2024, the Company entered into a Third Amended and Restated Note Purchase Agreement (the "Third Amended NPA") with Rafael, which amended and restated the Second Amended NPA dated August 21, 2024 in its entirety, pursuant to which the Company issued and sold a fourth convertible promissory note in the principal amount of $3,000,000 (the "September Note") to Rafael.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On October 8, 2024, the Company and Rafael entered into an Amendment to Convertible Promissory Notes, which amended the maturity date for each of the June Note, July Note, August Note and September Note to December 21, 2024.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On October 8, 2024, the Company entered into a Fourth Amended and Restated Note Purchase Agreement (the "Fourth Amended NPA") with Rafael, which amended and restated the Third Amended NPA dated September 9, 2024 in its entirety, pursuant to which the Company issued and sold a fifth convertible promissory note in the principal amount of $3,000,000 (the "October Note") to Rafael.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On November 7, 2024, the Company entered into a Fifth Amended and Restated Note Purchase Agreement (the "Fifth Amended NPA") with Rafael, which amended and restated the Fourth Amended NPA dated October 8, 2024 in its entirety, pursuant to which the Company issued and sold a sixth convertible promissory note in the principal amount of $2,000,000 (the "November Note," and together with the June Note, July Note, August Note, September Note and October Note, the "Notes," and each a "Note") to Rafael. Each Note matures on December 21, 2024 and bears interest at a rate of 5% per annum, payable upon maturity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Each Note may be prepaid by the Company in full at any time. The principal amount of each Note is convertible into shares of our common stock, prior to the repayment of such Note, at the option of Rafael; automatically if the Company enters into a Qualified Financing (as defined) and at the option of Rafael if a Sale Transaction (as defined) occurs prior to repayment of such Note, all at the price and on the terms and conditions set forth in such Note; provided, however, that Rafael may not elect to convert a Note if, following such conversion, Rafael will beneficially own more than 49.9% of the outstanding common stock of the Company. Upon the occurrence of an Event of Default (as defined) under any Note, including the failure of the Company to pay the principal or interest under any Note, when due, the obligations of the Company under each Note may be accelerated. The Company has used and intends to use the proceeds of the Notes for working capital and general corporate purposes.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Due to these embedded features within the Notes, the Company elected to account for the Notes and the embedded features at fair value at inception. Subsequent changes in fair value are recorded as a component of other income (loss) in the condensed consolidated statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Interest expense on the Notes totaled $129,452 and $163,973 for the three and nine months ended September 30, 2024 and is included in the fair value of the Notes.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table presents the Notes as of September 30, 2024:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of convertible Notes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,000,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Change in fair value of Notes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of September 30, 2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New

~~Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0.315 2000000 2000000 3000000 3000000 3000000 2000000 0.05 129452 163973 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of convertible Notes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,000,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Change in fair value of Notes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of September 30, 2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,178,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> </tbody></table> 0 10000000 2178000 12178000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(8) LEASES:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company entered into an operating lease in January 2023 for office and warehouse space, which has a lease term expiring in January 2026, with an option to extend for an additional three years. As it is not reasonably certain the Company will exercise the option to extend, the additional three years have not been included in the lease term. This lease replaced an existing operating lease which expired in January 2023. The Company also assumed an operating lease for office space which is being subleased to a third party. The lease and sublease agreement expired in August 2024.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Right-of-use lease assets are recorded net of accumulated amortization of $880,084 and $17,242 as of September 30, 2024 and December 31, 2023, respectively. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Lease expense for the three and nine months ended September 30, 2024 was $363,185 and $1,437,196, respectively. Lease expense for the three and nine months ended September 30, 2023 was $7,612 and $22,759, respectively.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> 880084 17242 363185 1437196 7612 22759 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(9) EQUITY TRANSACTIONS:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company accrues stock compensation expense over the period earned for employees and board members. Stock compensation expense for board members is included in “Board of Directors fees and costs” on our condensed consolidated statement of operations, and stock compensation expense for officers and employees that are not board members is included in “Personnel” and “Research and development” on our condensed consolidated statement of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In the three and nine months ended September 30, 2024, the Company recognized compensation expense of approximately $104,500 and $311,137 to board members, in addition to $92,000 of accrued stock compensation as of December 31, 2023 and issued 72,027 and 211,983 shares of common stock to board members in the three and nine months ended September 30, 2024. In the three and nine months ended September 30, 2023, the Company recognized compensation expense to board members of $75,460 and $185,635, in addition to $30,750 of accrued stock compensation as of December 31, 2022, and issued 55,485 and 195,537 shares of common stock to board members in the three and nine months ended September 30, 2023. The Company did not issue any shares to employees during the three and nine months ended September 30, 2024 and 2023.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 104500 311137 92000 72027 211983 75460 185635 30750 55485 195537 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(10) INCOME TAXES:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company reported a net loss for the three and nine months ended September 30, 2024 and 2023. The Company increased its deferred tax asset valuation allowance rather than recognize an income tax benefit.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(11) EQUITY INCENTIVE PLAN:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On August 29, 2019, the Company’s stockholders approved the Company’s 2019 Omnibus Equity Incentive Plan at a special meeting of stockholders (the “Incentive Plan”). The Incentive Plan provides for the issuance of up to 68,437 shares of common stock pursuant to the grant of shares of common stock, stock options or other awards, to employees, officers or directors of, and consultants to, the Company and its subsidiaries. Options granted under the Incentive Plan may either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986, or may be non-qualified options, and are exercisable over periods not exceeding ten years from date of grant. As of September 30, 2024, we had awarded 68,437 shares of common stock as awards under the Incentive Plan, with no shares of common stock remaining available for future awards under the Incentive Plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On June 24, 2021<i>, </i>the Company’s stockholders approved the Company’s 2021 Equity Incentive Plan at its annual meeting of stockholders (the “2021 Plan”). The 2021 Plan provides for the issuance of up to 3,000,000 shares of common stock pursuant to the grant of shares of common stock, stock options or other awards, to employees, officers or directors of, and consultants to, the Company and its subsidiaries. Options granted under the 2021<i> </i>Plan may<i> </i>either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986<i>,</i> as amended, or may<i> </i>be non-qualified options, and are exercisable over periods not<i> </i>exceeding ten years from date of grant. As of September 30, 2024<i>,</i> we had awarded 608,820 shares of common stock and granted options to purchase 1,671,441 shares of common stock under the 2021<i> </i>Plan, with 719,739 shares of common stock remaining available for future awards.~~

~~During the three months ended September 30, 2024, no options to purchase common stock were granted and during the nine months ended September 30, 2024, the Company granted options to purchase 879,341 shares of common stock under the 2021 Plan. The options granted during the nine months ended September 30, 2024 were valued using the Black Scholes option pricing model using the following assumptions: (i) expected term of 3.00 to 6.25 years; (ii) risk free interest rate of 4.41%; (iii) expected volatility of 102.97% to 111.25%; and (iv) dividend yield of 0.0%. The weighted-average grant date fair value of the options issued by the Company during the nine months ended September 30, 2024 ranged from $0.83 to $1.06 per share.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 68437 68437 3000000 608820 1671441 719739 879341 P3Y P6Y3M 0.0441 1.0297 1.1125 0 0.83 1.06 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(12) NET LOSS PER SHARE: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table sets forth the computation of basic and diluted earnings per common share.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Three Months Ended</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Nine Months Ended</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8,832,944</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,771,353</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New~~

~~Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(19,157,261</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14,414,893</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average common shares outstanding, basic and diluted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,729,641</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,191,723</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,674,910</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,394,920</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share, basic and diluted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.31</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.29</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.67</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company reported a net loss for the three and nine months ended September 30, 2024 and 2023, therefore, the basic and diluted net loss per share are the same in the respective periods because the inclusion of potential common shares would have an anti-dilutive effect. Potential shares of common stock that are excluded from the computation of diluted weighted-average shares outstanding are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Three Months Ended</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Nine Months Ended</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-~~

~~size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023 </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,779,161</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">790,945</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,779,161</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">790,945</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,686,916</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,733,117</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,686,916</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,733,117</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Three Months Ended</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Nine Months Ended</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p~~

style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8,832,944</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,771,353</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(19,157,261</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14,414,893</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average common shares outstanding, basic and diluted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,729,641</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,191,723</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,674,910</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-

~~family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,394,920</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share, basic and diluted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.31</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.29</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> (0.67</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> </tbody></table> -8832944 -4771353 -19157261 -14414893 28729641 16191723 28674910 14394920 -0.31 -0.29 -0.67 -1 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Three Months Ended</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Nine Months Ended</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,779,161</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">790,945</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,779,161</td> <td style="width:~~

~~1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">790,945</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,686,916</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,733,117</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,686,916</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,733,117</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 1779161 790945 1779161 790945 15686916 13733117 15686916 13733117 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(13) PURCHASE COMMITMENTS: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In connection with an agreement executed in January 2022 with Ashland, Inc., the Company committed to purchase the minimum amounts of goods used in its normal operations based on completion of certain milestones. The first milestone was met during the first quarter of 2023, and $980,000 of goods were purchased and received. In the second quarter of 2023, the Company was invoiced for the second milestone, and began to receive product during the first quarter of 2024. Milestone three was achieved in the third quarter of 2024 and final payment was made. No future minimum purchases remain as of September 30, 2024.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 980000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(14) SUBSEQUENT EVENTS:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> Nasdaq Delisting Notice</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On October 4, 2024, the Company received two letters from The Nasdaq Stock Market ("Nasdaq") stating that the Company was not in compliance with the following four Nasdaq Listing Rules: (1) failing to maintain a closing bid price of no less than $1.00 per share for 30 consecutive trading days, (2) stockholders' equity of the Company was below the minimum requirement of $2.5 million, (3) failing to maintain a minimum Market Value of Listed Securities of $35 million, and (4) failing to maintain net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pursuant to the Nasdaq Listing Rules, the Company has 180 calendar days from October 4, 2024 (until April 2, 2025) to regain compliance with the Nasdaq Listing Rules. In the event the Company does not regain compliance with item (1) above prior to the expiration of the compliance period, the Company may be granted an additional 180 calendar days to regain compliance, subject to certain conditions. In the event the Company does not regain compliance with item (2) above prior to the expiration of the compliance period, the Company will receive written notification from Nasdaq that its securities are subject to delisting.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Convertible Promissory Notes</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On October 8, 2024, the Company entered into the Fourth Amended NPA with Rafael, pursuant to which the Company issued and sold a convertible promissory note in the principal amount of $3,000,000 to Rafael. On November 7, 2024, the Company entered into the Fifth Amended NPA with Rafael, pursuant to which the Company issued and sold a convertible promissory note in the principal amount of $2,000,000 to Rafael. For additional information on these convertible promissory notes, please read Note 7, Convertible Notes Payable, to these condensed consolidated financial statements.</p> <div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> 3000000 2000000 <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Item 5. Other Information</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the fiscal quarter ended September 30, 2024, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement," as defined in Item 408(a) of Regulation S-K. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>~~

```
M1C83 "'^9]?;R4$C*GXS-)@JS/6:*J%'11S%#: V\5?@L88Y+\\*"(:V M9+ J>E'XV-=*:T/<1")O8FHU<9M1Y[;M,]#Q.A<(CIBBM5A9I8$?)( 55RSU
M[4U3E:D9LM#G-1MP(GX4KHW#")DZC$>]GCGP1U+/3IES F>*)2[JO6NS\%6/ M^:"]^_N"<_!W\NNS;7GKP#ML>8J=2^?7'\?B;O3O313S7LT468]"?
GUB^MNW MX'O%L++ (7"'J3]*[LR0!<=UW-BH:UT;4U4\*FN#&T#G9ENMX2976P+912C; M^X0:I3"(X@0+<1N)0]4PN F>MN8E
&EJPN8*I\HDA64Y;&"98#M1ST*N.$\9U,*1\[[*#K06J3W54_48T J<_@=; MBUKSR9@''=IEYC+9&W+5&2PBR'U#](F5F"^**K
RH[0PAS*V%ZPR2L8F6"E6 M5E^E[]>TG4+$Z1)6GA [[?$?_+2BT2PP(0O[WJ5G,T[8DCH5\,$T$(EM1DBI M7ZP(>J\#7K#]7Q RF&
@ZUJ!7O;_P0M+%IIC:@Y"VF" M0C[/7F5ZJTY+._$Y?5D(F[&MX!//WZ\OH(X;G2[<=P"V])MRS&R"K=>2BT,Z*ZH MMW=%B:
[E$KAG%A2M;34Z2&&P\J8@A,?0"1D/VU.RM,-W3>W 15PZJ+%]-*I+ M]=G@X4="<>R+70>H&+SLOGK]JGLZ>.7'KR8L@*5 $;5Z%
FM*WE0WE9S!P4= M)J&&##[;PP?)ME6OZWH/&H@XZIX<'74'@Y._F8@CV!D>UJ38Q!_P)RCE591U M3TY.NX
7@[^;.R[D;J7FY+3?/3U^^7#::C+'G^B/V$^XX1^RL M(N\OF[V5'#4PVS'L@+VKUY2EX;*=SNU!T5JP8T_-1I(1H']K\TE\MZ; MDD&49V,;0>%
(&,K!V^AXZPF.FE[2!$X*SH)P"(]>&C;W@)H* 5UL MCUD:&U^?I3+Z M9PJ75)L#18Q3$VX*"YE4;T7F:ZRPOMG[X;O35R>G
M;_,G!F_$;Z5&J.DXD_L>! YR^7-[VH(*:6B*+H MHQ2YUMB79 !\Z?TRT]4S]F ?:(ZPL6RJ<^YQ7#LBP7K(S#551)LE%SN)\BF!:^%1^Y=EXX'(:
X8Y5'=!6*"NV2O>N*!XU/I]1]%_;N$,Y&C:SNIFGF:9<.RF+5,[B# M@/-Y;*-I?\=BG:@TMJT!08<5B<5&[6:7GW1MS^_B]AV7COEQP3 M-
/>93]+]@CFM[8\OZ2AQ,/#>MF7:.]_8F>AQ 5TI"?F M"&HSOL"@ZBASSEI\+P[QS]YEY73?[)WO5(D#ZM(XZ3@7*09\"PK\L4,-NX.3
MU_;W@?]E[TYCH]'W3WY^2U?^;C8<=T].A]VCH]>.)>%G=?8<"OKO"6QR)M$O MOW46VL*4J\#=\F7;;.VT2'\U=<:I'=>9"4N["Z_3H??
VKC9'VD.#>D&4-:EK MTT=D&&_0,.Y]W^^]>BU.CK8^ M.=F[!6MY^&'+6HKCWHE_\&7ON+_UP=XG;ZK%RZ-_@$P&@_X_@A_WWM=L+4D_
ME/T5R?[&RK[)#AN+=ZGWU%X.Z1U =0_"=K!KZX([U,RA\#\K?^[VI4/L#8;Z MS=Z9-6RRV2R30;BP[A6?V%YLM8WWSKFTBPTZ-
=+YP6I'UR=M2%6&^[\U@*[. M/@[:#S_>%""/+;=,T>:E?S M*9$E-FZ%IP6JY51WD50'Z_GJ A,IPI*$X6Q(&28%NQO:O;TI.0O7=:6(($_@
M$UR;@_BJA7N76*UJ03O#V[:+2,0H+19TY",0)96/*3L77+&0A;E/S(Y! )_9 MTYN!E*L0%] P=8?X\JX]8>3.^I$8DSPJEX:NJ:( D""NNTZ KR0(I.%O3O"'
MW,+>D;9[!(;52=EA^TG9*_58N^@UUYDN[<&P9QN!;\QU\$>'KDR[NG-7J&$+ MYLWM]17\?,XYLXW*WD56V=RJ3OK!ZWUC$NU,8_;\X,-
HZ542B9/C?@>\U<42VV"4[YFI'@T3;+U]VD\9<,_GE;#M.BL8 M06!>-EO8:ZEL'S(V3671VK9\\:$A>U(ZL]?H!4T-<3499DO8!E'%,3%R/D>3
MP@8B..%'YX]D$-=O4NQ'8R^TP)02CDW.'H,!8&(:W*2RT8!<4:.X;8^-B 3> MQ.XP6HI]X()6;VIJM MNM;27>-
&@0N(RS>%4.ABA\U5$7Q#KT2R:8;@P+$[@Y%K=[%A<+0-O\'L4%14 M'6B>:G07E8IQ"P5U@MM;M9YKP5V[1Z
&5+VZ0MWFR[T::'[7Y99]>C]4^H3'LBIH 1V/4:W$.51K8\(K M!O@\7M#XAKR@CI58%3))6S4^G.Y'$S3PUM*__YW2VM+LYG6H%E+^)?W?K:B6
```

M3[$MKK5MDT")[=48\/"&\BH'-!)3MUQ_F[;^LX2-")8Z;-94/H&HGG6D0,U)/$V7-RBFR#!%ZS-W+6N9+GL%F*?(=6F"5B=F-MH5AD.S81D<%5UMIT?
$EVM9[_5OE]_G"'_G,/7#CFDVR\KV'C]S;K65-0#H3^-M*;,2H\%!V.Z#E6:%4=E1VV'Y7]W4&6)*2F^>9N3-=;U^E6:%4=E1VV'Y7]W4&6)*2F^>9N3-=/U^E6:%4=E1VV'Y7]W4&6)*2F^>9N3-\HF\H[X M?
71[.]I"2346NN(!20DK'8X*X*%*J&F9=>0PR%@'I:3:YV%VWA<(\7SLUE6?-MON[&!_3MIWYRUZCH3)'KL>/+$"O;G%%!\/AU7W3YOR9)O-C^?0,
(T>;TKS@8-M/LG(_]2!_]3_2Q$C_O<1JL?YGYGX*/,YGFU+U0Q>[?=.7N[S"6OW2Z%7]*\E-M3'51Z"7]B/?6J1P?@.]G&B(:^PM,X/_]C'?_!U!+-P04-"
!8I6U9U-J3-MPBD$-#?"@-&0-'AL+W=OO*'DRHT0BX(-#D-*9#(3;3**0B;[L-J'QA30BMU-NML0]M=O==MQB,):-MO*P0X*ZNXZO3U5M+].P7B
9>LU3HOK\P9GG>:NED@1G33;E$03#7HR-RD7>*]-YUG&U&:(J5SW_=!_(SSP-M^<)80FO06[(YCM'\7MXK.K4J+5.>H=!<"E-XZ_N7X?
FP8_D=PQ/'M=YZ!NO)-M1,IG>[B9]OW-L(4$V,U,/I;X0C3U"HB&"^E3K\R:06WG]^T7SO?R9<)TSB2-MZ9]\:A9]_]2'*-MRSCL(Q"5
I'#71AR**^888.>DPM0EINTV0?GJI,F<%S8I(R-HEM7\,32'!MPJ34:#7?(=*YP"EH2ME$#9GF&OYR7L-COAH8IC)Y_GN7
M0[4F=SOTC@-^36835!5R?5&3"\-7W*^8BD*H\^];U].HR"^*BF<$-H9YI-MB,UR,=7-Q0JU=5Y9U(CCT[>0;_,^AN<8W&>/,$$9ILK]6BM0
MTRLG5:^<[-DK;SWB?+X1RYS:AHFINW3>4X+Y#Y2_J#T%0AWU?\NDB&(<*]X@MY!T.R<@JV%,+R-@[-9=7;0NMXC-MJ@P.
\B4/H*@&9Q5]T$SCC]1NMX#U_'UQ8^%P;)(P.*45K;S6[%>-)L!Y\(-MWI_,*<)4+ALXB;]2DL,P^+KUZ%WQ%9^2[[#AF$Y=.=7DOE/EOK/WG-PJV+IA
MV:!I)"_FTHW6N6,B-MCNU^*]Y7[]/$&RV8F-M4P5:@(0*QO?!\M'HY]KZ,(9V9J6UM71DJ.9N-MM=+@UH5B_ZBHU?
9V62PM[^S%ZG?'U)Q>#)#BC$2#9I&UL?51-;]LP#+WG5Q#>-M,&R-5]OR=YL$:-H5W:%=T&;;8=A!<1C;J&VYDM)D_WZ4G63ID.8B41+?XZ,D-M4:
M05AAI@T#I^D%K["J#!'}>-YR6ON0!GAH[]AONMPIESE7>"6JG^5"%R,KL6"!-M2[ZJ](-8W^(VG]#P9:)2W0CKWC<(+!.;,;I4.S2)*QOS*
(I:TFE).#V^%QK!A_P@"_8-MK%#!QQF?5Z@^#1U-_;+R;9CPZ.HTUYG*N69SBRZ/\KE"]H
MC3^\\R+WXH2V8*\M.,4^OBX5SW.).>]^JUCN7@1^=8)AAAL-DTID3[^/:3_)-M?ES[K)"(K]X,Z,8UUG.4=.V#>R)Y^]@>F%-M@Q_9,8N-
$3#;2P*R6!C9ON^1%22A'7CL?^2-"7Y%+:C,>-5>&ME>$($7$H$?-M4GC7=I,06!0333*X?%[QML+-%IP&$+D0A0FD=LK8X)LN2'/BAN#9;IH-LUG(
M;/3]8#-3F@+(W?-M=1L%F5@UNB_)->Z^H5WV=?S/O>^&=USF9:.@PB5!W;.8^H?L.TR_T*+MJGHN-M-/6(SBRH*:,T#G2^%/39MPL38-
FQW\!4$L#!!0-(-%BE;5E?JSKG@(-M-%P&-9->&PO=V]R:W-H965T4-MV&BUD<@-S<4PL2V-DXD2*9,=Q;.;AR@/;2@;_U-NIMXYN]3#9AX5XX?@+Y4
MG3JGNJM8'*1ZU"6B@:=-:'KIE,:TUYZG\Q)KKJ]DBPWM[*2JN:&IVGNZ5-M;M'R/6[0_/>*YIY$TI1U=CH2C:@<+=T;H+K=63M>X-
*SSHDS%8)5LI'^WD-M0[%T?$L(!>;&(G#Z,-W*(0%(AK?1TQG"FD=3\=']'>]=M*RY1K?2/&E*DRY-M=%('"MSQ3IC/\O
>1SVQQG0F!G75#%_^_;AQ"'U-M?^/-1@?6\QX"]2S?P:H^&>/_.M0.!-81=5AP7]IU\N/$/!+827CX'60R#V-MFT-9W,G&E!INFP*+__I[1'IBSH[,U^PBX
;;*PA]%YC/H@MXX92)L,<+++V1"-MPZ#OG+S!.SKO;6OG6K<\QZ5#Q:%1_4!G]>*_OL-MFKA%E]!7&ZK%HJ-#-MD;O+!_6QXMM*5*8B*5][+?"
3P;60N:/W\[)NACXO"S*O,%ZB\JF?_86\W$2-MN#-[%O85SB::[4CS!<0N;;A^%M,X/0GQVI;V73:0DQ\]TP91"$-M)V&S3;5\)I**F0FZEK@R(,8'/$
<4>PXL"MTYF=ZAVI-(<9+@+''3,(4H-MG;N1SV9_FY(,LI14,H@REP71[$$:BL__GPM[9'QDB@&4$!:X61K2F#!C-M>H($SMT?
[Z3B:\O,]C6;/0HS%/^T.K7.FZ%C-#(?^NX=5_NJT2!P1Z[^U3QV-M0-V],>@8V?;]8RL-=:^6%+[1V4-;'\GJ7+&B0TP_5!6/P%02P,$%-@
M6*5M67*WNRUB-@-8-4-!D-!X;"]W;W)K&UL-M?51=;],P%'W?K[@R"('4+1_UC'-2&L'8@]#U3;@-?'@)C>_<<.MM-T-Q[;-M24,GNCZT]K7/.?=<.]?
35JHG72(:V%98Y*AL%@TK.*A2:20$*BQFYCJ[FB<-[P-^&K=Z;@ZMD-M)>63"V[S&0F=(>28&:=-[;#!!7+NA*R-/[TF&5(ZXOY\I_[%UVYK65&-"\E_
MLMR4,W))(,>"-MSVP24(@:[2154^V#BHFNI%N^W/8-M(UR&KQ#BGA![WUTB[_*&&II.E6Q!.;15QTX.-MLUV_7.F:9C@CMB$TJ@V2]-
V;Z"+\=.1;,GA+CJFG^Q=R@RL#O[Q/>,2M@3F7-MV=/O0Y:/BAZV/*>PNG)K=:-!UE$]M^G$H6C
M,/2_DT5)Q1J!"2@H4["AO/&D#AB/HLFEQ[U,:B_6]%G[V[59HP$-A\XSV/OJ-M*U1KW]O:NFN$Z1I@6!V>C^NN:_[!N[?GCJHU$QHX%I8:GDW.":BNG[O
R-KW-MT$H:VY%^6MHG$)4#V/U"VO+ZP"48'M7T+U!+-P04-"-!8I6U9O&TS$4H#-M-#8!P-&0-'AL+W=OLX_J3V/^!
Q\+,!==2[$$::XIF%I;J]29P56.2LM:2=BORT\M;H1&"$-[#-M+57-7T(IN$,)ZY))A'?W;_1G<>-\]34<9!R\?PJ[ZL.%/PF;P432Z5'#3%%B\
M]O<(XH@S?,&Y"D\&7&,[@G['Z/7>\7%OTRD7-MJF4Y+AQJ!87R"9WE;[\$B?_["6SQB"T^%7VYILXK.HX@MG##9%,UNX.LN+!B-MJLJ!-05<5[S36,
72P3N\5G#BHO\\>LQ3J=/O2\EXJNTG=V2R6L-I4%CO2$L-ME(OO)),9\XD.5K==C9)I(<],>7%37K_"NYD[BT(WBV,X-V+LIFG@1M.H%X/,-M#::I&R;!
(,=N3+]91OMGU]@(:@,;\L&V'!;OV1,=LD/(15U3IRMS30IH!"E-MMT37YYK.'>ZL&.XLG+EIF+E)'$"0N$$6D!@9;9+&;A;X0&=&&2U#_QOXEKBJ
M/@L_1B2L_B0:4/N3,'M9)>G-9.+[<'ZB0J9CA4S?7"&7C:XL-IINL,:\DY6N-MB/[-<\X[RAELI:CA2M1MIYF=A$?+ZHTU=!+7\;[X7PIKK0DAB-
804D"Y2ZEJ-MJ&+2S*?"FOZH.7M@4K)&D_'4368)I3B!(+3*'*#(/V)]EBNO(-I2]6]LV^*-MHN+K&MT/WE$[/EN7_;3^9MZ_>1^9W%6$G^.67/U)2MD%
[1H[>S>"$TO-M@5V6]/2B-:TOQ4TQP;!'#-^YLO_%!+-P04-"-!8I6U9.RNTWFL%-#-M(-&0-'AL+W=O_MSV?CE_&OGJF[!M?8BS
2Y;F_+JW%&)UV>_S9(DSQ"_H"N?RSIRR#-EYRA9]-MOF(8S4I1EO9-PW#[&2)Y;WA57KMGPRM;B)3D^)X!7F098C]N<$J?KWNP]WKA
M@2R60EWH#Z]6:($?L7A:W3-YUF\H,Y+AG!.:-X;GU[T1O(RAI01EB2\$/_._M8Z":.J7TFSKY,+ON&:I&.,6)4-@D_ZWQ&*>)I(LEZ?
^AO2:F$FX>O]*CLO&R-M,5/$\9BF7\E,+][7@_,\!P5J7B@SS&N&^0H7D)37OZ"YZKL0!9."BYH5HME-M#3*25__12_T@-@22TRXP:X&Y*[#?
$5BUP#HT@ET+[$,C.+7-.53@U@+W4,&@-M%@P.%7BUP"M[M^J.LB\#)-#PBM%GP%1I25,'I2%*M>Q"DBOO/@HF[Q*I$\,[-M*C"
X!Q\8@N4DW]0Y:A\!@+,$T96Y3F=N"2RGGX"3-I&4@_X110H/97B-MI\<-G/Q^>M47LDH*W$_J\#=5>/.=\!:XI;E8K]#WY>/HGD>
MYNOSN#$[@8]X=0$LXPR8AFFWU&=\N-QJ:\ZO10]_+7K4+;^CZPL-S7>C3[KE-MHV)Q-4SXKCSNE@,9R+-M-69+9?JV;-9ZTPS[Y>S!-%J.M5TNV"\'
M?>@,3!=N%PQ;"MHVM#U_AQAUMET->)=\A1)\W9,C&L=LC7O#/WZ#KO%G6[_J-MA,6:8%M];C=];G?V^8-
*33F>@1"QG.0+F:U&25)D18H$5BEM3A(B6O-4!78V-MG[QA&=#R;7.GTSNK<.33"@X.&^H,&^F$373"8GO_U;,\QW6]MU=ERQI.8PWG
MI^E@C/@2W#.Z)G*P-,?X.2)RP.2GX)/*\SDV)@TQE?YF:9Z?HQ61*#T=;QI\\"@-MY1UT;-
>R_9VW==P9\E@;'!PVU!DVT@F;Z(3%FF!;=O$:NWC=LQ4T1S@%,4UG-M;JYRIJ:K%^"O6YQ_,?L;_
L>BRG'WPN96D"X5K^O]]H<(+)&I,8_N>#W>^7V-=-M8;?M9[[9S_P?]KM%+R0K,NDUDDT+QJO,*-TXIERT+CITASG:=3II@59:J)46-M::5-
:MKF"&XZ^^-WK"OJMNG>EKUAJ[IWN^G4=(]DU>Y.A%N7);JY1[M,)RW0-M2@NUTB*MM-ELV5-HF27&NJ)6+NMO["!F:M*F=I,Y2&B1BVK+I;G:
[%B/RGW:-MG>LW\(,6ZX'\#*L]J/?\-7V^"UB"Y)SD.*Y#&5<#&1:9]6.&PO=V]R:W-H965TB#XP\MHE(HI>D[-3HQY>4%-ER%,87-LV#-M+=&<,Z-
S."0US&!-V1-?-CTG,0IO[(60BPO;9M'"T@P/Z=+2.4O,\H2+.0M-MF]M\R0!/;B"FZRO+M5X;-M[LA\(52#/1PL\1PF(.Z78R;O[-IE2A)(.:$I8C"
[LJ[=R]#M*8.\QP.!-=^Z-M1NI1'BE]4C=?IU>6HR*"&"*A(+#\6L$(XE@AR3A^EJ!6Y5,9;E^_HH?YP\N'-M>
<0<1C3^0:9B<65=6&@*,YS%XHZN_X#R@3H*+Z(QSS_1NNSK6"C*N*!):2PC-M2$A:?,/GDH@M-XG3;."5!MZN0?L=@U9IT-
K70[LT:._KH5,:=/8UZ)8&W9S[-M@JR=<\1+/!PPND9,]99HZB*7>[>6!)-4C:R)8/)7(NW$\$\J-GH"YH40PO1-M&9J0>4IF).*I0-
=11+-4D'2.QC0F$0&./OD@,(DY^@[/(L/Q9VE^/_'1IU_M#VPA@U+0=E0&<%,$X+T30-O=TE0L.-K2*4P;['V]?5]C;TLR*D:\5T9N/"W@
M!);GJ.6<(<_QV@WQC/8W;S4]SFG>@].\AWIS'R)I[C:9U[AL5:.KE>.UW\$;-M8;Y-.)VB_"+XF9$5CB$5__QA(1L9>U$CZP"&30-G0*]FZ.K.7(U['L7CNL,
M[-6V(MH@U-Q\R9@;Y;Q)@-*_LQ78-M+O?:"-[E_D-W@4EWX5MWKB/_FDGO5*1WM*1_35=RA%,YE;IAC?/U\ZZ(I9'B
MSAOM=RG6^CN4X@_=!2;=A3IW-7J[%;U=+;T_Y*2!U9C^3M$X8]%";BO0B":)-MI'DB:/2$_KZ%Y!'8/TUD:[$/?
+:123#?)%A@$BPT!%93NU>IW=//8'+K,25Q-MIK:?:-)1QHA06Y#@.8HSN=ZC&:.)DG^9B2+5Y/XEP"R5RPI'8V!HLL!,S7J)
MF@F;AD3O[230Z5YT^VYW)PT;.K9ZK9;K]NH=_7T1@WT10RU)1TIP44EPH94@-M)_#+C4RS*1KC%_E6(7>%*@?GH*
[/T%_+G'A=VFD]')IV)L%\DV"!2;#0$%A_M\WZE>?__3KO^V['?Z\D4<7>R[FV_7M_IMSL[.:\F"!CXTC,!I';-JM+J:W$=,[-9/Q\\>9K'5R<":;1/.
H@5&T4)3:'7O-M-\4/5U_].#&3]>-=328;K8<<'4=@-([0%%I=S$TIQ=774FYQM)!-\K5>R1AF-MFLAZ\ITEEH[6?H^,(
MC,81FD*KB[FI(+GZ$M(^]';S/JFRTF&04S3>%*%AA%"TVAU=7?5)1)&T&5^D/I(-MA:!)?KD-/-6F.LC?9Y2*UQOEH/KW@.%_4$L#!!0-(-%BE;5FS(_!&!-0
M-!(1-9->&PO=V]R:W-H965TY<$Z.N*';-.1;/>/@S[H-B,(U26?)*<7(?]^$FVZR1G1TURS8?$-MLDGJ>2B2)C/9"/FL5@-:?4T95U-OI75VZ?
LJ6D%*5$=DP,V3I9-IT68I$U]E-M$DA<**7,#X-@X*>$X]R-E$Y)I1#@\2J3Q-B7RY!B8V4P]KS<>:;+2-M]H8_FV0D@3GHI^Q!FI5?
6XEI"EQ1P9&$Y=2[PI&@5"HG/%#9JQI9*@LA-MGNWB4SSU-HL(&$3:FB#F9PTWP)BU9'\]8QZ]9Y6))@JOM&FD@T\%.5*B[12-@A2RLM?\K5R
MQ(Z"L=.N$%8*X;<*O0,*W4JA6Q-MD16T;HDFLXD4&R2MM+%F+PK?%-J&#>7V-M&.=:FJ?4Z.G9'T(#"M'/:%Z>(Q)+-*<)ITL:$;[1512)G&O*$_0@&
(TH*"-\-M1ZA$GPG+S>K#+6A"F?IH[C_:]&"S].?&V@V0W\J(]Q7<((#\-8HWO!]4JA-M7WD,\;Z^;RC5O,)77M>AT^-"YX;M_HM1$8=%^I=!YQN[>9N
M8:]WP-X-42M$>(PB>P%?H$>()WV;!VZ5!F)8.J90]_MKL&;_?0#'@2_M)W+.QG;H]ZOJ?>=U/4FK-+1%(A-?T7S&D]I=L8EV;Z.Z['-M0?
GYYHR:@KWA..QV1^UG-*B!#HX!FDBA%,JYJ=^LP,O,&EIC:M-$N+AJ-FX-M*1>T0QW64(?'0%W;J%K;J&I#-VSZLQU>4]#ISU$->/C=Z-YN*!4F[Q=
M4=OHSF4;;MF&Y[)UUZ3*[A%%R8W@7(;;U@*[>PO3.<$+NB?RV73]=SF/U:&:-MM5_;\/>5-
C>J4VO;>UG;]^&Y\\'NIN>D_JRRY4SQIHCS186W+0IV]R@'D;X9-MS_U&O]A-?6*[@K?]"G8W+&6,IF6,+HL8I28OE38UAG+TU)EW4"),HG(S(FHD
M%HPFQ,YYZK2BY$1QW0SA;3>$W>W0]SCBC?-U;GPR]Z$C6DKN-L[4F8),-MBF%+-?
0^FX]\%\58ZZ_%2__+3#%*S'O4\1@:52#SM#X7)8#>+G0(BMF-MV(709B(N+E=-8I!6P#Q?"E/:JX7=H/X,9/8_4$L#!!0-(-%BE;5E9WYC6-MV_,-,@3-9
>&PO=V]R:W-H965TZZ/[^$Z!X_V7#S(#8!"CV'-Y-C:*!5=V;:T-A-2V>(1,/UDQ45(E+X5-M;UM&-H@?@\+-=AVG9X>$,FLRBL?
F8C+B6Q50!G.!Y#8,B7BZ@8#OQQ:VG@?N-MZ7JCS(-]&45D#0M0?T=SH>_L+(M/0V"2O].D5C:G-1Y>/V?_'"]>+V9)-M)$QY__UU69L#2SDPXIL
W7/]U\@75#7Y/-X(.-/M$]C'0MY6ZEXF((U@Y"R-MY)L\IH4X-.@\Y0-W!;CG-MHIH!TO-&$6+^N6*#(9";Y'PD3K;.8BKDV,UJNA-MS,BX4$(_I1JG)M^Y
N2B3VB1Z(CX"BWHFM$5]0A3Z-KS^)8IRM9HS@/J49-Z-M^!L\H:\LVBJ)WM^"(C20'_3PE+,="$67-:!;6"KT[BN\VFC&F=I(=,=\\$OPTVK\L
)OZQIEA7*?"W7C5B9<0-1";>D5JE0?URM?H9K7Y=M>X>(_W>-1_]!2*LVUV5L]75JZ%DA<(,-MLL(,+M!K4-(XSO!(KQ-!!5K#C-
:P.;W.Z*_*V>KJU5"R0F&PD[_=G0L42\%%-M-=KM(\G*HU[I,7Q@/'!=U>ZI?$"?!8->4*#KH=-]4;7?9M43UQ6PJ6S%,KEY-MF=Q+%$S
1J+#ANKTCS4\&5>DE]L07-N'G*/B&5U8/7%M%?\/5X)S6X(O\24I-M^%B=;N=8Q9-Q17JY/<&U_4GB3'[P@"@:4/54NPD;=2E-92O6)_W+/@2SX)?
^A'6F!;_=M=S2'?6!^<6-LW0!C9J5IK(5_V'G;L6]Q*VDX.YA-QTI51F2D+(/-MSDI"$.OX"$FB^)0C.3;)1K-CJNOX<,;.PY,SKAD1:\HD"F"EH4ZKK^<5R;%1
M&L;5/*BU;J_#4.4U-D1=B!:Y.2F%;(@VIJO"-MU4HDA0,U+U*O+W%^_L=^YW$TN&Z+P5K#OM-#U-M/+@*H,"2=$P_B-U7[/.96KY<,.7^8=?
[1@'DG=*BZ<%&04.Y_Y*7O@Y[@#@^-M-HA[0.QT^T!.Y9)HDB92[$!:;\-F%RY5AS;B*+>7DFEI3JG!Z?2;T-@Q?(+,-MWPJ($C):<5K2G'-_WDN.JXIKV
M&,TI*N-\6Q->F17E<$>HA"?".K102Z?@-M;(F:4*;.K:O@6Y2:;ACVIVOR2JSU8X7-!N7/)-0F$2LGS'O1"R\Z/B+Z,ZP$-MU[6"+[S-XF]\:-HP5"%^J\
(B/DF887L!X^@CQ%$\@<=L"6M>JDGAC>T-M:%V7;H0V/>^6M1FR**V#.2^%J5]OV-##V$Y_U!+-P04-"-!8I6U9+3JX-M]^L!-#M-P-&0-'AL+W=O&?
D;U%3MTP^)E!CPP=)&W/X-M@E,_5X&O,M+%+QS&W/PZ@6IP9-0$]@J4T./)C]-_.-XGN!R5WPPAY/->-KA'/:"#-_=(7$@'-M/_!(
Y=O"T:^4$AGU42Z&DFS%TAS>#":.@>?=(WU_WCF!4K?/G<=1[Y+E_J>E-[M&-:^-ZCY21T"UML_;*1>Z[=D>TJLH4U
MWY>+@NW/!;"S$2BT;5PT!Y49-(W3F*/S+M^.(_R7/CZ$!VY;H1U(;#PTO?C@-MZ]IQN4:'3!\'NC/DUR.:G7^/:$."OV^,'^KDA-+S"R^?-%!+
P04-"-!8-MI6U9QUB-:)L#-7$-&0-'AL+W=O=%M(>4BAN60Z;>-M;!E/J51#OM-%SH%N2E*:Z-
@P'#VE<:;-)N7J.RB5/(1,PRQ&$[U>[,V]-L"27B-MGQA.XNP9%:FL&?M>#/[83#6C6!$D$,E"@JJ?(RP@20HEM8X?M:C6Q"R(Y_/
MZK^7R:MDUE3-@B5?XXW<3S5/0QO8TD,B']CI,]0)V85>Q!)1_D6G"NL8&HH.-M0K*T)JL5I'%6_=+'>B/."$JGGX!K-FX3K!

```
<(I":0UT:P:H+UV@AV32A3UZO< MRXT+J*2S"6RMTOV6J_XJPPRDIR]396/#G[DTE !/V*'N (V0'$ M^>/Z"2TYVQPBB3X$(&FX'";
.;'GXPS/<'^+I*O,D>/V<_QX."*\AO$#$^(6Q@JV<]B]?325\ZUT4/ M_W?TB\T@C15(J6>]H/H,<6",<7"D<0NJF$WU;"O MM%[%M\]
<0!P7MRRUZ$%9V/2LEO.Z,&P[A)@MYW5AEF=;)NYWGM/DZKS.>9^7 M\T'?#-3@I\5W:8 D7LD,GJHMO,-EWL7=F[M>;G MYNW"
[)D/BJZW;*Q^RE#-<2Q)JEQ_%M#K4:G%CR\?J)_+B>O)G/' MD+'FA?P."__DGW=U[%(4.22)[6P&D$2 MI=5_]E ;XD! <88%W%K [0M,7Q"8U
*3MVJ8U@+3MVHXK@7*J=O5W$O#>4RR MY5SP/1&ZMZ+IB]+ZI;2R5Y3JA7(KA7H:*3FYO.(2R)3\0B[9/UR0=:D11$Y8 M&I+;(LOB2-
_]Y(%D49R3K_@"Q;_/+>ETJX9=E!K6E6:W!HKUPB\A>R(3)Q/Q'7[C='M[S'M-N#]^DI3/' MXV:.QQ^[-M7#KUL!\.PE9UJ\QC&-7;R8,
\3YB/!.HZ=-8Z=F1W[S)^?R#4( MW:8^4H:<4O$H/5A)LQ'@G7<2ITVP7&0H\@,'.N7FF9>^AZJ3A^+UC7Y04Y) M,6+I(@AXD37-
E*T,='DA7:%M+DU1DFG3^G]7RF(>UFA7H&;SWM$VQZ3YPU,X.WDA6MKLGJ*D]Z]$R^@$QCRJT<&"FN&CTGPL M6M>_;9)/L;-
\,W"T:U#+ 72X!.'VMQ4DI5V;MQ4!BE(2>&T'&IG/F %H'\ MGOK BN510*Z8+ 2+RU_8UEM(HH#%\2.YY&&TB4"U/08Q#^%!@HC25P(.M8*
M2O-0:3X6K?M+85M$<+&+"&;@6->@TCQWN"31+\>]VJUKS+8\X)K+ PB1U(D1 M!4JR&![ '"SF48WV"&KY
)7F8]&Z_FW+!ZZY?/".8$&M(:#2O)K6BP*']H/E MM6Z5,>V#HQKJ>^J^/".3D_(SK/JUOFEMSN%NTK>KZF ^T>/?>K4S8M
MOCKT<\G$O=Y08M@H56J[5FF!J,[15#>29^5!D3LNU<=>>;D%%H+0'=3S#>?R MZ48K:$XS+?\'4$L#!!0 ( %BE;5F%IR9F @, .,( 9
>&PO=V]R M:W-H965TWF3>C^,U@KP[*Q&2R%N+15+[E<\LQ0, ATR8"Q=<3W #G)A!B_.UB M6OTGC?&P_!K]2Y,[YK*F"FX$_\-
RO9M;B45RV-":ZWNQ_PI=/J&)EPFNFB?9 M=UK'(EFMM"@Z,Q(4K&S?]+D;AP.#&QPQ>)W!>Z_![PQ^DVA+UJ1U2S5=S*38
M$VG4&,T4FK%IW)@-*\TLKK3$7H8^O?@A-)"(?")762;J4BNRI"]TS8'0,C>- MLH:T?\? M8C,5:U'6BF2B,+-(S?:9@FUCA0<0D1LFJ3]@'-
&G4DT8G25?U^A,'/-_P3*N$8IKP;C^^3+%&8U8W2>,!ZECE M!7Y\##7N4>.3J'<@MR![/CPOI@CC\7Q&B9\,",>J((D#YPAATA,F)PE_ZAW(
M*:AD#)4XWG"&QZH UV(PS93V3.E)IE]"X_JC@T.H.8%IMTJ[330YG.GHQ(E" MSTV3X6X?Z^(@C -WN-
OM@RO(7/]W5&Y9J0B'#3J=BQC3E^V5VE:TJ)I;:2TT MWG%-<8=_(2"- /LW F^FKF(NNOZ_9O$/4$L#!!0 ( %BE;5DLQC0V>@4 M + U 9
>&PO=V]R:W-H965T.Q9 MWQ[#8L^0S8PW+/Z>+"GEY#4,HN2JM>1\=:DHR6Q)0R]ILQ6-Q)47%H<>%\UX MH22KF'KS7!0&BJZJ?
27T_*@U&>?G'N/)F*4\\"/Z&),D#4,O?KNA =MLX=\>=4:MLB$'0+0?=40:\0]$X5 M] M!_U3!H!
,3A4,"\'P5,&H$.3^4K;O7_[F&Q[W)N.8;4B<]1:T["!W4*X6 M[[D?969_YK&XZ@L=G]PS3LF _$YN6;2F,?>G 279R80\>F]>UOIB4.[Y04+^
MHJ\\]8*OHO>W9X-\^?7K6.%B#!E)F17Q;K;Q] /Q.N2.17R9$#.:TWF-_E:N M'TGTBKCW\@70WU^ &UT*?*:K-
NFH%T17]6[=>,Z3&W+Y/5NWB:H=E)MR^<., M"_GPH-PZ8?#JZ*#O!>/!L1AP=R/%LD%<:-9F_Q[1\,IC?^K<[J4E\U2E\G*F]&KEIB&
M$AJO:6ORVR]:7_VCSF9(F(&$F4B8A8392)B#A+D@6,7(W=+(7:F1#3KEPKP) MCU.Q*N&9D3D583AY\CB](,]QM"VTX;V8H/5';:F^L
MK/=->U(O0SK&[^ M#=Z.YU]ID*;&1<(,),Q$PBPDS$;"'"3,!<$J[AZ5[AY!\Z^4UM3&2)B!A)E( MF(6$V4B8,SJ:,K<.!06M.%13=__65<_+P-?
I(A7?RH[F8'F-XX(3%+0S7V,9)F0&DFE&9!:3:4YD!I+HI6-?NNGJ;) M"VJ-$S.TG@:E&5":":59!>UH*K6A81THS471JE[=EK578E/.[/&=\_6-
4OIQCD; M6@2$T@PHS832+"C-AM(<*,U%T:J?@UTQ4,-6 ^6XQH:&U@.UX_6HPJO08A^4 M9D-I#I3FHFA5K^[*@MHY=<%:MT)K@%":
:694)H%I=E0F@.EN2A:U=*[6J F M+P8^;"(:)TM_=>0'E7),8R-#RX!0F@FE65":#:4Y4)I;T#1];_93VQVM]^&W
M&,K>;H^0QHM\JU!"9MF$O]WX49XMMR-=YYMPE%WW[5ZF.R]>^%%" OHBI&I[
M();T\79[T+;!V2K?.S)EG+,P/UQ2;T[CK(.X_L+$VKIH9 '*35J3_P%02P,$ M% @ 6*5M68_C&ULK59=;YLP%/TK%INF5FH#
(9_K"%*3;FH?.D6-NCU,>W#@ E:-S6R3 MM/]^MJ$T;0C:HN8AV.:>XW.NC:^#+1-W1P3YH2!'5N*,."EHH3!4B!9YCD63W.@ M?
#MS^L[SP!U),V4&W# H< HK4/?%4NB>V[#$) -/S>DT4QK@;ON9_9OU MKKVLL80%IS])K+*9,W50#
DNJ;KCVVNH_8P,7\2IM/]H6\=Z#HI*J7A>@[6" MG+#JB1_K/.P -$\[P*\!_EO \ !@4 ,&UFBES-JZP@J'@>!;)$RT9C,-FQN+
MUFX(,ZNX4D*_)1JGPN]< 9J@<[3@; -"D34%9 8E6N(G;'KG:*7W3ESJ)D\Z MXDZN0&%"Y:E&W*^NT,G'T\!56J.9R8UJ/?-*CW]
SV=TRYG*)/K*8HA?XUWM MK3'H/QN<^YV$*RAZ:."=(=_SARUZ%O\.'W3(&33Y'EB^X0&^&RE+S"*;RNA- M*MNR5;&-
+9OY(C=AWZM^@;O9M;$?^!+Q2NFP43KL5'J'$PP477,:$Y;*,W3# MHA[Z=0OY&L3O-JV=?.8XNI %CF#FZ/-&@MB $W[ZT!]
[7]J6Y9W(7ED?-=9' MG=;GF)HU:O-8 4>M::Z$=U(?*7S<"!^_Z^X:[[DYL+LZISW2U*0Q->DTM<@P M2P$1AA),!-I@6EJ#ATQ-]DSY_IL?
NL.G^%]^NOW.&_]7O M[I20'$1J*ZO4FZADJCILF]&F>%_:FO5F?*Z+>E6#7VBJ&\$M%BEA$E%(-*77 MF^@E$E65K3J*%
[90K;G29<\V,WTQ 6$"]/N$ZQ6O.V:"YJH3_@502P,$% M @ 6*5M66J%/(!* P # X !D !X;"]W;W)K&ULK5=;;]HP&/TK5C9-
K=0V5P)E@$0AL$WM6I5U>YCV8,('1$WBS#:7[M?/ M=M*,2\A S4OBRW?.B7V^^-):$?K,Y@ M*:$1YJ)*9SI+*.") D6A;AF&JT&QV VY[)!
[[02/(,1\*?D@8J:GK-,@@AB%I 849BVM:[9'+HR7@5\ M#V#%-LI(CF1,R+.L?)ZT-4-^$(3@<\F Q6L)/0A#220^XW?&J>62$KA9?F4?
MJ+&+L8PQ@QX)?P03/F]K#0U-8(H7(7\DJT^0C:=%B4K1&6T8),%Y:]""T>"6&;BB%/1&P@<[WPE'% #
M7:);$(8R=-8'CH.0H6^PY@L.O2_"ZF*A\MJS7V;JQ2@F_X/@*V>8%L@S++AI/ M.7P$B8 ;"NX4P/O'PXO4O;>I#]ZF/BR']\$_-
'5;5MAYXMJ*SSG =Y\ Q3R( M9VGF7B"UB%Z2Z>43 ]1E#/@%ZD:$\N /EJM>4?J62LA-H,D2[$-;$ZL\ [H$
MK?/AG>D:'XN\3\E<128W@&6GT3",AICJY:;'56IZQVD.JM0<[FN:=:&S7-ANU'=?VP^JN:6T'>?M!IF/7S6MW
MQX[].,NJUZZWHX85#7/+CEIN1ZW1%Z4TIWI1)5F_M2C*O2K)!E63#BLBVLL3-L\0MS9);$,NL^%<+?EZ>'5;O$[GVBM498ECA4!PK
M:%241^5"-GH!3%E1SI0"3\V9*LF\*LD&59(-*R)+D^ZPW06Q R%,!52QE5=_PT MO7ND%4X2=?0=$RX.TJHX%]&UL MS5C;CN(X$/T5*
[M:]4@]G7NX+" U))!>J5>M82X/JWTPI(!HDIBQ'>C^^W4N MG8$0 FC\L"_$=NJ8OHTA M(ONAHBOO Y_"]89G ^IHL,5KF
/_LGVAHJ=6+$$80\)"DB *JZ'RJ/?];F:? M&WP-8<\.VBA;R8*0[UGG*1@J6C8AB&#),P8L'CN80!1E1&(:/TI.I7*9 0_; M[^S3?.UB+0O,8$*B;V' -
T.EJZ 5CB-^">R]Z%[!-C7>G!* M@%,'.&< G1+0N=9#MP3DT0S:\&6-7)!Y&@1PC#)I#OG M5+P-!8Z/_B8<4 ]]1-Z/-.1OZ#/%"<.YKABZ2\
U#7A) T(#WVO&]2_A9.UXW6@A4L6W5 MWAGO>SI[_F?=8. M=V$IX/I9N'\]W&B)I%E]!6;.9YWA&Q-, _0,\0(H0_\4C7\;YC5NY;D9%FELQOI
MFF5KVD#='>KKU*QC6T[-RCNU,G5=-SO'9M,&GUW;,>UCLYG,=?J2R(Z";5?! MMEN#[<(**!61GI XBRK."[>#<(MCGV_04Q*$NS
01^W]L66+%EH=WZH%F62N M3#)/)ME4)MG,/M%R3_QQJ'T8_JF5J77LGU9'LG(J63F7EJ:R5RF+XGL2!B=2AB=5F%X\38B;P ()P$J
MJINVJJ:5[-;PRB1S99)Y,LFF,LEF,LE\261'PNM6PNO^/S)2]^2+KF7<2>M$ M;]7A17?
>18OI18N9S"G[DL@*&:@'5PPQT'5^W<30DJ0)+VK>:K2ZT7K,+W)J MXQ.][^H-XY[>GS:-S_2^7UQD_71;7*L]8[H.$X8B6(DI:
\=L;.TN*HJ.IQL M\XN/!>&/NE@71V:B M[1AI\R&Q9)Z'1SRO*>J->;EC_(M84RK10QA$XJJSEG)ST>V*Q9J&1)RS#8W4
M.TO&0R+5(5]UQ893XJ5!8= U#6/0#8D?=2:7Z;D[/KEDL0S\B-YQ).(P)/SQ MF@9L=]7!G?V)>W^UELF)[N1R0U;T
Y5_;.ZX.NH6%,\/:21\%B%.EU>=*;YP MS7X2D+;XY-.=J+Q&R:7,&?N2'+SSKCI&DA$-Z$(F"*+^;.F,!D%"4GE\S:&= MHL\DL/IZ3W?
3BU<7,R>"SECPV??D^JHSZB"/+DDA'V5_RD ]$)0#WC@28>8!Y&-_$F#E =9+>^CE ;W# M@.&1@'X>T']I#X,\8)".?
398Z4C;1)+))6<[Q)/6BI:\2,N51JL!]J-$61\D M5^_Z*DY.WC-)$<;H#7*^QKY\1.^B!8V2:J.[@$3H9YM*X@<"?:0/,B;!+ZKE
MCZB+Q)IP*BZ[4N60D+J+O+]9UI]YI#\+W;!(K@5R(H]Z#?&./GZLB>^J:R\& MP-P/P+6I!?X>1^?(])TATS!QT_7HPS_0S3FRC#2\UQ!NZ\-
O"%?A^&BX\_]Z M=_7ATWBEKGVX=X9#X:RV MR0UD.S'.C5Y/B7A;E0!0IS5!] I!]%Y+$,[#1MV<5'O;W_H>C;RC>M"FV%8/ MD# ;$N9D,
(RK>CB0 E!_-2GT"RGTM5*X\2,_C$/TYPT-YY3_U50I+:%MI2!A M-B3,@82Y0+!:30=%30>O_O'^2'G8I!5M9FVU @FS(6&.O@ 6>J2$-RW#7*
L M:KH8%KH8OI8N/J>/"JK]=$NY>O1!GUB@V$&R=#UV ] FVU8JD# ;$N8,GRX( M\+EACH<'=P&@3FO*&!7*&)U:&;=
[*;Q5$5(@/T)WE/O,:Q!'V@2I!R-:$523 M1+19MY4(),R&A#D9;%1;,HZL WT ]5C3Q[C0QUB_2B /SZX2M(2VM8*$V9 P M!Q+F L%J-
<5&Z3$8W^PZ09]:6[F TFQ0FO-,$0;96@%9*$P=E":90"54UTG% MB\+?T[I!GVUKZ4#2;%":D],.U@X8F_V#>P-4MW6!F*5
S.]R^:!/N[52(&DV M*,W)::/Z(G-P*!.@/NLR*6U(K/8#SMO>$M9Z)IR72MSZJU#$!=2U":D].. M%RZO[RD<25Q:DEAOB;UT[D?_-
"NA%,M>#_K;!:@/"4JS06D.*,V%HM554AJ4 M^.0.I7KR]'D6E$T2C?( ]1Y!:?8S0X2-H^:R YJ("T6K:Z&T)+'>D\QF#!,?
M^0:$]M,/ZAN"TFQ0F@-*I'ER3_*_+!?U6;6=,4!I-BC-R6E5R>/!$#_]@@I4MW4A ME*:C>7+3\>EDL"5^0.8!14O&,WDTB@'48,QIU0$?
XO'0&M?'VP;MU7EAKRY4 MK_4JE\ZA>7+GL%@>",GCY V!;N5:U5VNU3+AZ&306'A0OS"G54M@'-8HA0A*<\P& M"]$8C&PO M=V]R:W-
H965T](V7>^ M)T2@YSPK>-_8"U'>F"9?[TF.^34M20$G6\IR+&#+=B8O&<$;!O[!_4;5#+8^8DS'-OJ4;L>\;70-MR!8? M,K&DQSM2U].1?
&N:&\ W!K@OC>"5P.\]T;HU !5NEG5KH2+L,"#'J-'Q*0WL,F%4E^A0:^TD'V2 M" :G*>#$8$8%0;:#/J,9-.4]Y1PM"$/)'C,"QABS(BUV;>-51
1.,_X)CE=) MA*Y^_M0S!:0B"".NB*2W$GJ.XV)"-!A]=QH<7\"9(T.C@O.@P MW-X]Q!$:?HV7P]L8S5;34;Q$\R]H/)].YS.4W V7
M<8)&PV0R1L-9A*+)_4HBYJN'Y $,D]DMNDH+Q.5#PK6/1)5#IY6^TPV>2<<,-+O"9] P!3M@3,0:_M_&3[UF^ZU]1'DD4?219_$-G)903-
903_0YL&[VI3K=>K-M5ZO6K3X)_;U&S- M CEA.S6$<;2FAT)47X#&VLQY0S7>G-E']LW8UM@CF NK,>X'?3543C';I05'
M&=E"*.LZ@*>*58-:M1&T5)/((Q4PUZCE'F9;PJ0#G&\I3"/U1@9HIN7!WU!+ M P04 " !8I6U94+4D??P" "R"@ &0 'AL+W=OS, M=J#]][.=-
;.;K:QE\0^/M]WKG%.;\/XHU@!2/24)E3TK9646=>V1;2"%(M+ ME@%5)PO&4RS5EB]MD7' L0&EB>TY3FBGF%!KT#.R*1_T6"X30F'*D_W"
M_L'$KF*98P'7+'D@L5SUK2L+Q;# >2+OV>8CE/&T-%_$$F&>:%/J.A:*>H!7 KQ]0' X)<__U@+00D(CK70*@$F=+N(W21N MC"4>]#C;
(*ZU%9M>F.P;M,H7H;I/9I*K4Z)PU83LJW1L5[GD'W//1#:-R)="$QA#7X,?-^$X#WE:IJO+E MO>1KY#42SB"[1+[S#GF.%]3X\T1E/\K*X/B8:
<8[H$O7Z'[C)S&WR[@70._'M=_1LMZ%NR*S(<0=]2UZ MO@9K\/:-
&SKOZY)_2K+Q*N.UVQPW=GKW>3OIKO7;'Z02M7;7QD723W]+MY*!5Y:#5F(,'K/M2-K9B M(\.?MN(IR<:G))NO%VL4_;;ONVY[KQN/
M99PD7 M?3'-W6"^)%2@!!;*E'/95N[R8D(J-I)E9@28,ZD&"K-KB?[>X*4=!Y 0!A\(Z!HK#!B; N2-"&3\[SJ"_MT@'WYP_LU]X[>EE2
Q/%O['25J/@(B EK&C#[:W:?H+.SQO'5RAN_#_9=K%1 M0(K&6"4Z,"H03+8CW75YV ,@SV% W 'BIX#T&4#2 1)OM%7F;4VII7FFU99H
M%XUL;N)SX]'HADGWB@NK\90ASN:?E04R3,AK,F]T46%"R$0)P2R^E#7D9 J6 M,F[(%]C9AO)3#!R;BE-9GI$;60S(]QF()>@?
AQGVC^\64W+R\C0++>IVMX=% MI_&JU1@_HS$A,R5M9<@'64+Y)SY$O[WI^,'T57R4<$;U@"3#,Q)'<7) S^0X M? $UPB,/3X_(2?
HW2#Q?^@S?@;R=D8]*E:9/:4FFC69R3>:@F2H/Y;"]X]S? MX6IWD[^[B/"7A9M]:T>EN)YQ:6I:P"C IF! ;R#(7[T8GD?OCQA->Z/I_QN]
M!==LG+<9#J(19"Q4@Y].&V2?OGCK]NA%_VZCS4GZ5^H>L]8:#?^\9C M2.&$ML76[_:];>Q+.GP,;QLC?GQK)@WAL$)H-
'B+G4&WS:9=6%7[>ETJB]7O MIQ7V9] N ,]7"FNV6[@+^HZ?_P902P,$% @ 6*5M66"KY*AG @ +@< M !D
!X;"]W;W)K&ULK9513]LP$,>_BI5-$TBL M2=.6(99&@G8('M@0'=O#M *NWEU#S^ 0S+:U_LFT=&P4L*RWJO!93!KE0U9OOZCKL"?
K#9P1Q+8C_5S"H M!0,/6F7FL:8<>9H8O67&19.;:_C:>#71".56<8:&1@7I,/VL$5A_R-ZS63FW M\%""0O9I0T_+#J:
7$C+OL(.2RX/6Z+8CVO(YV!^TM@M7W*0[%++A5 K>\2N M5-;;#[B;3=G!V\,D1,KBSJ'[$XBH](^C MCVV,KV3VA'C0$
```

\ZB:Y+A6V@7>ZO12\,COV9NY4 MVJ2#R/^2<-/"-&R8AIU,]*?R*_?O9>ST>2G-*YD]01XUR*-77<;17Y6/_ZA\ MQ=0YZTN9PKW3S-
TDU]RLA+),PI+LH]X'FLU4IW/505WX VZND8Y+WUS3A0;& M!=#X4M,"UQUW9C979/H;4$L#!!0 (%BE;5G?L%;H.0, -(3 -
M>&POWJ65A7FM&\!E(IPGZOEX0EY9*,AG)17I6F M#J9J(4U&DBX4N-O7/"-1\I$$3FZL[TIT7J[4QAI$''O)QQSS&:*D_
MY_%V3D<.VST=#0LE-UL;$Q>PZK1DP3T5&1E3P2>: ZN@)1L.Z!02Y$9[!/7& TK*@Q3,LK MVVD&-\$G4-"V;U>5=3C3=!7US\F&T-
QLDHG2.=-=FHBL0Z.A8 78T7PVA[M1 M50B@,:JTC9S3F9*T\;!FM TK.V5"W,"S^+/8T5X66_O6@UV37=,::IM.QG5 M?UO-
:6_+QJ_2#2I^K\R7A9V.;/I0W>Q:LX(OF_ZRZ Q@ZA&N3JM*K#X+/I,E M,T?\BJ_VG%\\:\L-[]5]@U[/;8OV$,W>?X63":';S).#]]C
M>\@Y=).#MV#R,+<[; \96R>9G7-,%PW@O)B1'W#Z%)NDP63!A>&R[1MXD0'*&: 2#3GZTUOMMXA3Q?!]B>/EP
MVH'\_CQ04WY.',.N8MZP)QA'TA1#H!;]-9HDR.HD\/'O#_:4Q'&:^A' _[B M&$/@:<01S %XP) X;MZ#>^^C"C?_Q1L] E!+ P04 " !8I6U9EXJ[
M', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6 M!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X
4BV M)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(= MI7\=Q_:0T^FO8R*T>EOH^7%H5
J.W&,EC'%BM/XU@LD/['X 4$L#!!0 (M %BE;5G96/ <%P0 *8> / >&PO=V]R:V)O;VLN>&ULQ9E+C],P$(#_ MBI43'*"-DW8?HDC+
[@*5EJ6B%5?D)FYK2.QB.]W'KV?LJ%H'R, EWE,;QTV_ M3#3^QI,W=TK_6"OU@]S7E32S9&?
M_GPT,L6.U\R\5GLNX]18]5Y4ENLK9OD'K9J] MD%MW&;B+47 ;/@['SS:(Y_I_PJ@V&U'P*U4T-9>VC:/FE0.49B?V)B&2U7R6
M'*>0"UF2:VDA2&0NVTO!7'>G\-?SLKUK"[A!#/6Y@!-Z7GKPX2 OE2RY-+PD M\,VH2I3 49)WK&*RX"2 I @D?4;(;S2 S!#([%D@EPX'?AI
Y@AD_HR0G4A. M$,C)04@9P."WD+JR-)R2OR66^9%(]^!F&0ZE?<%#J /$$@3R) 4H!< M-G7-] -1&[(46RG@]TS: /(4@3R-)D!Y!=^X++A)L
Z0[#.(F#E@/6)?5>: M7#;&JIIKXY_QL@F7[S&V?H\C8$X $W*E@*FZG>*>]*7F98B):F9@SWC,*6!> M%
(5JI#5DP1X8,/AP7H28F&C2@4WC,4_::!Y<;>((W6#+&V)BJDD'=HW'/ 7, M&\Y,)V%23"[IP';Q6&> =?VS<=7.2C-IF*\A.XR86]*!Y=*NVV.
G,L"$IJL MV'TW@IA4TBA629]"./=)#04N64"Q$V)B6DEC>"5U8KF%?[A1!M*#:[+<,-0%U \%J*3WA3=
MQ\302U\]UBF_*:87&D,O845&7JRCL('4STE4X,"_V]A>"R/L3$+)1[M"XV.[T5+OA&2E[?P%P;&"U85"TW<1]NDS2>N;
[)IJNH2QC[+&\7*XVO6XROB MM[\ 4$L#!!0 (%BE;5FX-L3&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'/-V;MNPD 0A>%707X
EIE9;A%0I:&-> $+EHLPV/)N M%'C[("C@6"G2H#V5M;8_AM_LM:SKU"5Z5"?X_[0Q-[E5)WCO-BGU'PX%]?[
M<"ICOV["^79E6[>G,MV6[ZG;H]Q'T(J>JNRW84T+]RE>IZ.[GZ0_FURT5MNYD6[W$CA
M<@BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HK MZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ;01Z6V>SA$!O0[V-0&]#O8U ;T.]C4!O M0[V-
0&]#O8U ;T.]C4!OCWI[KT]ZNT)]/:HMR?0VZ/>GD!OW]GL)M#;H][^ MG7K'=*U"?/8\UOC\=U*=;O>&Y^/OR\?)S@MUQ]G![['%+U!+ P04 "
!8 MI6U94]DK*;(! !3&P $P %M#;VYT96YT7U1Y<&5S72YX;6S-F60U_ 338D(HDMVU!X^SKA1VI%HR(J=2ZQ$N_.C+W2 M=\GT;6?
(#;9UU;A95'AO'AAS:4&U-Z&SZ[4S2RR5+EH\+@O;+UFD3*F*E/EPS[;--DW ME]'!(0Z=78TK2N.&H2!B9QW:G9\-#GVO&[*VS&BP4-
:_J#I4L6W%G-]5Y.)^ MB3,9=9Z7*64Z7=>A)7;&DLI<0>3K*MZ+#ON=?;AAVC_YU?Z=3)]AJ%Q8;5R8 MF*7+[8XC:;M')@B1]67_$4^.0?
KJ\U$[[8RR7WJ'Z_W0=M7-P[%NN?Z.O\[X MI']A#@&20X+D2$!RW(#DF(#DN 7)<0>2XQXD!Q^C!$$A*D=!*D=A*D>!*D>A M*D?!*D?
A*D&UL4$L! A0# M% @ 6*5M69)^V8CN *P(!$ (!KP &1O8U!R M;W!S+V-O&UL4$L! A0#% @ 6*5M69E&PO=V]R:W-H965T M&UL4$L!
A0#% @ 6*5M6:M$-IR$!@ 9A@ !@ M ("!Q X 'AL+W=O&PO=V]R:W-H965T&UL4$L! M A0#% @ 6*5M67!MQ%%A"P LW0 !@ ("!;" 'AL
M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 6*5M6:FZ M$"<1'@ 3E@ !@ ("!E$@ 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @
6*5M62A>/$XZ P R 8 !D ("!27, 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 6*5M620^ M:8^[P @@D !D ("!JX$
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 6*5M6!P &0 @(%=D >&PO M=V]R:W-H965T&UL4$L! A0#% @ 6*5M60T"'FW. @ +@H
!D ("! M#)D 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 6*5M60_P4,#' @ \@4 !D ("!., 'AL+W=O&PO=V]R:W-H965T&UL4$L!
A0#% @ 6*5M6;,C\$8$! A !D M ("!FM< 'AL+W=O&PO=V]R M:W-H965T3? !X;"]W;W)K&UL M4$L! A0#% @ 6*5M62TZN/?K 0 [0, !D
("!A.(M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M6*5M686G)F8" P XP@ !D ("!A.T 'AL+W=O&PO=V]R:W-H965T MR#%).@8
&8T 9 " @1H! 0!X;"]W;W)K&UL4$L! A0#% @ 6*5M6;.J["%L P .0L !D M ("!BP&PO=V]R:W-H M965T0(/T% 9 M " @6$.
0!X;"]W;W)K&UL4$L! M A0#% @ 6*5M66"KY*AG @ +@< !D ("!1! 'AL M+W=O&PO / " M ?P7 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 "
!8I6U9N#;$W*D! N M&P &@ @ % ' $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"% ,4 " !8I6U94]DK*;(! !3&P $P @ $A L'@$ 6T-
O;G1E;G1?5'EP97-=+GAM;%!+!08 -0 U &H. $($! end XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by
staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their
employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show=
{};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var
e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?
w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a)
{var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none')
{d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent)
{a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL
DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px
solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report
table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-
align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px;
overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black;
text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt
Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color:
#acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold
10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px;
white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; }
.report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-
color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re,
.report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou {
background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-
bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num,
.report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px
2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width:
17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width:
10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL
DOCUMENT 3.24.3 html 176 216 1 false 56 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet
http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information Document And Entity Information Cover 1
false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.ctd-
holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated
Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets
(Current Period Unaudited) (Parentheticals) Sheet http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-
balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited)
(Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)
Sheet http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed
Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated
Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://www.ctd-holdings.com/20240930/role/statement-condensed-
consolidated-statements-of-stockholders-equity-deficit-unaudited Condensed Consolidated Statements of Stockholders' Equity
(Deficit) (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows
(Unaudited) Sheet http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited
Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 -
Organization and Description of Business Sheet http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-
description-of-business Note 1 - Organization and Description of Business Notes 7 false false R8.htm 007 - Disclosure - Note 2 -
Summary of Significant Accounting Policies Sheet http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-
significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note
3 - Revenues Sheet http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues Note 3 - Revenues Notes 9 false false
R10.htm 009 - Disclosure - Note 4 - Major Customers and Suppliers Sheet http://www.ctd-holdings.com/20240930/role/statement-note-
4-major-customers-and-suppliers Note 4 - Major Customers and Suppliers Notes 10 false false R11.htm 010 - Disclosure - Note 5 -
Concentrations of Credit Risk Sheet http://www.ctd-holdings.com/20240930/role/statement-note-5-concentrations-of-credit-risk Note 5

~~- Concentrations of Credit Risk Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Accounts Payable and Accrued Expenses Sheet http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses Note 6 - Accounts Payable and Accrued Expenses Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Convertible Notes Payable Notes http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable Note 7 - Convertible Notes Payable Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Leases Sheet http://www.ctd-holdings.com/20240930/role/statement-note-8-leases Note 8 - Leases Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Equity Transactions Sheet http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions Note 9 - Equity Transactions Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Income Taxes Sheet http://www.ctd-holdings.com/20240930/role/statement-note-10-income-taxes Note 10 - Income Taxes Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Equity Incentive Plan Sheet http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan Note 11 - Equity Incentive Plan Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Net Loss Per Share Sheet http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share- Note 12 - Net Loss Per Share Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Purchase Commitments Sheet http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments Note 13 - Purchase Commitments Notes 19 false false R20.htm 019 - Disclosure - Note 14 - Subsequent Events Sheet http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events Note 14 - Subsequent Events Notes 20 false false R21.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 21 false false R22.htm 995465 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies 22 false false R23.htm 995466 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies 23 false false R24.htm 995467 - Disclosure - Note 3 - Revenues (Tables) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-tables Note 3 - Revenues (Tables) Tables http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues 24 false false R25.htm 995468 - Disclosure - Note 6 - Accounts Payable and Accrued Expenses (Tables) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-tables Note 6 - Accounts Payable and Accrued Expenses (Tables) Tables http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses 25 false false R26.htm 995469 - Disclosure - Note 7 - Convertible Notes Payable (Tables) Notes http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-tables Note 7 - Convertible Notes Payable (Tables) Tables http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable 26 false false R27.htm 995470 - Disclosure - Note 12 - Net Loss Per Share (Tables) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-tables Note 12 - Net Loss Per Share (Tables) Tables http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share- 27 false false R28.htm 995471 - Disclosure - Note 1 - Organization and Description of Business (Details Textual) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual Note 1 - Organization and Description of Business (Details Textual) Details http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business 28 false false R29.htm 995472 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables 29 false false R30.htm 995473 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Values (Details) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details Note 2 - Summary of Significant Accounting Policies - Fair Values (Details) Details 30 false false R31.htm 995474 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Key Inputs (Details) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details Note 2 - Summary of Significant Accounting Policies - Key Inputs (Details) Details 31 false false R32.htm 995475 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Changes in Fair Value of Notes (Details) Notes http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-changes-in-fair-value-of-notes-details Note 2 - Summary of Significant Accounting Policies - Changes in Fair Value of Notes (Details) Details 32 false false R33.htm 995476 - Disclosure - Note 3 - Revenues (Details Textual) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-details-textual Note 3 - Revenues (Details Textual) Details http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-tables 33 false false R34.htm 995477 - Disclosure - Note 3 - Revenues - Revenues by Product (Details) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-revenues-by-product-details Note 3 - Revenues - Revenues by Product (Details) Details 34 false false R35.htm 995478 - Disclosure - Note 4 - Major Customers and Suppliers (Details Textual) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual Note 4 - Major Customers and Suppliers (Details Textual) Details http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers 35 false false R36.htm 995479 - Disclosure - Note 6 - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details Note 6 - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details) Details 36 false false R37.htm 995480 - Disclosure - Note 7 - Convertible Notes Payable (Details Textual) Notes http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual Note 7 - Convertible Notes Payable (Details Textual) Details http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-tables 37 false false R38.htm 995481 - Disclosure - Note 7 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) Notes http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-schedule-of-convertible-notes-payable-details Note 7 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) Details 38 false false R39.htm 995482 - Disclosure - Note 8 - Leases (Details Textual) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-8-leases-details-textual Note 8 - Leases (Details Textual) Details http://www.ctd-holdings.com/20240930/role/statement-note-8-leases 39 false false R40.htm 995483 - Disclosure - Note 9 - Equity Transactions (Details Textual) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions-details-textual Note 9 - Equity Transactions (Details Textual) Details http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions 40 false false R41.htm 995484 - Disclosure - Note 11 - Equity Incentive Plan (Details Textual) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual Note 11 - Equity Incentive Plan (Details Textual) Details http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan 41 false false R42.htm 995485 - Disclosure - Note 12 - Net Loss Per Share - Earnings Per Share (Details) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-earnings-per-share-details Note 12 - Net Loss Per Share - Earnings Per Share (Details) Details 42 false false R43.htm 995486 - Disclosure - Note 11 - Net Loss Per Share - Antidilutive Securities Weighted Average Shares Outstanding (Details) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-11-net-loss-per-share-antidilutive-securities-weighted-average-shares-outstanding-details Note 11 - Net Loss Per Share - Antidilutive Securities Weighted Average Shares Outstanding (Details) Details 43 false false R44.htm 995487 - Disclosure - Note 13 - Purchase Commitments (Details Textual) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments-details-textual Note 13 - Purchase Commitments (Details Textual) Details http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments 44 false false R45.htm 995488 - Disclosure - Note 14 - Subsequent Events (Details Textual) Sheet http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events-details-textual Note 14 - Subsequent Events (Details Textual) Details http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events 45 false false All Reports Book All Reports ctdh-20240930.xsd ctdh-20240930_cal.xml ctdh-20240930_def.xml ctdh-20240930_lab.xml ctdh-20240930_pre.xml ctdh20240930_10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 64 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ctdh20240930_10q.htm": { "nsprefix": "ctdh", "nsuri": "http://www.ctd-holdings.com/20240930", "dts": { "schema": { "local": ["ctdh-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",~~

"https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["ctdh-20240930_cal.xml"] }, "definitionLink": { "local": ["ctdh-20240930_def.xml"] }, "labelLink": { "local": ["ctdh-20240930_lab.xml"] }, "presentationLink": { "local": ["ctdh-20240930_pre.xml"] }, "inline": { "local": ["ctdh20240930_10q.htm"] } }, "keyStandard": 178, "keyCustom": 38, "axisStandard": 28, "axisCustom": 0, "memberStandard": 26, "memberCustom": 26, "hidden": { "total": 36, "http://fasb.org/us-gaap/2024": 20, "http://xbrl.sec.gov/dei/2024": 5, "http://xbrl.sec.gov/ecd/2024": 4, "http://www.ctd-holdings.com/20240930": 7 }, "contextCount": 176, "entityCount": 1, "segmentCount": 56, "elementCount": 367, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 461, "http://xbrl.sec.gov/dei/2024": 32, "http://xbrl.sec.gov/ecd/2024": 5 }, "report": { "R1": { "role": "http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "unique": true } }, "R3": { "role": "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "ctdh:CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "unique": true } }, "R5": { "role": "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited", "longName": "004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "longName": "005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "unique": true } }, "R7": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business", "longName": "006 - Disclosure - Note 1 - Organization and Description of Business", "shortName": "Note 1 - Organization and Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "ctdh:OrganizationAndDescriptionOfBusinessTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "ctdh:OrganizationAndDescriptionOfBusinessTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "longName": "007 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues", "longName": "008 - Disclosure - Note 3 - Revenues", "shortName": "Note 3 - Revenues", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "longName": "009 - Disclosure - Note 4 - Major Customers and Suppliers", "shortName": "Note 4 - Major Customers and Suppliers", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "ctdh:MajorCustomersAndSuppliersDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "ctdh:MajorCustomersAndSuppliersDisclosureTextBlock",

"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef":
"ctdh20240930_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-
5-concentrations-of-credit-risk", "longName": "010 - Disclosure - Note 5 - Concentrations of Credit Risk", "shortName": "Note 5 -
Concentrations of Credit Risk", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11",
"firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef":
"ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-
gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body",
"html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.ctd-
holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses", "longName": "011 - Disclosure - Note 6 -
Accounts Payable and Accrued Expenses", "shortName": "Note 6 - Accounts Payable and Accrued Expenses", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2024-01-01_2024-
09-30", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-
US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-
gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R13": { "role":
"http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "longName": "012 - Disclosure - Note 7 -
Convertible Notes Payable", "shortName": "Note 7 - Convertible Notes Payable", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-
gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"],
"reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-
01_2024-09-30", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R14": { "role":
"http://www.ctd-holdings.com/20240930/role/statement-note-8-leases", "longName": "013 - Disclosure - Note 8 - Leases", "shortName":
"Note 8 - Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor":
{ "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef":
"ctdh20240930_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-
9-equity-transactions", "longName": "014 - Disclosure - Note 9 - Equity Transactions", "shortName": "Note 9 - Equity Transactions",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef":
"d_2024-01-01_2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang":
"en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef":
"ctdh20240930_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-
10-income-taxes", "longName": "015 - Disclosure - Note 10 - Income Taxes", "shortName": "Note 10 - Income Taxes", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2024-01-
01_2024-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang":
"en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique":
true } }, "R17": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan", "longName": "016 -
Disclosure - Note 11 - Equity Incentive Plan", "shortName": "Note 11 - Equity Incentive Plan", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang":
"en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-
gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } },
"R18": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-", "longName": "017 - Disclosure -
Note 12 - Net Loss Per Share", "shortName": "Note 12 - Net Loss Per Share", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-
gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"],
"reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-
01_2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R19": { "role":
"http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments", "longName": "018 - Disclosure - Note 13 -
Purchase Commitments", "shortName": "Note 13 - Purchase Commitments", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-
gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef":
"ctdh20240930_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-
14-subsequent-events", "longName": "019 - Disclosure - Note 14 - Subsequent Events", "shortName": "Note 14 - Subsequent Events",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef":
"d_2024-01-01_2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first":
true, "unique": true } }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure -
Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name":
"ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"],
"reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-
01_2024-09-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": ["body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R22": { "role":
"http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies", "longName": "995465 - Disclosure -
Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-
30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef":
"ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-
gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-
gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true,
"unique": true } }, "R23": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-
policies-tables", "longName": "995466 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)", "shortName":
"Note 2 - Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType":

~~"tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-tables", "longName": "995467 - Disclosure - Note 3 - Revenues (Tables)", "shortName": "Note 3 - Revenues (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-tables", "longName": "995468 - Disclosure - Note 6 - Accounts Payable and Accrued Expenses (Tables)", "shortName": "Note 6 - Accounts Payable and Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-tables", "longName": "995469 - Disclosure - Note 7 - Convertible Notes Payable (Tables)", "shortName": "Note 7 - Convertible Notes Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-tables", "longName": "995470 - Disclosure - Note 12 - Net Loss Per Share (Tables)", "shortName": "Note 12 - Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual", "longName": "995471 - Disclosure - Note 1 - Organization and Description of Business (Details Textual)", "shortName": "Note 1 - Organization and Description of Business (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-11-12_LineOfCreditFacilityAxis-RafaelHoldingsIncMember_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:LongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ctdh:OrganizationAndDescriptionOfBusinessTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "unique": true } }, "R29": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "longName": "995472 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "unique": true } }, "R30": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details", "longName": "995473 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Values (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Fair Values (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "name": "ctdh:FinancialInstrumentsAmortizedCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "unique": true } }, "R31": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details", "longName": "995474 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Key Inputs (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Key Inputs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30_LongtermDebtTypeAxis-ConvertibleDebtMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember_RangeAxis-MinimumMember", "name": "ctdh:ConvertibleDebtMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_LongtermDebtTypeAxis-ConvertibleDebtMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember_RangeAxis-MinimumMember", "name": "ctdh:ConvertibleDebtMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-changes-in-fair-value-of-notes-details", "longName": "995475 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Changes in Fair Value of Notes (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Changes in Fair Value of Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "i_2023-12-31_FairValueByLiabilityClassAxis-ConvertibleNotesPayableMember", "name": "us-~~

~~gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_FairValueByLiabilityClassAxis-ConvertibleNotesPayableMember", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-details-textual", "longName": "995476 - Disclosure - Note 3 - Revenues (Details Textual)", "shortName": "Note 3 - Revenues (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": null, "uniqueAnchor": null }, "R34": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-revenues-by-product-details", "longName": "995477 - Disclosure - Note 3 - Revenues - Revenues by Product (Details)", "shortName": "Note 3 - Revenues - Revenues by Product (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_ProductOrServiceAxis-TrappsolCycloMember", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "unique": true } }, "R35": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual", "longName": "995478 - Disclosure - Note 4 - Major Customers and Suppliers (Details Textual)", "shortName": "Note 4 - Major Customers and Suppliers (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-ThreeMajorCustomersMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "ctdh:MajorCustomersAndSuppliersDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-ThreeMajorCustomersMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "ctdh:MajorCustomersAndSuppliersDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details", "longName": "995479 - Disclosure - Note 6 - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details)", "shortName": "Note 6 - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual", "longName": "995480 - Disclosure - Note 7 - Convertible Notes Payable (Details Textual)", "shortName": "Note 7 - Convertible Notes Payable (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "i_2024-09-30_LineOfCreditFacilityAxis-RafaelHoldingsIncMember", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_LineOfCreditFacilityAxis-RafaelHoldingsIncMember", "name": "us-gaap:InterestExpenseDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "unique": true } }, "R38": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-schedule-of-convertible-notes-payable-details", "longName": "995481 - Disclosure - Note 7 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details)", "shortName": "Note 7 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ProceedsFromConvertibleDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_LineOfCreditFacilityAxis-RafaelHoldingsIncMember", "name": "us-gaap:ConvertibleNotesPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "unique": true } }, "R39": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-8-leases-details-textual", "longName": "995482 - Disclosure - Note 8 - Leases (Details Textual)", "shortName": "Note 8 - Leases (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "ctdh:OperatingLeaseRightOfUsseAssetAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "ctdh:OperatingLeaseRightOfUsseAssetAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "unique": true } }, "R40": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions-details-textual", "longName": "995483 - Disclosure - Note 9 - Equity Transactions (Details Textual)", "shortName": "Note 9 - Equity Transactions (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30_TitleOfIndividualAxis-BoardMembersMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_TitleOfIndividualAxis-BoardMembersMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual", "longName": "995484 - Disclosure - Note 11 - Equity Incentive Plan (Details Textual)", "shortName": "Note 11 - Equity Incentive Plan (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-~~

gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-earnings-per-share-details", "longName": "995485 - Disclosure - Note 12 - Net Loss Per Share - Earnings Per Share (Details)", "shortName": "Note 12 - Net Loss Per Share - Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_StatementScenarioAxis-ApproximationMember", "name": "us-gaap:EarningsPerShareBasic", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "unique": true } }, "R43": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-11-net-loss-per-share-antidilutive-securities-weighted-average-shares-outstanding-details", "longName": "995486 - Disclosure - Note 11 - Net Loss Per Share - Antidilutive Securities Weighted Average Shares Outstanding (Details)", "shortName": "Note 11 - Net Loss Per Share - Antidilutive Securities Weighted Average Shares Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "unique": true } }, "R44": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments-details-textual", "longName": "995487 - Disclosure - Note 13 - Purchase Commitments (Details Textual)", "shortName": "Note 13 - Purchase Commitments (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "d_2023-01-01_2023-03-31_CounterpartyNameAxis-AshlandIncMember_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentMember", "name": "ctdh:PurchaseCommitmentGoodsPurchasedDuringPeriod", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-03-31_CounterpartyNameAxis-AshlandIncMember_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentMember", "name": "ctdh:PurchaseCommitmentGoodsPurchasedDuringPeriod", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events-details-textual", "longName": "995488 - Disclosure - Note 14 - Subsequent Events (Details Textual)", "shortName": "Note 14 - Subsequent Events (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "i_2024-10-08_DebtInstrumentAxis-OctoberNoteMember_LineOfCreditFacilityAxis-RafaelHoldingsIncMember_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "ctdh20240930_10q.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "ctdh_APICMergerRecapitalizationOptionIncreaseForCostRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "APICMergerRecapitalizationOptionIncreaseForCostRecognition", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "ctdh_APICMergerRecapitalizationOptionIncreaseForCostRecognition", "negatedLabel": "Merger recapitalization transaction costs", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under merger recapitalization." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "totalLabel": "Total accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r32", "r33"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r30", "r33", "r38", "r671"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r30", "r569"] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": ["r524"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accounts receivable, net of allowances of $0 and $10,272, respectively", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r623"] }, "ctdh_AccruedBoardExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "AccruedBoardExpenseCurrent", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "Accrued board expense", "documentation": "Amount of accrued board expense, classified as current." } } }, "auth_ref": [] }, "us-gaap_AccruedBonusesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedBonusesCurrent", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "Accrued bonus compensation", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r33"] }, "ctdh_AccruedClinicalResearchCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "AccruedClinicalResearchCurrent", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "Accrued clinical research", "documentation": "Amount of accrued clinical research, classified as current." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r43", "r569", "r727"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r448", "r609", "r610", "r611", "r613", "r672", "r730"] }, "ctdh_AdjustmentsToAPICMergerRecapitalizationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "AdjustmentsToAPICMergerRecapitalizationLiability", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Adjustment to merger recapitalization liability", "documentation": "Amount of increase (decrease) in APIC sue to merger recapitalization liability." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r23", "r24", "r267"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "totalLabel": "Total adjustments", "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method." } } }, "auth_ref": ["r59"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": ["r88"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r299", "r307"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "terseLabel": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r108", "r178", "r183", "r184", "r185", "r696"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-net-loss-per-share-antidilutive-securities-weighted-average-shares-outstanding-details", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities (in shares)", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r154"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-net-loss-per-share-antidilutive-securities-weighted-average-shares-outstanding-details", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r12"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-net-loss-per-share-antidilutive-securities-weighted-average-shares-outstanding-details", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r12"] }, "ctdh_ApproximationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "ApproximationMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-earnings-per-share-details"], "lang": { "en-us": { "role": { "label": "Approximation [Member]", "documentation": "Related to approximation." } } }, "auth_ref": [] }, "ctdh_AquaplexMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "AquaplexMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-revenues-by-product-details"], "lang": { "en-us": { "role": { "label": "Aquaplex [Member]", "documentation": "Represents information about Aquaplex." } } }, "auth_ref": [] }, "ctdh_AshlandIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "AshlandIncMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments", "http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments-details-textual"], "lang": { "en-us": { "role": { "label": "Ashland, Inc. [Member]", "documentation": "Represents Ashland, Inc." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "TOTAL ASSETS", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r74", "r85", "r104", "r126", "r159", "r163", "r169", "r170", "r180", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r339", "r341", "r370", "r409", "r481", "r541", "r542", "r569", "r586", "r639", "r640", "r686"] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r100", "r111", "r126", "r180", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r339", "r341", "r370", "r569", "r639", "r640", "r686"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "auth_ref": [] }, "ctdh_AugustNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "AugustNoteMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual"], "lang": { "en-us": { "role": { "label": "August Note [Member]", "documentation": "Represents the August note." } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r270", "r271", "r272", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r294", "r295", "r296", "r297", "r298"] }, "ctdh_BasicNaturalAndChemicallyModifiedCyclodexterinsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "BasicNaturalAndChemicallyModifiedCyclodexterinsMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": { "role": { "label": "Basic Natural and Chemically Modified Cyclodexterins [Member]", "documentation": "Represents information pertaining to basic natural and chemically modified cyclodexterins." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "ctdh_BoardMembersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "BoardMembersMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions", "http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Board Members [Member]", "documentation": "information regarding awards relating to board members." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r189", "r190", "r191", "r192", "r193", "r336", "r556", "r557"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r25", "r26", "r189", "r190", "r191", "r192", "r193", "r336", "r556", "r557"] }, "ctdh_BusinessAcquisitionMaximumReimbursementOfCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "BusinessAcquisitionMaximumReimbursementOfCosts", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "ctdh_BusinessAcquisitionMaximumReimbursementOfCosts", "terseLabel": "Business Acquisition, Maximum Reimbursement of Costs", "documentation": "Amount of maximum reimbursement of costs in the business acquisition." } } }, "auth_ref": [] }, "ctdh_BusinessAcquisitionNumberOfWarrantsAbleToReceiveCash": { "xbrltype": "sharesItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "BusinessAcquisitionNumberOfWarrantsAbleToReceiveCash", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "ctdh_BusinessAcquisitionNumberOfWarrantsAbleToReceiveCash", "terseLabel": "Business Acquisition, Number of Warrants Able to Receive Cash", "documentation": "The number of warrants able to receive cash in the business acquisition." } } }, "auth_ref": [] }, "ctdh_BusinessAcquisitionTerminationFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "BusinessAcquisitionTerminationFee", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "ctdh_BusinessAcquisitionTerminationFee", "terseLabel": "Business Acquisition, Termination Fee", "documentation": "Amount of fee if termination of the business acquisition occurs." } } }, "auth_ref": [] }, "us-

~~gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "Merger liabilities", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r27", "r73"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "terseLabel": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r10", "r103", "r531"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r103"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents, fair value", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r673", "r674"] }, "ctdh_CashAndCashEquivalentsGrossUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "CashAndCashEquivalentsGrossUnrealizedGain", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Money market funds invested in U.S. government obligations, gross unrealized losses", "documentation": "Amount of unrealized gain before deducting unrealized loss on cash and cash equivalents." } } }, "auth_ref": [] }, "ctdh_CashAndCashEquivalentsGrossUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "CashAndCashEquivalentsGrossUnrealizedLoss", "crdr": "debit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Money market funds invested in U.S. government obligations, fair value", "documentation": "Amount of unrealized loss before deducting unrealized gain on cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r11"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "CASH AND CASH EQUIVALENTS, beginning of period", "periodEndLabel": "CASH AND CASH EQUIVALENTS, end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r10", "r57", "r123"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r57"] }, "ctdh_ChangeInFairValueOfConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "ChangeInFairValueOfConvertibleNotesPayable", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-schedule-of-convertible-notes-payable-details"], "lang": { "en-us": { "role": { "label": "ctdh_ChangeInFairValueOfConvertibleNotesPayable", "terseLabel": "Change in fair value of Note", "documentation": "Amount of change in fair value of convertible notes payable." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_CityAreaCode", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r97", "r105", "r106", "r107", "r126", "r148", "r149", "r151", "r153", "r161", "r162", "r180", "r201", "r203", "r204", "r205", "r208", "r209", "r229", "r230", "r233", "r236", "r242", "r370", "r442", "r443", "r444", "r445", "r448",~~

~~"r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r469", "r490", "r507", "r518", "r519", "r520", "r521", "r522", "r595", "r606", "r614"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r39", "r77", "r411", "r468"] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r67", "r195", "r196", "r525", "r629", "r634"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r577", "r578", "r579", "r581", "r582", "r583", "r584", "r609", "r610", "r613", "r672", "r726", "r730"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r42"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r42", "r469"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r42"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r5", "r42", "r469", "r487", "r730", "r731"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Preferred stock, par value $.0001 per share, 5,000,000 shares authorized, 0 outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r42", "r413", "r569"] }, "ctdh_ComputersAndVehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "ComputersAndVehiclesMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Computers and Vehicles [Member]", "documentation": "Represents long-lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and the equipment used primarily for road transportation." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r14", "r15", "r28", "r29", "r173", "r524"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r14", "r15", "r28", "r29", "r173", "r439", "r524"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r14", "r15", "r28", "r29", "r173", "r524", "r599"] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-5-concentrations-of-credit-risk"], "lang": { "en-us": { "role": { "label": "Concentration Risk Disclosure [Text Block]", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": ["r61"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r14", "r15", "r28", "r29", "r173"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r14", "r15", "r28", "r29", "r173", "r524"] }, "ctdh_ConvertibleDebtMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "ConvertibleDebtMeasurementInput", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details"], "lang": { "en-us": { "role": { "label": "Key inputs", "documentation": "Value of input used to measure convertible debt." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": ["http://www.ctd-~~

~~holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details"], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": ["r69", "r210", "r211", "r216", "r217", "r218", "r221", "r222", "r223", "r224", "r225", "r545", "r546", "r547", "r548", "r549"] }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtTableTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-tables"], "lang": { "en-us": { "role": { "label": "Convertible Debt [Table Text Block]", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-schedule-of-convertible-notes-payable-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ConvertibleNotesPayable", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": ["r7", "r76", "r695"] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Convertible note payable", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": ["r33"] }, "us-gaap_ConvertibleNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayableMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-changes-in-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable [Member]", "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": ["r32", "r75"] }, "ctdh_CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Cost of goods sold (exclusive of direct and indirect overhead and handling costs)", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period, excluding direct and indirect overhead and handling costs." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CostsAndExpenses", "totalLabel": "Total expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": ["r56"] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "EXPENSES" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments", "http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments-details-textual"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r128", "r129", "r213", "r231", "r392", "r401", "r408", "r534", "r536"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": ["r62", "r173"] }, "ctdh_CyclodexterinComplexesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "CyclodexterinComplexesMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": { "role": { "label": "Cyclodexterin Complexes [Member]", "documentation": "Represents information pertaining to Cyclodexterin complexes." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r7", "r32", "r33", "r75", "r76", "r130", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r545", "r546", "r547", "r548", "r549", "r568", "r607", "r630", "r631", "r632", "r681", "r682"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual"], "lang": { "en-us": { "role": { "label": "Convertible notes payable, amortized cost", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r210", "r378", "r379", "r546", "r547", "r568"] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Convertible notes payable, fair value", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": ["r218", "r369", "r546", "r547", "r674", "r675", "r676", "r677", "r678"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r35", "r211"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events-details-textual", "http://www.ctd-~~

~~holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r7", "r130", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r545", "r546", "r547", "r548", "r549", "r568", "r607", "r630", "r631", "r632", "r681", "r682"] }, "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense", "crdr": "debit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense", "terseLabel": "Deferred Compensation Arrangement with Individual, Compensation Expense", "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement." } } }, "auth_ref": ["r21", "r72"] }, "us-gaap_DepositLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "Sub-lease deposit liability", "documentation": "The current portion, due within one year or one operating cycle, if longer, of deposits held other than customer deposits." } } }, "auth_ref": ["r33"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r3", "r159", "r166", "r170", "r541", "r542"] }, "us-gaap_DepreciationNonproduction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationNonproduction", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives." } } }, "auth_ref": ["r3", "r19"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-tables"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r642"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r265", "r269", "r300", "r301", "r302", "r559"] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business", "http://www.ctd-holdings.com/20240930/role/statement-note-10-income-taxes", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-", "http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-holdings.com/20240930/role/statement-note-5-concentrations-of-credit-risk", "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-note-8-leases", "http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions"], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_DocumentPeriodEndDate", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_DocumentQuarterlyReport", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r590"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_DocumentTransitionReport", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r591"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_DocumentType", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-earnings-per-share-details"], "lang": { "en-us": { "role": { "label": "BASIC AND DILUTED NET LOSS PER COMMON~~

~~SHARE (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r118", "r136", "r137", "r138", "r139", "r140", "r141", "r147", "r148", "r151", "r152", "r153", "r158", "r334", "r338", "r351", "r352", "r405", "r422", "r539"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r12", "r13", "r155"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r146", "r154", "r156", "r157"] }, "ctdh_EmployeeAndBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "EmployeeAndBoardMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions", "http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Employee and Board [Member]", "documentation": "Person or persons classified as employees and members of the board of directors." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-11-net-loss-per-share-antidilutive-securities-weighted-average-shares-outstanding-details", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r588"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityCommonStockSharesOutstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityCurrentReportingStatus", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-10-income-taxes", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-11-net-loss-per-share-antidilutive-securities-weighted-average-shares-outstanding-details", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-earnings-per-share-details", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-tables", "http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments", "http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-changes-in-fair-value-of-notes-details", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-revenues-by-product-details", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-tables", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-5-concentrations-of-credit-risk", "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses", "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details", "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-tables", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-~~

~~payable-schedule-of-convertible-notes-payable-details", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-tables", "http://www.ctd-holdings.com/20240930/role/statement-note-8-leases", "http://www.ctd-holdings.com/20240930/role/statement-note-8-leases-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions", "http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r588"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityFileNumber", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r588"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityInteractiveDataCurrent", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r594"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityRegistrantName", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r588"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityShellCompany", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r588"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r588"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r588"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r5", "r98", "r115", "r116", "r117", "r131", "r132", "r133", "r135", "r140", "r142", "r144", "r160", "r181", "r182", "r194", "r243", "r324", "r325", "r331", "r332", "r333", "r335", "r337", "r338", "r343", "r344", "r345", "r346", "r347", "r348", "r350", "r371", "r372", "r373", "r374", "r375", "r376", "r380", "r382", "r389", "r421", "r433", "r434", "r435", "r448", "r507"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r356", "r357", "r564"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r673", "r674"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r218", "r256", "r257", "r258", "r259", "r260", "r261", "r353", "r355", "r356", "r357", "r358", "r365", "r366", "r368", "r396", "r397", "r398", "r546", "r547", "r553", "r554", "r555", "r563", "r564"] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-changes-in-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": ["r359", "r360", "r361", "r362", "r363", "r364", "r367"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r354", "r355", "r356", "r358", "r563", "r676", "r679"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":~~

~~"FairValueInputsLevel1Member", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r218", "r256", "r261", "r355", "r366", "r396", "r553", "r554", "r555", "r563"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r218", "r256", "r257", "r258", "r259", "r260", "r261", "r355", "r356", "r357", "r358", "r366", "r398", "r546", "r547", "r553", "r554", "r555", "r563", "r564"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-changes-in-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": ["r359", "r360", "r361", "r362", "r363", "r364", "r367"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables"], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": ["r359", "r364", "r367"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r354", "r355", "r356", "r358", "r563", "r676", "r679"] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-changes-in-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "Change in fair value of Note", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": ["r360", "r367"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-changes-in-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "Issuance of Convertible Note", "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r362", "r367"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-changes-in-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r359", "r367"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r218", "r256", "r257", "r258", "r259", "r260", "r261", "r353", "r355", "r356", "r357", "r358", "r365", "r366", "r368", "r396", "r397", "r398", "r546", "r547", "r553", "r554", "r555", "r563", "r564"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r563", "r673", "r674", "r675", "r676", "r677", "r679"] }, "ctdh_FinancialInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "FinancialInstrumentFairValue", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Total, fair value", "documentation": "Fair value portion of financial instrument." } } }, "auth_ref": [] }, "ctdh_FinancialInstrumentGrossUnrealizedLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "FinancialInstrumentGrossUnrealizedLosses", "crdr": "debit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Total, gross unrealized losses", "documentation": "Amount of gross unrealized losses on financial instruments." } } }, "auth_ref": [] }, "ctdh_FinancialInstrumentsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "FinancialInstrumentsAmortizedCost", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Total, amortized cost", "documentation": "Amount of amortized cost of financial instruments." } } }, "auth_ref": [] }, "ctdh_FourMajorCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "FourMajorCustomersMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": { "role": { "label": "Four Major Customers [Member]", "documentation": "Represents information pertaining to four major~~

~~customers." } } }, "auth_ref": [] }, "ctdh_FreightAndShipping": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "FreightAndShipping", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Freight and shipping", "documentation": "Represents the costs related to freight and shipping." } } }, "auth_ref": [] }, "ctdh_GainFromChangeInFairValueOfConvertiblePromissoryNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "GainFromChangeInFairValueOfConvertiblePromissoryNotes", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Convertible notes payable, gross unrealized gains", "documentation": "Represents the gain from the change in fair value of convertible promissory notes." } } }, "auth_ref": [] }, "ctdh_GainLossOnChangeInFairValueOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "GainLossOnChangeInFairValueOfConvertibleDebt", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "ctdh_GainLossOnChangeInFairValueOfConvertibleDebt", "terseLabel": "Loss on change in fair value of convertible promissory note", "negatedTerseLabel": "Loss on change in fair value of convertible promissory note", "documentation": "The amount of gain (loss) on change in fair value of convertible debt." } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 0.0 }, "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_GainLossOnDispositionOfAssets", "negatedLabel": "Loss on disposal of equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property." } } }, "auth_ref": ["r605", "r627", "r628"] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": ["r266", "r268", "r270", "r271", "r272", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r294", "r295", "r296", "r297", "r298"] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": ["r266", "r268", "r270", "r271", "r272", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r294", "r295", "r296", "r297", "r298"] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_GrossProfit", "totalLabel": "GROSS PROFIT", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r48", "r50", "r84", "r126", "r180", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r370", "r540", "r541", "r616", "r618", "r619", "r620", "r621", "r639"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "LOSS BEFORE PROVISION FOR INCOME TAXES", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r49", "r80", "r84", "r406", "r419", "r540", "r541", "r616", "r618", "r619", "r620", "r621"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-10-income-taxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r127", "r311", "r315", "r316", "r317", "r318", "r319", "r322", "r326", "r328", "r329", "r330", "r447", "r562"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "PROVISION FOR INCOME TAXES", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r86", "r95", "r143", "r144", "r159", "r167", "r170", "r314", "r315", "r327", "r423", "r562"] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r114", "r312", "r313", "r319", "r320", "r321", "r323", "r441"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "terseLabel": "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-~~

gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } },
"presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable, net",
"documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from
customers for the credit sale of goods and services." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit",
"calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited":
{ "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order":
7.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-
unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventory, net",
"documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting
entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r2"] }, "us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-
condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Increase or decrease in:" } } },
"auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.ctd-
holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } },
"presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInOtherOperatingAssets", "negatedLabel": "Other", "documentation":
"Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": ["r2"] }, "us-
gaap_IncreaseDecreaseInPrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInPrepaidInsurance", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-
condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } },
"presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidInsurance", "negatedLabel": "Prepaid insurance and
services", "documentation": "Amount of increase (decrease) of consideration paid in advance for insurance that provides economic
benefits in future periods." } } }, "auth_ref": ["r2"] }, "ctdh_IncreaseDecreasePrepaidClinicalExpenses": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "IncreaseDecreasePrepaidClinicalExpenses",
"crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-
flows-unaudited": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
"weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-
statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "ctdh_IncreaseDecreasePrepaidClinicalExpenses",
"negatedLabel": "Prepaid clinical expenses", "documentation": "The increase (decrease) during the reporting period in the amount of
outstanding money paid in advance for clinical expenses that bring economic benefits for future periods." } } }, "auth_ref": [] },
"ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTradingArrLineItems", "auth_ref": ["r592"] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": ["http://www.ctd-
holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual"], "lang": { "en-us": { "role": { "label": "us-
gaap_InterestExpenseDebt", "terseLabel": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds
accounted for as interest expense for debt." } } }, "auth_ref": ["r54", "r223", "r227", "r548", "r549"] }, "us-gaap_InterestPaidNet": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit",
"presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding
capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted
interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing
attributable to accreted interest of debt discount." } } }, "auth_ref": ["r119", "r121", "r122"] }, "us-gaap_InventoryNet": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": {
"http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.ctd-
holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role":
{ "label": "Inventory, net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed
within one year or operating cycle, if longer." } } }, "auth_ref": ["r110", "r532", "r569"] }, "us-gaap_InventoryPolicyTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [
"http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label":
"Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including,
but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory
classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [
"r87", "r102", "r109", "r186", "r187", "r188", "r403", "r537"] }, "us-gaap_InventoryValuationReserves": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryValuationReserves", "crdr": "credit",
"presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-
textual"], "lang": { "en-us": { "role": { "label": "us-gaap_InventoryValuationReserves", "terseLabel": "Inventory Valuation Reserves",
"documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": ["r65", "r602"] }, "ctdh_JulyNoteMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "JulyNoteMember", "presentation": [
"http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-
holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual"], "lang": { "en-us": { "role": { "label": "July
Note [Member]", "documentation": "Represents the July note." } } }, "auth_ref": [] }, "ctdh_JuneNoteMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "JuneNoteMember", "presentation": [
"http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-
holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual"], "lang": { "en-us": { "role": { "label": "June
Note [Member]", "documentation": "Represents the June note." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": [
"http://www.ctd-holdings.com/20240930/role/statement-note-8-leases", "http://www.ctd-holdings.com/20240930/role/statement-note-8-
leases-details-textual"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by
contractual term of lease arrangement." } } }, "auth_ref": ["r387", "r600"] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": [
"http://www.ctd-holdings.com/20240930/role/statement-note-8-leases", "http://www.ctd-holdings.com/20240930/role/statement-note-8-
leases-details-textual"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term
of lease arrangement." } } }, "auth_ref": ["r387", "r600"] }, "us-gaap_LeaseIncome": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LeaseIncome", "crdr": "credit", "calculation": { "http://www.ctd-
holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-
gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.ctd-
holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": {
"label": "Lease income", "documentation": "Amount of lease income from operating, direct financing, and sales-type leases. Includes,
but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and
payable to lessor." } } }, "auth_ref": ["r388"] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.ctd-
holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.ctd-
holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",

~~"http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-10-income-taxes", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-11-net-loss-per-share-antidilutive-securities-weighted-average-shares-outstanding-details", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-earnings-per-share-details", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-tables", "http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments", "http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-changes-in-fair-value-of-notes-details", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-revenues-by-product-details", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-tables", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-5-concentrations-of-credit-risk", "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses", "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details", "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-tables", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-schedule-of-convertible-notes-payable-details", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-tables", "http://www.ctd-holdings.com/20240930/role/statement-note-8-leases", "http://www.ctd-holdings.com/20240930/role/statement-note-8-leases-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions", "http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": ["r385"] }, "ctdh_LesseeOperatingLeaseExtensionOptionRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "LesseeOperatingLeaseExtensionOptionRenewalTerm", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-8-leases-details-textual"], "lang": { "en-us": { "role": { "label": "ctdh_LesseeOperatingLeaseExtensionOptionRenewalTerm", "terseLabel": "Lessee, Operating Lease, Extension Option, Renewal Term", "documentation": "Term of lessee's operating lease renewal under extension option, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-8-leases"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r381"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r47", "r78", "r415", "r569", "r608", "r625", "r680"] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r34", "r101", "r126", "r180", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r340", "r341", "r342", "r370", "r569", "r639", "r686", "r687"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesNoncurrent", "totalLabel": "Total long-term liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r7", "r37", "r38", "r39", "r40", "r126", "r180", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r340", "r341", "r342", "r370", "r639", "r686", "r687"] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "LONG-TERM LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-schedule-of-convertible-notes-payable-details"], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": ["r31", "r36", "r607", "r637", "r638"] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":~~

"LineOfCreditFacilityLenderDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-schedule-of-convertible-notes-payable-details"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": ["r31", "r36", "r607", "r637"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_LocalPhoneNumber", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebt", "terseLabel": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r7", "r76", "r217", "r226", "r546", "r547", "r568", "r695"] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable"], "lang": { "en-us": { "role": { "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": ["r68"] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r7", "r630", "r631", "r632"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r7", "r20", "r630", "r631", "r632"] }, "ctdh_LossFromChangeInFairValueOfConvertiblePromissoryNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "LossFromChangeInFairValueOfConvertiblePromissoryNotes", "crdr": "debit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Convertible notes payable, gross unrealized losses", "documentation": "Represents the loss from a change in the fair value of convertible promissory notes." } } }, "auth_ref": [] }, "ctdh_MachineryAndFurnitureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "MachineryAndFurnitureMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Machinery and Furniture [Member]", "documentation": "Represents the tangible person property used to produce good and services and equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities." } } }, "auth_ref": [] }, "ctdh_MajorCustomersAndSuppliersDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "MajorCustomersAndSuppliersDisclosureTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers"], "lang": { "en-us": { "role": { "label": "Major Customers and Suppliers Disclosure [Text Block]", "documentation": "The entire disclosure for major customers and suppliers during the reporting period." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": ["r173", "r552", "r571", "r574", "r642", "r697", "r698", "r699", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details"], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": ["r197", "r198", "r199", "r200", "r263", "r308", "r358", "r402", "r431", "r432", "r438", "r460", "r461", "r513", "r514", "r515", "r516", "r517", "r526", "r527", "r543", "r550", "r558", "r564", "r565", "r566", "r567", "r572", "r641", "r688", "r689", "r690", "r691", "r692", "r693"] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details"], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": ["r675", "r676", "r677"] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details"], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": ["r675", "r676", "r677"] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details"], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": ["r564", "r675", "r676", "r677"] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details"], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": ["r675", "r676", "r677"] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputSharePriceMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details"], "lang": { "en-us": { "role": { "label": "Measurement Input, Share Price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": ["r675", "r676", "r677"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-

~~significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r356", "r357", "r358", "r564"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r356", "r357", "r358", "r564"] }, "ctdh_MergerAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "MergerAgreementMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "Merger Agreement [Member]", "documentation": "Represents the merger agreement." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details"], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": ["r197", "r198", "r199", "r200", "r263", "r308", "r358", "r402", "r431", "r432", "r438", "r460", "r461", "r513", "r514", "r515", "r516", "r517", "r526", "r527", "r543", "r550", "r558", "r564", "r565", "r566", "r572", "r641", "r688", "r689", "r690", "r691", "r692", "r693"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r644"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r593"] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": ["r173", "r552", "r571", "r574", "r642", "r697", "r698", "r699", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r120"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES", "terseLabel": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r57", "r58", "r59"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-earnings-per-share-details"], "lang": { "en-us": { "role": { "label": "Net loss", "totalLabel": "NET LOSS", "terseLabel": "Net loss", "negatedLabel": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r51", "r59", "r81", "r99", "r112", "r113", "r117", "r126", "r134", "r136", "r137", "r138", "r139", "r140", "r143", "r144", "r150", "r180", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r334", "r338", "r352", "r370", "r420", "r489", "r505", "r506", "r585", "r639"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r593"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r593"] }, "us-gaap_NoninterestExpenseDirectorsFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoninterestExpenseDirectorsFees", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-~~

~~condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Board of Director fees and costs", "documentation": "Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits." } } }, "auth_ref": ["r79"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other income (expense), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r53"] }, "ctdh_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "ctdh_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "ctdh_NovemberNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "NovemberNoteMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual"], "lang": { "en-us": { "role": { "label": "November Note [Member]", "documentation": "Represents the November note." } } }, "auth_ref": [] }, "ctdh_NumberOfMajorCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "NumberOfMajorCustomers", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": { "role": { "label": "ctdh_NumberOfMajorCustomers", "terseLabel": "Number of Major Customers", "documentation": "Represents the number of major customers." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r542", "r617"] }, "ctdh_OctoberNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "OctoberNoteMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual"], "lang": { "en-us": { "role": { "label": "October Note [Member]", "documentation": "Represents the October note." } } }, "auth_ref": [] }, "ctdh_OfficeLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "OfficeLeaseMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-8-leases", "http://www.ctd-holdings.com/20240930/role/statement-note-8-leases-details-textual"], "lang": { "en-us": { "role": { "label": "Office Lease [Member]", "documentation": "Represents information regarding an office lease." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "LOSS FROM OPERATIONS", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r84", "r540", "r616", "r618", "r619", "r620", "r621"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-8-leases-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseExpense", "terseLabel": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r683"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Current portion of lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r384"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Lease liabilities, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r384"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "RIGHT-OF-USE LEASE ASSETS, NET", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r383"] }, "ctdh_OperatingLeaseRightOfUsseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "OperatingLeaseRightOfUsseAssetAmortization", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-8-leases-details-textual"], "lang": { "en-us": { "role": { "label": "ctdh_OperatingLeaseRightOfUsseAssetAmortization", "terseLabel": "Operating Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from operating lease." } } }, "auth_ref": [] }, "ctdh_OrganizationAndDescriptionOfBusinessTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "OrganizationAndDescriptionOfBusinessTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business"], "lang": { "en-us": { "role": { "label": "Organization and Description of Business [Text Block]", "documentation": "Disclosure for organization and description of business." } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r33"] }, "us-gaap_OtherIncomeDisclosureNonoperatingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeDisclosureNonoperatingAbstract", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "OTHER INCOME (EXPENSE)" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype":~~

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Investment and other income (expense), net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r55"] }, "us-gaap_OtherSellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherSellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Office and other", "documentation": "Amount of selling, general and administrative expense classified as other." } } }, "auth_ref": ["r52"] }, "ctdh_OwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "OwnershipPercentage", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual"], "lang": { "en-us": { "role": { "label": "ctdh_OwnershipPercentage", "terseLabel": "Ownership Percentage", "documentation": "Percentage of ownership." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfMergerRelatedCostsFinancingActivities", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities", "negatedLabel": "Merger transaction costs", "documentation": "The cash outflow for financing costs associated with business combinations." } } }, "auth_ref": ["r9"] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670"] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r41", "r229"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r41", "r469"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding (in shares)", "terseLabel": "Preferred Stock, Shares Outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r41", "r469", "r487", "r730", "r731"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock, par value $.0001 per share, 250,000,000 shares authorized, 28,768,055 and 28,556,072 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r41", "r412", "r569"] }, "us-gaap_PrepaidExpenseNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseNoncurrent", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "NON-CURRENT PREPAID CLINICAL EXPENSES", "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r601"] }, "ctdh_PrepaidExpensesCurrentExcludingPrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "PrepaidExpensesCurrentExcludingPrepaidInsurance", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Prepaid clinical expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer, excluding prepaid insurance." } } }, "auth_ref": [] }, "ctdh_PrepaidExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "PrepaidExpensesPolicyTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Prepaid Expenses [Policy Text Block]", "documentation": "Disclosure of accounting policy for prepaid expenses." } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Prepaid insurance and services", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r533", "r544", "r626"] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-schedule-of-convertible-notes-payable-details"], "lang": { "en-us": { "role": { "label": "Net proceeds from issuance of convertible note",

~~"terseLabel": "Issuance of convertible Note", "documentation": "The cash inflow from the issuance of a long-term debt instrument~~
~~which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or~~
~~the holder." } } }, "auth_ref": ["r8"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri":~~
~~"http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.ctd-~~
~~holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-~~
~~gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.ctd-~~
~~holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": {~~
~~"label": "Net proceeds from sale of stock", "documentation": "The cash inflow from the additional capital contribution to the entity." }~~
~~} }, "auth_ref": ["r1"] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-~~
~~gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "calculation": { "http://www.ctd-~~
~~holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-~~
~~gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.ctd-~~
~~holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": {~~
~~"label": "Net proceeds from sale of warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares~~
~~at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": ["r1"] }, "us-~~
~~gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":~~
~~"ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-~~
~~condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",~~
~~"weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-~~
~~statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromStockOptionsExercised",~~
~~"terseLabel": "Exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment~~
~~arrangement." } } }, "auth_ref": ["r1", "r6"] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri":~~
~~"http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://www.ctd-~~
~~holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-~~
~~gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.ctd-~~
~~holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": {~~
~~"label": "us-gaap_ProceedsFromWarrantExercises", "terseLabel": "Exercise of warrants", "documentation": "The cash inflow associated~~
~~with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r604"] }, "us-~~
~~gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":~~
~~"ProductAndServiceOtherMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues",~~
~~"http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-revenues-by-product-details"], "lang": { "en-us": { "role": {~~
~~"label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and~~
~~act of providing assistance, classified as other." } } }, "auth_ref": ["r643"] }, "us-gaap_ProductConcentrationRiskMember": {~~
~~"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductConcentrationRiskMember",~~
~~"presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": { "role": { "label":~~
~~"Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified~~
~~product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the~~
~~percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant~~
~~product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright~~
~~protection; or technological obsolescence." } } }, "auth_ref": ["r63"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType",~~
~~"nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-3-revenues", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-~~
~~revenues-by-product-details", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers",~~
~~"http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": {~~
~~"role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r171", "r404", "r424", "r425", "r426", "r427", "r428", "r429", "r430",~~
~~"r530", "r551", "r570", "r572", "r573", "r575", "r576", "r635", "r636", "r642", "r697", "r698", "r699", "r700", "r701", "r702", "r703",~~
~~"r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720",~~
~~"r721", "r722", "r723", "r724", "r725"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri":~~
~~"http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-3-revenues", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-~~
~~revenues-by-product-details", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers",~~
~~"http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": {~~
~~"role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r171", "r404", "r424", "r425", "r426", "r427", "r428", "r429",~~
~~"r430", "r530", "r551", "r570", "r572", "r573", "r575", "r576", "r635", "r636", "r642", "r697", "r698", "r699", "r700", "r701", "r702",~~
~~"r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719",~~
~~"r720", "r721", "r722", "r723", "r724", "r725"] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri":~~
~~"http://fasb.org/us-gaap/2024", "localname": "ProfessionalFees", "crdr": "debit", "calculation": { "http://www.ctd-~~
~~holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-~~
~~gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-~~
~~condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Professional fees",~~
~~"documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded~~
~~to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } },~~
~~"auth_ref": ["r541", "r585", "r728", "r729"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType",~~
~~"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role":~~
~~{ "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce~~
~~goods and services and not intended for resale." } } }, "auth_ref": ["r4", "r386"] }, "us-gaap_PropertyPlantAndEquipmentNet": {~~
~~"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr":~~
~~"debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-~~
~~period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.ctd-~~
~~holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role":~~
~~{ "label": "FURNITURE AND EQUIPMENT, NET", "documentation": "Amount after accumulated depreciation, depletion and~~
~~amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale.~~
~~Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } }~~
~~}, "auth_ref": ["r4", "r386", "r407", "r418", "r569"] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype":~~
~~"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock",~~
~~"presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": {~~
~~"role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for~~
~~long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art,~~
~~historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r4", "r91", "r94", "r417"] }, "us-~~
~~gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":~~
~~"PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-~~
~~of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-~~
~~policies-details-textual"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of~~
~~long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.~~
~~Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to,~~
~~office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r66", "r386"] }, "us-~~
~~gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":~~
~~"PropertyPlantAndEquipmentUsefulLife", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-~~

~~significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments", "http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments-details-textual"], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]", "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers." } } }, "auth_ref": ["r39", "r77"] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments", "http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments-details-textual"], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]", "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": ["r39", "r77"] }, "ctdh_PurchaseCommitmentGoodsPurchasedDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "PurchaseCommitmentGoodsPurchasedDuringPeriod", "crdr": "debit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments-details-textual"], "lang": { "en-us": { "role": { "label": "ctdh_PurchaseCommitmentGoodsPurchasedDuringPeriod", "terseLabel": "Purchase Commitment, Goods Purchased During Period", "documentation": "Represents the amount of goods purchased on a purchase commitment during the period." } } }, "auth_ref": [] }, "us-gaap_PurchaseCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments", "http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments-details-textual"], "lang": { "en-us": { "role": { "label": "Purchase Commitment [Member]", "documentation": "Purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. Excludes long-term commitments." } } }, "auth_ref": ["r39", "r77"] }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted", "terseLabel": "Purchase Commitment, Remaining Minimum Amount Committed", "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations." } } }, "auth_ref": ["r39", "r77"] }, "ctdh_RafaelHoldingsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "RafaelHoldingsIncMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-schedule-of-convertible-notes-payable-details"], "lang": { "en-us": { "role": { "label": "Rafael Holdings, Inc. [Member]", "documentation": "Represents Rafael Holdings, Inc." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r197", "r198", "r199", "r200", "r255", "r263", "r295", "r296", "r297", "r308", "r358", "r399", "r400", "r402", "r431", "r432", "r438", "r460", "r461", "r513", "r514", "r515", "r516", "r517", "r526", "r527", "r543", "r550", "r558", "r564", "r565", "r566", "r567", "r572", "r579", "r633", "r641", "r676", "r689", "r690", "r691", "r692", "r693"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r197", "r198", "r199", "r200", "r255", "r263", "r295", "r296", "r297", "r308", "r358", "r399", "r400", "r402", "r431", "r432", "r438", "r460", "r461", "r513", "r514", "r515", "r516", "r517", "r526", "r527", "r543", "r550", "r558", "r564", "r565", "r566", "r567", "r572", "r579", "r633", "r641", "r676", "r689", "r690", "r691", "r692", "r693"] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesPolicyTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": ["r175", "r176", "r177", "r179", "r624"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r174", "r262", "r390", "r391", "r410", "r416", "r463", "r464", "r465", "r466", "r467", "r486", "r488", "r512"] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r174", "r262", "r390", "r391", "r410", "r416", "r463", "r464", "r465", "r466", "r467", "r486", "r488", "r512", "r685"] }, "ctdh_RepairsAndMaintenance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "RepairsAndMaintenance", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Repairs and maintenance", "documentation": "Represents the costs related to repairs and maintenance." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments", "http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments-details-textual"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [~~

"r128", "r129", "r213", "r231", "r392", "r401", "r408", "r535", "r536"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r310", "r528", "r541", "r694"] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r309"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r103"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r44", "r71", "r414", "r436", "r437", "r446", "r470", "r569"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r98", "r131", "r132", "r133", "r135", "r140", "r142", "r144", "r181", "r182", "r194", "r324", "r325", "r331", "r332", "r333", "r335", "r337", "r338", "r343", "r345", "r346", "r348", "r350", "r380", "r382", "r433", "r435", "r448", "r730"] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-revenues-by-product-details"], "lang": { "en-us": { "role": { "label": "Product sales", "terseLabel": "Total revenues", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": ["r82", "r83", "r159", "r164", "r165", "r168", "r170", "r171", "r172", "r173", "r252", "r253", "r404"] }, "ctdh_RevenueFromContractWithCustomerShippingAndHandlingFeesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "RevenueFromContractWithCustomerShippingAndHandlingFeesPolicyPolicyTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Shipping and Handling Fees, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the classification of shipping and handling fees, including whether the fees are included in cost of sales or included in other income statement accounts." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r96", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r254"] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": ["r491", "r529", "r538"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "REVENUES" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r593"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r593"] }, "us-gaap_SalariesAndWages": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalariesAndWages", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Personnel", "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": ["r603"] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r173", "r598"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-earnings-per-share-details"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": ["r145", "r264", "r596", "r612"] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":

~~"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r12"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r615"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r587"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r589"] }, "ctdh_SeptemberNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "SeptemberNoteMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual"], "lang": { "en-us": { "role": { "label": "September Note [Member]", "documentation": "Represents the September note." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r2"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r285"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r296"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r297"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": ["r295"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r561"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r22"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":~~

"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r278"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r288"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual"], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r270", "r271", "r272", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r294", "r295", "r296", "r297", "r298"] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r265", "r273", "r292", "r293", "r294", "r295", "r298", "r303", "r304", "r305", "r306"] }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedPaymentArrangementNonemployeeMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonemployee [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": ["r266", "r270", "r271", "r272", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r294", "r295", "r296", "r297", "r298"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r560"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r294"] }, "ctdh_SharebasedCompensationNonemployees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "SharebasedCompensationNonemployees", "crdr": "debit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "ctdh_SharebasedCompensationNonemployees", "terseLabel": "Stock compensation to nonemployees", "documentation": "The aggregate amount of noncash, equity-based nonemployee remuneration." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r60", "r124"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r97", "r105", "r106", "r107", "r126", "r148", "r149", "r151", "r153", "r161", "r162", "r180", "r201", "r203", "r204", "r205", "r208", "r209", "r229", "r230", "r233", "r236", "r242", "r370", "r442", "r443", "r444", "r445", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r469", "r490", "r507", "r518", "r519", "r520", "r521", "r522", "r595", "r606", "r614"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r5", "r42", "r45", "r46", "r98", "r115", "r116", "r117", "r131", "r132", "r133", "r135", "r140", "r142", "r144", "r160", "r181", "r182", "r194", "r243", "r324", "r325", "r331", "r332", "r333", "r335", "r337", "r338", "r343", "r344", "r345", "r346", "r347", "r348", "r350", "r371", "r372", "r373", "r374", "r375", "r376", "r380", "r382", "r389", "r421", "r433", "r434", "r435", "r448", "r507"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-10-income-taxes", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual", "http://www.ctd-

~~holdings.com/20240930/role/statement-note-11-net-loss-per-share-antidilutive-securities-weighted-average-shares-outstanding-~~
~~details", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-12-net-loss-per-share-earnings-per-share-details", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-12-net-loss-per-share-tables", "http://www.ctd-holdings.com/20240930/role/statement-~~
~~note-13-purchase-commitments", "http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments-details-~~
~~textual", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-14-subsequent-events-details-textual", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-changes-in-fair-value-of-notes-details",~~
~~"http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",~~
~~"http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details",~~
~~"http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details",~~
~~"http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-3-revenues", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-~~
~~details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-revenues-by-product-details",~~
~~"http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-tables", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-5-concentrations-of-credit-risk", "http://www.ctd-holdings.com/20240930/role/statement-~~
~~note-6-accounts-payable-and-accrued-expenses", "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-~~
~~accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-tables", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-~~
~~note-7-convertible-notes-payable-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-~~
~~payable-schedule-of-convertible-notes-payable-details", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-~~
~~notes-payable-tables", "http://www.ctd-holdings.com/20240930/role/statement-note-8-leases", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-8-leases-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-9-~~
~~equity-transactions", "http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions-details-textual",~~
~~"http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label":~~
~~"Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to~~
~~disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r131",~~
~~"r132", "r133", "r160", "r382", "r404", "r440", "r459", "r462", "r463", "r464", "r465", "r466", "r467", "r469", "r472", "r473", "r474",~~
~~"r475", "r476", "r477", "r478", "r479", "r480", "r482", "r483", "r484", "r485", "r486", "r488", "r491", "r492", "r493", "r494", "r495",~~
~~"r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r507", "r580"] }, "us-gaap_StatementOfCashFlowsAbstract": {~~
~~"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us":~~
~~{ "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": {~~
~~"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": {~~
~~"en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-~~
~~gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":~~
~~"StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } },~~
~~"auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":~~
~~"StatementScenarioAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-",~~
~~"http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-earnings-per-share-details"], "lang": { "en-us": {~~
~~"role": { "label": "Scenario [Axis]" } } }, "auth_ref": ["r145", "r264", "r596", "r597", "r612"] }, "us-gaap_StatementTable": { "xbrltype":~~
~~"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.ctd-~~
~~holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",~~
~~"http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-1-organization-and-description-of-business", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-10-income-taxes", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-~~
~~incentive-plan", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-11-net-loss-per-share-antidilutive-securities-weighted-average-shares-outstanding-~~
~~details", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-12-net-loss-per-share-earnings-per-share-details", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-12-net-loss-per-share-tables", "http://www.ctd-holdings.com/20240930/role/statement-~~
~~note-13-purchase-commitments", "http://www.ctd-holdings.com/20240930/role/statement-note-13-purchase-commitments-details-~~
~~textual", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-14-subsequent-events-details-textual", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-changes-in-fair-value-of-notes-details",~~
~~"http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",~~
~~"http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-fair-values-details",~~
~~"http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-key-inputs-details",~~
~~"http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-3-revenues", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-~~
~~details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-revenues-by-product-details",~~
~~"http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-tables", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-5-concentrations-of-credit-risk", "http://www.ctd-holdings.com/20240930/role/statement-~~
~~note-6-accounts-payable-and-accrued-expenses", "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-~~
~~accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-tables", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-~~
~~note-7-convertible-notes-payable-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-~~
~~payable-schedule-of-convertible-notes-payable-details", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-~~
~~notes-payable-tables", "http://www.ctd-holdings.com/20240930/role/statement-note-8-leases", "http://www.ctd-~~
~~holdings.com/20240930/role/statement-note-8-leases-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-9-~~
~~equity-transactions", "http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions-details-textual",~~
~~"http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label":~~
~~"Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other~~
~~comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r131", "r132", "r133", "r160",~~
~~"r174", "r382", "r404", "r440", "r459", "r462", "r463", "r464", "r465", "r466", "r467", "r469", "r472", "r473", "r474", "r475", "r476",~~
~~"r477", "r478", "r479", "r480", "r482", "r483", "r484", "r485", "r486", "r488", "r491", "r492", "r493", "r494", "r495", "r496", "r497",~~
~~"r498", "r499", "r500", "r501", "r502", "r503", "r504", "r507", "r580"] },~~
~~"ctdh_StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.ctd-~~
~~holdings.com/20240930", "localname": "StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrants", "presentation": [~~
~~"http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"~~

~~], "lang": { "en-us": { "role": { "label": "Sale of common stock (in shares)", "documentation": "Amount of common stock and prefunded warrants issued during the period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Stock issued to nonemployees (in shares)", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross", "terseLabel": "Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture (in shares)", "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Exercise of stock options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r5", "r41", "r42", "r71", "r279"] }, "ctdh_StockIssuedDuringPeriodSharesWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Exercise of warrants (in shares)", "documentation": "Number of shares issued as a result of the exercise of warrants during the current period." } } }, "auth_ref": [] }, "ctdh_StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrants", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Sale of common stock", "documentation": "value of common stock and prefunded warrants issued during period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Stock issued to nonemployees", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r5", "r42", "r45", "r46", "r71"] }, "ctdh_StockIssuedDuringPeriodValueWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "crdr": "credit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Exercise of warrants", "documentation": "Value of stock issued as a result of the exercise of warrants." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total stockholders' equity (deficit)", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r42", "r45", "r46", "r64", "r471", "r487", "r508", "r509", "r569", "r586", "r608", "r625", "r680", "r730"] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r70", "r125", "r228", "r230", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r243", "r349", "r510", "r511", "r523"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r377", "r394"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r377", "r394"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business", "http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events", "http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events-details-textual", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r377", "r394"] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-14-subsequent-events"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r393", "r395"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION" } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": {~~

~~"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-tables", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-tables", "http://www.ctd-holdings.com/20240930/role/statement-note-6-accounts-payable-and-accrued-expenses-tables", "http://www.ctd-holdings.com/20240930/role/statement-note-7-convertible-notes-payable-tables"], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "ctdh_The2019OmnibusIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "The2019OmnibusIncentivePlanMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual"], "lang": { "en-us": { "role": { "label": "The 2019 Omnibus Incentive Plan [Member]", "documentation": "Represents the 2019 Omnibus Equity Incentive Plan." } } }, "auth_ref": [] }, "ctdh_The2021EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "The2021EquityIncentivePlanMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan", "http://www.ctd-holdings.com/20240930/role/statement-note-11-equity-incentive-plan-details-textual"], "lang": { "en-us": { "role": { "label": "The 2021 Equity Incentive Plan [Member]", "documentation": "Represents the 2021 Equity Incentive Plan." } } }, "auth_ref": [] }, "ctdh_ThreeMajorCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "ThreeMajorCustomersMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": { "role": { "label": "Three Major Customers [Member]", "documentation": "Represents information pertaining to three major customers." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions", "http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": ["r622", "r684"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions", "http://www.ctd-holdings.com/20240930/role/statement-note-9-equity-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ctdh_TrappsolCycloMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "TrappsolCycloMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-revenues-by-product-details"], "lang": { "en-us": { "role": { "label": "Trappsol Cyclo [Member]", "documentation": "Represents information about Trappsol Cyclo." } } }, "auth_ref": [] }, "ctdh_TrappsolHPBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "TrappsolHPBMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues", "http://www.ctd-holdings.com/20240930/role/statement-note-3-revenues-revenues-by-product-details"], "lang": { "en-us": { "role": { "label": "Trappsol HPB [Member]", "documentation": "Represents information bout Trappsol HPB." } } }, "auth_ref": [] }, "ctdh_TwoMajorCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "TwoMajorCustomersMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers", "http://www.ctd-holdings.com/20240930/role/statement-note-4-major-customers-and-suppliers-details-textual"], "lang": { "en-us": { "role": { "label": "Two Major Customers [Member]", "documentation": "Represents information pertaining to two major customers." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r16", "r17", "r18", "r89", "r90", "r92", "r93"] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-11-net-loss-per-share-antidilutive-securities-weighted-average-shares-outstanding-details", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-"], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r577", "r578", "r581", "r582", "r583", "r584"] }, "ctdh_WarrantsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "WarrantsPolicyTextBlock", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Warrants [Policy Text Block]", "documentation": "The disclosure for the accounting policy for warrants." } } }, "auth_ref": [] }, "ctdh_WarrantsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "WarrantsToPurchaseCommonStockMember", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-document-and-entity-information", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.ctd-holdings.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Warrants To Purchase Common Stock [Member]", "documentation": "Represents warrants outstanding to purchase common stock." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.ctd-holdings.com/20240930/role/statement-note-12-net-loss-per-share-earnings-per-share-details"], "lang": { "en-us": { "role": { "label": "WEIGHTED AVERAGE NUMBER OF COMMON SHARES BASIC AND DILUTED OUTSTANDING (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r147", "r153"] }, "ctdh_WorkingCapitalDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "WorkingCapitalDeficit", "crdr": "debit", "presentation": ["http://www.ctd-holdings.com/20240930/role/statement-note-1-organization-and-description-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "ctdh_WorkingCapitalDeficit", "terseLabel": "Working Capital Deficit", "documentation": "The difference between the current assets and current liabilities that is used as a financial metric for operating liquidity." } } }, "auth_ref": [] }, "ctdh_statement-statement-note-11-net-loss-per-share-antidilutive-securities-weighted-average-shares-outstanding-details": { "xbrltype": "stringItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "statement-statement-note-11-net-loss-per-share-antidilutive-securities-weighted-average-shares-outstanding-details", "lang": { "en-us": { "role": { "label": "Note 11 - Net Loss Per Share - Antidilutive Securities Weighted Average Shares Outstanding (Details)" } } }, "auth_ref": [] }, "ctdh_statement-statement-note-12-net-loss-per-share-earnings-per-share-details": { "xbrltype": "stringItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "statement-statement-note-12-net-loss-per-share-earnings-per-share-details", "lang": { "en-us": { "role": { "label": "Note 12 - Net Loss Per Share - Earnings Per Share (Details)" } } }, "auth_ref": [] }, "ctdh_statement-statement-note-12-net-loss-per-share-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "statement-statement-note-12-net-loss-per-share-tables", "lang": { "en-us": { "role": { "label": "Note 12 - Net Loss Per Share" } } }, "auth_ref": [] }, "ctdh_statement-statement-note-2-summary-of-significant-accounting-policies-changes-in-fair-value-of-notes-details": { "xbrltype": "stringItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-changes-in-fair-value-of-notes-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Changes in Fair Value of Notes (Details)" } } }, "auth_ref": [] }, "ctdh_statement-statement-note-2-summary-of-significant-accounting-policies-fair-values-details": { "xbrltype": "stringItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-fair-values-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Fair Values (Details)" } } }, "auth_ref": [] }, "ctdh_statement-statement-note-2-summary-of-significant-accounting-policies-key-inputs-details": { "xbrltype": "stringItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-key-inputs-details",~~

```
"lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Key Inputs (Details)" } } }, "auth_ref": [] },
"ctdh_statement-statement-note-2-summary-of-significant-accounting-policies-tables": { "xbrltype": "stringItemType", "nsuri":
"http://www.ctd-holdings.com/20240930", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-
tables", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies" } } }, "auth_ref": [] },
"ctdh_statement-statement-note-3-revenues-revenues-by-product-details": { "xbrltype": "stringItemType", "nsuri": "http://www.ctd-
holdings.com/20240930", "localname": "statement-statement-note-3-revenues-revenues-by-product-details", "lang": { "en-us": { "role":
{ "label": "Note 3 - Revenues - Revenues by Product (Details)" } } }, "auth_ref": [] }, "ctdh_statement-statement-note-3-revenues-
tables": { "xbrltype": "stringItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "statement-statement-note-3-
revenues-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Revenues" } } }, "auth_ref": [] }, "ctdh_statement-statement-note-6-
accounts-payable-and-accrued-expenses-schedule-of-accounts-payable-and-accrued-liabilities-details": { "xbrltype": "stringItemType",
"nsuri": "http://www.ctd-holdings.com/20240930", "localname": "statement-statement-note-6-accounts-payable-and-accrued-expenses-
schedule-of-accounts-payable-and-accrued-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 6 - Accounts Payable and
Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details)" } } }, "auth_ref": [] }, "ctdh_statement-statement-
note-6-accounts-payable-and-accrued-expenses-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.ctd-
holdings.com/20240930", "localname": "statement-statement-note-6-accounts-payable-and-accrued-expenses-tables", "lang": { "en-us":
{ "role": { "label": "Note 6 - Accounts Payable and Accrued Expenses" } } }, "auth_ref": [] }, "ctdh_statement-statement-note-7-
convertible-notes-payable-schedule-of-convertible-notes-payable-details": { "xbrltype": "stringItemType", "nsuri": "http://www.ctd-
holdings.com/20240930", "localname": "statement-statement-note-7-convertible-notes-payable-schedule-of-convertible-notes-payable-
details", "lang": { "en-us": { "role": { "label": "Note 7 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details)" } }
}, "auth_ref": [] }, "ctdh_statement-statement-note-7-convertible-notes-payable-tables": { "xbrltype": "stringItemType", "nsuri":
"http://www.ctd-holdings.com/20240930", "localname": "statement-statement-note-7-convertible-notes-payable-tables", "lang": { "en-
us": { "role": { "label": "Note 7 - Convertible Notes Payable" } } }, "auth_ref": [] }, "ctdh_statement-statement-significant-accounting-
policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.ctd-holdings.com/20240930", "localname": "statement-
statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } },
"auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)",
"SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28",
"Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-
10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-
1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-
2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10",
"Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r8": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section":
"45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
}, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic":
"10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r10":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10",
"Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r11": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10",
"Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r12": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10",
"Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-
10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260",
"SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-
2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275",
"SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-
18" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275",
"SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-
20" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275",
"SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-
4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275",
"SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-
8" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275",
"SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-
9" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360",
"SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r22": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph":
"2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r23": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph":
"12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r24": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph":
"13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r25": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph":
"2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r26": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph":
"3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r27": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph":
"6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r28": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph":
"20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r29": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph":
"21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r30": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)
```

~~(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-~~
~~gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",~~
~~"Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-~~
~~S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards~~
~~Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI":~~
~~"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",~~
~~"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-~~
~~02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-~~
~~gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",~~
~~"Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI":~~
~~"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",~~
~~"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)~~
~~(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-~~
~~gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",~~
~~"Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-~~
~~S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards~~
~~Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI":~~
~~"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",~~
~~"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-~~
~~02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-~~
~~gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",~~
~~"Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-~~
~~S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards~~
~~Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI":~~
~~"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",~~
~~"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-~~
~~02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-~~
~~gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",~~
~~"Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI":~~
~~"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",~~
~~"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)~~
~~(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-~~
~~gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",~~
~~"Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-~~
~~S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards~~
~~Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI":~~
~~"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",~~
~~"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-~~
~~02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-~~
~~gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",~~
~~"Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-~~
~~S99-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards~~
~~Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI":~~
~~"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220",~~
~~"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-~~
~~03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r51": { "role": "http://fasb.org/us-~~
~~gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",~~
~~"Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-~~
~~S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards~~
~~Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI":~~
~~"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220",~~
~~"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-~~
~~03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-~~
~~gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",~~
~~"Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-~~
~~S99-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards~~
~~Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI":~~
~~"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220",~~
~~"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)",~~
~~"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r57": { "role": "http://fasb.org/us-~~
~~gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph":~~
~~"24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r58": { "role": "http://fasb.org/us-~~
~~gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph":~~
~~"25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r59": { "role": "http://fasb.org/us-~~
~~gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph":~~
~~"28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r60": { "role": "http://fasb.org/us-~~
~~gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":~~
~~"https://asc.fasb.org/235/tableOfContent" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name":~~
~~"Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r62": { "role":~~
~~"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":~~
~~"50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"~~
~~}, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards~~
~~Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI":~~
~~"https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310",~~
~~"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic~~
~~4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r65": { "role": "http://fasb.org/us-~~
~~gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",~~
~~"Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-~~
~~S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards~~
~~Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":~~
~~"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440",~~
~~"Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r68": { "role":~~
~~"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":~~
~~"https://asc.fasb.org/470/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic":~~
~~"20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI":~~
~~"https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505",~~
~~"Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r71": { "role":~~
~~"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":~~
~~"S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-~~
~~10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting~~
~~Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483043/710-~~

~~10-30-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-~~

~~10-45-1A" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-~~

~~10-50-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":~~

~~"https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-~~

~~10-50-13" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":~~

~~"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r274": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r276": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r278": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)
(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r280": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)
(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r282": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r284": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)
(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r286": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)
(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r288": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r290": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r292": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB
Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r305": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB
Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r307": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)",~~

~~"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-~~

~~40-50-6" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI":~~

~~"https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r428": { "role":~~

~~"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX
210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r430": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r431": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r434": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification",
"Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r437": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification",
"Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB
Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r439": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r440": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX
210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r442": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX
210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r444": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX
210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r446": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r447": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r448": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r452": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r455": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r458": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r462": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r464": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r466": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI":~~

~~"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":~~

~~"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB",~~

~~"URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "
(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r545": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
}, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-
69B" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-
69C" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-
69E" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-
69F" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r552": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
}, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r555": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r556": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
}, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715",
"SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r560": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
}, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r565": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r566": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-
107" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r572": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section":
"55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r573": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section":
"55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
}, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r578": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r581": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX
210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r583":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX~~

~~210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r595": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r597": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards~~

~~Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r665": { "role":~~

~~"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)
(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r667": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)
(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r669": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)
(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r671": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r672": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r674": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-
10-50-2" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r677": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r679": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-
10-50-6A" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r684": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r685": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" },
"r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r688": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)
(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r690": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)
(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r692": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)
(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r694": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification",
"Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r695": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "
(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r697": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-
30-50-2B" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r700": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r701": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r703": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification",~~

~~"Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 65 0001437749-24-035006-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-035006-xbrl.zip M4$L#!!0 (%BE;5GK.S=X5Q $.\ 1 8W1D:"TR,#(T,#DS,"YX MN+ILYT'HX3F)7G"G%CXQG[=AE.S-SFX)(2,*&(AF MM*W]]=L-/D1*($5*D$U'.KA, 0UT-_I#H_$B/_[Z-'&,!\H%\]SC5G>OTS*HM:WDVMURO]>NG?_[CX[],\PMU*2!?]1N/SX^[CWN[WE\U.YU.MWV7U>7=Y*V%1-;7N@& M?)H6>!IP9T]0:V_D/;3CS#8R3L$]CA7/2288\]!/<6>Y4TD=>=POY.6"#F' MEBCB$>?FF-B4J:DA(T\8<#.8^E3D1))%4&?(;F,VENF8G:[9ZR8EJ66K64!&MC@5UPTDO3QHU9Z_3ID\!=04;.-1$,K0@6%^8O;U4>_IDC0L804Z.D\/<[VH] MP';[;~~